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Traumatic neck injuries commonly result from rear-end motor vehicle collisions and are associated with a
high incidence of neck pain and considerable annual costs. The facet joint is the most common source of neck
pain. That joint is innervated by nociceptors that are activated by tensile stretching of the joint's capsular
ligament. Although activation of those joint afferents and joint inflammation contribute to facet-mediated
pain, the cellular response(s) within the joint that initiate pain via the joint afferents are unknown. Similarly,
the mechanisms that induce central sensitization and maintain facet pain are not fully defined. Nerve growth
factor (NGF) is a potent mediator of inflammatory cascades and is hypothesized to contribute to joint pain.
Further, NGF regulates brain-derived neurotrophic factor (BDNF), which, when released in the spinal cord,
sensitizes spinal neurons. Despite their roles in inflammatory pain, no studies have identified whether the
neurotrophins NGF and/or BDNF contribute to facet joint-mediated pain. These studies utilize a rat model of
mechanical facet joint injury to investigate the roles of NGF and BDNF in facet pain. Because joint afferents
are crucial for the initiation and maintenance of facet pain, the innervation pattern of the C6/C7 facet joint in
the rat is quantitatively defined. NGF expression is measured in the facet joint and the dorsal root ganglion
(DRG) following a painful facet joint distraction. Further, the role of intra-articular NGF in the initiation and
maintenance of facet-mediated pain and spinal neuronal hyperexcitability is evaluated by selectively blocking
intra-articular NGF signaling. BDNF expression is quantified in the DRG and spinal cord after joint injury.
Selective inhibition of spinal BDNF is utilized to determine its contribution to facet-mediated pain. This
thesis demonstrates that throughout the peripheral and central nervous systems neurotrophins are key
mediators of behavioral hypersensitivity and contribute to the hyperexcitability of spinal neurons after a
painful facet joint injury. This work further establishes the need for future studies to integrate investigations
throughout all aspects of the pain pathway to fully understand the mechanisms underlying facet-mediated
pain.
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ABSTRACT 
 
THE ROLE OF INTRA-ARTICULAR NERVE GROWTH FACTOR IN FACET-
MEDIATED PAIN: RELATIONSHIPS TO SPINAL BDNF AND NEURONAL 
HYPEREXCITABILITY 
 
 
Jeffrey V. Kras 
 
Beth A. Winkelstein 
 
 
 
Traumatic neck injuries commonly result from rear-end motor vehicle collisions 
and are associated with a high incidence of neck pain and considerable annual costs. The 
facet joint is the most common source of neck pain. That joint is innervated by 
nociceptors that are activated by tensile stretching of the joint’s capsular ligament. 
Although activation of those joint afferents and joint inflammation contribute to facet-
mediated pain, the cellular response(s) within the joint that initiate pain via the joint 
afferents are unknown. Similarly, the mechanisms that induce central sensitization and 
maintain facet pain are not fully defined. Nerve growth factor (NGF) is a potent mediator 
of inflammatory cascades and is hypothesized to contribute to joint pain. Further, NGF 
regulates brain-derived neurotrophic factor (BDNF), which, when released in the spinal 
cord, sensitizes spinal neurons. Despite their roles in inflammatory pain, no studies have 
identified whether the neurotrophins NGF and/or BDNF contribute to facet joint-
mediated pain. These studies utilize a rat model of mechanical facet joint injury to 
investigate the roles of NGF and BDNF in facet pain. Because joint afferents are crucial 
iv 
for the initiation and maintenance of facet pain, the innervation pattern of the C6/C7 facet 
joint in the rat is quantitatively defined. NGF expression is measured in the facet joint 
and the dorsal root ganglion (DRG) following a painful facet joint distraction. Further, 
the role of intra-articular NGF in the initiation and maintenance of facet-mediated pain 
and spinal neuronal hyperexcitability is evaluated by selectively blocking intra-articular 
NGF signaling. BDNF expression is quantified in the DRG and spinal cord after joint 
injury. Selective inhibition of spinal BDNF is utilized to determine its contribution to 
facet-mediated pain. This thesis demonstrates that throughout the peripheral and central 
nervous systems neurotrophins are key mediators of behavioral hypersensitivity and 
contribute to the hyperexcitability of spinal neurons after a painful facet joint injury. This 
work further establishes the need for future studies to integrate investigations throughout 
all aspects of the pain pathway to fully understand the mechanisms underlying facet-
mediated pain. 
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Chapter 1 
Introduction and Background 
 
 
1.1. Overview 
 In the United States, neck and back syndromes are the most common cause of 
job-related disability, with costs exceeding $50 billion each year (Strine and Hootman, 
2007).  The annual incidence of neck pain is estimated to be as high as 50% within the 
general population (Hogg-Johnson et al., 2008; van Eerd et al., 2010). Rear end motor 
vehicle collisions are a major cause of neck pain, with as many as one in three people 
involved reporting a minor neck injury (Quinlan et al., 2004; Zuby and Lund, 2010). 
Such motor vehicle collisions cause whiplash injuries, the most frequent symptom of 
which is neck pain (Berglund et al., 2000; Eck et al., 2001). Whiplash injuries incur 
annual costs of nearly $4 billion, including medical care, disability, and lost productivity 
(Eck et al., 2001; Freeman et al., 1999). As many as 50% of whiplash patients experience 
chronic pain (Carroll et al., 2009; Pedler et al., 2013). Yet, despite these high instances 
and staggering socioeconomic costs, the physiological mechanisms that lead to persistent 
pain from mechanical injury to the neck are still poorly understood (Chen et al., 2006; 
Dong and Winkelstein, 2010; Panjabi et al., 1998; Winkelstein et al., 2000). This lack of 
clear mechanistic understanding of the cellular signals that sensitize sensory neurons and 
lead to pathological pain after injury makes it challenging to develop and implement 
effective strategies to prevent the transition to chronic pain (Elliott et al., 2009). 
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 Exposure to non-physiological spinal motions, particularly those associated with 
dynamic neck loading scenarios, has the potential to injure many innervated structures in 
the neck, including the vertebrae, intervertebral discs, facet joints, muscles, and 
ligaments, among others. Anesthetic nerve blocks have identified the cervical facet joints 
as the source of pain in up to 65% of neck pain patients (Barnsley et al., 1995; Lord et al., 
1996; Manchikanti et al., 2002; van Eerd et al., 2010). Further, the cervical facet joints in 
the lower cervical spine are those most commonly symptomatic after neck injury 
(Bogduk, 2011; Bogduk and Aprill, 1993). In particular, biomechanical studies 
simulating whiplash identify the C6/C7 facet joint capsule as undergoing the greatest 
ligament strains among all of the cervical facet joints (Panjabi et al., 1998; Pearson et al., 
2004). Further, those capsular ligament strains resulting from whiplash simulations are 
significantly larger than the corresponding strains reported for physiological neck 
motions (Bogduk and Aprill, 1993; Panjabi et al., 1998; Pearson et al., 2004). Together, 
such studies support the C6/C7 joint as being one of the most relevant to injury-induced 
neck pain.  Although the facet joint undergoes a combination of compression, shear, and 
tensile loading during dynamic neck loading, tensile stretch of the capsular ligament that 
encloses the facet joint is, by itself, capable of activating nociceptors innervating the joint 
(Chen et al., 2006; Lu et al., 2005), which suggests that joint loading may be sufficient to 
induce pain. Moreover, tensile stretch of the facet capsular ligament induces pain in 
association with spinal neuronal hyperexcitability and a host of other cellular responses in 
both the peripheral and central nervous systems in the rat (Crosby et al., 2013; Dong and 
Winkelstein, 2010; Kras et al., 2014a; Lee and Winkelstein, 2009; Quinn et al., 2010). 
Spinal neuronal hyperexcitability is one component of central sensitization, which is a 
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state of increased neuronal excitability and synaptic efficacy that contributes to 
widespread and persistent pain (Latremoliere and Woolf, 2009). However, there is little 
data defining the relationship between local responses in the joint to the nociceptive, 
biochemical, and cellular responses of the primary sensory neurons and neurons in the 
central nervous system (CNS) in facet-mediated pain. 
 Clinically, facet joint interventions, such as anesthetic nerve blocks and 
radiofrequency neurotomy, are one of the largest contributors to the growth in 
expenditures among chronic pain patients (Manchikanti et al., 2013). The use of those 
treatments increased more than 300% between 2000 and 2011 (Manchikanti et al., 2013). 
The growing utilization of treatments targeting the nerve supply to painful facet joints 
supports a role for facet joints and the neurons that innervate them in chronic pain. The 
facet joint and its capsular ligament are densely innervated, receiving afferents from both 
the spinal level above and below the joint in humans (Barnsley and Bogduk, 1993; van 
Eerd et al., 2010). Because studies identify innervation of some facet joints as more 
complex in the rat, with several spinal levels contributing fibers to the joint (Ohtori et al., 
2002; Ohtori et al., 2003), characterization of the specific joint innervation patterns is 
necessary in order to define those relevant mechanisms contributing to joint pain. Further, 
afferent fibers may be classified as peptidergic (those neurons expressing neuropeptides) 
or non-peptidergic (those neurons binding isolectin B4) (Merighi et al., 2008), and each 
type of neuron responds to different environmental signals and initiates different cellular 
responses that contribute to pain (Joseph and Levine, 2010; Merighi et al., 2008; Seybold, 
2009). Peptidergic fibers have been identified in the facet joint capsules of both humans 
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(Kallakuri et al., 2004) and rats (Ohtori et al., 2003), yet it remains to be seen if this or 
other classes of neurons have an important role in facet joint pain. 
 Many pro-inflammatory cascades that are associated with pain, such as increased 
levels of cytokines and prostaglandins, are initiated in joint inflammation and arthritis 
(Kidd et al., 1996; Longo et al., 2013; Schaible and Grubb, 1993; Woolf et al., 1997). 
Inflammation in the facet joint is sufficient to induce pain (Tachihara et al., 2007), and 
local treatment with an anti-inflammatory drug alleviates loading-induced facet joint pain 
(Dong et al., 2011). Both of these studies support a role for inflammation in the evolution 
of pain after a mechanical facet joint injury. Although tensile loading of the facet joint 
differentially increases mRNA levels of cytokines in the DRG and upregulates 
prostaglandin and cytokine expression in the spinal cord (Kras et al., 2014a; Lee et al., 
2008), it is unclear how localized inflammation in the facet joint leads to neuronal 
hyperexcitability in the CNS and behavioral hypersensitivity. Within inflamed tissue, 
increased levels of the neurotrophin nerve growth factor (NGF) sensitize neurons and 
increase sensitivity to mechanical, as well as thermal, stimuli (Amaya et al., 2004; 
McMahon, 1996; Merighi et al., 2004; Pezet and McMahon, 2006). In fact, NGF and its 
receptor have been identified within the synovial fluid of arthritic joints and in the 
adjacent synovial tissue (Barthel et al., 2009; Kidd et al., 1996; Raychaudhuri et al., 
2011), as well as in degenerative facet joints (Surace et al., 2009). Although those 
findings suggest that intra-articular NGF and its downstream signaling cascades may 
contribute to facet pain after mechanical injury, such a role for NGF in joint pain remains 
undefined. 
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 In addition to mechanical sensitivity, inflammation is commonly associated with 
an increased sensitivity to thermal stimuli (Amaya et al., 2004; Woolf et al., 1997). 
Moreover, pain patients suffering from whiplash report increased sensitivity to both heat 
and cold stimuli (Chien et al., 2009; Smith et al., 2014), phenomena that are alleviated by 
ablating the neurons innervating the facet joints in the neck (Smith et al., 2014), which 
suggests that facet joint injury may induce thermal sensitivity in addition to mechanical 
sensitivity. Studies in the rat demonstrate that painful inflammatory joint conditions such 
as arthritis reduce the latency to withdrawal from heat stimuli (Luo et al., 2014); yet, it is 
unknown if tensile loading of the facet joint is sufficient to induce thermal sensitivity in 
addition to the well-documented mechanical sensitivity. 
 Painful facet joint loading damages the primary afferent axons that innervate the 
joint capsule (Kallakuri et al., 2008) and also induces immediate and sustained neuronal 
hyperexcitability in the spinal cord (Crosby et al., 2013; Quinn et al., 2010). Of note, the 
neural circuits that relay painful stimuli to the central nervous system extend beyond the 
spinal cord.  Nociceptive sensory stimuli received in the spinal cord are transmitted to 
higher centers in the central nervous system via the spinothalamic tract (Merighi et al., 
2008), and the thalamus is believed to be the key relay for supraspinal processing and 
transmission of nociceptive stimuli (Slack et al., 2005). Some of the neurons projecting to 
the thalamus are sensitive to the neurotrophin brain-derived neurotrophic factor (BDNF), 
a central pain mediator whose expression is regulated by NGF (Merighi et al., 2008; 
Slack et al., 2005). Some neurons within the thalamus are activated by joint stimulation 
(Schaible et al., 2009); moreover, thalamic neurons with joint input become 
hyperexcitable when the innervated joint is inflamed, in association with pain (Gautron 
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and Guilbaud, 1982). Despite the known role of inflammation in painful mechanical facet 
joint injury and the sensitization of spinal neurons to mechanical stimuli, it is unknown if 
higher order neurons are also sensitized by painful facet joint loading. 
 Studies in this thesis aim to identify a mechanism through which local joint 
responses following tensile loading of the facet joint induce neuronal hyperexcitability in 
the CNS and persistent pain by specifically defining roles for the neurotrophins NGF and 
BDNF in the initiation and maintenance of joint pain in a rat model. Behavioral 
sensitivity to both mechanical and thermal stimuli is evaluated to define the pain 
modalities associated with mechanical facet joint injury. The innervation of the C6/C7 
facet joint is determined using retrograde neuronal tracing in order to identify the 
distribution pattern and subtypes of neurons innervating the joint in the rat. The temporal 
and spatial neurotrophin responses in the DRG and spinal cord also are quantified after 
joint loading in order to determine if this class of proteins contributes to persistent joint 
pain. Complementary studies using anti-NGF antibodies and purified NGF evaluate the 
specific contribution of intra-articular NGF to the initiation and maintenance of facet pain 
and spinal neuronal plasticity. The role of spinal BDNF in the maintenance of facet-
mediated pain is also determined by spinal administration of a BDNF sequestering 
protein after joint injury-induced pain is established. In addition, since the thalamus is a 
major relay center for nociceptive information (Merighi et al., 2008; Millan, 1999) and 
may be sensitive to spinal BDNF signaling (Slack et al., 2005), neuronal excitability is 
quantified in the thalamus at day seven after injury since that time point coincides with 
pain maintenance in this model. 
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1.2. Background 
1.2.1. Cervical Spine & Facet Joint Anatomy 
 The cervical spine consists of seven bony vertebrae (C1-C7) separated by 
intervertebral discs between each pair of vertebrae and is stabilized by a network of soft 
tissues including ligaments and muscles (Figure 1.1A) (Jansen et al., 2008). On the lateral 
sides of each spinal motion segment, which itself consists of two adjacent vertebrae and 
the associated intervertebral disc, a pair of facet joints is formed at the junction of the 
inferior and superior facets (Figure 1.1). The facet joints are the only diarthrotic joints in 
the spine, and they permit articulation between the vertebrae while also providing support 
and absorbing loading along the axial spine (Kirpalani et al., 2008; Li et al., 2011). The 
facet joint space is enclosed by a capsular ligament that is innervated by primary afferent 
neurons that carry sensory information from the joint to the spinal cord where it is 
processed and further relayed to the brain. 
 
Figure 1.1. Right lateral view of a human cervical spinal column and generic motion 
segment. (A) The capsular ligament encloses the joint space between the inferior and 
superior articular facets at each cervical level. (B) A magnified view of a spinal 
motion segment shows the facet joint capsular ligament in red. 
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1.2.2. Neural Anatomy 
 The cervical facet joints from C3-C7 are innervated by the medial branches of the 
dorsal rami of the spinal nerves at the levels immediately superior and inferior to each 
joint (van Eerd et al., 2010). The cell bodies of those sensory neurons that innervate the 
joint reside in the dorsal root ganglion (DRG) proximal to the transverse foramen 
(Figures 1.1B & 1.2) (Kallakuri et al., 2004; van Eerd et al., 2010). Although there are 
only seven cervical vertebrae, there are eight DRGs in the cervical space, with C8 located 
caudal to the C7 vertebra. In addition to innervating the facet joints, the cervical spinal 
nerves also innervate the neck, shoulders, and upper limbs (Lee et al., 2008). Specifically, 
the sensory neurons of the C6-C8 spinal nerves have receptive fields that extend into the 
hands (Lee et al., 2008). In the rat, the C6-C8 dermatomes are similar to those in the 
human and innervate the neck, shoulders, and forepaws (Takahashi and Nakajima, 1996). 
 
Figure 1.2. Anatomy of the dorsal root ganglion (DRG) and spinal cord. Sensory 
information is transmitted from the periphery to the spinal cord via primary afferent 
neurons with their cell bodies in the DRG. The afferents synapse in specific laminae in 
the dorsal horn (laminae I-VI), in accordance with the afferent phenotype. 
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Sensory neurons can be classified into several categories based on the diameter of 
the cell body and the thickness of the myelin sheath surrounding the axons. Aβ-fibers are 
large diameter myelinated neurons that typically respond to light touch or are involved in 
proprioception; under normal circumstances, these neurons do not transmit pain signals 
(Basbaum et al., 2009; Merighi et al., 2008). Both the medium diameter thinly myelinated 
Aδ-fibers and the small diameter unmyelinated C-fibers can function as nociceptors and 
transmit sensory information related to pain (Basbaum et al., 2009; Merighi et al., 2008). 
Among mechanoreceptive nerve fibers innervating the facet joint capsule, both 
proprioceptors and nociceptors that are responsive to capsular ligament stretch have been 
identified (Cavanaugh et al., 1989; Cavanaugh et al., 1996; Chen et al., 2006; Lu et al., 
2005), suggesting that joint loading alone may be sufficient to induce pain.  
Primary afferents also can be classified as either peptidergic (those neurons 
expressing the neuropeptides substance P (SP) and/or calcitonin gene-related peptide 
(CGRP)) or non-peptidergic (those neurons that bind isolectin B4) (Merighi et al., 2008). 
Although nociceptors include both populations of afferents, peptidergic and non-
peptidergic afferents can be functionally distinct. Peptidergic afferents are sensitive to the 
neurotrophin nerve growth factor (NGF), whereas non-peptidergic neurons express 
receptors for glial cell line-derived neurotrophic factor (GDNF) (Stucky and Lewin, 
1999). Moreover, the two populations exhibit distinct electrophysiological properties and 
sensitivities to heat stimuli (Fang et al., 2006; Stucky and Lewin, 1999). The IB4-
negative neurons fire shorter duration action potentials and, when activated by noxious 
heat, exhibit larger inward currents than do the IB4-binding afferents (Fang et al., 2006; 
Stucky and Lewin, 1999). Such differences suggest that the two populations of afferents 
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might transmit distinct types of nociceptive information, especially given their divergent 
central projections (Basbaum et al., 2009; Merighi et al., 2008). Up to 11% of neurons 
innervating facet joints are IB4-positive (Ishikawa et al., 2005); therefore, activation of 
this population of afferents may contribute to facet-mediated pain. Based on expression 
of the neuropeptides substance P and CGRP in the facet joint (Kallakuri et al., 2004; 
Ohtori et al., 2003), peptidergic neurons have been reported to innervate that joint. Since 
both substance P and CGRP can act as neurotransmitters and are capable of sensitizing 
nociceptive circuits (Seybold et al., 2009), neurons expressing these peptides in the joint 
capsule further support the facet joint as a source of injury-induced pain. 
 Peripheral stimuli activate primary sensory neurons, whose cell bodies are located 
in the DRG, that relay the signal to the spinal cord via the dorsal nerve roots where they 
synapse with second order neurons in the dorsal horn (Figure 1.2). The dorsal horn, 
where most primary afferent neurons synapse, is arranged into laminae with distinct 
anatomical and electrophysiological characteristics (Basbaum et al., 2009; Merighi et al., 
2008). Most large diameter sensory neurons that transmit non-noxious stimuli project to 
the deep laminae (III-VI) (Merighi et al., 2008), whereas small diameter peptidergic and 
non-peptidergic afferents primarily synapse in distinct layers of the superficial laminae 
(I-II), although some thinly myelinated nociceptors also reach deeper laminae (Figure 
1.2) (Basbaum et al., 2009; Merighi et al., 2008). Specifically, the peptidergic afferents 
synapse in lamina I and the outer portion of lamina II, whereas the non-peptidergic 
neurons synapse in the inner portion of lamina II (Stucky and Lewin, 1999). Further, 
unmyelinated afferents with input from joints project to both lamina I and laminae V-VI 
(Millan, 1999). Second order neurons in the dorsal horn can be classified as low threshold 
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mechanoreceptive (LTM), nociceptive specific (NS), or wide dynamic range (WDR) 
based on their responses to cutaneous stimulation (Dostrovsky and Craig, 2013). LTM 
neurons respond to non-noxious mechanical stimuli, as opposed to NS neurons that are 
unresponsive to gentle cutaneous stimuli but are are activated by high threshold stimuli 
sufficient to induce pain. WDR neurons exhibit a graded response to innocuous and 
noxious stimuli (Coghill et al., 1993; Dostrovsky and Craig, 2013; Millan, 1999). NS 
neurons are most commonly located in the superficial laminae (I-II) of the dorsal horn, 
but in the deeper laminae (IV-VI), WDR neurons predominate (Coghill et al., 1993; 
Dostrovsky and Craig, 2013). 
From the spinal cord, nociceptive information is transmitted to many higher order 
structures in the brain such as the brainstem, periaqueductal gray matter, amygdala, 
thalamus and cortex (Figure 1.3) (Basbaum et al., 2009; Merighi et al., 2008; Steeds, 
2009). Neurons in laminae I and IV-VI of the dorsal horn that directly project to the 
thalamus constitute the spinothalamic tract (STT), which has traditionally been thought of 
as the main nociceptive pathway to the brain (Basbaum et al., 2009; Merighi et al., 2008; 
Steeds, 2009). The thalamus encodes sensory signals relating to the type, intensity, and 
topographical location of pain and relays nociceptive information to the somatosensory 
cortex (Basbaum et al., 2009; Millan, 1999; Steeds, 2009). Of the multiple distinct 
regions of the thalamus in which the STT terminates, the ventral posterolateral (VPL) 
nucleus provides intense input to the somatosensory cortex and has a role in the sensory-
discriminative aspect of pain (Millan et al., 1999). 
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1.2.3. Central Sensitization 
In many chronic pain conditions, hyperexcitability of neurons in the CNS can lead 
to normally non-noxious stimuli being perceived as painful (Latremoliere and Woolf, 
2009). This hyperexcitable state can persist even in the absence of ongoing tissue injury 
or inflammation and is thought to maintain chronic pain (Latremoliere and Woolf, 2009). 
In the spinal cord, enlarged receptive fields, increased neuronal responses to 
suprathreshold stimuli, and the conversion of neurons to the WDR phenotype all 
Figure 1.3. Schematic of the brain regions involved in nociception. A spinothalamic 
tract neuron (green) receives input from nociceptors in the dorsal horn and ascends to 
the thalamus where it synapses with thalamic neurons that project to the cortex. 
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contribute to the enhanced excitability characteristic of central sensitization (Latremoliere 
and Woolf, 2009; Millan, 1999). Indeed, injury to the facet joint induces hyperexcitability 
in spinal neurons and increases the proportion of WDRs in the spinal dorsal horn in 
association with pain (Crosby et al., 2013; Dong et al., 2013b, Quinn et al., 2010), 
supporting that central sensitization likely has a role in persistent facet-mediated pain.  
During inflammation or after a peripheral nerve injury associated with pain, 
activation of primary afferents leads to upregulation and release of a number of 
molecules that sensitize spinal neurons. The molecular mediators of hyperexcitability in 
the spinal cord are varied, including prostaglandins, neurotrophins such as BDNF, 
excitatory amino acids, and neuropeptides (Latremoliere and Woolf, 2009; Merighi et al., 
2008; Millan, 1999). Release of these transmitters upon stimulation of the primary 
afferents potentiates glutamate receptor signaling and alters sodium, potassium, and 
calcium currents in neurons, leading to an increase in membrane excitability 
(Latremoliere and Woolf, 2009; Millan, 1999). Many of the pain mediators, including 
substance P, prostaglandin E2 (PGE2), and the glutamate receptor mGluR5, that 
contribute to spinal neuronal sensitization are upregulated in the DRG or spinal cord after 
a painful facet joint injury (Crosby et al., 2014; Dong and Winkelstein, 2010; Kras et al., 
2014a; Lee and Winkelstein, 2009). Such increases occur at times when spinal neurons 
are hyperexcitable after facet injury, supporting their contribution to central sensitization 
in facet-mediated pain. 
Central sensitization cannot be explained simply as an increased expression 
and/or release of pro-nociceptive mediators in the spinal cord. Rather, structural 
reorganization can occur in the spinal cord in response to injury, with the Aβ-fibers that 
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normally transmit innocuous mechanical sensation sprouting into the superficial dorsal 
horn (Latremoliere and Woolf, 2009; Millan, 2002). Typically, only nociceptors synapse 
in the superficial dorsal horn, and sprouting of Aβ-fibers into that region can cause those 
fibers to activate nociceptive second order neurons (Millan, 2002). Such Aβ-fiber 
sprouting is one mechanism thought to underlie the perception of innocuous stimuli as 
painful in the sensitized nervous system. Additionally, peripheral inflammation can 
induce Aβ-fibers to begin expressing neuropeptides and neurotrophins that are normally 
expressed by smaller diameter nociceptors (Latremoliere and Woolf, 2009; Millan, 
2002). Activation of those Aβ-fibers then induces release of the pro-nociceptive 
neuropeptides, leading to further sensitization at the level of the spinal cord in association 
with pain (Millan, 2002). Although direct evidence of Aβ-fiber sprouting has not been 
demonstrated after facet joint injury, excitatory synapses are more abundant after painful 
facet loading (Crosby et al., 2015). Such an increase in excitatory synapses suggests that 
other forms of neuronal plasticity may also contribute to spinal neuronal hyperexcitability 
that is associated with facet pain. 
In addition to neuronal mechanisms of central sensitization, glial cells can also 
increase neuronal excitability (Latremoliere and Woolf, 2009). Normally, glial cells such 
as astrocytes and microglia function to maintain homeostasis in the CNS (Bradesi, 2010). 
Yet, under inflammatory conditions or after neural tissue injury, both microglia and 
astrocytes become activated and release pro-inflammatory cytokines, such as IL-1β and 
TNFα, that can enhance neuronal excitability (Bradesi, 2010; Latremoliere and Woolf, 
2009). Painful facet joint injury consistently activates astrocytes in the spinal cord by day 
seven after injury, but microglial activation varies with age (Crosby et al., 2014; Dong et 
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al., 2013a; Weisshaar et al., 2010; Winkelstein and Santos, 2008). Adolescent rats exhibit 
increased microglial activation seven days after injury, but microglia are not activated at 
that time in association with facet pain in adult rats (Weisshaar et al., 2010; Winkelstein 
and Santos, 2008). Further, astrocytes have a significant role in the clearance of 
glutamate from the synaptic cleft, but facet joint injury downregulates astrocytic 
glutamate transporters while upregulating glutamate receptor expression and activation 
(Crosby et al., 2014; Dong and Winkelstein, 2010). This combination of diminished 
glutamate clearance together with increased glutamate receptor expression could directly 
increase the excitability of spinal neurons and contribute to the behavioral sensitivity that 
develops and persists after a joint injury. As such, the glial response to facet joint injury, 
in particular the activation of spinal astrocytes, has important implications for the 
maintenance of central sensitization in facet pain through the regulation of extracellular 
glutamate and the potential release of inflammatory mediators that collectively increase 
the excitability of neurons in the CNS. 
Such adaptive responses of resident cells in the CNS are not restricted to the 
spinal cord but can also occur in supraspinal centers such as the thalamus (Iwata et al., 
2011; Merighi et al., 2008; Millan, 1999; Slack et al., 2005). In fact, neuronal firing 
patterns are altered in the thalamus in neuropathic and inflammatory pain (Huh et al., 
2012; Iwata et al., 2011; Millan, 1999; Syré et al., 2014). As a result, efforts to treat 
chronic pain may benefit from targeting supraspinal sites in order to achieve pain relief. 
Further, descending pathways also alternately contribute to the inhibition or facilitation of 
spinal neuronal hyperexcitability (Millan, 1999; Millan, 2002). Inflammatory joint pain is 
maintained in part due to descending facilitation via the rostroventral medulla (Carr et al., 
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2014). Yet, it is not known if supraspinal mechanisms contribute to facet joint-mediated 
pain. Although increased excitability of neurons in the CNS is a major component of 
persistent pain, there is no single mechanism that produces neuronal hyperexcitability 
(Latremoliere and Woolf, 2009). However, the neurotrophins are one family of molecules 
that is expressed throughout the nervous system, and they are able to sensitize both 
primary afferents and neurons in the CNS (Pezet and McMahon, 2006). Consequently, 
increased neurotrophin expression and signaling may initiate and/or sustain facet joint 
injury-induced neuronal hyperexcitability and the associated pain. 
 
1.2.4. Neurotrophins & Pain 
 In general, inflammation is a common local response in injured tissues that helps 
initiate tissue repair (Watkins et al., 1995). However, inflammatory cascades also have 
the potential to contribute to persistent pain via the release of various chemicals, among 
which nerve growth factor (NGF) has a major role (Kras et al., 2014a; McMahon, 1996; 
Woolf et al., 1997). NGF released during inflammation sensitizes nociceptors and 
increases the excitability of sensory neurons (Dawes et al., 2013; Woolf et al., 1997). 
NGF is a member of the neurotrophin family of growth factors that has a major role in 
the growth, development, and survival of sensory neurons through activation of its high 
affinity receptor, tyrosine receptor kinase A (trkA) (Pezet and McMahon, 2006). In 
adulthood, NGF is also capable of sensitizing sensory neurons and contributing to pain 
through post-translational regulation of ion channels as well as increased expression of 
many pain-associated genes, such as substance P, CGRP, and BDNF (Dawes et al., 2013; 
Pezet and McMahon, 2006). NGF levels are increased in injured and inflamed tissues 
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through release from a number of different types of immune cells, such as macrophages 
(McMahon, 1996). Increased levels of NGF have profound effects on responses to 
thermal stimuli, via increased expression and phosphorylation of the heat sensitive 
transient receptor potential vanilloid 1 (TRPV1), and mechanical sensitivity (Figure 1.4) 
(Amaya et al., 2004; Dawes et al., 2013; Longo et al., 2013; Sah et al., 2003; Woolf, 
1996). Both intradermal and intramuscular injections of NGF in human volunteers elicit 
decreases in the heat pain threshold as well as increased sensitivity to mechanical stimuli 
(Dyck et al., 1997; Gerber et al., 2011; Rukwied et al., 2010). Similarly, NGF injection 
induces both thermal and mechanical pain in the rat (Amann et al., 1995; Malik-Hall et 
al., 2005; Woolf, 1996). Since NGF levels are increased in inflamed tissue, NGF is 
considered to be a major contributor to inflammatory pain (Amaya et al., 2004; Ma and 
Woolf, 1997; McMahon, 1996). Recent studies identify upregulation of inflammatory 
cytokines and prostaglandin E2 in association with loading-induced facet pain in the rat 
(Kras et al., 2014a; Lee et al., 2008). Moreover, intra-articular injection of the non-
steroidal anti-inflammatory drug ketorolac one day after a painful facet joint injury 
alleviates behavioral hypersensitivity (Dong et al., 2013a). Those findings support a role 
for joint inflammation in facet-mediated pain. Because inflammation is necessary for 
persistent pain following facet joint injury, it is likely that NGF contributes to the 
development of facet pain. 
NGF and its receptor have been identified in arthritic joints and degenerative facet 
joints (Barthel et al., 2009; Surace et al., 2009). Further, systemic anti-NGF therapy has 
shown success in alleviating osteoarthritis pain in clinical trials (Brown et al., 2012; Lane 
et al., 2010), demonstrating a role for NGF in that form of joint pain. Although animal 
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studies implicate NGF as contributing to arthritis pain (Longo et al., 2013; McNamee et 
al., 2010; Orita et al., 2011), very little is known about the potential relationship between 
NGF and loading-induced facet joint pain; in addition, the mechanism(s) through which 
NGF contributes to joint pain is poorly understood. 
 
 In parallel with the overall behavioral effects that are induced by NGF exposure, 
NGF acts on peptidergic afferents to increase expression of the neuropeptides CGRP and 
substance P, as well as the neurotrophin BDNF, in the rat (Figure 1.4) (McMahon, 1996; 
Pezet and McMahon, 2006; Woolf, 1996). Because these proteins are transported to, and 
released in, the spinal cord where they contribute to the activation and sensitization of 
second order sensory neurons, NGF has a role in central sensitization despite its not 
reaching the spinal cord itself (Dawes et al., 2013; McMahon, 1996). In fact, peripheral 
Figure 1.4. NGF activation of primary afferent neurons innervating peripheral targets. 
NGF binds to trkA receptors expressed on the peripheral terminals of peptidergic Aδ- 
and C-fiber sensory neurons resulting in increased expression of CGRP, substance P 
(SP) and BDNF. The C-fibers enter the spinal cord and synapse in the superficial 
dorsal horn; the Aδ-fibers synapse in both the superficial laminae and deeper laminae. 
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injection of NGF is associated with increased excitability of spinal neurons (Hoheisel et 
al., 2007). Despite increased expression of neuropeptides and hyperexcitability of spinal 
neurons after painful facet joint injury (Crosby et al., 2013; Lee and Winkelstein, 2009; 
Quinn et al., 2010), no study has determined if NGF contributes to that spinal 
hyperexcitability or altered protein expression in association with facet-mediated pain. 
 BDNF expression is regulated by NGF and is a central mediator of pain in nerve 
injury and inflammation induced chronic pain (Li et al., 2006; Mannion et al., 1999; 
Merighi et al., 2008; Pezet and McMahon, 2006). Peptidergic neurons produce BDNF 
and transport it to the superficial dorsal horn in the spinal cord where its release activates 
tyrosine receptor kinase B (trkB) receptors (Merighi et al., 2008; Pezet and McMahon, 
2006). BDNF-trkB signaling contributes to central sensitization by facilitating spinal 
neurotransmission through a combination of increased neuropeptide release and 
potentiation of ion channels such as glutamate receptors (Merighi et al., 2008; Pezet and 
McMahon, 2006). BDNF released in the dorsal horn activates pre-synaptic trkB receptors 
and induces the release of substance P and CGRP into the synaptic cleft (Merighi et al., 
2008). Those neuropeptides, in turn, facilitate neurotransmission via their downstream 
effects on glutamate receptor activation (Seybold, 2009). Increased spinal BDNF 
expression and release also activates glutamate receptors in association with pain in both 
neuropathic and inflammatory injury models (Geng et al., 2010; Matayoshi et al., 2005; 
Slack et al., 2004). Moreover, the increased expression of the glutamate receptor 
mGluR5, as well as phosphorylation of the NR1 subunit of NMDA glutamate receptors, 
in the spinal cord that is induced by painful joint injury demonstrates altered glutamate 
signaling in facet-mediated pain (Crosby et al., 2014; Dong and Winkelstein, 2010). 
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Because spinal BDNF induces phosphorylation of NR1 (Slack et al., 2004), BDNF might 
affect spinal glutamate signaling associated with facet-mediated pain. Pharmacological 
inhibition of BDNF-trkB signaling alleviates behavioral sensitivity in many experimental 
neural tissue injury models (Coull et al., 2005; Matayoshi et al., 2005; Zhang et al., 
2011), further demonstrating a role for spinal BDNF in persistent pain. Although 
increased BDNF expression has been identified in the synovial tissue of arthritic joints 
(Grimsholm et al., 2008), the contribution of BDNF to joint pain, particularly from 
mechanical injury, has not been investigated. 
 In addition to sensitizing spinal neurons in association with persistent pain, BDNF 
can also activate supraspinal targets, including those in the thalamus (Merighi et al., 
2008; Millan, 1999). A majority of the STT neurons projecting from the superficial and 
deep laminae of the dorsal horn are sensitive to BDNF, and increased activity of thalamic 
neurons is associated with elevated thalamic BDNF expression (Millan, 1999; Slack et 
al., 2005), which supports the potential for thalamic plasticity in painful conditions via 
BDNF signaling. Moreover, joint inflammation is associated with thalamic plasticity; 
arthritic rats exhibit altered gene expression in the thalamus as well as increased 
excitability of thalamic neurons with joint input (Gautron and Guilbaud, 1982; Millan, 
1999; Neto et al., 2008). Despite evidence of joint inflammation and increased 
excitability of neurons in the dorsal horn in response to painful facet joint injury (Crosby 
et al., 2013; Dong et al., 2013a; Quinn et al., 2010), thalamic plasticity has not been 
investigated in facet-mediated pain. 
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1.2.5. General Neck Injury Kinematics & Symptoms 
 The kinematics of the cervical spine during rear-end motor vehicle impacts have 
been extensively studied using both cadaveric simulations and studies of human 
volunteers (Berglund et al., 2000; Bogduk and Yoganandan, 2001; Cusick et al., 2001; 
Panjabi et al., 1998; Pearson et al., 2004; Yoganandan et al., 2002). Beginning 
approximately 50ms after the rear-end impact of the car, the cervical spine takes on an S-
shaped curvature as the lower cervical spine extends while the upper segments flex 
(Bogduk and Yoganandan, 2001; Pearson et al., 2004). By 120ms after the impact, the 
full cervical spine extends to form a C-shape (Bogduk and Yoganandan, 2001). During 
these spinal motions, the lower cervical facet joints undergo compressive, shear, and 
tensile motions, which can stretch the capsular ligament surrounding the joint space 
(Cusick et al., 2001; Panjabi et al., 1998; Pearson et al., 2004). Between 50 and 150ms 
after the impact, the capsular ligaments of the lower cervical joints sustain the peak 
ligament strain, with the greatest strains being reported in the C6/C7 facet joints (Panjabi 
et al., 1998; Pearson et al., 2004). This excessive ligament stretch, which is beyond the 
physiologic range, has been proposed as an injury mechanism underlying neck pain 
(Pearson et al., 2004; Siegmund et al., 2001; Yoganandan et al., 2002). Furthermore, the 
peak capsular ligament strains recorded during human cadaveric whiplash simulations 
reach 39.9±26.3% in the C6/C7 facet joint (Pearson et al., 2004) and are greater than the 
average capsule strain reported to be sufficient to induce persistent pain symptoms in rat 
models of both quasistatic (27.7±11.9% strain) and dynamic (24.0±10.0% strain) facet 
capsular ligament stretch (Dong et al., 2008; Dong and Winkelstein, 2010; Lee et al., 
2004). As such, the nearly 40% capsular ligament strain that is induced during whiplash 
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simulations supports the facet joint as being susceptible to painful loading during rear-
end motor vehicle impacts and the facet capsule as being a potential source of chronic 
pain when ligament strains exceed physiological limits. 
 Loading-induced neck injuries are associated with hypersensitivity extending 
beyond the region of the neck. In addition to the neck, many whiplash patients report pain 
extending into the shoulders and arms (Chien et al., 2009; Ferrari et al., 2005; Moog et 
al., 2002). Further, whiplash is associated with an increased sensitivity to heat in the 
neck, shoulder, and arm; pressure pain thresholds are decreased in these same regions as 
well as in the hand (Fernandez-Perez et al., 2012; Scott et al., 2005; Sterling et al., 2003). 
This widespread sensitivity in regions outside the primary site of injury supports central 
sensitization as being established in whiplash patients. For many patients, this increased 
sensitivity only persists for an acute (less than six months) time period before resolving 
(Borchgrevink et al., 1998; Sterling et al., 2003). However, in 14-42% of the patients, 
hypersensitivity can become chronic, persisting for longer than six months (Barnsley et 
al., 1994; Carroll et al, 2009; Sterling et al., 2003). Although clinical studies of whiplash 
patients document symptoms of neck injury, such studies do not relate those pain 
symptoms with the cellular responses to loading-induced joint injury, necessitating the 
use of animal models to better understand the mechanisms underlying chronic neck pain. 
Since the neurons that innervate the neck at the lower cervical levels are located 
in the same dermatomes (C6-C8) that innervate the shoulders, arms, and hands (Lee et 
al., 2008), it is not surprising that injury to the neck may result in pain in those remote 
sites. In the rat, the C6-C8 dermatomes similarly innervate the shoulder, forelimb, and 
forepaw, suggesting neck injury in the rat may also induce pain extending into the upper 
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extremities. A facet joint injury model that applies tensile loading to the C6/C7 facet joint 
in the rat induces hypersensitivity to mechanical stimulation in both the shoulders and the 
forepaws (Dong and Winkelstein, 2010; Lee et al., 2008; Lee and Winkelstein, 2009). 
This facet injury-induced sensitization of tissues is similar to that reported in humans 
(Fernandez-Perez et al., 2012; Scott et al., 2005); yet, it is unknown if that rat model also 
induces an immediate development and persistence of thermal sensitivity. Recent studies 
in which the non-steroidal anti-inflammatory drug (NSAID) ketorolac was injected into 
the facet joint after its injury demonstrate that joint inflammation may be necessary for 
the maintenance, but not initiation, of loading-induced facet pain (Dong et al., 2011; 
Dong et al., 2013a). In those studies, the intra-articular anti-inflammatory treatment 
alleviates facet-mediated mechanical hypersensitivity when given one day after joint 
injury but is ineffective when given at the time of injury (Dong et al., 2011; Dong et al., 
2013a). Joint inflammation and arthritis in animal models are associated with both 
mechanical and thermal hypersensitivity (Longo et al., 2013; Luo et al., 2014; Tachihara 
et al., 2007), suggesting that the joint inflammation associated with painful facet joint 
loading may also induce thermal sensitivity in addition to mechanical hyperalgesia. Yet, 
no study has investigated if facet joint injury is sufficient to induce thermal sensitivity. 
 
1.2.6. Clinical Treatment of Joint Pain in the Spine 
Clinically, several treatments are used currently to relieve facet joint-mediated 
pain. As described in Section 1.2.2, the medial branches of the dorsal rami innervate the 
cervical facet joints. Anesthetic blocks of those nerve branches using the sodium channel 
blocker bupivacaine alleviate facet-mediated pain and have been used to identify the facet 
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joint as the source of neck pain (Lord et al., 1996; van Eerd et al., 2010). However, such 
nerve blocks have also been utilized to treat facet pain, with one study reporting pain 
relief lasting fourteen to sixteen weeks in some patients suffering from chronic (greater 
than six months) facet-mediated neck pain (Manchikanti et al., 2008). Yet, anesthetic 
nerve blocks do not always provide such prolonged pain relief; a similar study with 
bupivacaine-induced medial branch nerve blocks reports pain relief lasting on the order 
of several hours in most patients, with only a small group experiencing sustained relief 
for several days (Barnsley et al., 1993). Of note, those two studies use different patient 
populations. All patients in the study by Barnsley exhibited facet-mediated pain after a 
motor vehicle collision (Barnsley et al., 1993); however, only 32% of the neck pain 
patients in the study by Manchikanti had experienced a motor vehicle impact prior to the 
initiation of pain (Manchikanti et al., 2008). The difference in the patient populations 
between those two studies might contribute to the differing effectiveness of anesthetic 
nerve blocks in alleviating facet pain, despite the use of similar injection techniques and 
anesthetic doses. Moreover, injection of bupivacaine into the intra-articular space of 
symptomatic facet joints, as opposed to blocking the nerves innervating those joints, also 
provides only temporary pain relief; fewer than 50% of patients report pain relief beyond 
one week (Barnsley et al., 1994). Ablation of the nerves innervating the painful facet 
joint via radiofrequency neurotomy is effective in alleviating facet pain in approximately 
60% of patients, with pain relief lasting at least three months (Lord et al., 1996; Smith et 
al., 2014). In fact, Lord reports average pain relief lasting 263 days using that technique 
(Lord et al., 1996); yet, when the pain returns, a second radiofrequency neurotomy is not 
always effective (Lord et al., 1996). Although the effectiveness of anesthetic nerve blocks 
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and radiofrequency neurotomy in facet joint pain relief identifies the facet joint as the 
source of pain and supports ongoing input from the joint as driving persistent pain, such 
techniques only provide temporary pain relief of variable duration. 
Anti-NGF is a targeted treatment for joint pain that is currently undergoing 
clinical trials. Indeed, a single dose of intravenous anti-NGF alleviates hip and knee joint 
pain in osteoarthritis as well as non-radicular low back pain for at least eight weeks (Katz 
et al., 2011; Lane et al., 2010; Schnitzer et al., 2014). The anti-NGF therapy is only 
applied every eight weeks; yet, it alleviates joint pain to a greater extent than does daily 
oral NSAID treatment (Schnitzer et al., 2014). Although current systemic anti-NGF 
therapies show promise in alleviating joint pain from osteoarthritis and chronic low back 
pain, those treatments are associated with several adverse events, including headache, 
hyperesthesia, paresthesia, and even joint degeneration (Brown et al., 2012; Katz et al., 
2011; Lane et al., 2010). The occurrence of rapidly progressing osteoarthritis is more 
frequent with systemic anti-NGF therapy than it is with NSAID treatment (Schnitzer et 
al., 2014), and accelerated osteoarthritis progression exhibits a trend of increased 
prevalence with higher doses of anti-NGF (Schnitzer et al., 2014). As such, continued 
efforts are underway to identify safe and effective doses for anti-NGF-mediated pain 
relief. In addition, although anti-NGF therapy provides pain relief for clinical 
osteoarthritis patients for at least sixteen weeks when doses are applied every eight weeks 
(Lane et al., 2010; Schnitzer et al., 2014), the long-term consequences of continued anti-
NGF treatment beyond sixteen weeks are not known.  
Because systemic anti-NGF alleviates low back pain, and the facet joint is the 
source of pain in 45% of patients with low back pain (Manchikanti et al., 1999), anti-
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NGF therapy may also alleviate facet-mediated pain. Further, a possible role for intra-
articular NGF in joint pain is suggested by the elevated levels of NGF that are identified 
in painful joints, both clinically and in pain models of inflamed or arthritic joints (Barthel 
et al., 2009; Orita et al., 2011; Saito et al., 2000; Surace et al., 2009). Yet, it is currently 
unknown if NGF contributes to facet joint pain. Because current treatments for facet-
mediated pain have proven to be only transiently effective (Barnsley, 2005; Manchikanti 
et al., 2008; van Eerd et al., 2014), defining the role of intra-articular NGF in the 
development and maintenance of facet joint pain is necessary to identify if anti-NGF is an 
effective alternative intervention. Moreover, understanding the mechanism through which 
NGF contributes to joint pain will also determine whether ongoing responses within the 
joint maintain pain or if there is a transition to central pain maintenance, which dictates 
whether localized joint treatment or systemic intervention is needed.  
Despite biomechanical and clinical evidence that the cervical facet joint is a 
common source of neck pain, the molecular mechanisms involved in the initiation and 
maintenance of facet joint-mediate pain are incompletely defined. Evidence suggests that 
the neurotrophins NGF and BDNF likely contribute to injury-induced facet pain, yet no 
studies have identified their contributions, if any, to behavioral hypersensitivity and 
central sensitization that develops after non-physiological facet joint loading (Crosby et 
al., 2013; Dong et al., 2013b; Quinn et al., 2010). The overall hypothesis and aims of this 
thesis will address many of these unknown aspects of facet pain as detailed in Chapter 2. 
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Chapter 2 
Rationale, Context, and Hypotheses 
 
 
2.1. Rationale & Context 
 Annually, neck pain affects nearly half of the adult population in the United States 
(Hogg-Johnson et al., 2008; van Eerd et al., 2010). Whiplash injuries are a frequent cause 
of persistent neck pain (Zuby and Lund, 2010). As a result of its rich sensory fiber 
innervation and susceptibility to non-physiological mechanical loading, the cervical facet 
joint is the most common source of pain in the neck (Barnsley et al., 1995; Bogduk and 
Aprill, 1993; Manchikanti et al., 2002; Panjabi et al., 1998; Pearson et al., 2004; van Eerd 
et al., 2010). Although cadaveric simulations and clinical studies, as well as more recent 
studies utilizing animal models, support the facet joints in the lower cervical spine as a 
source of pain (Bogduk and Aprill, 1993; Dong et al., 2010; Lee et al., 2004; Manchikanti 
et al., 2002; Panjabi et al., 1998; Pearson et al., 2004), the cellular mechanisms by which 
persistent pain is produced from facet injury are still not well-defined. Previous work in 
our laboratory has demonstrated that tensile loading of the facet joint capsule, as occurs 
during traumatic neck injury, is associated with immediate and persistent mechanical 
hypersensitivity (Crosby et al., 2013; Dong et al., 2013a, Kras et al., 2013c). In addition 
to behavioral hypersensitivity, facet joint injury also induces local inflammation in the 
joint, altered gene expression in the primary afferents whose dermatomes include the 
neck, shoulder, and upper extremity, and plasticity in spinal neurons (Crosby et al., 2013; 
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Dong et al., 2008; Dong et al., 2013a; Kras et al., 2013a; Kras et al., 2014a; Lee and 
Winkelstein, 2009; Quinn et al., 2010). However, despite the behavioral hypersensitivity 
and neuronal sensitization that are induced by facet joint injury, the role of neurotrophins, 
which are key mediators of neuronal excitability and persistent pain (Pezet and 
McMahon, 2006), in the development and maintenance of injury-induced facet pain is 
still undefined. Yet, neurotrophins are upregulated and released at the peripheral sites of 
tissue injury or inflammation as well as in the central nervous system (CNS) (McMahon, 
1996; Merighi et al., 2008; Pezet and McMahon, 2006). Because neurotrophin signaling 
in peripheral tissues and the CNS is associated with pain after injury or inflammation 
(Pezet and McMahon, 2006), neurotrophins may be molecular mediators through which 
local responses in the facet joint after its injury induce central sensitization and persistent 
pain. Therefore, the overall aim of this thesis is to define the peripheral and central 
contributions of two neurotrophins, nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF), to facet loading-induced pain. 
 Although the afferents innervating the facet joint are believed to be crucial to the 
maintenance of facet-mediated neck pain clinically (Barnsley et al., 1994; Bodguk, 2011; 
Rambaransingh et al., 2010), the phenotypes of the afferents innervating the C6/C7 facet 
joint and those sensory neurons that are activated during painful facet joint loading and 
may initiate pain are not fully defined. A study of the C5/C6 facet joint in the rat 
identified that although C5/C6 joint afferents originate from the DRGs at the C3-T3 
spinal levels, the C5 level contains at least twice as many joint afferents as any of the 
other levels (Ohtori et al., 2002). Defining the innervation pattern of the C6/C7 facet joint 
will similarly identify the spinal level(s) supplying the most afferents to that joint and, as 
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such, are the most likely to exhibit cellular modifications after its injury. In addition, 
identifying the joint afferents as either peptidergic or non-peptidergic will help identify 
potential signaling pathways that contribute to joint-mediated pain since those 
populations of afferents respond to distinct signals and initiate different cellular responses 
from one another (Joseph and Levine, 2010; Merighi et al., 2008; Seybold, 2009). 
Accordingly, in Aim 1, the innervation pattern of the C6/C7 facet joint was defined to 
determine which spinal levels contain afferents innervating that joint in the rat (Aim 1a). 
Further, peptidergic neurons are typically sensitive to NGF signaling and also synthesize 
BDNF (Pezet and McMahon, 2006). If that class of neurons does indeed innervate the 
facet joint, the role for neurotrophins in facet-mediated pain would be further supported. 
As such, the relative abundance of peptidergic afferents with projections to the C6/C7 
joint was also defined (Aim 1c). NGF and BDNF levels were quantified in the dorsal root 
ganglion (DRG) (Aim 1b) to determine the extent to which those neurotrophins are 
modulated by painful facet joint distraction. Collectively, those studies identify the spinal 
levels most relevant to facet joint injury and establish modifications in neurotrophin 
signaling as associated with facet joint loading-induced pain. 
 Inflammation is associated with increases in many pain mediators like NGF 
(McMahon, 1996; Watkins et al., 1995; Woolf et al., 1997), and NGF contributes to 
arthritic joint pain (Brown et al., 2012; Lane et al., 2010; Longo et al., 2013; McNamee et 
al., 2010; Orita et al., 2011). Yet, it is not known if intra-articular NGF has a role in 
mechanical injury-induced joint pain. Given that painful facet joint injury is associated 
with local inflammation in the joint and spinal cord (Dong et al., 2013a; Kras et al., 
2014a; Lee et al., 2008), studies in this thesis specifically investigate if intra-articular 
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NGF is sufficient to induce facet-mediated pain (Aim 2a) and also identify signaling in 
the different neuronal populations (peptidergic, non-peptidergic) involved in initiating 
behavioral sensitivity in NGF-induced pain (Aim 2b). Further, the role of intra-articular 
NGF in the initiation of loading-induced facet pain and subsequent spinal plasticity is 
determined by blocking NGF signaling in the joint using an anti-NGF antibody given 
intra-articularly (Aim 2c). Although NGF itself is not transported to the spinal cord 
(Dawes et al., 2013), it does regulate expression of the neurotrophin BDNF, which is 
transported to, and released in, the dorsal horn and has a role in the sensitization of 
sensory circuits (Dawes et al., 2013; McMahon, 1996; Merighi et al., 2008; Pezet and 
McMahon, 2006). As such, spinal BDNF mRNA and protein are quantified after painful 
facet joint injury at early (day one) and late (day seven) time points (Aim 3a), and the 
cellular sources of spinal BDNF are identified via double immunolabeling (Aim 3b). The 
functional role of spinal BDNF in facet-mediated pain is determined by sequestering 
spinal BDNF to disrupt its binding to the trkB receptor after injury-induced pain is 
established (Aim 3c). 
 
2.2. Overall Hypothesis & Specific Aims 
 The goal of this thesis is to identify a cellular mechanism local to the facet joint 
that underlies injury-induced facet pain by defining the roles of the neurotrophins NGF 
and BDNF in the initiation and maintenance of facet-mediated pain after a mechanical 
joint injury. The central hypothesis of this work is that NGF acting on the primary 
afferent neurons that innervate the facet joint is a key initiator of facet joint-mediated 
pain, inducing upregulation of neurotrophins in peripheral nociceptors and increasing 
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spinal BDNF and neuronal excitability. Further, interruption of NGF signaling in the joint 
immediately after injury prevents the increase in spinal neuronal excitability while also 
preventing pain. This thesis defines the role of intra-articular NGF in the induction and 
maintenance of facet joint-mediated pain, as well as identifies the contribution of BDNF 
signaling in the peripheral and central nervous systems to the maintenance of pain after 
mechanical facet joint injury through three aims. 
 
Hypothesis 1. Multiple cervical spinal levels supply sensory nerve fibers to the C6/C7 
facet joint, some of which are peptidergic, and painful facet joint loading shifts the 
phenotype of peptidergic joint afferents from primarily small diameter neurons to larger 
diameter neurons. Further, mechanical joint injury increases the levels of the 
neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) 
in the primary afferents having cell bodies in the dorsal root ganglion (DRG). 
 
Aim 1. Characterize the innervation pattern of the C6/C7 facet joint following painful 
whiplash-like tensile loading of the C6/C7 facet capsular ligament in the rat. Define the 
neurotrophin response to joint injury by quantifying the levels of NGF and BDNF in the 
DRG at an early (day one) and a later (day seven) time point after joint injury. 
Aim 1a. Identify the number and distribution of afferents innervating the facet using 
fluorescent retrograde tracing administered in the joint in separate groups of 
rats undergoing either a painful facet joint distraction or a sham procedure. 
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Aim 1b. Determine which neurotrophins undergo altered expression in the dorsal root 
ganglion after painful facet joint injury by quantifying mRNA and protein of 
NGF and BDNF. 
Aim 1c. Define the phenotypes of the neurons that innervate the C6/C7 facet joint 
identified in Aim 1a, using immunohistochemical analysis of CGRP. 
 
Hypothesis 2. Intra-articular NGF is sufficient to induce facet joint-mediated behavioral 
hypersensitivity and spinal neuronal hyperexcitability via activation of peptidergic, but 
not non-peptidergic, joint afferents. Further, intra-articular NGF contributes to the 
initiation of loading-induced facet pain and the subsequent hyperexcitability of spinal 
neurons. Immunologic blockade of intra-articular NGF prevents the development of 
facet-mediated pain and neuronal hyperexcitability. 
 
Aim 2. Identify the role of intra-articular NGF in facet joint-mediated pain. 
Aim 2a. Apply intra-articular NGF in naïve uninjured rats to define its effect on 
behavioral hypersensitivity (mechanical hyperalgesia), spinal neuronal 
hyperexcitability, and the expression of NGF and BDNF in the DRG at day 
one and day seven after NGF application. 
Aim 2b. Inject intra-articular substance P-saporin, IB4-saporin, or blank-conjugated 
(control) saporin into the C6/C7 facet joints of uninjured rats to ablate 
peptidergic (substance P) or non-peptidergic (IB4) joint afferents, in separate 
groups. Two weeks after saporin injection, apply intra-articular NGF to define 
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which subpopulation of afferents is necessary for NGF-induced mechanical 
and thermal hyperalgesia and spinal neuronal hyperexcitability. 
Aim 2c. Immediately after a painful facet joint injury, block NGF signaling in the facet 
joint by intra-articular application of an anti-NGF antibody to define the effect 
of blocking intra-articular NGF on behavioral hypersensitivity and spinal 
neuronal excitability at days one and seven. In separate rats, inject intra-
articular anti-NGF one day after a facet joint injury to determine if intra-
articular NGF is involved in maintaining injury-induced facet pain and spinal 
neuronal hyperexcitability that is typically observed at day seven. 
 
Hypothesis 3. Painful facet joint distraction induces an upregulation of brain-derived 
neurotrophic factor (BDNF) in neurons in the spinal cord that contributes to the 
maintenance, but not the initiation, of loading-induced facet pain. 
 
Aim 3. Define the role of spinal BDNF in facet joint injury in association with facet-
mediated pain. 
Aim 3a. Measure spinal BDNF levels after a painful C6/C7 facet joint injury by 
quantifying protein expression using immunohistochemical labeling and 
mRNA levels using RT-PCR at an early (day one) and a later (day seven) time 
point. 
Aim 3b. Identify the cellular sources of spinal BDNF in facet-mediated pain using 
double immunofluorescent labeling to detect BDNF and cellular markers of 
spinal microglia, astrocytes, and neurons at days one and seven after injury. 
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Aim 3c. Inhibit spinal BDNF to define its temporal contribution to joint-mediated pain 
by applying a BDNF sequestering molecule (trkB-Fc) in the intrathecal space 
via lumbar puncture five days after a painful facet joint injury, and assess 
forepaw mechanical hyperalgesia and activation of extracellular signal-
regulated kinase (ERK), a cellular marker associated with BDNF-trkB 
signaling, in the spinal cord using Western blot. 
 
 Although not explicitly included in any of the specific aims characterizing the 
roles of neurotrophins in facet-mediated pain, additional studies are included in this thesis 
that expand the understanding of several responses of this joint pain model. Behavioral 
paradigms quantifying mechanical and thermal hyperalgesia associated with facet joint 
injury were implemented. In addition, studies of injury-induced central sensitization 
quantify evoked firing in the thalamus in order to identify modifications to neuronal 
excitability after painful facet injury that may contribute to chronic pain. NGF-induced 
pain is associated with both mechanical and thermal hyperlagesia in rats (Hoheisel et al., 
2007; Lewin et al., 1994; McMahon, 1996) and in humans (Dyck et al., 1997). 
Accordingly, Aim 2b quantifies behavioral responses to both mechanical and thermal 
stimulus modalities after intra-articular NGF injection in the facet joint. Clinically, 
mechanical facet joint injury is also associated with both mechanical and thermal 
hyperalgesia (Scott et al., 2005; Smith et al., 2014; Sterling et al., 2003; Sterling and 
Kenardy, 2008); yet, despite a hypothesized role for NGF in facet-mediated pain, it is 
unknown if our rat model of facet joint injury sufficient to induce mechanical 
hyperalgesia also induces thermal hyperalgesia. As such, studies in Chapter 3 expand our 
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behavioral testing paradigms after facet joint injury in the rat to quantify both mechanical 
and thermal hyperalgesia in order to further characterize the full array of clinically-
relevant symptoms.  
Although the specific aims of this thesis investigate the neurotrophin responses to 
facet injury in the facet joint and its primary afferents at the injured spinal level, as well 
as in the spinal cord, supraspinal centers such as the thalamus also contribute to chronic 
pain (Merighi et al., 2008; Millan, 1999). Because activation of some higher order 
structures, such as the thalamus, are associated with joint pain and because BDNF is 
capable of activating thalamic neurons (Gautron and Guilbaud, 1982; Neto et al., 2008; 
Slack et al., 2005), neuronal sensitization in the thalamus is also investigated in 
preliminary work included in Chapter 7 of this thesis in order to establish whether or not 
supraspinal centers are also modified by painful facet injury.    
 In addition to Chapters 3 and 7 described above, this thesis is organized into 
chapters arranged by relevant studies that summarize experiments addressing the major 
aims and associated hypotheses as presented in this chapter. The chapters are presented 
with studies investigating the molecular and neuronal responses to facet joint injury 
progressing anatomically from the peripheral tissues to the central nervous system. 
Detailed background information is provided at the beginning of each chapter as 
appropriate. Studies in Chapter 4 characterize the distribution pattern of neurons 
innervating the C6/C7 facet joint (Aim 1a) and identify the phenotypes of those joint 
afferents (Aim 1c). In Chapter 5, the role of intra-articular NGF in the initiation and 
maintenance of facet-mediated pain and spinal neuronal hyperexcitability is defined 
(Aims 2a and 2c), and the subpopulations of neurons necessary for NGF-induced 
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mechanical and thermal hyperalgesia are assessed using selective neurotoxins (saporin 
conjugates) (Aim 2b). Studies related to Aims 1b, 3a, and 3b are presented in Chapter 6, 
which characterizes the expression of BDNF following painful facet joint loading and 
establishes a role for spinal BDNF in the maintenance of facet pain. Finally, in Chapter 8, 
the overall collection of studies is integrated into the broader context of mechanisms of 
joint pain, specifically facet-mediated pain, and a discussion of the limitations of this 
work is presented, as well as directions for future studies. 
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Chapter 3 
Mechanical and Thermal Sensitivity in the Rat are 
Mediated by Facet Capsular Ligament Loading 
 
 
3.1. Overview 
 Chronic neck pain is a frequent consequence of injury to the cervical spine 
(Berglund et al., 2000; Eck et al., 2001; Freeman et al., 1999), with the facet joints being 
identified as the most frequent source of neck pain following whiplash, in particular 
(Lord et al., 1996). Indeed, there is biomechanical evidence suggesting that tensile 
loading across the facet joint capsular ligament, as occurs during whiplash-like loading of 
the neck, may be sufficient to induce pain (Barnsley et al., 1995; Bogduk and Aprill, 
1993; Chen et al., 2006; Lu et al., 2005; Panjabi et al., 1998; Pearson et al., 2004; 
Sundararajan et al., 2004). Whiplash is associated with hypersensitivity to a variety of 
sensory modalities, such as pressure, vibration, heat, and cold stimuli (Elliott et al., 2009; 
Scott et al., 2005; Sterling and Kenardy, 2008). In addition, hypersensitivity is also 
reported in body regions that are remote from the neck, including the shoulder, arm, and 
leg (Chien et al., 2009; Curatolo et al., 2001; Fernandez-Perez et al., 2012; Greening et 
al., 2005; Sterling and Kenardy, 2008; Sterling et al., 2002); these symptoms have been 
reported to differentiate whiplash-associated pain from other types of neck pain (Scott et 
al., 2005). In order to better define the mechanisms that contribute to whiplash-like facet 
loading-induced pain, animal models that accurately reflect the symptoms of whiplash 
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patients are needed. Our lab has previously developed a model of loading-induced facet 
joint injury in the rat and characterized sensitivity to mechanical stimulation, as well as 
functional deficits after injury using that model (Dong and Winkelstein, 2010; Dunk et 
al., 2011; Kras et al., 2013a; Lee et al., 2004). Despite the prevalence of thermal 
hypersensitivity reported for whiplash pain patients (Scott et al., 2005; Smith et al., 2014; 
Sterling et al., 2003; Sterling and Kenardy, 2008), the thermal responses following 
mechanical facet joint injury remain undefined. 
 The studies presented in this chapter summarize the behavioral responses to 
mechanical and thermal stimuli following dynamic mechanical loading-induced facet 
joint injury known to produce mechanical sensitivity. Specifically, this work tests the 
hypothesis that non-physiologic whiplash-like tensile loading of the cervical facet joint 
induces both mechanical and thermal sensitivity in the rat. As such, a previously 
validated model of painful facet joint loading was used, and the withdrawal threshold to 
mechanical stimulation and latency for withdrawal from a thermal stimulus are quantified 
after a facet joint distraction of sufficient magnitude to induce persistent sensitivity 
(Crosby et al., 2013; Dong and Winkelstein, 2010; Kras et al., 2013a). To provide 
biomechanical context, the severity of loading applied to the facet joint capsular ligament 
is quantified using distraction and strain metrics to ensure injury consistency and to 
enable comparisons with previously reported findings from this model. Although studies 
included in this chapter do not match directly to any specific sub-aim of this thesis, the 
injury model and associated behavioral assessment techniques presented in this chapter 
are utilized in subsequent chapters to study the cellular responses to facet joint injury in 
the context of behavioral sensitivity. 
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3.2. Relevant Background 
 Several modalities of pain are observed in whiplash patients, including sensitivity 
to mechanical and thermal stimuli among others (Fernandez-Perez et al., 2012; Scott et 
al., 2005; Sterling et al., 2003; Sterling and Kenardy, 2008). Although spontaneous pain 
is the most commonly reported symptom in chronic pain patients and is frequently 
reported after neck trauma (Hagström et al., 1996; Mogil et al., 2010), metrics for 
quantifying this type of pain in animal models, such as food intake, grooming, and paw 
guarding, have proven unreliable in their specificity due to inherent susceptibility to 
confounding factors unrelated to pain (Mogil and Crager, 2004; Mogil et al., 2010). 
Evoked pain measures, such as allodynia and hyperalgesia, provide a repeatable method 
to quantify sensitivity, both clinically and in pre-clinical animal models (Boivie, 2003; 
Chaplan et al., 1994; Gregory et al., 2013; Lee and Winkelstein, 2009; Mogil and Crager, 
2004; Sterling and Kenardy, 2008). Allodynia is the perception of pain in response to a 
non-noxious stimulus, whereas hyperalgesia is an increased response to a noxious 
stimulus and includes all states of heightened pain sensitivity (Loeser and Treede, 2008; 
Ringkamp et al., 2013). One of the characteristics of hyperalgesia is a decreased pain 
threshold (Ringkamp et al., 2013). In fact, decreased thresholds to thermal and 
mechanical stimuli are evident in whiplash pain patients in the neck, as well as in remote 
locations like the shoulder, arm, and hand (Fernandez-Perez et al., 2012; Herren-Gerber 
et al., 2004; Scott et al., 2005; Sterling et al., 2003; Sterling et al., 2008). Evoked 
response thresholds to mechanical and thermal stimuli can be measured in both humans 
and animals (Chaplan et al., 1994; Hargreaves et al., 1988; Scott et al., 2005). Because 
whiplash patients with pain frequently exhibit hyperalgesia for both stimulus modalities, 
40 
quantification of those evoked responses in animal models of whiplash-like neck injury 
collectively offers a suitable measure of pain in those animal models that mimic the 
human condition. 
 Painful mechanical and thermal stimuli can activate both unmyelinated C-fibers 
and thinly myelinated Aδ-fibers (Ringkamp et al., 2013; Yeomans et al., 1996; Ziegler et 
al., 1999). Aβ-, Aδ-, and C-fibers all innervate articular joints, including the facet joint 
(Cavanaugh et al., 1996; Lu et al., 2005; Schaible and Grubb, 1993). With the exception 
of the cartilage, free nerve endings extend into all of the structures within joints, 
including the capsular ligament (Cavanaugh et al., 1996; Schaible and Grubb, 1993; 
Schaible et al., 2009), supporting the potential for injury to the joint tissues to induce 
pain. As reviewed more extensively in Section 1.2.2 of Chapter 1, non-physiologic 
loading of the facet capsular ligament is a potential mechanism thought to contribute to 
facet-mediated pain (Pearson et al., 2004; Siegmund et al., 2001; Yoganandan et al., 
2002). In a goat model of loading-induced facet joint injury, both Aδ- and C-fibers 
innervating the cervical facet joint capsular ligament are activated by tensile stretch of 
that ligament (Chen et al., 2006; Lu et al., 2005). Since both Aδ- and C-fibers are able to 
detect thermal and mechanical stimuli, loading-induced activation of capsule afferents 
may contribute to the hypersensitivity to heat and mechanical stimulation that is observed 
in patients after neck trauma (Fernandez-Perez et al., 2012; Herren-Gerber et al., 2004; 
Scott et al., 2005; Sterling et al., 2008). In our rat model of facet joint loading that 
simulates a traumatic neck injury and induces non-physiological distraction of the C6/C7 
facet joints, facet capsular ligament strains of 24.0±10.0% are sufficient to induce 
immediate and sustained mechanical hypersensitivity in the shoulders as well as the 
41 
forepaws (Dong and Winkelstein, 2010; Kras et al., 2014a; Lee et al., 2004; Lee et al., 
2008). Despite the fact that thermal hypersensitivity is also evident in whiplash patients 
(Scott et al., 2005; Sterling and Kenardy, 2008) and sensory fibers in the joint capsule 
that may be capable of transducing thermal stimuli are activated (Chen et al., 2006; Lu et 
al., 2005; Ringkamp et al., 2013; Yeomans et al., 1996), it is not known if facet joint 
injury induces an immediate development and persistence of thermal sensitivity. 
 Standardized methods for quantifying withdrawal responses to mechanical and 
thermal stimulation of many body regions in the rat, including the head, shoulders, and 
paws, have been developed and validated (Chaplan et al., 1994; Hargreaves et al., 1988; 
Ivanusic et al., 2011; Lee et al., 2008). Mechanical sensitivity can be evaluated by 
measuring the withdrawal response threshold to stimulation using a calibrated series of 
von Frey filaments to apply localized pressure to the target anatomic region (Berge et al., 
2013; Chaplan et al., 1994; Decosterd and Woolf, 2000; Hubbard and Winkelstein, 2005; 
Le Bars et al, 2001; Lee et al., 2008). Because hyperalgesia is a frequent characteristic of 
pain in humans (Chaplan et al., 1994), decreases in the withdrawal threshold provide a 
quantitative measure of that sensitivity in animal models designed to mimic human pain 
states (Le Bars et al., 2001). Variations of the up-down method originally described by 
Chaplan have been widely utilized to detect differences in withdrawal thresholds in 
response to nerve injury, peripheral inflammation, and joint inflammation and arthritis 
(Chaplan et al., 1994; Coull et al, 2005; Decosterd and Woolf, 2000; Gong et al., 2011; 
Hubbard and Winkelstein, 2005; Longo et al., 2013; Mannion et al., 1999; Matayoshi et 
al., 2005). In one variation, an ascending series of von Frey filaments is applied to the 
forepaw, and a filament that elicits a paw withdrawal is recorded as the withdrawal 
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threshold if the next higher filament in the series also elicits a positive response (Dong et 
al., 2011; Kras et al., 2013b; Lee et al., 2008; Lee and Winkelstein, 2009). That modified 
method has been used to quantify differences in withdrawal threshold in the shoulder and 
the forepaw between injured and control rats throughout the post-injury time period in a 
model of facet joint loading-induced pain (Dong et al., 2011; Kras et al., 2013b; Lee et 
al., 2008; Lee and Winkelstein, 2009). Thermal hyperalgesia can be measured by 
recording the length of time that a rat is able to tolerate a focused heat stimulus applied to 
the paw before withdrawing it (Hargreaves et al., 1988). A radiant heat source is applied 
to the paw and synchronized with a timer that stops automatically when the paw is 
withdrawn from the testing surface (Hargreaves et al., 1988; Nicholson et al., 2014). This 
method of evaluating withdrawal latency as a measure of sensitivity has been used to 
detect temporal changes in thermal sensitivity following a nerve root injury or 
inflammation-induced arthritis, as well as to quantify the effectiveness of treatments in 
the alleviation of inflammatory pain (Amaya et al., 2004; Fischer et al., 2013; Longo et 
al., 2013; Nicholson et al., 2014; Okun et al., 2011). Because facet joint injury is 
associated with joint inflammation (Dong et al., 2013a), measurement of thermal 
hyperalgesia has utility for fully characterizing the pain response after facet injury. 
 Studies presented in this chapter test the hypothesis that facet joint distraction of a 
magnitude sufficient to produce persistent mechanical hypersensitivity in the forepaws 
also induces thermal hyperalgesia in the forepaws. Joint capsule distraction and ligament 
strains are quantified during a controlled distraction of the bilateral C6/C7 facet joints 
using previously validated methods (Dong et al., 2008; Dong and Winkelstein, 2010; 
Kras et al., 2014a) as measures of the severity of the applied joint loading. Although the 
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initial development of this injury model applied quasistatic joint loading, studies 
presented in this chapter apply a dynamic joint distraction to load the joint at a rate 
(500%/s) comparable to the range reported for whiplash-like injuries (150-1000%/s) 
(Dong et al., 2008). Forepaw withdrawal thresholds to mechanical stimulation, as well as 
thermal withdrawal latencies, are measured for up to seven days following joint 
distraction. Although studies presented here include only a small number of animals in 
each group, the findings define the behavioral responses for the joint loading conditions 
that will be used in subsequent chapters and are included to provide a basis for behavioral 
studies with larger group sizes in those later chapters that also define the cellular 
responses to facet joint injury in the context of pain. 
 
3.3. Methods 
3.3.1. Surgical Procedures & Quantification of Joint Mechanics 
 Male Holtzman rats (Harlan Sprague-Dawley, Indianapolis, IN) (396±21g) were 
housed under USDA- and AAALAC-compliant conditions with free access to food and 
water. All experimental procedures were approved by the University of Pennsylvania 
IACUC and carried out under the guidelines of the Committee for Research and Ethical 
Issues of the IASP (Zimmermann, 1983). 
 All surgical procedures were performed under inhalation isoflurane anesthesia 
(4% induction; 2.5% maintenance). The hair on the back of the neck was shaved, and the 
exposed skin was scrubbed and sterilized with betadyne. Under a surgical microscope 
(Carl Zeiss Inc.; Thornwood, NY), a midline incision was made along the back of the 
neck, and the paraspinal musculature was separated from the C4-T2 spinous processes. 
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The laminae and bilateral facet joints were then cleared of inserting muscles from C5-T1. 
The supraspinous ligament, ligamentum flavum, and interspinous ligament were resected 
at each level from C5-T1 in order to enable attachment of the rat to the loading device. 
The C6 and C7 laminae were attached to a customized loading device via microforceps 
(Figure 3.1), and the C6 vertebra was distracted rostrally by a stepper motor (TM-400, 
20µm resolution; Danaher Precision Systems; Boxborough, MA) at 200,000 steps/sec or 
15mm/s while the C7 vertebra was held fixed (n=9 rats) (Dong et al., 2008; Dong et al., 
2013a; Kras et al., 2013c). 
 
A linear variable differential transducer (LVDT) (S-DVRT-24; Microstrain Inc.; 
Williston, VT; 24mm stroke; 5.7µm resolution) coupled to the C6 microforceps 
continuously monitored the displacement of the forceps, while a load cell (WMC-5; 
microscope 
surgical platform 
nose cone 
C6 
microforceps 
C7 
microforceps 
stepper 
motor 
LVDT 
load cell 
Figure 3.1. Customized facet joint loading device. The nose cone is used for 
anesthesia delivery. A surgical microscope equipped with a high speed camera 
mounted above the device acquires image data throughout the applied distraction. The 
microforceps coupled to the C6 vertebra are displaced using the stepper motor 
automated by a MATLAB program, and the LVDT records the displacement of the C6 
forceps. The microforceps coupled to the C7 vertebra remain stationary while the 
attached load cell continuously records the force across the C6/C7 joint. 
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Interface Inc.; Scottsdale, AZ) attached to the C7 forceps monitored the force applied 
across the joint during the distraction (Figure 3.1). In order to measure the vertebral 
distraction, polystyrene microspheres (Spherotech Inc.; Libertyville, IL) were placed on 
the C6 and C7 laminae, and a grid of microspheres was placed on the joint capsular 
ligament in order to quantify the capsular ligament distraction and strain (Figure 3.2). A 
high speed camera (Phantom v5.1; Vision Research Inc.; Wayne, NJ) mounted to the 
surgical scope recorded the joint distraction and tracked the corresponding motion of the 
microspheres at a rate of 500 frames/sec. Additional rats underwent an identical sham 
procedure that included device attachment but no distraction applied to the facet joint 
(n=4). Following surgical procedures, all wounds were closed using polyester suture and 
surgical staples, and the incision site was cleaned with betadyne. Rats were allowed to 
recover in room air.  
 Images of the laminae and right facet joint immediately prior to initiation of 
distraction and at the peak of joint distraction (Figure 3.2) were digitized using ImageJ 
software (National Institutes of Health; Bethesda, MD) in order to calculate the vertebral 
and joint deformations. The capsular ligament strains were calculated using LS-DYNA 
software (Livermore Software Technology Corp.; Livermore, CA) according to 
previously established methods for study of this joint in vivo (Dong et al., 2008; Dong 
and Winkelstein, 2010; Kras et al., 2013a). The input file for LS-DYNA was generated 
using a Matlab code that is provided in Appendix A. Both the maximum principal strain 
and the maximum tensile strain oriented along the rostrocaudal direction were quantified 
for each rat to assess the severity of joint loading and to ensure consistency with previous 
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studies using this injury model (Dong et al., 2008; Dong and Winkelstein, 2010; Lee et 
al., 2008). 
 
3.3.2. Assessment of Mechanical Withdrawal Threshold 
 After the surgical procedures, mechanical sensitivity was quantified by measuring 
the withdrawal threshold to mechanical stimulation in each forepaw. Sensitivity was 
measured on day one (n=9 distraction; n=4 sham) and in a subset of those rats 
additionally on days three, five, and seven (n=6 distraction; n=2 sham). On each testing 
day, rats were placed individually into elevated cages with a wire mesh floor and allowed 
to acclimate to the testing environment for at least 15 minutes. Rats underwent three 
rounds of testing on each day with each round separated by at least ten minutes. During 
each testing round, a series of calibrated von Frey filaments (1.4g-26g) (Stoelting; Wood 
Dale, IL) was applied to the plantar surface of each forepaw in ascending order to 
determine the threshold filament that would elicit a response. A positive response is 
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Figure 3.2. Representative images showing the exposed facet joint capsule prior to 
injury (A) and at the peak of distraction (B). The C6 and C7 laminae are labeled with 
vertebral markers (arrows in B), and the grid of markers placed over the capsular 
ligament is circled in A. Vertebral distraction is calculated as the change in the vector 
length between the C6 and C7 vertebral markers before and after distraction. Capsule 
distraction and ligament strains are calculated from the grid of markers on the capsule.  
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defined as a rapid withdrawal of the paw following stimulation that may or may not be 
accompanied by vigorous shaking or licking of the paw (Chaplan et al., 1994; Crosby et 
al., 2013; Kras et al., 2013a; Lee et al., 2008). Each filament was applied for five 
consecutive stimulations at a frequency of approximately one stimulation per second. The 
filament strength eliciting a response was recorded as the withdrawal threshold if the next 
consecutive filament also elicited a positive response. If no filament elicited a response, 
then a threshold of 26g, corresponding to the highest magnitude filament, was recorded. 
For each testing round, a withdrawal threshold was determined for each paw separately, 
and thresholds were averaged over the three rounds and between the right and left paws 
in order to obtain a single withdrawal threshold for each rat on each testing day. 
Withdrawal thresholds were also quantified for three days prior to any surgical procedure 
in order to establish baseline sensitivity responses for each rat. Mechanical withdrawal 
thresholds were compared using a repeated-measures two-way ANOVA with Tukey’s 
Honestly Significant Difference (HSD) test with group (distraction, sham) and testing day 
as factors. 
 
3.3.3. Assessment of Thermal Withdrawal Latency 
 Thermal hyperalgesia was evaluated following mechanical behavioral assessment 
on day one for all rats and again on day seven for those rats that were followed to the 
later time point. Rats were placed in wire mesh cages on top of a glass surface and 
allowed to acclimate to the testing environment for 30 minutes (Figure 3.3). The glass 
surface was maintained at 30°C in order to reduce the effects of differences in initial skin 
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temperature on withdrawal latencies (Berge, 2013; Dirig et al., 1997; Nicholson et al., 
2014).  
 
A commercially available device (UC San Diego; San Diego, CA) was used to 
focus a radiant heat source (projection bulb) onto the plantar surface of each forepaw 
(Figure 3.3) using previously validated methods to quantify the latency to paw 
withdrawal (Dirig et al., 1997; Hargreaves et al., 1988; Nicholson et al., 2014). An angled 
mirror attached to the stimulator enables accurate positioning of the heat source under the 
plantar surface of the forepaw. A timer synchronized to the thermal stimulus measures 
the latency time between the initial application of the heat source and when the paw is 
withdrawn (i.e. the withdrawal latency). On each testing day, the withdrawal latency was 
measured three to five times for each forepaw, with a ten minute rest between each 
measurement. Paw withdrawals associated with normal ambulation of the rat were not 
considered. The average withdrawal latency for each rat was calculated by averaging 
timer 
surface 
temperature 
mesh 
cage 
thermal 
stimulus 
Figure 3.3. Device for measuring thermal sensitivity in the paws of the rat. The glass 
surface is warmed to 30°C, and the rat is placed in the wire mesh cage on the surface. 
The thermal stimulus is positioned underneath the forepaw, and the timer records the 
time from initiation of heating to the time when the rat withdraws the paw. 
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results from the right and left forepaws across all testing rounds for each day. Withdrawal 
latencies for each rat were quantified for three days prior to any surgical procedure in 
order to establish baseline responses for comparison. Differences in withdrawal latency 
between groups were determined using a two-way repeated measures ANOVA with 
Tukey’s HSD test with group (distraction, sham) and time point (day zero, day one, day 
seven) as factors. Separate paired t-tests compared differences in withdrawal latency at 
each time point to baseline for the distraction and sham groups. 
 
3.4. Results 
 No adverse effects were observed following surgery, with rats displaying normal 
grooming behavior, mobility, and consistent weight gain. Analysis of the videos recorded 
during the injury, as well as visual inspection of the bilateral C6/C7 joints at the 
termination of each study, confirm that the joint capsules remained intact for all rats in 
the distraction and sham groups. The digitization error in the methods used to calculate 
capsule distraction and strain was only 1.5±0.8%. The joint loading device applied a 
consistent distraction for all rats in the distraction group, with an average displacement of 
the C6 microforceps of 2.50±0.02mm, corresponding to an average vertebral distraction 
of 0.50±0.19mm and a capsular distraction of 0.28±0.12mm (Table 3.1). The applied 
distraction rate was 13.58±0.66mm/sec, corresponding to an applied strain rate of 
452±22% across the joint (Table 3.1). Distraction of the joint capsule produced capsular 
ligament strains oriented primarily in the rostrocaudal direction (Figure 3.4). Maximum 
principal strain in the capsule averaged 22.18±13.57%, and maximum strain in the 
rostrocaudal direction was 14.34±11.68% (Figure 3.4; Table 3.1). At the time of peak 
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joint distraction, the joint supported an average tensile load of 2.24±0.90N (Table 3.1). In 
addition, the individual force-displacement loading curves, capsule strain fields, and 
maximum vertebral and capsule distractions for each rat included in this study are 
detailed in Appendix B. 
Table 3.1. Summary of maximum mechanical data for the distraction group. 
Rat 
Displacement 
of C6 forceps 
(mm) 
Vertebral 
distraction 
(mm) 
Capsule 
distraction 
(mm) 
Distraction 
rate 
(mm/s) 
Maximum 
principal 
strain (%) 
Rostrocaudal 
strain (%) 
Tensile 
force 
(N) 
413 2.47 0.44 0.19 13.27 15.03 5.41 2.93 
415 2.50 0.36 0.25 13.17 17.92 17.81 3.17 
417 2.50 0.59 0.32 13.89 21.40 19.28 3.58 
418 2.50 0.96 0.59 13.00 54.59 40.97 2.89 
A 2.50 0.45 0.27 12.38 17.67 8.93 1.26 
B 2.53 0.45 0.17 14.38 30.84 8.68 1.45 
I 2.48 0.34 0.26 13.93 7.91 2.14 1.84 
D 2.51 0.55 0.25 13.92 18.41 18.00 1.19 
E 2.54 0.35 0.23 14.27 15.84 7.87 1.87 
avg 
(SD) 
2.50 
(0.02) 
0.50 
(0.19) 
0.28 
(0.12) 
13.58 
(0.66) 
22.18 
(13.57) 
14.34 
(11.68) 
2.24 
(0.90) 
Strain (%) Strain (%) 
Strain Vectors at 
Peak Distraction 
Lateral 
Medial 
Rostral Caudal 
Strain Field 
at Peak Distraction (B) (A) 
Figure 3.4.  (A) Representative maximum principal strain field on the capsular 
ligament at its peak joint distraction. The strain field image was generated using LS-
DYNA software and digitized images of the joint capsule markers just prior to joint 
distraction and at peak distraction. (B) Corresponding strain vector field of maximum 
principal strain at peak joint distraction. The maximum principal strain mainly occurs 
in the rostrocaudal direction. 
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Distraction of the C6/C7 facet joint induces an immediate reduction in the 
forepaw withdrawal threshold to mechanical stimulation by day one compared to baseline 
responses (p<0.001) (Figure 3.5). The withdrawal threshold remains significantly lower 
than baseline at all time points through day seven after joint distraction (p<0.001) (Figure 
3.5). Moreover, the withdrawal threshold at day one is significantly lower after 
distraction than after a sham procedure (p<0.035); yet, statistical significance is not 
achieved at any other time point for comparisons between distraction and sham with 
these small group sizes (Figure 3.5). No change from baseline is detected in the sham 
group at any post-surgical time point (Figure 3.5). Detailed mechanical withdrawal 
threshold data for each rat in this study are included in Appendix C. 
 
Similar to the decrease in the mechanical withdrawal threshold that is observed, 
joint distraction significantly reduces the withdrawal latency to thermal stimulation at day 
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Figure 3.5. Mechanical sensitivity in the forepaw as measured by the withdrawal 
threshold in response to von Frey filament stimulation. Withdrawal threshold 
significantly decreases (*p<0.001) after joint distraction compared to baseline on all 
post-operative days as well as compared to sham (#p<0.035) at day one. 
52 
one (p<0.029) compared to baseline (Figure 3.6). There is a trend towards a further 
decrease in latency at day seven but with no significant differences from baseline 
(p<0.061) at day seven (Figure 3.6). Withdrawal latencies in the sham group do not 
change significantly from baseline at either time point (Figure 3.6). No differences are 
detected between the distraction and sham groups at any time point.  The withdrawal 
latency measured for each rat in this study is tabulated in Appendix C. 
 
3.5. Discussion 
 The results of the studies in this chapter demonstrate that a mechanical facet joint 
injury sufficient to induce mechanical hypersensitivity in the rat also increases sensitivity 
to thermal stimuli. The 2.50±0.02mm displacement recorded by the LVDT, with a 
variability of only 0.8%, supports that the loading device reliably produces a consistent 
distraction across the rat’s C6/C7 facet joint. Further, digitization errors associated with 
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Figure 3.6. Thermal hyperalgesia in the forepaw as measured by the withdrawal 
latency to thermal stimulation. Withdrawal latency significantly decreases (*p<0.029) 
after joint distraction compared to baseline on post-operative day one and trends to 
significance (p<0.061) at day seven. 
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the method of image analysis and capsule distraction and strain calculation are small 
(1.5±0.8%) and so are unlikely to substantially affect the distractions and strains. The 
metrics that quantify the mechanics of the joint distraction, including the vertebral 
distraction (0.50±0.19mm), tensile force across the joint (2.24±0.90N), and maximum 
principal strain in the capsule (22.18±13.57%) (Table 3.1), all agree closely with previous 
studies characterizing the mechanics of this type of injury: with (0.47-0.75mm) vertebral 
distractions, (3.00-4.04N) tensile forces, and (21.5-31.2%) maximum principal strains 
(Dong et al., 2008; Dong and Winkelstein, 2010; Dong, 2011; Dong et al., 2011; Dong et 
al., 2013a). This consistency in the joint loading mechanics across multiple studies 
further demonstrates that the dynamic mechanical joint injury used here is highly 
reproducible. 
 The injury applied to the C6/C7 facet joint in the current study closely simulates 
the tensile joint loading that occurs in a traumatic neck injury such as whiplash. The 
maximum principal strain of 22.18±13.57% is within the range of capsular ligament 
strains (8.7-39.9%) reported for the C6/C7 facet joint in whiplash simulations using 
cadavers (Panjabi et al., 1998; Pearson et al., 2004), which supports the current in vivo 
model as a reasonable model for further study of the behavioral and cellular effects of 
whiplash-like loading. In a goat model of facet joint injury, the majority of Aδ- and C-
fibers innervating the capsular ligament are activated by strains of 10.7±3.3% and 
10.0±4.6%, respectively (Lu et al., 2005). Since sensory fibers of these types transmit 
nociceptive stimuli to the spinal cord, their activation under joint loading that produces 
capsular ligament strains of 22.18±13.57% suggests that similar loading-induced 
54 
activation of capsule afferents in the rat may contribute to the behavioral sensitivity that 
is observed in the current study (Figures 3.5 & 3.6). 
 The significant reduction in mechanical withdrawal threshold from baseline at all 
time points after injury (Figure 3.5) is consistent with previous work using this injury 
model (Dong and Winkelstein, 2010; Lee and Winkelstein, 2009) and supports the use of 
this model to study both the immediate (day one) and the longer term (day seven) cellular 
mechanisms by which joint loading contributes to facet joint-mediated pain. Mechanical 
hypersensitivity is also evident when compared to sham at day one but only exhibits 
trends toward significance at other time points after injury (Figure 3.5). Changes in 
threshold after day one are not significant despite a continued decrease in the withdrawal 
threshold in the distraction group at the later time points. Studies using this same injury 
model report a significant reduction in the withdrawal threshold immediately after injury 
that remains significantly lower than control groups for at least seven days (Dong et al., 
2011; Kras et al., 2013b); however, those studies used group sizes of at least four rats 
each. In the studies for this chapter, the small size of the sham group (n=2 rats) at all time 
points after day one likely precludes detecting any significant differences between groups 
because of the low power of the comparisons. Indeed, power analysis indicates that a 
group size of at least four is necessary to detect differences between injury and sham, a 
finding corroborated by the significant difference detected at day one between distraction 
(n=9) and sham (n=4) as well as by the studies in the later chapters (Chapters 4, 5, & 6). 
Because decreased threshold for withdrawal to mechanical stimulation seven days after 
injury has been well-documented by previous studies using this same injury model (Dong 
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and Winkelstein, 2010; Lee and Winkelstein, 2009), additional sham animals were not 
added to the current study. 
 Significant thermal hyperalgesia developed by day one after injury (Figure 3.6), 
but no significant changes in thermal sensitivity were observed in shams at either time 
point (Figure 3.6). Although the withdrawal latency decreases from baseline in the sham 
group at day one, this difference was not significant and is likely due to the response of a 
single animal in the sham group. Of the four rats tested at day one (see Table C.2 in 
Appendix C), one animal (Rat G) exhibited a decrease in withdrawal latency of 44% of 
its baseline, while none of the other three rats exhibited a decrease of more than 5%. 
These individual data suggest that the overall trend toward decreased withdrawal latency 
in the sham group at that day may be biased by the response of that outlier. Although 
additional studies are needed to fully define the thermal response to the sham procedure, 
such studies are not included in this thesis. However, studies identifying the contribution 
of intra-articular nerve growth factor and the subpopulations of joint afferents involved in 
the initiation of facet-mediated thermal hyperalgesia are included in Chapter 5. 
Despite reports that some whiplash patients experience increased sensitivity to 
thermal stimuli (Scott et al., 2005; Smith et al., 2014), thermal sensitization is not a 
universal consequence of whiplash (Chien et al., 2008; Chien et al., 2009; Curatolo et al., 
2001). Chien reports that sensitivity to heat stimuli in the hands of whiplash patients is 
unchanged compared to controls (Chien et al., 2009), supporting the current finding of no 
change in sensitivity to heat stimuli in the forepaw of injured rats compared to sham. 
However, data presented here (Figure 3.6) represent thermal responses measured only in 
the forepaw. Whiplash patients report increased sensitivity in multiple regions, including 
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the neck, shoulder, arm, and even the leg (Scott et al., 2005; Smith et al., 2014; Sterling et 
al., 2003), suggesting that sensitivity may develop in other locations not evaluated in the 
current study. After a neck injury, the most common body regions that patients report as 
painful are the posterior neck and shoulders (Hincapié et al., 2010), suggesting those 
regions may be more relevant to injury-induced hypersensitivity in the rat than the 
forepaw. In fact, mechanical sensitivity is increased in the shoulder of rats after a painful 
facet joint distraction (Lee and Winkelstein, 2009), supporting its potential for pain after 
joint injury. Additional studies characterizing thermal sensitivity with more rats and in 
additional relevant anatomical regions are necessary to fully define the thermal response 
to whiplash-like facet joint injury. 
 
3.6. Conclusions & Integration 
 The studies in this chapter demonstrate that distraction of the C6/C7 facet joint is 
a highly reproducible biomechanical injury model of whiplash-like joint loading that 
mediates the development of both mechanical and thermal sensitivity (Figures 3.5 & 3.6). 
Because a major focus of this thesis is to define mechanism(s) through which local intra-
articular responses to joint injury contribute to the development of pain, and because 
loading-induced mechanical and thermal sensitivity are evident at day one (Figures 3.5 & 
3.6), additional experiments to increase the group sizes to determine if thermal sensitivity 
is maintained after injury were not carried out. Throughout the remainder of this thesis, at 
least four rats are included in each experimental group to ensure that statistical 
comparisons have enough power to detect differences between groups. Based on the 
finding of thermal hyperalgesia at day one after injury, thermal withdrawal latencies are 
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quantified at day one after intra-articular injections to determine the role of NGF in facet-
mediated pain (Chapter 5). 
The loading-induced strains in the joint capsule (Table 3.1) have similar 
magnitudes to strains that induce firing of joint capsule afferents (Chen et al., 2006; Lu et 
al., 2005), which suggests that loading-induced excitation of afferents innervating the 
facet joint may contribute to behavioral hypersensitivity after injury. The cellular 
mechanisms by which mechanical joint injury can induce pain remain unknown. In order 
to begin to define the role of the facet joint and its local responses to injury that underlie 
loading-induced facet pain, Chapter 4 uses neuronal tracing techniques in combination 
with the painful injury conditions defined in this chapter to characterize the innervation 
of the facet joint and the effects of painful joint loading on the afferents innervating the 
joint. Studies in Chapter 5 further utilize the loading condition defined in this chapter to 
define one mechanism through which local intra-articular responses in the joint 
immediately following injury contribute to the development of loading-induced facet 
pain. 
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CHAPTER 4 
Characterization of the C6/C7 Facet Joint 
Afferents After Painful Joint Loading in the Rat 
 
Parts of this chapter are adapted from: 
Kras JV, Tanaka K, Gilliland TM, Winkelstein BA (2013). An Anatomical and 
Immunohistochemical Characterization of Afferents Innervating the C6-C7 Facet Joint 
After Painful Joint Loading in the Rat. Spine, 38(6): E325-E331. 
 
4.1. Overview 
 In Chapter 3, non-physiologic loading of the facet joint was shown to induce 
mechanical and thermal hypersensitivity in the rat (Figures 3.5 & 3.6). In order to begin 
to define the molecular responses underlying loading-induced joint pain, the neuronal 
innervation patterns of the facet joint must be characterized. Several studies in both 
humans and rats have demonstrated that cervical facet joints are innervated by primary 
afferent neurons that originate from multiple spinal levels (Barnsley and Bogduk, 1993; 
Ohtori et al., 2003). Further, tensile loading of the cervical facet joint has been shown to 
activate the nociceptors that innervate that joint (Chen et al, 2006; Lu et al., 2005). 
Despite that collection of works, the distribution of primary afferents that innervate many 
of the cervical facet joints, and C6/C7 in particular, is unknown in the rat. Primary 
afferents can be classified as either peptidergic or non-peptidergic (See Chapter 1 for a 
more extensive review) (Merighi et al., 2008). Peptidergic afferents upregulate 
expression of both substance P and calcitonin gene-related peptide (CGRP) in response to 
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inflammation and nerve injury (Seybold, 2009; Weissner et al., 2006), and CGRP 
signaling has been associated with arthritis-induced spinal neuronal hyperexcitability 
(Bird et al., 2006). Although increased neuropeptide expression and spinal 
hyperexcitability both have been associated with painful facet joint distraction (Crosby et 
al., 2013; Lee and Winkelstein, 2009; Quinn et al., 2010), the expression of 
neuropeptides in afferents innervating the C6/C7 facet joint, normally or after its painful 
injury, has not been characterized. Studies presented in this chapter characterize the 
segmental innervation pattern of the C6/C7 facet joint in the rat (Aim 1a) and test the 
hypothesis that painful facet joint injury upregulates neuropeptide expression in those 
joint afferents in the dorsal root ganglion (DRG) in association with behavioral 
hypersensitivity. Accordingly, CGRP expression also was quantified in the DRG in those 
neurons innervating the C6/C7 facet joint (Aim 1c) after a painful joint distraction. 
Additional studies quantifying neurotrophin expression in neurons in the DRG (Aim 1b) 
are included as part of a later chapter (Chapter 6). 
 
4.2. Relevant Background 
Neck injuries are reported in up to one-in-three rear-end motor vehicle collisions 
(Zuby and Lund, 2011), and the cervical facet joint has been identified as the source of 
pain in as many as 67% of neck pain patients (Bogduk, 2011).  Anesthetic nerve blocks 
and radiofrequency neurotomy of the branches of the nerves innervating the facet joint 
provide pain relief (Barnsley et al., 1994; Bodguk, 2011; Rambaransingh et al., 2010), 
further demonstrating facet joint innervation to have a direct relationship to pain.  
Mechanical facet joint injury is sufficient to activate nociceptors in the joint (Chen et al., 
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2006; Lu et al., 2005) and to induce persistent pain (Dong et al., 2008; Lee et al., 2004; 
Quinn et al., 2010) in animal models. The C5/C6 facet joint in the rat is multi-
segmentally innervated, and the expression pattern of neuropeptides is altered in the joint 
afferents after transection of the capsular ligament (Ohtori et al., 2003).  Although the 
afferents innervating the cervical facet joint are suggested to be crucial to the 
maintenance of joint-mediated neck pain, the pattern of neurons innervating the C6/C7 
facet joint is not known; it is also not known how injury to this joint affects its 
innervation and/or how the molecular responses of the joint afferents may contribute to 
pain. 
 Many pain mediators are upregulated in the DRG in response to joint 
inflammation and injury (Dong et al., 2008; Dong et al., 2011; Lee et al., 2008; Ohtori et 
al., 2002; Tachihara et al., 2007).  Specifically, the neuropeptide CGRP, which is 
normally produced in 40% of the primary afferents (Lee et al., 1985), has been implicated 
as a contributor to joint pain and neuronal excitability (Iwakura et al., 2010; Ohtori et al., 
2003; Orita et al., 2011; Staton et al., 2007; Sun et al., 2004). Moreover, CGRP is 
commonly used to identify peptidergic neurons due to its high expression in that 
subpopulation (Ferrari et al., 2010; Ohtori et al., 2003; Stucky and Lewin, 1999).  Recent 
evidence suggests that some forms of pain can be mediated by specific subpopulations of 
primary sensory neurons (Ferrari et al., 2010; Hucho et al., 2005) or by a change in the 
phenotype of peptidergic afferents (Michael et al., 1999; Ohtori et al., 2002; Ohtori et al., 
2003; Zhou et al., 1999).  Despite the association of peptidergic afferents and CGRP 
expression with joint pain, no study has investigated the relationship between CGRP 
expression in facet joint afferents and painful mechanical facet injury. 
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 Distraction of the C6/C7 facet joint, as may occur during whiplash and other neck 
injuries, induces persistent pain, upregulates the neuropeptide substance P in the DRG 
and induces neuronal hyperexcitability in spinal neurons at day 7 in the rat (Dong et al., 
2008; Lee et al., 2004; Quinn et al., 2010; Dong and Winkelstein, 2010; Lee and 
Winkelstein, 2009).  Specifically, painful joint distraction upregulates substance P in the 
C7 DRG at day 7 after injury (Lee and Winkelstein, 2009), which suggests that the 
peptidergic afferents at this spinal level have a particularly important role in joint-
mediated pain. Although peptidergic fibers are identified in the human facet joint capsule 
(Kallakuri et al., 2004; Kallakuri et al., 2012), no study has defined the effect of a 
biomechanical, and clinically-relevant, painful C6/C7 facet injury on neuropeptide 
expression in joint afferents.  The goal of this study was to identify the distribution of 
afferents that project to the C6/C7 facet joint after a painful joint distraction using 
neuronal tracing methods (Ohtori et al., 2003; Sameda et al., 2001).  Because of the 
suspected contribution of peptidergic afferents at the C7 level to injury-induced pain, the 
frequency of peptidergic neurons identified in that group of joint afferents was also 
investigated as compared to all other neurons in the DRGs at the C7 level. 
 
4.3. Methods 
4.3.1. Surgical Procedures & Behavioral Assessment 
 Male Holtzman rats (Harlan Sprague-Dawley, Indianapolis, IN) (414±26g) were 
housed under USDA- and AAALAC-compliant conditions with a 12-12 hour light-dark 
cycle and free access to food and water.  Experimental procedures were approved by the 
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IACUC and carried out under the guidelines of the Committee for Research and Ethical 
Issues of the International Association for the Study of Pain (Zimmermann, 1983). 
 All surgical procedures were performed under inhalation isoflurane anesthesia 
(4% induction, 2.5% maintenance).  All rats received a bilateral intra-articular C6/C7 
facet joint injection of 20µg of the retrograde neuronal tracing molecule cholera toxin 
subunit B (CTb) conjugated to the fluorescent dye Alexa Fluor 488 (Life Technologies; 
Carlsbad, CA) and dissolved in sterile phosphate buffered saline (PBS).  The C6/C7 facet 
joints and their capsules were exposed according to the procedures described in Section 
3.3.1 of Chapter 3 (Kras et al., 2013a; Kras et al., 2014a).  A 10µL syringe (Hamilton 
Company; Reno, NV) with a 33-gauge beveled needle was advanced into the facet joint, 
and 5µL of the CTb solution was slowly injected.  Following injection, the exposure was 
closed in layers using 3-0 polyester suture and surgical staples. 
 Three days after the CTb injection, a subset of rats underwent either a painful 
cervical facet joint distraction injury (n=4) or sham procedure (n=5), as described in 
Section 3.3.1 of Chapter 3 (Dong et al., 2008; Dong et al., 2011; Kras et al., 2013a).  
Under inhalation anesthesia, the surgical staples and suture were removed, and the C6 
and C7 laminae were rigidly attached to a customized loading device via microforceps.  
For the painful distraction group, the bilateral C6/C7 facet joints were distracted by 
displacing the C6 vertebra rostrally while holding the C7 vertebra fixed (Crosby et al., 
2013; Dong et al., 2011; Kras et al., 2014a).  A camera mounted to a surgical dissecting 
scope tracked markers on the C6 and C7 laminae during injury in order to quantify the 
distraction.  An additional group of rats underwent sham surgical procedures with device 
attachment but no applied joint distraction.  Following surgery, the incision was closed 
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and rats were recovered. The remaining group of rats (normal, n=4) received no surgical 
procedures after the initial CTb injection. 
Bilateral forepaw mechanical hyperalgesia was evaluated in those rats undergoing 
the painful joint injury or sham control procedure using methods identical to those 
described in Chapter 3 (Section 3.3.2) (Lee and Winkelstein, 2009; Quinn et al., 2010; 
Weisshaar et al., 2010).  Baseline measurements were recorded for 2 days after the CTb 
injection. Hyperalgesia was measured on days 1, 3, 5 and 7 after the injury or sham 
procedure. A given filament was recorded as the response threshold if the next higher 
filament also induced a positive response.  Because the applied joint distraction is a 
bilateral injury, response thresholds were averaged between the right and left forepaws 
for each rat.  At each time point, response thresholds were compared between groups and 
to the respective baseline values using a two-way repeated measures ANOVA with 
Tukey’s HSD test, with time and group as the factors. 
 
4.3.2. DRG Harvest & CGRP Immunohistochemistry 
  On day 7 after the injury or sham procedures, rats were given an overdose of 
sodium pentobarbital (65mg/kg) and perfused transcardially with 300mL of PBS and 
250mL of 4% paraformaldehyde in PBS (pH7.4).  The DRGs on the right side were 
harvested and post-fixed in the same fixative solution for 2.5 hours at 4ºC.  DRGs were 
then transferred to 30% sucrose for five days at 4ºC before being embedded in Tissue-
Tek® OCT Compound (Sakura Finetek; Torrance, CA).  Each DRG was axially 
sectioned at a 14µm thickness through its entire length, and sections were thaw-mounted 
onto slides.  All sections were washed and blocked with normal donkey serum 
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(Chemicon; Temecula, CA) for two hours before incubation with a polyclonal rabbit anti-
CGRP antibody (1:5000; T-4032; Peninsula Laboratories; San Carlos, CA) overnight at 
4ºC.  The following day, sections were washed and incubated with a Cy3-conjugated 
donkey-anti-rabbit secondary antibody (1:500; Jackson ImmunoResearch; West Grove, 
PA) for two hours at room temperature and cover-slipped using Fluoro-Gel anti-fade 
medium (EMS; Hatfield, PA). 
A fluorescent microscope equipped with a digital camera (Olympus; Center 
Valley, PA) was used to image each DRG section that contained at least one neuron 
positively labeled with CTb.  The total number of neurons that were positive for CTb was 
counted for each DRG; care was taken to avoid double-counting neurons that appeared in 
multiple consecutive sections.  The total number of CTb-positive neurons was summed 
for each group at each DRG level.  Also, for those CTb-positive neurons, both the cross-
sectional area and the intensity of CGRP labeling were quantified using ImageJ software 
(National Institutes of Health; Bethesda, MD).  Each neuron was identified as being 
either CGRP-positive or CGRP-negative based on its intensity of CGRP labeling. The 
number of CTb-positive neurons also positively labeled for CGRP was counted at each 
level for each rat; the total number of those double-labeled neurons at each level was 
computed for each group.  The average percentage of all CTb-positive neurons that were 
also positive for CGRP also was determined for each group in each DRG.  Also, the 
average cross-sectional area of CTb-positive neurons expressing CGRP was determined.  
The number of CTb-positive neurons at each level was compared using a two-way 
ANOVA with Tukey’s HSD test, with group and level as the factors. A two-way 
ANOVA with Tukey’s HSD test (with group and level as factors) compared the average 
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cross-sectional area of neurons positive for both CGRP and CTb; a separate two-way 
ANOVA with Tukey’s HSD test compared the ratio of CTb-positive neurons that were 
CGRP-positive to the total number of CTb-positive neurons.  All statistical analyses were 
performed using JMP 8 (SAS Institute; Cary, NC) software. 
To assess the frequency of peptidergic neurons among joint afferents compared to 
all neurons in the DRG at the C7 level, three sections were chosen from C7 at random 
from each rat by an evaluator who was blinded to the rat identifications and tissue 
samples. The cross-sectional area and CGRP labeling intensity of all neurons were 
quantified.  All neurons in the C7 DRG were classified as either CGRP-positive or 
CGRP-negative.  Both the ratio of CGRP-positive neurons to all neurons in each section 
and the average cross-sectional area of all CGRP-positive neurons in each section were 
determined.  Separate comparisons of the ratio and the average cross-sectional area of 
CGRP-positive neurons were made between two populations of neurons in the C7 DRG: 
(1) joint afferents (those identified as CTb-positive neurons) and (2) all other neurons.  
Comparisons were tested using a two-way ANOVA with Tukey’s HSD and group 
(distraction, sham, normal) and neuron population (CTb-positive neurons, all other 
neurons) as factors.   
 
4.4. Results 
4.4.1. Behavioral Response Following Injury 
 All rats undergoing a facet joint injury received the same magnitude of 
distraction, and no macroscopic injuries to the facet joint capsular ligament were 
observed during any of the applied distractions.  The average applied distraction was 
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0.47±0.05mm.  A summary of the vertebral distractions for each rat included in this study 
can be found in Appendix B.  
There were no differences in the baseline withdrawal threshold between the 
distraction and sham groups.  Behavioral sensitivity was induced in all rats undergoing a 
joint distraction (Figure 4.1).  The withdrawal threshold was significantly reduced 
(p≤0.001) from baseline responses in the distraction group at all time points after injury, 
but sham procedures did not change responses from baseline at any time point (Figure 
4.1). The withdrawal threshold was significantly reduced (p≤0.0002) after distraction 
compared to sham at all time points (Figure 4.1). The detailed mechanical withdrawal 
threshold data for all individual rats are summarized in Appendix C. 
 
 
 
Figure 4.1.  Mechanical hyperalgesia in the forepaw as measured by the average±S.D. 
withdrawal threshold (g) elicited by von Frey filament stimulation.  Forepaw 
hyperalgesia is induced after facet joint injury compared to baseline (p≤0.001) on all 
days, but sham responses are unchanged from baseline.  The withdrawal threshold in 
the distraction group is significantly reduced (*p≤0.0002) compared to sham at each 
post-operative time point. 
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4.4.2. CGRP Expression in Joint Afferents After Injury 
 Neurons positive for CTb labeling were detected in all of the DRG levels that 
were assayed (Figures 4.2 & 4.3, Table 4.1). Significantly more (p≤0.0001) CTb-positive 
neurons were identified in the C7 DRG than any other DRG (Table 4.1). The C8 DRG 
contained significantly more (p≤0.0202) CTb-positive neurons than either of the C6 or 
C5 DRGs. Although the C6 DRG contained more CTb-positive neurons than the C5 
DRG (Table 4.1), that difference was not significant. Although these trends were 
observed within each of the distraction, sham, and normal groups, statistical significance 
was only achieved when considering all groups together. A summary of the CTb-positive 
neuron counts for each rat at each spinal level is included in Appendix H. 
 
Figure 4.2.  CTb and CGRP labeled neurons in the C7 DRG from the distraction 
(A,D,G), sham (B,E,H), and normal (C,F,I) groups.  (A-C) CTb-labeled neurons are 
detected in all groups.  (D-F) CGRP-labeling identifies peptidergic neurons.  CTb co-
localized with neurons that both express CGRP (arrowheads) and that do not express 
CGRP (arrow) (G-I).  Scale bar in (A) is 50µm and applies to all panels. 
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Table 4.1. Ratio and average percentages of CGRP-positive neurons that are also CTb-
positive compared to the number of CTb-positive neurons. 
 
Ratio of peptidergic CTb-positive neurons* 
C5 C6 C7 C8 total 
distraction  
(n=4 rats) 2/3 6/11 35/64 19/31 62/109 
sham  
(n=5 rats) 1/4 16/21 38/61 30/41 85/127 
normal  
(n=4 rats) 2/6 15/27 37/83 33/45 87/161 
total  
(n=13 rats) 5/13 37/59 110/208 82/117 234/397 
 
Average % of peptidergic CTb-positive neurons* 
C5 C6 C7 C8 total 
distraction  
(n=4 rats) 
66.7±57.7
% 45.0±33.2% 56.2±18.4% 61.1±13.0% 56.4±9.4% 
sham  
(n=5 rats) 
25.0±35.4
% 78.4±25.5% 59.8±14.7% 69.4±43.3% 66.9±18.3% 
normal  
(n=4 rats) 
41.7±52.0
% 47.8±32.6% 45.9±12.6% 75.1±19.8% 53.1±13.7% 
total  
(n=13 rats) 
46.9±47.1
% 57.1±31.9% 54.4±15.3%
‡
 
68.6±28.3% 59.4±14.8% 
*Note: The denominator is the total number of CTb-positive neurons from all rats in 
each group for each DRG level; the numerator is the corresponding total number 
of neurons from all rats in each group that are positive for both CTb and CGRP.  
The percent values represent the average percent of CTb-positive neurons that 
are also CGRP-positive for each group and DRG level. 
‡ p=0.0084 compared to the percentage of all neurons that are CGRP-positive at C7. 
Figure 4.3.  Magnified view of merged CTb (green) and CGRP (red) labeled neurons 
from the C7 DRG from distraction, sham, and normal rats showing punctate 
fluorescence of CTb within the cell body.  In panel (A), the arrow indicates a CTb-
labeled neuron that is not positive for CGRP labeling.  Scale bar in (A) is 50µm. 
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Further, there were no differences in the number of CTb-positive neurons between 
groups at any of the cervical levels evaluated (Table 4.1). There were no significant 
differences detected in the ratio of CTb-positive neurons that were positive for CGRP to 
the total number of CTb-positive neurons between any groups at any level (Table 4.1). 
Similarly, there were no differences in the average cross-sectional area of the neurons 
positive for both CTb and CGRP between any groups at any level (Table 4.2). 
 
Table 4.2. Average cross-sectional area of neurons positive for both CTb and CGRP. 
 
Cross-Sectional Area (µm2 ± S.D.) 
C5 C6 C7 C8 
distraction 660±353 840±264 757±142 825±71 
sham 741‡ 732±220 688±173 802±189 
normal 599±206 864±139 738±79 754±134 
total 652±212 804±200 724±133* 794±130 
‡ Only one neuron found. 
*p=0.0005 compared to all CGRP-positive neurons in the C7 DRG. 
 
4.4.3. CGRP Expression in Joint Afferents Compared to All Other Afferents 
 In the C7 DRG, 41.5±5.4% of all of the neurons were CGRP-positive.  However, 
54.4±15.3% of CTb-positive neurons at that level expressed CGRP (Table 4.1), and this 
difference in the ratios of CGRP-positive neurons between these two populations of 
neurons was significant (p=0.0084).  This trend was also observed in each of the groups 
but was not significant for any of the groups.  Interestingly, the average cross-sectional 
area of neurons positive for both CTb and CGRP at the C7 level (724±133µm2) was 
significantly smaller (p=0.0005) than the average area of all the CGRP-positive neurons 
in the C7 DRG (892±116µm2) (Table 4.2).  Although this relationship was consistent for 
all of the experimental groups, the differences within each group were not significant. 
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Data summarizing the ratio of CGRP-positive neurons among all afferents as well as 
specifically among joint afferents are included in Appendix H. 
 
4.5. Discussion 
 These data characterize a multi-segmental innervation of the C6/C7 facet joint in 
the rat and demonstrate that the joint innervation is unchanged at day 7 after painful 
mechanical joint loading (Tables 4.1 & 4.2).  The applied distraction of 0.47±0.05mm in 
the current study is in close agreement with a previously identified distraction magnitude 
(0.49±0.09mm) that was found to be sufficient to induce sustained behavioral sensitivity, 
while a lower magnitude of distraction (0.19±0.03mm) does not induce even transient 
mechanical sensitivity (Dong et al., 2011).  In that context, it is not likely that the joint 
distractions used in this study (~ 0.5mm) are induced by the normal head movements in 
the rat, though the physiological range of C6/C7 facet joint distraction during normal 
movement has not been defined explicitly.  Of the spinal levels analyzed, the greatest 
number of neurons with projections to the C6/C7 joint had cell bodies in the C7 DRG, 
followed by the C8, C6, and C5 DRGs (Table 4.1).  This trend in the segmental joint 
innervation is maintained despite an injury-induced increase in sensitivity to mechanical 
stimulation of the forepaw (Figure 4.1; Table 4.1).  Although painful injury does not alter 
the percentage of joint afferents expressing CGRP in the C7 DRG, greater than one-half 
of the joint afferents are peptidergic (Table 4.1), but only slightly more than 40% of all 
neurons in the C7 DRG are peptidergic.  Further, the average cell body is smaller for the 
peptidergic joint afferents (724±133µm2) than for all of the peptidergic neurons 
(892±116µm2) in the C7 DRG (Table 4.2).  Although a previous study defined the C5/C6 
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facet innervation with or without a complete disruption of its capsule (Ohtori et al., 
2003), that study did not quantify pain.  This study is the first to characterize the 
innervation of the C6/C7 facet joint in the context of injury-induced pain, and by doing so 
suggests that future studies to identify the cellular responses to painful injury to this joint 
should be directed at assessments of the C7 spinal level. 
 The distribution pattern of neurons innervating the C6/C7 facet joint identified 
here is consistent with studies characterizing innervation of other cervical facet joints in 
that joint afferents originate from multiple spinal levels with one level (C7 in this case) 
having a dominant number of neurons (Ohtori et al., 2001; Ohtori et al., 2003).  Indeed, 
multi-segmental innervation of facet joints is also evident in humans in which the lower 
cervical facets receive fibers from the medial branches of the dorsal rami above and 
below the joint (Barnsley and Bogduk, 1993).  The finding that the most C6/C7 joint 
afferents originate in the C7 and C8 DRGs (Table 4.1) supports the observation of 
forepaw hypersensitivity (Figure 4.1) since the C7 and C8 dermatomes in the rat extend 
from the neck to the forepaw (Takahashi and Nakajima, 1996).  Further, neurons 
innervating lumbar facet joints have been identified with dichotomizing axons projecting 
to peripheral targets (Sameda et al., 2001; Umimura et al., 2012), suggesting that some 
neurons innervating the C6/C7 facet joint may also possess dichotomizing axons 
extending into the forelimb and contributing to referred pain.  Studies using multiple 
retrograde tracers are necessary to determine the incidence of dichotomizing axons 
projecting to the C6/C7 facet joint and forepaw.  Nevertheless, these data indicate that the 
C7 spinal level is likely a major contributor to C6/C7 facet joint-mediated pain. 
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 Both the ratio of CGRP-positive joint afferents and their phenotype are 
unchanged by injury (Figure 4.2; Tables 4.1 & 4.2).  This finding is surprising since 
several studies have identified a shift in the phenotypic expression of pain-associated 
proteins like CGRP and brain-derived neurotrophic factor towards larger-diameter 
afferents in response to facet inflammation or traumatic injury (Ohtori et al., 2002; Ohtori 
et al., 2003).  Despite the lack of change in the phenotype of joint afferents, injury-
induced behavioral sensitivity may still result from afferent sensitization. Joint 
inflammation sensitizes afferents innervating the inflamed joint such that the threshold to 
activation is decreased and normally innocuous stimuli can be perceived as painful 
(Guilbaud et al., 1985; Schaible and Grubb, 1993; Schaible et al., 2009). Moreover, 
neuropeptides such as CGRP contribute to joint inflammation-induced pain and spinal 
neuronal sensitization (Schaible et al., 2009), demonstrating a role for neuropeptides in 
inflammatory joint pain.  While it is unlikely that the discs and other spinal ligaments 
contribute to pain in this model, previous work with this same injury model demonstrated 
that intra-articular injection of an NSAID abolishes facet joint injury-induced pain (Dong 
et al., 2011). Joint inflammation is associated with hyperexcitability of the afferents 
innervating the joint and pain (Guilbaud et al., 1985; Tachihara et al., 2007), and 
inflammation contributes to facet joint loading-induced pain (Dong et al., 2011). 
Combining those observations with the findings of the current study that greater than 
50% of joint afferents express CGRP supports a contribution of joint afferents to pain 
after facet joint distraction.  Yet, the subpopulations of joint afferents contributing to 
injury-induced pain still remain unknown.  CGRP- and substance P-containing fibers 
have been identified in human cervical facet capsular ligaments (Kallakuri et al., 2004; 
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Kallakuri et al., 2012), supporting the assertion that peptidergic afferents likely mediate 
pain in this joint.  In the C7 DRG in the rat, CGRP-positive neurons account for a greater 
percentage of neurons innervating the C6/C7 joint than they do among all neurons in the 
C7 DRG (Table 4.1).  Taken together, these data indicate that peptidergic joint afferents 
may make a greater contribution to facet joint pain than other neuronal subpopulations.  
Studies specifically investigating the roles of these and other populations of joint 
afferents in joint injury would determine their relative contributions to facet-mediated 
pain, helping to identify specific mechanisms contributing to joint pain as potential 
targets for its treatment. 
 Although these data provide insight into the innervation of the C6/C7 facet joint 
in the rat from C5 to C8, additional spinal levels also may contain joint afferents. In fact, 
Ohtori found that the C5/C6 facet joint in the rat contains fibers originating in the DRGs 
from C3-T3, although the vast majority originates in the cervical DRGs (Ohtori et al., 
2003).  Nevertheless, the C6/C7 facet joint is likely innervated by additional neurons with 
cell bodies in the upper thoracic DRGs.  Only the right DRGs were analyzed in this 
study, despite the application of a bilateral joint distraction; there is not expected to be 
differences based on sides since this injury is symmetric (Lee et al., 2004).  Of note, CTb 
may not label all joint afferents because not all sensory neurons express the ganglioside 
GM1, to which CTb binds.  Since the majority of sensory neurons (85% of small, 45% of 
medium, and 60% of large diameter neurons) do express GM1 (Gong et al., 2002), the 
joint afferent count data (Table 4.1) likely represent the majority of neurons innervating 
the C6/C7 facet joint. However, it is possible that some neurons, especially among the 
larger myelinated neurons, may not be labeled by CTb because GM1 is not universally 
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expressed. The use of additional and distinct retrograde neuronal tracing agents would 
provide a more robust characterization of the full extent of the facet joint’s innervation. 
However, because nociceptors have primarily small or medium diameter cell bodies 
(Merighi et al., 2008) and GM1 is expressed on 85% and 45% of these afferents, 
respectively (Gong et al., 2002), the majority of the nociceptive afferents are likely 
captured using the current technique. Further, although no visible leakage of the CTb 
solution from the facet joint was observed immediately after injection, a small amount 
may have leaked from the joint into the surrounding soft tissues. Nonetheless, any such 
leakage likely had only a minimal impact on the neuronal counts since the number of 
labeled neurons innervating the facet joint in our study is consistent with those reported 
in a study without joint injury in which cyanoacrylate was applied as a joint sealant 
(Ohtori et al., 2003).   
This study identified no differences in the ratio or cross-sectional area of CGRP-
positive joint afferents after injury; however, other peptides such as substance P may be 
differentially upregulated in these neurons.  Previous work using this model identified 
increased substance P and the prostaglandin E2 receptor, EP2, in the DRG after painful 
joint injury (Lee and Winkelstein, 2009; Kras et al., 2013a), supporting that additional 
targets may be upregulated by afferents after injury.  The lack of change in the ratio and 
cross-sectional area of CGRP-positive joint afferents observed in this study after injury 
(Tables 4.1 & 4.2) may be due to the small sample sizes.  Indeed, a previous study by 
Ohtori required nearly twice as many rats in each group to identify changes in the ratio 
and size of joint afferents expressing CGRP after a joint capsule transection compared to 
controls (Ohtori et al., 2003). Additional studies including larger group sizes are 
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necessary to verify our pilot studies finding that the ratio and cross-sectional area of the 
peptidergic joint afferents are unchanged by painful facet joint distraction. Despite these 
known injury-induced changes in the DRG, the specific roles of joint afferents in the 
generation and maintenance of facet-mediated pain are unknown.   
 
4.6. Conclusions & Integration 
By characterizing the segmental innervation of the C6/C7 facet joint and 
identifying a greater prevalence of neuropeptide expression among joint afferents 
compared to all other neurons in the DRG, this study has identified the C7 spinal level as 
most likely contributing to facet joint pain and provides direction for future studies 
investigating the cellular mechanisms underlying joint injury-induced pain. Because this 
study identified that more C6/C7 facet joint afferents originate from the C7 spinal level 
than any other level, studies in later chapters investigate cellular responses to injury at 
that level. In addition to CGRP and/or substance P, peptidergic afferents express the trkA 
receptor and are thus responsive to nerve growth factor (NGF) in the innervated tissue 
(Merighi et al., 2004; Pezet and McMahon, 2006). The abundance of peptidergic fibers 
innervating the C6/C7 facet joint (Figure 4.2; Table 4.1) suggests that the peptidergic 
afferents, and consequently NGF signaling, may make an important contribution to the 
development of joint pain. In fact, elevated levels of NGF are a common component of 
tissue inflammation (Amaya et al., 2004; Ma and Woolf, 1997; McMahon, 1996; Merighi 
et al., 2004), and Dong has recently shown joint inflammation is necessary for the 
maintenance of loading-induced facet joint pain (Dong et al., 2011), further supporting a 
potential role for NGF in facet pain.  
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Exposure to NGF has wide-ranging effects including: upregulation and increased 
release of neuropeptides and brain-derived neurotrophic factor (BDNF) (Merighi et al., 
2004; Pezet and McMahon, 2006), hyperexcitability of spinal neurons (Hoheisel et al., 
2007), and both mechanical and thermal behavioral sensitivity (Amaya et al., 2004; 
Malik-Hall et al., 2005). Nearly all of the aforementioned effects of NGF exposure have 
been documented in the rat following painful facet joint distraction (Dong et al., 2010; 
Kras et al., 2013c; Lee and Winkelstein, 2009; Quinn et al., 2010), including both 
mechanical (Figure 4.1) and thermal hypersensitivity (Figure 3.6). The previous findings 
of behavioral hypersensitivity in association with joint inflammation (Dong et al., 2013a) 
and spinal neuronal hyperexcitability (Crosby et al., 2013; Quinn et al., 2010) strongly 
implicate NGF as a key contributor to facet-mediated pain. In fact, elevated levels of 
NGF have been reported in painful arthritic joints in humans (Aloe et al., 1992; Barthel et 
al., 2009; Raychaudhuri et al., 2011; Saito et al., 2000), and recent studies found that 
intravenous anti-NGF treatment alleviates pain from osteoarthritis and low back pain 
(Brown et al., 2012; Katz et al., 2011; Lane et al., 2010), suggesting NGF has a role in 
joint pain. Therefore, in order to begin to define the mechanisms by which initial joint 
injury leads to persistent pain, studies in Chapter 5 will identify the role of intra-articular 
NGF in facet joint loading-induced pain, as well as the role of the peptidergic and non-
peptidergic afferents in mediating the onset of mechanical and thermal hyperalgesia due 
to NGF injection in the facet. Further, increased expression of BDNF in primary afferents 
and second order sensory neurons occurs downstream of NGF signaling (Merighi et al., 
2004; Pezet and McMahon, 2006). Because BDNF has been linked to inflammatory and 
neuropathic pain as well as hyperexcitability of spinal neurons (Grimsholm et al., 2008; 
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Lu et al., 2009; Mannion et al., 1999; Ohtori et al., 2002), Chapter 6 will characterize the 
expression of BDNF after painful facet joint injury and define its role in the maintenance 
of facet-mediated pain. 
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CHAPTER 5 
Development of Injury-Induced Facet Joint Pain 
and Central Sensitization: Contributions of Intra-
Articular Nerve Growth Factor 
 
Parts of this chapter are adapted from: 
Kras JV, Kartha S, Winkelstein BA (2014). Intra-Articular Nerve Growth Factor 
Regulates Development, But Not Maintenance, of Injury-Induced Facet Joint Pain & 
Spinal Neuronal Hypersensitivity. Osteoarthritis and Cartilage, in revision. 
 
5.1. Overview 
 Studies in Chapters 3 and 4 demonstrate facet joint distraction as inducing both 
mechanical and thermal hyperalgesia (Figures 3.5 & 3.6) and identify greater than 50% 
of facet joint afferents as peptidergic (Table 4.1). Despite evidence from those animal 
studies (Chapters 3 & 4), and from clinical studies (Lord et al., 1996; Manchikanti et al., 
2002; van Eerd et al., 2010) that identifies the facet joint as a source of pain after 
mechanical neck injury, the local initiators of pain in the C6/C7 facet joint after its injury 
remain poorly defined. Inflammatory cascades, such as prostaglandin E2 (PGE2) 
signaling, are evident in the joint and spinal cord following painful facet joint injury at 
the time when the corresponding spinal neurons at the level of the injured joint are also 
hyperexcitable (Crosby et al., 2013, Dong et al., 2013a, Kras et al., 2014a). Nerve growth 
factor (NGF) is increased in inflamed tissues and is sufficient to induce both mechanical 
and thermal hypersensitivity and spinal neuronal hyperexcitability (Hoheisel et al., 2007; 
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Lewin et al., 1994; McMahon, 1996). During development, most small diameter primary 
afferent neurons require NGF for survival (Merighi et al., 2008; Pezet and McMahon, 
2006); however, mainly peptidergic afferents that are capable of transmitting nociceptive 
information continue to express the NGF receptor, trkA, and remain sensitive to NGF in 
the adult (Merighi et al., 2004). Because a high proportion of joint afferents are 
peptidergic (Table 4.1; Kras et al., 2013b), NGF may induce joint pain by sensitizing the 
facet joint afferents. Animal models of pain resulting from inflammation demonstrate 
increased NGF as contributing to the development and maintenance of pain (Amaya et 
al., 2004; Woolf et al., 1994). Both clinically and in pain models of inflamed or arthritic 
joints, elevated levels of NGF are identified in the painful joint, suggesting a possible role 
for intra-articular NGF in joint pain (Barthel et al., 2009; Orita et al., 2011; Surace et al., 
2009). Although increases in NGF are associated with inflammation and inflammatory 
responses contribute to facet joint loading-induced pain (Dong et al., 2013a; Kras et al., 
2014a; McMahon, 1996; Woolf et al., 1994), it is not known if intra-articular NGF 
induces and/or maintains pain. NGF is a target for ongoing development of clinical 
treatments in several other musculoskeletal pain modalities, such as low back and knee 
pain (Brown et al., 2012; Katz et al., 2011). As such, defining whether or not NGF has a 
similar role in injury-induced facet pain will help identify if NGF signaling is a common 
mechanism across a range of musculoskeletal pain modalities. In addition, similarities in 
the mechanisms of arthritis- and injury-induced joint pain could indicate that mechanical 
joint injury initiates a degenerative process similar to osteoarthritis. A role for NGF in 
facet pain would support expanding current anti-NGF pain therapies being developed to 
include facet-mediated pain and local anti-NGF delivery in the joint as a new treatment. 
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 Studies presented in this chapter summarize experiments under Aim 2, and test 
the hypothesis that NGF increases in the facet joint after a painful joint distraction and is 
both necessary and sufficient for the initiation of both behavioral and spinal neuronal 
hypersensitivity after injury. As such, NGF expression is quantified within the facet joint 
as well as in the dorsal root ganglion (DRG) to determine if joint injury modulates local 
NGF levels. Further, behavioral responses are evaluated after intra-articular application 
of NGF (Aim 2a) to assess whether or not intra-articular NGF is sufficient to induce pain. 
In addition to behavioral outcomes, neuronal excitability is quantified in the spinal cord 
after application of NGF to the facet joint to determine if intra-articular NGF is sufficient 
to induce central sensitization, which is a state of increased neuronal excitability and 
synaptic efficacy that contributes to chronic pain (Latremoliere and Woolf, 2009). Based 
on those findings, targeted ablation of joint afferents involved in either peptidergic or 
non-peptidergic signaling is performed in separate groups of rats prior to NGF 
application to identify those neurons that contribute to NGF-mediated joint pain (Aim 
2b). The role of intra-articular NGF in the development of facet joint distraction-induced 
pain and spinal hyperexcitability is evaluated using an anti-NGF antibody to locally block 
NGF signaling in the joint (Aim 2c). Additional studies in Aim 2c also apply the anti-
NGF antibody to the facet joint after the initiation of loading-induced pain to determine if 
intra-articular NGF also maintains pain after joint injury. 
 
5.2. Relevant Background 
Musculoskeletal pain, especially joint and neck/back pain, is the most common 
type of chronic pain (Johannes et al., 2010; Pizzo et al., 2011). Among the fibers that 
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innervate articular joints, the Aδ- and C-fibers exhibit increased mechanosensitivity 
during joint inflammation and can be activated by normal joint motions (Guilbaud et al., 
1985; Schaible et al., 2009). Joint inflammation has been shown to sensitize neurons in 
the spinal cord and to expand receptive fields to include adjacent non-inflamed tissues in 
rat models (Martindale et al., 2007; Schaible et al., 2009; Woolf and Wall, 1986), 
supporting a role for central sensitization in joint pain.  
The facet joint is the most common source of pain in chronic neck pain patients 
(Manchikanti et al., 2002). Non-physiological loading of the facet joint activates 
nociceptors in its capsule (Lu et al., 2005) and induces hyperexcitability of spinal neurons 
and pain (Crosby et al., 2013; Dong et al., 2013b; Lee et al., 2008; Quinn et al., 2010). 
Moreover, intra-articular non-steroidal anti-inflammatory drug treatment alleviates pain 
after mechanical facet injury (Dong et al., 2013a), suggesting inflammatory contributions 
to loading-induced facet pain. Because arthritis-induced joint pain and injury-induced 
facet joint pain exhibit similar inflammatory and neuronal responses (Boettger et al., 
2008; Dong et al., 2013a; Martindale et al., 2007; Quinn et al., 2010), common 
mechanisms may contribute to both types of joint pain. Yet, the local molecular 
mechanisms that lead to the onset of facet pain are not defined. 
 Nerve growth factor sensitizes adult sensory neurons, and is increased in inflamed 
tissues (McMahon, 1996). Injection of NGF into peripheral tissues in animals (Lewin et 
al., 1994) and humans (Dyck et al., 1997) induces mechanical and thermal sensitivity. 
Treatment with anti-NGF antibodies alleviates pain from inflammation and injury in rat 
models (Wild et al., 2007; Woolf et al., 1994), and systemic anti-NGF reduces 
osteoarthritic joint pain (Brown et al., 2012), further supporting a role for NGF in joint 
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pain. NGF and its high-affinity receptor, trkA, have been identified in arthritic joints 
(Barthel et al., 2009) and degenerative facets (Surace et al., 2009). Although these studies 
suggest that intra-articular NGF may contribute to degenerative joint pain, its 
contribution, if any, to injury-induced facet pain is unknown. 
 Studies tested the hypothesis that intra-articular NGF contributes to the 
development of spinal neuronal hyperexcitability and behavioral hypersensitivity after 
facet joint injury using a validated rat model (Crosby et al., 2013). After painful injury, 
NGF expression was evaluated in the facet joint and in the DRG because NGF is 
transported to the cell bodies of mainly peptidergic primary afferents (Pezet and 
McMahon, 2006). Based on those findings, intra-articular NGF was administered to 
determine if it induces pain and spinal hyperexcitability. Targeted ablation of peptidergic 
or non-peptidergic joint afferents prior to intra-articular NGF application was utilized to 
identify which population of afferents regulates NGF-induced joint pain. An anti-NGF 
antibody was injected into the intra-articular space after an otherwise painful facet joint 
injury to determine if intra-articular NGF contributes to initiation of injury-induced spinal 
hyperexcitability and facet pain. In addition, the same anti-NGF antibody was injected 
into the joint one day after a painful facet joint injury, when behavioral hypersensitivity is 
evident, in order to assess whether or not joint pain is maintained by intra-articular NGF. 
 
5.3. Methods 
5.3.1. Facet Joint Distraction & Mechanical Behavioral Assessment 
Male Holtzman rats (Harlan Sprague-Dawley, Indianapolis, IN) weighing 
392±31g were housed under USDA- and AAALAC-compliant conditions with free 
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access to food and water. All experimental procedures were approved by the University 
of Pennsylvania IACUC and carried out under the guidelines of the Committee for 
Research and Ethical Issues of the IASP (Zimmermann, 1983). Three complementary 
studies were performed to: (1) first characterize NGF expression after painful facet joint 
injury, (2) identify whether or not intra-articular NGF is sufficient to induce pain and 
spinal neuronal hyperexcitability, and (3) define the contribution of intra-articular NGF to 
injury-induced facet pain and central sensitization. 
All surgical procedures were performed under inhalation isoflurane anesthesia 
(4% induction; 2.5% maintenance). A detailed procedure for the painful facet joint 
distraction (FJD) in the rat has been reported previously (Dong et al., 2008; Kras et al., 
2014a). Briefly, an incision was made along the midline of the back of the neck, and the 
C5-T1 laminae and facet joints were exposed and cleared of inserting muscles. The 
interspinous ligaments from C5-T1 were resected, and a loading device attached to the 
C6 and C7 laminae via microforceps applied a distraction across the bilateral C6/C7 facet 
joints by displacing the C6 vertebra rostrally and holding C7 fixed. The displacements of 
markers attached to the C6 and C7 laminae were recorded during the joint distraction by 
a camera mounted to the surgical dissecting scope and used to quantify the applied joint 
loading, as described previously (Kras et al., 2013a). The magnitude of distraction was 
compared between all groups of rats using an ANOVA with post hoc Tukey’s HSD test. 
Rats (n=8) were followed for one day after distraction injury. Sham procedures including 
device attachment with no applied joint distraction were performed in an additional group 
of rats followed for one day (n=8). Wounds were closed with polyester suture and 
surgical staples, and rats were recovered in room air. 
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Forepaw mechanical withdrawal thresholds were quantified for all rats using 
customary methods (Dong et al., 2011; Kras et al., 2013b). Rats were individually placed 
in elevated cages with wire mesh floors and allowed to acclimate to the testing 
environment for 15 minutes. An ascending series of von Frey filaments (Stoelting; Wood 
Dale, IL) was applied to each forepaw, and the lower of two consecutive filaments that 
elicit a positive response, defined as emphatic lifting of the forepaw, was taken as the 
threshold for the paw being tested. Thresholds were determined for each forepaw in three 
testing rounds separated by at least ten minutes, and the bilateral responses were averaged 
to obtain the withdrawal threshold for each rat. Thresholds were quantified for three days 
prior to any surgical procedure to establish baseline responses as well as post-operatively 
until the time of tissue harvest or electrophysiological experiments. Withdrawal 
thresholds were compared between groups using a two-way repeated measures ANOVA 
with group and time as factors and a post hoc Tukey’s HSD test. All statistical analyses 
were performed using JMP Pro v10.0.2 (SAS Institute Inc.; Cary, NC). 
 
5.3.2. Facet Joint Processing & NGF Assessments 
NGF expression was assessed in the facet joints of a subset of rats at day one 
(FJD n=3; sham n=3) using immunohistochemistry (IHC). Following behavioral 
assessment on day one after distraction or sham procedures, rats were given an overdose 
of sodium pentobarbital (65mg/kg) and transcardially perfused with phosphate buffered 
saline (PBS). Spinal columns from C4-T2 were harvested en bloc and post-fixed in 4% 
paraformaldehyde in PBS for three days. Columns were transferred to 30% sucrose in 
PBS for seven days and decalcified in 10% Ethylenediaminetetraacetic Acid (EDTA) in 
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PBS for three weeks, changing EDTA every three to four days. The C6/C7 spinal motion 
segment was isolated and embedded in Tissue-Tek OCT Compound (Sakura Finetek; 
Torrance, CA). The bilateral facet joints were sectioned (16µm) in the frontal plane, 
thaw-mounted onto slides, and labeled for NGF using previously published methods 
(Kartha et al., 2014). Endogenous peroxidase activity was quenched with 0.3% hydrogen 
peroxide in 0.01M PBS. Sections were incubated in DeCal Antigen Retrieval (BioGenex; 
Fremont, CA) solution for 30 minutes. Slides were washed, blocked with normal horse 
serum (Vector Laboratories; Burlingame, CA), and incubated in rabbit anti-NGF (1:250; 
Santa Cruz Biotechnology) primary antibody overnight at 4°C. The next day, sections 
were incubated with a biotinylated horse anti-rabbit secondary antibody (1:1000; Vector 
Laboratories) for 30 minutes and developed with 3,3-diaminobenzidine (Vector 
Laboratories). Sections were imaged on an Olympus BX51 microscope (Olympus; Center 
Valley, PA). 
NGF expression was also quantified in the soft tissues of the facet joint, including 
the capsular ligament and synovium, from a separate group of rats at day one (FJD n=5; 
sham n=5) using Western blot. Following behavioral assessment on day one, rats were 
transcardially perfused with PBS as described above. Capsular ligament and synovial 
tissue was harvested from the bilateral C6/C7 facet joints, immediately frozen on dry ice, 
and stored at -80°C until further use. Protein was extracted from the tissue using the 
RIPA Lysis Buffer System (Santa Cruz Biotechnology; Santa Cruz, CA) according to the 
manufacturer’s instructions. Proteins were prepared, separated, and transferred to an 
Immobilon-FL transfer membrane (Millipore; Billerica, MA) as described previously 
(Kras et al., 2013c). Membranes were blocked for one hour with 5% nonfat dry milk in 
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0.1% Tween-20 Tris-buffered saline (TBS) and incubated overnight at 4°C with a rabbit 
anti-NGF (1:200; Santa Cruz Biotechnology) antibody. On the following day, membranes 
were washed three times with 0.1% Tween-20 TBS and incubated for two hours at room 
temperature with a goat anti-rabbit IRDye 800CW (1:15,000; LI-COR; Lincoln, NE) 
secondary antibody. Membranes were imaged using the Odyssey Infrared Imaging 
System (LI-COR), then stripped and re-probed for β-tubulin using mouse anti-β-tubulin 
(1:2000; Covance; Princeton, NJ) primary and goat anti-mouse IRDye 680LT (1:15,000 
with 0.02% SDS; LI-COR) secondary antibodies. Quantitative analysis of NGF and β-
tubulin was performed using Image Studio Lite version 3.1 software (LI-COR).  NGF 
expression was normalized to β-tubulin as the loading control for each sample, and NGF 
expression after FJD is presented relative to expression in the sham group. NGF 
expression in the FJD and sham groups was compared by a t-test. 
 
5.3.3. Saporin Joint Injection 
Because peptidergic neurons are activated by NGF, those fibers are hypothesized 
to have an important role in facet mediated pain. In order to identify the contribution of 
peptidergic signaling in joint afferents to the development of facet joint injury-induced 
pain, neurons expressing the NK1 receptor were ablated using a targeted substance P 
conjugate of the neurotoxin saporin, [Sar9,Met(O2)11]-substance P-saporin (SSP-Sap) 
(Advanced Targeting Systems; San Diego, CA). Non-targeted saporin (Blank-Sap) 
served as a control (Advanced Targeting Systems). Because saporin is known to induce 
cell death within fourteen days (Weisshaar et al., 2014; Wiley et al., 2007), saporin was 
administered fourteen days prior to any joint procedures using established methods for 
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intra-articular injection (Dong et al., 2013a; Kras et al., 2013b). Briefly, the bilateral 
C6/C7 facet joints were exposed as described above. A 33-gauge beveled needle attached 
to a 10µL syringe (Hamilton Company; Reno, NV) was advanced into the facet joint, and 
100ng of SSP-Sap in 5µL of PBS was slowly injected into the bilateral facet joints (SSP-
Sap n=11). This dose of SSP-Sap was selected from the literature as sufficient to ablate 
spinal neurons expressing the substance P receptor when injected intrathecally 
(Weisshaar et al., 2014; Wiley et al., 2007). To serve as controls, 100ng of Blank-Sap 
was injected into the bilateral facet joints of separate rats (Blank-Sap+FJD n=7). 
Following joint injections, wounds were closed using polyester suture and surgical 
staples, and rats recovered in room air.  
Fourteen days after joint injections under inhalation isoflurane anesthesia, the 
surgical staples and suture were removed, and rats underwent either a facet joint 
distraction (SSP-Sap+FJD n=7; Blank-Sap+FJD n=7) or sham (SSP-Sap+sham n=4) 
procedure as described above. Wounds were closed again, and rats recovered in room air. 
Forepaw mechanical withdrawal thresholds were determined for each rat at baseline (day 
0) as well as on days one, three, five, and seven following facet joint distraction or sham 
procedures. Behavioral responses were compared using a two-way repeated measures 
ANOVA with post hoc Tukey’s HSD test. 
 
5.3.4. DRG Processing & NGF Immunohistochemistry 
Following behavioral testing on day seven, rats were given an overdose of sodium 
pentobarbital and transcardially perfused with PBS followed by 4% paraformaldehyde in 
PBS. The bilateral C7 DRGs were harvested and post-fixed overnight in the same fixative 
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used for perfusion. DRGs were transferred to 30% sucrose for six days before they were 
embedded in OCT (Sakura Finetek; Torrance, CA). Serial axial sections (14µm) of the 
DRGs were thaw-mounted onto slides and incubated in DeCal Antigen Retrieval 
(BioGenex; Fremont, CA) solution for two hours. Slides were washed, blocked with 
normal goat serum, and incubated overnight with rabbit-anti-NGF antibody (1:100; Santa 
Cruz Biotechnology) at 4°C. The next day, sections were incubated in an Alexa488 
conjugated goat-anti-rabbit secondary antibody (Life Technologies; Grand Island, NY) 
for two hours at room temperature, washed, and coverslipped. Sections of DRGs from 
naïve normal rats as well as sections with no primary antibody incubation were included 
as controls. Four sections from each rat were imaged on an Olympus BX51 microscope 
(Olympus; Center Valley, PA), and NGF labeling was quantified in each section by 
automated densitometry to detect the number of pixels above a detection threshold 
determined using the normal tissue sections (Kras et al., 2013c; Weisshaar et al., 2010). 
NGF expression was compared between groups using an ANOVA with a Bonferroni test. 
 
5.3.5. Intra-Articular NGF Injection 
In order to identify if intra-articular NGF is sufficient to induce behavioral 
sensitivity, rats received 3µg of rat β-NGF (R&D Systems; Minneapolis, MN) in 5µL of 
sterile PBS injected into the intra-articular space of the bilateral C6/C7 facet joints using 
the same procedure described above (NGF n=6). This dose was selected based on 
published reports of pain following intradermal or endoneurial injections of NGF 
(Amann et al., 1995; Malik-Hall et al., 2005; Obata et al., 2004). Additional rats 
underwent control joint injections of 5µL of sterile PBS (vehicle n=3). Mechanical 
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withdrawal thresholds were measured in the forepaws of all rats that underwent NGF or 
vehicle joint injections prior to injection to establish baseline responses, as well as at days 
one, three, five, and seven after injection to establish the time course of the behavioral 
response to the joint injections. Differences in withdrawal threshold were compared 
between the NGF and vehicle groups using a two-way repeated measures ANOVA with 
group and time as factors. Based on those behavioral time course studies of NGF or 
vehicle injection, additional groups of rats received the same bilateral intra-articular 
C6/C7 facet joint injections of either NGF (n=7) or vehicle (n=6). Rats were assessed for 
forepaw mechanical sensitivity at baseline and at one day post-injection and prepared for 
spinal electrophysiological recordings immediately following behavior testing on day one 
after injections. 
 
5.3.6. Spinal Electrophysiological Recordings 
Rats were prepared for spinal electrophysiological recordings (NGF n=7; vehicle 
n=6) after behavior testing on day one (Crosby et al., 2013). Rats were anesthetized with 
sodium pentobarbital (45mg/kg, i.p.), the mid-cervical trachea was exposed, cannulated, 
and ventilated (CWE Inc.; Ardmore, PA), and the rat was mounted onto a stereotaxic 
frame (Figure 5.1). The C6-C8 spinal cord was exposed via a bilateral laminectomy and 
removal of the overlying dura and bathed in 37°C mineral oil. Core temperature was 
maintained at 35-37°C using a feedback controlled heating plate with a rectal probe 
(Physitemp Instruments Inc.; Clifton, NJ). A thoracotomy was performed to minimize 
respiration-induced motion of the spinal cord during recordings. Anesthesia was 
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maintained throughout all procedures with supplementary doses of sodium pentobarbital 
(5-10mg/kg, i.p.) as needed. 
 
 Extracellular potentials were recorded in the C6-C7 spinal cord using tungsten 
electrodes lowered into the deep laminae (III-VI) of the spinal cord dorsal horn with a 
micropositioner. The deep laminae were selected because they include mainly wide 
dynamic range neurons that contribute to central sensitization (Coghill et al., 1993; 
Crosby et al., 2013; Dostrovsky and Craig, 2013; Quinn et al., 2010). The signal was 
amplified with a gain of 1,000, filtered with a passband between 300 and 3,000Hz, and 
ear bars 
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Figure 5.1. For electrophysiological recordings, the spinal cord was exposed from the 
C6-C8 levels. A tracheotomy enabled mechanical ventilation during the experiment. 
The rat was loaded onto a stereotaxic frame via ear bars and a bite plate. A clamp 
attached to the T2 spinous process held the spinal column such that the spinal cord 
was parallel to the ground. An electrode was lowered into the dorsal horn of the spinal 
cord via a micropositioner, and the stimulus train was applied to the right forepaw. 
Each von Frey filament was coupled to a load cell in order to synchronize stimulus 
application with the extracellular voltage recording. 
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sampled at 25kHz (Dong et al., 2013b). Sensory neurons with input from the forepaw 
were identified by applying a light brush to the plantar surface of the forepaw using a 
cotton swab. A stimulus train, consisting of light brush (applied for 10 seconds), a series 
of non-noxious and noxious von Frey filaments (1.4g, 4g, 10g, 26g) that span the range 
used during mechanical withdrawal threshold testing (each applied for five stimulations 
of one second followed by one second of recovery), and a noxious pinch (applied for 10 
seconds), was applied to the paw (Figure 5.2). Stimulus trains were applied at 30 second 
intervals, and the evoked spikes were recorded. 
 
 Recordings during the stimulus train were spike-sorted using Spike2 (CED; 
Cambridge, UK) in order to analyze individual neurons. Evoked spikes were summed 
Figure 5.2. In the order of application, the stimulus train consisted of a light brush, 
followed by stimulation with the 1.4g, 4g, 10g, and 26g von Frey (vF) filaments in 
order of increasing strength, and a pinch applied via a 60g microvascular clip. The 
brush was applied ten times with a one second interval between applications. Each 
von Frey filament was applied for one second followed by a one second rest period for 
a total of five stimulations per filament. After stimulation with the 26g von Frey 
filament, the pinch was applied for ten seconds. 
92 
over the continuous 10-second stimulus period for both the brush and pinch stimuli. 
Evoked spikes during the clip stimulus were used to classify neurons as either a low 
threshold mechanoreceptor (LTM) or a wide dynamic range (WDR) neuron (Quinn et al., 
2010). The number of spikes evoked from the initial application of a von Frey filament 
until one second after the 5th application of the filament were summed for each neuron. 
Baseline firing was quantified by counting the number of evoked spikes one second prior 
to the initial application of each filament. Baseline spikes were subtracted from the total 
spike count for each filament. The total number of evoked spikes for each stimulus was 
compared between groups using a two-way nested ANOVA with group and stimulus as 
factors and neurons nested within rats and rats nested within group, with post hoc 
Tukey’s HSD test. Differences in the ratio of WDR neurons were compared between 
groups using Pearson’s chi-square test. 
 
5.3.7. Saporin & NGF Injections 
Additional groups of rats received intra-articular injections of the neurotoxin, 
saporin, separately targeted to neurons involved in peptidergic or non-peptidergic 
signaling in order to establish the roles of these signaling pathways in NGF-mediated 
joint pain. Separate groups of rats received bilateral intra-articular injections of SSP-Sap 
(n=28) or Blank-Sap (n=20) as described above. Fourteen days after SSP-Sap or Blank-
Sap injections, rats were given an intra-articular injection of 3µg of NGF (SSP-Sap+NGF 
n=16; Blank-Sap+NGF n=12) or sterile PBS (SSP-Sap+veh n=12; Blank-Sap+veh n=8) 
as described above. Additional separate groups of rats received bilateral intra-articular 
injections of 5µg of saporin conjugated to isolectin B4 (IB4-Sap n=18) in 5µL of PBS to 
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ablate the non-peptidergic neurons. The dose of IB4-Sap was selected from a previously 
published report as sufficient to ablate non-peptidergic afferents (Tarpley et al., 2004). 
Separate rats received control injections of 5µg of unconjugated saporin (Saporin n=8) in 
5µL of PBS. Fourteen days after IB4-Sap or Saporin injections, rats were given an intra-
articular injection of 3µg of NGF (IB4-Sap+NGF n=12; Saporin+NGF n=8) or sterile 
PBS (IB4-Sap+veh n=6). In order to minimize the number of rats used, a Saporin+veh 
group was not included in this study since that inactive control saporin was not expected 
to be different from the unconjugated control group Blank-Sap+veh. Forepaw mechanical 
withdrawal thresholds were quantified at baseline and day one after NGF or vehicle 
injection for all rats and compared as described above. 
 
5.3.8. Thermal Behavioral Assessment & Spinal Electrophysiological Recordings 
Because NGF sensitizes neurons to both mechanical and thermal stimuli, rats 
were evaluated for thermal sensitivity after targeted neuronal ablation and NGF or 
vehicle administration (SSP-Sap+NGF n=8; SSP-Sap+veh n=8; Blank-Sap+NGF n=4; 
Blank-Sap+veh n=4; IB4-Sap+NGF n=8; IB4-Sap+veh n=6; Saporin+NGF n=5). 
Thermal hyperalgesia was evaluated in the forepaw following mechanical behavioral 
assessment for three days prior to NGF or vehicle joint injections and on day one using 
customary methods that also were detailed earlier in Chapter 3 (Nicholson et al., 2014). 
Rats were placed in wire mesh cages on top of a glass surface that was maintained at 
30°C and were allowed to acclimate to the testing environment for 30 minutes. A 
commercially available device (UC San Diego; San Diego, CA) was used to focus a 
radiant heat stimulus onto the plantar surface of each forepaw. A timer synchronized to 
94 
the thermal stimulus measured the withdrawal latency as the time between the initial 
application of the heat source and when the paw was withdrawn. Paw withdrawals 
associated with normal ambulation of the rat were not considered. On each testing day, 
the withdrawal latency was measured three times for each forepaw, with a ten minute rest 
period between each measurement. The withdrawal latency for each rat for each day was 
calculated by averaging the latency from the right and left forepaws across all testing 
rounds. Differences in withdrawal latency between groups were tested using a two-way 
repeated measures ANOVA with Tukey’s HSD test with group and time point as factors. 
Spinal neuronal excitability was quantified in a subset of rats following 
behavioral testing on day one after targeted neuronal ablation and NGF or vehicle 
administration (SSP-Sap+NGF n=4; SSP-Sap+veh n=4; IB4-Sap+NGF n=5; IB4-
Sap+veh n=4). Groups of rats received bilateral intra-articular injections of the SSP-Sap 
or IB4-Sap conjugates as described in Section 5.3.7. Fourteen days after the SSP-Sap or 
IB4-Sap injections, rats were given an intra-articular injection of 3µg of NGF or sterile 
PBS as described above in Section 5.3.7. In order to minimize the number of animals 
used and because excitability data from the NGF and vehicle groups without any saporin 
injections were already acquired, spinal neuronal excitability was not quantified in the 
non-targeted saporin groups (Blank-Sap+NGF; Blank-Sap+veh; Saporin+NGF). 
Following behavioral testing on day one after NGF or PBS joint injections, rats were 
prepared for electrophysiological recordings in the spinal cord (detailed in Section 5.3.6). 
Differences in neuronal excitability and the ratio of WDR neurons were compared 
between groups using a two-way nested ANOVA and Pearson’s chi-square test, 
respectively, as described above in Section 5.3.6. 
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5.3.9. Facet Joint Distraction & Intra-Articular Anti-NGF Injection 
In order to determine if intra-articular NGF contributes to the development of 
injury-induced joint pain, additional groups of rats underwent FJD or sham procedures as 
described in the first study (see Section 5.3.1 for details). Immediately following those 
surgical procedures and prior to wound closure, rats received bilateral intra-articular 
injections of either a rabbit polyclonal anti-NGF antibody or a control rabbit IgG 
(Millipore; Billerica, MA) in the C6/C7 facet joints, using the injection methods detailed 
above in Section 5.3.3. Rats undergoing joint distraction received a bilateral 10µg intra-
articular injection of either a rabbit polyclonal anti-NGF antibody (FJD+anti-NGF) or a 
non-specific control rabbit IgG (FJD+veh) in 5µL of PBS, a dose previously used in rat 
models of inflammatory and neuropathic pain (Amaya et al., 2004; Obata et al., 2003). 
Subsets of rats undergoing sham procedures also received bilateral intra-articular 
injections of the anti-NGF antibody (sham+anti-NGF) or control IgG (sham+veh). 
Following injection, wounds were closed, and the rats were followed for either one day 
(FJD+veh n=5; FJD+anti-NGF n=5; sham+veh n=5) or seven days (FJD+veh n=5; 
FJD+anti-NGF n=6; sham+veh n=5; sham+anti-NGF n=5). Forepaw mechanical 
withdrawal thresholds were measured in all rats to determine baseline responses as well 
as post-surgically on day one or on days one, three, five, and seven, according to their 
designated endpoint in the study. After behavioral testing on the designated day, rats 
were prepared for spinal electrophysiological recordings as described in Section 5.3.6. 
Differences in withdrawal thresholds were compared using a two-way repeated measures 
ANOVA with post hoc Tukey’s HSD test. Differences in neuronal excitability were 
compared between groups using a two-way nested ANOVA with group and stimulus as 
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factors and neurons nested within rats and rats nested within group, with post hoc 
Tukey’s HSD test. Differences in the ratio of WDR neurons were compared between 
groups using Pearson’s chi-square test. 
In order to determine if intra-articular NGF also contributes to the maintenance of 
injury-induced joint pain, an additional group of rats underwent FJD procedures as 
described above except that no intra-articular injections were applied immediately after 
joint distraction. Wounds were closed with polyester suture and surgical staples, and rats 
were recovered in room air. Following behavioral testing on day one, rats were 
anesthetized with inhalation isoflurane anesthesia (4% induction; 2.5% maintenance), the 
surgical staples and suture were removed, and the bilateral C6/C7 facet joints were re-
exposed. Those rats received a bilateral 10µg intra-articular injection of the rabbit 
polyclonal anti-NGF antibody (FJD+anti-NGFD1 n=8) in 5µL of PBS, and wounds were 
closed as described above. Forepaw mechanical withdrawal thresholds were measured at 
baseline as well as post-distraction on days one, three, five, and seven, at which time rats 
were prepared for spinal electrophysiological recordings as described above. Differences 
in withdrawal thresholds and neuronal excitability were compared between groups 
(FJD+anti-NGF, FJD+veh, FJD+anti-NGFD1) as described in the earlier methods. 
 
5.4. Results 
5.4.1. Facet Joint Distraction & Applied Joint Injury Magnitudes 
All rats undergoing FJD in these studies underwent the same magnitude of joint 
injury. The average vertebral distraction applied to the rats that were followed for one 
day for either assessment of capsular ligament NGF expression or to identify the role of 
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intra-articular NGF in the initiation of joint pain was 0.71±0.18mm. That vertebral 
distraction was not different from the distraction applied to those rats (0.70±0.27mm) that 
were followed for seven days in order to measure NGF expression in the DRG or 
determine the contribution of intra-articular NGF to joint pain. There were no significant 
differences in the applied distraction between any of the subgroups of joint-injured rats 
used in the studies characterizing NGF expression after injury or administering intra-
articular anti-NGF after the joint injury. As such, any outcomes from the different studies 
using the distraction groups can be taken as the same, with no variability due to the injury 
itself. The maximum vertebral and capsule distractions, as well as the associated 
maximum capsular ligament strains, for each rat in this study are detailed in Appendix B. 
 
5.4.2. Injury-Induced Expression of NGF in the Facet Joint & DRG 
 Rats undergoing FJD exhibit significantly lower mechanical withdrawal 
thresholds on day one after facet joint distraction than their corresponding baseline 
responses (p<0.001) and also compared to the sham group at day one (p<0.001) (Figure 
5.3A). Yet, the thresholds in the sham group are unchanged from baseline (Figure 5.3A; 
see Appendix C for the detailed forepaw mechanical withdrawal data for each rat 
included in this study. NGF labeling is evident in the C6/C7 facet joint on day one after 
its distraction and more dense than in the sham group at that time point (Figures 5.3B & 
5.3C). Quantification of NGF expression in the bilateral C6/C7 facet capsular ligaments 
and synovial tissues by Western blot identifies significantly greater levels of NGF after 
FJD compared to sham (p=0.031) (Figures 5.3D & 5.3E). The quantification of NGF 
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expression by Western blot is summarized in Appendix F. These results demonstrate an 
elevation in intra-articular NGF in association with painful facet joint injury. 
 
Figure 5.3. (A) Facet joint distraction (FJD) reduces the forepaw withdrawal 
threshold to mechanical stimulation at day one compared to baseline (#p<0.001) and 
to a sham procedure (*p<0.001). Immunolabeling for NGF is increased in the soft 
tissues surrounding the joint (arrows) at day one after FJD (B) compared to sham (C). 
(D) Western blots showing NGF and β-tubulin expression in the capsular ligament and 
synovium. (E) FJD increases NGF in the capsular ligament and synovium (*p=0.031) 
over levels in sham at day one. Scale bar in (B) is 50µm and applies to (B) and (C). 
The amplified inset boxes in (B) and (C) are 50µm wide. 
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 Because NGF activates peptidergic neurons, we also evaluated if peptidergic 
afferents in the facet joint contribute to the development of loading-induced pain using 
targeted ablation of the afferents involved in peptidergic signaling. Intra-articular 
injection of the inactive Blank-Sap before a typically painful facet joint distraction does 
not alter the development of injury-induced mechanical sensitivity; the withdrawal 
threshold significantly decreases by day one relative to baseline and remains significantly 
below baseline at all post-injury points in that group (p<0.001) (Figure 5.4A). However, 
intra-articular injection of SSP-Sap to ablate neurons involved in peptidergic signaling 
before a distraction prevents the development of injury-induced mechanical 
hypersensitivity (Figure 5.4A). The withdrawal threshold of the SSP-Sap+FJD group is 
unchanged from baseline after distraction, a response that is also exhibited by the SSP-
Sap+sham group (Figure 5.4A). Moreover, the withdrawal threshold for Blank-Sap+FJD 
is significantly lower than for SSP-Sap+FJD (p<0.001) or SSP-Sap+sham (p<0.001) at 
all post-injury days (Figure 5.4A). The individual mechanical withdrawal thresholds for 
each rat are summarized in Appendix C. 
Immunolabeling of the C7 DRG in these groups at day seven indicates that many 
neurons express NGF in the C7 DRG after a FJD with no ablation of afferents (Figure 
5.4B) but relatively few such NGF-labeled neurons are evident in either of the groups 
with the SSP-Sap injection (Figures 5.4C & 5.4D). Quantification of NGF expression 
with automated densitometry reveals a significant elevation of NGF expression in Blank-
Sap+FJD over levels in both the SSP-Sap+FJD (p<0.001) and SSP-Sap+sham (p<0.001) 
groups (Figure 5.4E). A summary of the quantitative densitometry for NGF expression in 
the DRG for individual rats is included in Appendix E. 
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Figure 5.4. (A) The forepaw withdrawal threshold to von Frey filament stimulation is 
significantly reduced by day one and remains reduced through day seven (p<0.001) 
after intra-articular injection of Blank-Sap into the facet prior to FJD (Blank-
Sap+FJD). Withdrawal thresholds for Blank-Sap+FJD are significantly lower than 
those for either SSP-Sap+FJD (*p<0.001) or SSP-Sap+sham (#p<0.001) at all post-
surgical time points, neither of which is changed from baseline. NGF is increased at 
day seven in the DRG after Blank-Sap+FJD (B) compared to SSP-Sap+FJD (C) and 
SSP-Sap+sham (D). Quantification by automated densitometry indicates these 
differences are significant (*p<0.001 vs. SSP-Sap+FJD; #p<0.001 vs. SSP-Sap+sham) 
(E). Scale bar in (D) is 50µm and applies to all panels. 
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5.4.3. Intra-Articular NGF-Induced Pain & Neuronal Hyperexcitability 
Because NGF is upregulated in the joint early after injury and along the time 
course of pain onset and maintenance (Figures 5.3, 5.4A, & 5.4E), we next determined if 
intra-articular NGF administered alone is sufficient to induce behavioral sensitivity. The 
withdrawal threshold at day one after intra-articular NGF injection is significantly 
decreased (p<0.010) but returns to, and remains at, baseline for all assessment times after 
day one (Figure 5.5A). Joint injection of vehicle does not alter the withdrawal threshold 
(Figure 5.5A). Because an NGF-induced reduction in withdrawal threshold is only 
evident on day one after injection (Figure 5.5A), additional rats were given intra-articular 
NGF or vehicle injections and followed for only one day to determine if intra-articular 
NGF also increases excitability in spinal neurons. The additional NGF injected rats used 
for electrophysiological assessment exhibited the same behavioral outcomes (Figures 
5.5A & 5.5B), with a significant reduction in withdrawal threshold at day one compared 
to baseline (p<0.001) and to the vehicle group at day one (p<0.001) (Figure 5.5B). There 
was no change in the withdrawal threshold for the vehicle injection group (Figure 5.5B).  
A total of 91 mechanosensitive spinal neurons with input from the forepaw were 
recorded at an average depth of 681±22µm in those rats. Representative traces during 
stimulation with each of the four von Frey filaments illustrate increased evoked firing in 
the NGF group compared to the vehicle group (Figure 5.5C). Quantification of the 
evoked spikes across rats and neurons demonstrates a trend towards increased firing at 
each von Frey filament strength in the NGF group that is significantly elevated over 
vehicle responses for the noxious 26g filament (p<0.040) (Figure 5.5D). In addition, 
significantly more neurons were classified as wide dynamic range (WDR) on day one 
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after NGF injection (93.2%) than after vehicle injection (74.5%) (p=0.016) (Figure 5.5E). 
Mechanical withdrawal thresholds and the spinal neuronal firing data for each rat are 
summarized in Appendix C and Appendix G, respectively. 
 
Figure 5.5. (A) Intra-articular application of NGF, but not the vehicle, significantly 
reduces the withdrawal threshold from baseline at day one (*p<0.010), but it returns to 
baseline by day three. (B) In additional rats followed for one day, intra-articular NGF 
reduces the withdrawal threshold at day one relative to baseline (*p<0.001) and to 
vehicle controls at day one (‡p<0.001). (C) Representative extracellular recordings in 
the spinal cord at day one demonstrate increased evoked neuronal firing in rats in the 
NGF group compared to the vehicle group. (D) The number of evoked spikes is 
significantly increased (‡p<0.040) for the noxious 26g filament after NGF injection 
over vehicle injection. (E) The number of wide dynamic range (WDR) neurons 
increases in the NGF group compared to the vehicle group (‡p=0.016). 
103 
 Although ablating neurons in the facet joint that are involved in peptidergic 
signaling by administering SSP-Sap prevents the development of NGF-induced facet pain 
at day one, giving Blank-Sap does not alter the development of NGF-mediated pain 
(Figures 5.6A & 5.6B). Mechanical withdrawal thresholds for Blank-Sap+NGF are 
significantly reduced at day one from baseline (p<0.001), whereas no other groups 
exhibited a change from baseline (Figure 5.6A). Further, the withdrawal threshold for 
Blank-Sap+NGF is significantly lower at day one than any of the other groups (SSP-
Sap+NGF (p<0.001), SSP-Sap+veh (p<0.001), Blank-Sap+veh (p<0.001)), none of 
which are different from each other (Figure 5.6A). When the vehicle is administered 
before NGF (Blank-Sap+NGF) the thermal withdrawal latency at day one is also reduced 
from the baseline latency (p<0.009) (Figure 5.6B). Similar to the mechanical response, 
ablation of neurons involved in peptidergic signaling prevents the development of NGF-
induced thermal sensitivity (Figure 5.6B). When peptidergic signaling is intact (Blank-
Sap+NGF), NGF reduces the withdrawal latency compared to both SSP-Sap+NGF 
(p<0.022) and SSP-Sap+veh (p<0.011). Moreover, the withdrawal latency trends towards 
a decrease in Blank-Sap+NGF compared to Blank-Sap+veh, but this difference does not 
reach significance (p=0.098) (Figure 5.6B). Although mechanosensitive spinal neurons 
with input from the forepaw were identified in both groups receiving the ablation (SSP-
Sap+NGF and SSP-Sap+veh; 63 neurons; average depth of 678±21µm) (Figure 5.6C), no 
differences in the number of evoked spikes elicited by von Frey stimulation (Figure 5.6D) 
nor the proportion of WDR neurons (Figure 5.6E) were detected between groups, 
indicating that central sensitization driving facet injury-induced pain is driven by 
peptidergic input from the joint. Detailed mechanical withdrawal thresholds and thermal 
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withdrawal latencies for each rat are included in Appendix C; the individual spinal 
neuronal firing data for each rat is summarized in Appendix G. 
 
Figure 5.6. (A) Mechanical withdrawal threshold is reduced from baseline when intra-
articular Blank-Sap, but not SSP-Sap, is given prior to NGF (Blank-Sap+NGF) 
(*p<0.001). The withdrawal threshold at day one for Blank-Sap+NGF is reduced 
compared to all other groups (+#‡p<0.001). (B) The thermal withdrawal latency is 
reduced at day one compared to baseline for Blank-Sap+NGF (*p<0.009) but not for 
any other group. Blank-Sap+NGF has a shorter withdrawal latency than either SSP-
Sap+NGF (+p<0.022) or SSP-Sap+veh (#p<0.011). (C) Extracellular recordings in the 
spinal cord show similar firing between the SSP-Sap+NGF and SSP-Sap+veh groups. 
There is no difference in total evoked spikes for any filament (D) nor in the proportion 
of WDR neurons (E) between the SSP-Sap+NGF and SSP-Sap+veh groups. 
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In contrast to ablating the peptidergic signaling (Figure 5.6A), eliminating the 
non-peptidergic joint afferents does not affect the intra-articular NGF-induced sensitivity 
to mechanical stimuli (Figure 5.7A). In fact, mechanical withdrawal thresholds for both 
IB4-Sap+NGF and Saporin+NGF are reduced at day one from their respective baseline 
responses (p<0.001) and are not different from each other (Figure 5.7A). However, IB4-
Sap+veh shows no change in mechanical sensitivity, and IB4-Sap+NGF and Sap+NGF 
both exhibit significantly lower withdrawal thresholds at day one than does IB4-Sap+veh 
at that time (p<0.008) (Figure 5.7A). Both IB4-Sap+NGF (p<0.012) and Saporin+NGF 
(p<0.006) exhibit shorter thermal withdrawal latencies at one day after NGF injection 
than at baseline; yet, the control group, IB4-Sap+veh, is unchanged from baseline (Figure 
5.7B). No differences are detected between any groups at day one, despite IB4-Sap+NGF 
and Saporin+NGF trending lower than IB4-Sap+veh (Figure 5.7B). Mechanical and 
thermal hyperalgesia data for each rat in this study are summarized in Appendix C. 
Representative traces of extracellular voltage spikes in neurons in the spinal cord 
evoked by each of the von Frey filaments demonstrate increased firing in the IB4-
Sap+NGF group relative to the IB4-Sap+veh group (78 total neurons; average depth 
731±20µm) (Figure 5.7C). Stimulation by the 26g von Frey filament evokes significantly 
more spikes in the IB4-Sap+NGF group compared to the IB4-Sap+veh group (p<0.029) 
(Figure 5.7D), but the number of WDR neurons is not different between groups (Figure 
5.7E). Spinal neuronal firing data for each rat in this study is included in Appendix G. 
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Figure 5.7. (A) Intra-articular NGF significantly reduces the mechanical withdrawal 
threshold at day one compared to baseline in rats given IB4-Sap (*p<0.001) or the 
unconjugated control Saporin (#p<0.001), but no change is evident in the IB4-
Sap+veh control group. In addition, both IB4-Sap+NGF and Saporin+NGF exhibit 
significantly lower thresholds than the IB4-Sap+veh control group at day one 
(‡p<0.008). (B) Thermal withdrawal latency is reduced for both IB4-Sap+NGF 
(*p<0.012) and Saporin+NGF (#p<0.006) compared to baseline, but neither is 
different from IB4-Sap+veh at day one. Representative extracellular recordings in the 
spinal cord (C) demonstrate the increased firing that is evoked by von Frey filament 
stimulation for IB4-Sap+NGF compared to IB4-Sap+veh and that is significant for the 
26g filament (‡<0.029) (D). However, the ratio of wide dynamic range neurons is not 
different between groups (E). 
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5.4.4. Blocking Intra-Articular NGF in Injury-Induced Facet Pain 
 After establishing that intra-articular NGF is sufficient to induce facet-mediated 
pain, we identified if intra-articular NGF contributes to the development of sustained 
behavioral sensitivity and spinal hyperexcitability induced by facet joint injury. By day 
one after facet joint distraction with a bilateral intra-articular injection of vehicle IgG 
(FJD+veh), the same reduction in the mechanical withdrawal threshold as is observed by 
injury alone (Figure 5.3) is evident, which is maintained through day seven (p<0.001) 
(Figure 5.8A). The withdrawal thresholds were unchanged from baseline after either of 
the sham procedures (sham+veh or sham+anti-NGF) at any time point (Figure 5.8A). 
However, intra-articular anti-NGF (FJD+anti-NGF) inhibits the development of 
mechanical sensitivity after joint injury, preventing any change in withdrawal threshold 
from baseline responses at any post-injury time point (Figure 5.8A). Anti-NGF treatment 
maintains mechanical withdrawal thresholds at a magnitude comparable to sham+veh and 
sham+anti-NGF (Figure 5.8A) and at a level that is significantly elevated over FJD+anti-
NGF (p<0.015) responses (Figure 5.8A). Detailed mechanical withdrawal thresholds for 
each rat in this study are presented in Appendix C. 
Recordings were made from 186 spinal neurons (average depth 620±13µm) at day 
seven after injury. Stimulation of the forepaw with either the 10g or 26g von Frey 
filaments evokes significantly more spikes for the FJD+veh group than for any other 
group (FJD+anti-NGF p<0.001; sham+veh p<0.012; sham+anti-NGF p<0.001) (Figure 
5.8B). No differences are detected between any other groups for any of the von Frey 
filaments. Noxious pinch of the forepaw elicits a similar response, with more evoked 
spikes in the FJD+veh group than any of the other three groups (p<0.001) (Figure 5.8C); 
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no differences in evoked spikes are detected between any groups for light brushing of the 
paw (Figure 5.8C). Individual spinal neuronal spike counts for each rat in this study are 
included in Appendix G. There is a significant effect of injury group on the proportion of 
WDR neurons recorded in the spinal cord (p<0.005), with FJD+veh exhibiting the 
highest frequency of WDR neurons (Figure 5.8D). 
The behavioral and electrophysiological studies performed at day one after injury 
in these same groups (Figure 5.9) mimic the results observed at day seven. The forepaw 
withdrawal threshold is significantly reduced in the FJD+veh group compared to the 
FJD+anti-NGF (p<0.001) and sham+veh (p<0.001) groups, which themselves are not 
different from each other, at day one (Figure 5.9A); Appendix C provides a detailed list 
of the withdrawal thresholds for each rat in this study. Electrophysiological recordings 
were made from 107 spinal neurons (average depth 729±19µm) at day one after injury or 
sham procedures. Similar to the findings at day seven (Figure 5.8B), stimulation of the 
forepaw with the 26g von Frey filament evokes significantly more spikes for the 
FJD+veh group at day one than for either of the other two groups (FJD+anti-NGF 
p<0.006; sham+veh p<0.001) (Figure 5.9B) at that time point. Although there is a trend 
toward an increase in the number of spikes evoked by stimulation with the 10g filament 
in the FJD+veh group compared to the other groups, this difference is only significant for 
comparison with the sham+veh group (p<0.007). 
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Figure 5.8. (A) The withdrawal threshold is reduced from baseline at all time points 
for FJD+veh (p<0.001). The withdrawal threshold is reduced for FJD+veh compared 
to FJD+anti-NGF (*p<0.015), sham+veh (#p<0.001), and sham+anti-NGF (‡p<0.001) 
at all post-injury days. (B) At day seven, the number of evoked spikes is increased in 
the FJD+veh group compared to all other groups (*#‡p<0.012) for the 10g and 26g 
filaments. (C) Pinch evokes more spikes for FJD+veh compared to all other groups 
(*#‡p<0.001). (D) There is an effect of group on the proportion of WDR neurons 
(+p<0.005), with FJD+veh having the largest number. (E) Representative recordings 
illustrate increased spikes in the FJD+veh group compared to the other groups. 
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Noxious pinch of the forepaw evokes more spikes in the FJD+veh group 
compared to sham+veh (p<0.005), but the difference between FJD+veh and FJD+anti-
NGF is not significant at day one (Figure 5.9C). No differences are detected between 
sham+veh and FJD+anti-NGF for any of the von Frey filaments or either the brush or 
pinch stimuli. Mirroring the results at day seven, there is a significant effect of injury 
group on the proportion of WDR neurons recorded in the spinal cord (p<0.042), with 
FJD+veh exhibiting the highest frequency of WDR neurons (Figure 5.9D). Individual 
spinal neuronal spike counts at day one for each rat in this study are included in 
Appendix G. Together, these behavioral and electrophysiological findings early after 
injury (Figure 5.9), as well as at a later time point (day seven) after injury (Figure 5.8), 
support a role for intra-articular NGF in the development of persistent pain and spinal 
hyperexcitability after facet joint injury. 
In contrast to the lack of change in mechanical withdrawal threshold after 
immediate anti-NGF treatment (FJD+anti-NGF), intra-articular anti-NGF injections given 
one day after FJD (FJD+anti-NGFD1) do not abolish injury-induced reductions in the 
withdrawal threshold (Figure 5.10A). On day one after joint distraction, the withdrawal 
threshold significantly decreases for the FJD+anti-NGFD1 group compared to baseline 
(p<0.001) and is not different from FJD+veh but is significantly lower than FJD+anti-
NGF (p<0.012) at that time (Figure 5.10A). Intra-articular injection of the anti-NGF 
antibody after behavior testing on day one does not increase the withdrawal threshold. On 
the contrary, the withdrawal threshold for FJD+anti-NGFD1 remains significantly lower 
than baseline (p<0.028) as well as FJD+anti-NGF (p<0.043) at all post-surgical time 
points and is not different from FJD+veh on any day (Figure 5.10A). 
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Figure 5.9. (A) The forepaw withdrawal threshold is reduced from baseline at day one 
for FJD+veh (p<0.001); yet, there is no change from baseline for sham+veh or 
FJD+anti-NGF at day one. The withdrawal threshold is reduced for FJD+veh 
compared to FJD+anti-NGF (*p<0.001) and sham+veh (#p<0.001) at day one. (B) 
The number of spikes evoked by von Frey filament stimulation is increased in the 
FJD+veh group over the FJD+anti-NGF (*p<0.006) and sham+veh (#p<0.001) groups 
for the 26g filament and is also increased over sham+veh (#p<0.007) for the 10g 
filament at day one. (C) Pinch evokes more spikes for FJD+veh compared to 
sham+veh (#p<0.005). (D) There is a significant effect of group on the proportion of 
WDR neurons (+p<0.042), with FJD+veh having the largest number. (E) 
Representative recordings illustrate increased spikes evoked by stimulation of the 
forepaw in the FJD+veh group compared to the other groups. 
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Quantification of evoked spikes from 61 spinal neurons (average depth 
724±25µm) at day seven after FJD+anti-NGFD1 identifies significantly more firing 
evoked by the 26g filament compared to FJD+anti-NGF (p<0.022) but not with the pinch 
(Figures 5.10B & 5.10C). Spikes evoked by the noxious 26g von Frey filament are not 
different between the FJD+anti-NGFD1 and FJD+veh groups (Figures 5.10B & 5.10C). 
In the context of the behavioral findings (Figure 5.10A), these electrophysiological data 
suggest that intra-articular NGF is not a contributor to the maintenance of injury-induced 
facet pain or the associated spinal neuronal hyperexcitability. Detailed mechanical 
withdrawal thresholds for each rat included in this study are summarized in Appendix C; 
individual spinal neuronal firing data for each rat are included in Appendix G. 
 
Figure 5.10. (A) Withdrawal threshold decreases at all days (d) after FJD+veh 
compared to FJD+anti-NGF (*). FJD+anti-NGFD1 also exhibits decreases in 
threshold at all days compared to FJD+anti-NGF (#). (B) At day seven, the number of 
spikes evoked by noxious von Frey stimulation (26g) decreases for FJD+anti-NGF 
relative to FJD+veh (*) and FJD+anti-NGFD1 (#), but both FJD+anti-NGF (*) and 
FJD+anti-NGFD1 (+) exhibit fewer evoked spikes than FJD+veh for noxious pinch. 
(C) Representative spikes are shown for the 26g and pinch stimuli for each group. 
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5.5. Discussion 
This study defines a role for intra-articular NGF in the development of facet joint-
mediated pain. NGF expression increases in the injured joint as early as one day after 
painful injury and within the DRG at day seven (Figures 5.3 & 5.4). Exogenous intra-
articular NGF induces transient mechanical and thermal behavioral sensitivity lasting one 
day, implicating intra-articular NGF in pain initiation (Figures 5.5, 5.6, & 5.7). Intra-
articular NGF induces behavioral sensitivity that is associated with spinal neuronal 
hyperexcitability (Figure 5.5). Pharmacologic ablation of neurons involved in 
peptidergic, but not non-peptidergic, signaling from the joint prevents the development of 
both of these NGF-induced responses, strongly supporting peptidergic signaling in NGF-
mediated joint pain (Figures 5.6 & 5.7). Interruption of peptidergic signaling in the joint 
prevents the increases in NGF expression in the DRG that are evident with injury-
induced pain (Figure 5.4). Local administration of anti-NGF in the joint immediately 
after its injury also prevents the development of both behavioral and spinal neuronal 
hypersensitivity (Figure 5.8). Yet, delayed administration of intra-articular anti-NGF one 
day after joint injury does not abolish behavioral sensitivity or the associated spinal 
neuronal hyperexcitability (Figure 5.10). Taken together, these data identify NGF as the 
intra-articular initiator of joint injury-induced pain and support early localized treatment 
targeting NGF as a potential effective therapy. 
NGF has been shown to contribute to arthritis-related joint pain. NGF is 
upregulated in inflamed tissues (McMahon, 1996) and increases in the soft tissues of 
experimental knee arthritis in the rat (Orita et al., 2011). Increased NGF also has been 
reported in the synovial fluid of painful inflamed and arthritic joints in humans (Barthel 
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et al., 2009; Raychaudhuri et al., 2011; Saito et al., 2000). Because intra-articular NGF 
induces pain, albeit only transiently, in our study, elevated intra-articular NGF is a likely 
source of clinical joint pain, especially since NGF induces pain in humans when applied 
to skin or muscle tissue (Dyck et al., 1997; Svensson et al., 2003). The elevated intra-
articular NGF across several types of painful conditions, including our model of painful 
joint trauma, together with the fact that local anti-NGF prevents pain development, 
suggests that regardless of the etiology, NGF likely has a role in a broad range of painful 
joint conditions, including other traumatic joint injuries or arthritis. 
 The prevention of injury-induced pain by immediate, but not delayed (day one), 
intra-articular anti-NGF supports traumatic joint pain being mediated by early NGF 
signaling cascades (Figures 5.8, 5.9 & 5.10). Yet, NGF-induced joint pain is transient and 
only evident for one day (Figure 5.5). As such, several mechanisms may induce persistent 
joint pain, with NGF as the initiator. Painful facet joint distraction is associated with 
increased expression of prostaglandin E2 (PGE2), a known regulator of inflammation and 
pain (Lin et al., 2006), by day one after injury (Kras et al., 2014a); NGF facilitates 
inflammatory hyperalgesia by inducing a switch to a PKCε-dependent mechanism for 
PGE2 signaling (Joseph and Levine, 2010; Parada et al., 2005). Such a priming 
mechanism may explain why intra-articular NGF induces only short-lasting transient pain 
and that intra-articular anti-NGF given at injury, but not at later times, prevents 
development of long-lasting facet pain (Figure 5.5, 5.8, 5.9 & 5.10). Early anti-NGF 
treatment may prevent nociceptor priming by blocking the early intra-articular NGF after 
injury, a notion further supported by the finding that intra-articular anti-NGF given on 
day one when behavioral sensitivity is evident does not alleviate pain (Figure 5.10). 
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Indeed, intra-articular ketorolac, which disrupts synthesis of prostaglandins, has no effect 
on pain responses when given at the time of joint injury (Dong et al., 2013a), which is 
consistent with our finding that NGF is an early mediator of injury-induced joint pain. 
However, in contrast, intra-articular ketorolac does abolish facet pain when given later, 
after pain has developed (Dong et al., 2013a). The different effects of the anti-NGF and 
NSAID may be due to early NGF facilitating later PGE2-mediated nociception; although 
NGF is sufficient to initiate pain, additional mediators may contribute to its maintenance. 
 Ablating joint afferents involved in peptidergic signaling prevents NGF-induced 
mechanical hypersensitivity, but eliminating non-peptidergic joint afferents has no effect 
(Figures 5.6 & 5.7). This is not surprising since the NGF receptor, trkA, is expressed 
mainly by peptidergic afferents (McMahon, 1996; Merighi et al., 2004), which comprise 
over 50% of the afferents innervating the rat’s C6/C7 facet joint (Kras et al., 2013b). 
Increased peptidergic fiber density is reported in painful osteoarthritic joints (Saito et al., 
2000), and peptidergic fibers sprout into the synovium in models of painful arthritis 
(Ghilardi et al., 2012; Longo et al., 2013). Neuropeptides are typically expressed by 
nociceptive C- and Aδ-fibers (Galeazza et al., 1995), so sprouting of peptidergic fibers in 
the facet may also induce joint pain. Our results demonstrate a role for peptidergic 
signaling among joint afferents in injury-induced pain since ablating them prior to injury 
prevents the development of behavioral sensitivity (Figure 5.4). Intra-articular NGF also 
increases thermal sensitivity, which is abolished when peptidergic signaling is disrupted 
prior to NGF injection (Figure 5.6). However, when non-peptidergic neurons are ablated, 
thermal sensitivity after NGF injection is not different from controls, confirming that 
non-peptidergic afferents also contribute to thermal pain (Figure 5.7). The transient 
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receptor potential vanilloid-1 responds to noxious thermal stimuli and is expressed on 
both peptidergic and non-peptidergic afferents in the rat (Okun et al., 2011; Yu et al., 
2008), so both afferent populations may contribute to thermal sensitivity, which is also 
supported by our findings. Peptidergic signaling also contributes to mechanical 
sensitivity after NGF injection or after facet joint distraction; because non-peptidergic 
joint afferents do not contribute to NGF-induced mechanical sensitivity those afferents 
likely do not contribute to facet joint distraction-mediated mechanical sensitivity either. 
Together, these findings identify peptidergic signaling as having more influence than 
non-peptidergic signaling in both NGF- and injury-induced facet joint pain. 
 Intra-articular NGF also induces hyperexcitability in dorsal horn neurons, with 
equivalent noxious mechanical stimulation of the forepaw eliciting more spinal neuronal 
activity in the NGF-injected rats compared to control rats (Figure 5.5). This increased 
excitability is evident also when non-peptidergic joint afferents are eliminated before 
NGF injection (Figure 5.7). However, disruption of peptidergic signaling in the joint 
prevents NGF-induced hyperexcitability of spinal neurons (Figure 5.6).  Many of the 
neurons in the deep dorsal horn are WDR neurons that respond to both non-noxious and 
noxious signals (Pezet et al., 1999; Seal et al., 2009). WDRs have an important role in 
central sensitization, the enhancement of the excitability or synaptic efficacy of neurons 
in the central nervous system, and contribute to many forms of persistent pain (Calvino et 
al., 1987; Latremoliere and Woolf, 2009; Martindale et al., 2007). With injection of intra-
articular NGF, there is an increase in the number of neurons in the dorsal horn responding 
as WDRs to mechanical stimulation (Figure 5.5). The increases in spinal neuronal 
excitability and WDRs that are induced by NGF suggest that intra-articular NGF may 
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mediate the central modifications underlying joint pain. One common consequence of 
central sensitization is an expansion of the receptive fields of sensory neurons 
(Latremoliere and Woolf, 2009), which has been reported for monoarthritis in the rat 
knee with the neurons innervating the ipsilateral ankle becoming hyperexcitable 
(Martindale et al., 2007). Indeed, whiplash patients with neck pain experience 
hypersensitivity to mechanical stimuli in the neck, as well as in the shoulder, arm, and 
even the hand (Fernandez-Perez et al., 2012; Scott et al., 2005; Sterling et al., 2003). The 
finding that NGF injected in the facet joint induces behavioral hypersensitivity in the 
forepaw further supports central sensitization as an underlying mechanism in facet-
mediated pain. 
Painful facet joint distraction increases dorsal horn neuronal excitability and 
induces a shift from low threshold mechanosensitive neurons to WDRs (Crosby et al., 
2013; Quinn et al., 2010). Together with our findings that NGF increases in the facet after 
its injury and is sufficient to induce pain and spinal neuronal hyperexcitability, early 
intra-articular NGF is strongly implicated as mediating injury-induced facet pain. Indeed, 
intra-articular application of an anti-NGF antibody prior to joint injury prevents the 
development of both behavioral hypersensitivity and spinal neuronal hyperexcitability 
(Figures 5.8 & 5.9). Although current systemic anti-NGF therapies show promise in 
alleviating joint pain from osteoarthritis and chronic low back pain, they are associated 
with adverse events, such as headache, hyperesthesia, paresthesia, and even joint 
degeneration (Brown et al., 2012; Katz et al., 2011; Lane et al., 2010). Our findings 
suggest local anti-NGF treatment to be effective at preventing the onset of joint pain. Of 
note, all rats receiving anti-NGF exhibited normal weight gain and grooming behavior 
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and were otherwise indistinguishable from control rats, with no obvious ill-effects 
associated with the local anti-NGF treatment.  
In contrast to the findings that immediate intra-articular anti-NGF application 
prevents injury-induced pain and the spinal neuronal hyperexcitability associated with it 
(Figures 5.8 & 5.9), delayed application of intra-articular anti-NGF until one day after 
joint injury does not mitigate existing behavioral or spinal neuronal hypersensitivity 
(Figure 5.10). Only a single time point (day one) for post-injury anti-NGF treatment was 
assessed here, and there may be earlier post-injury time points at which intra-articular 
anti-NGF treatment is effective for preventing or alleviating pain. Indeed, blocking intra-
articular sodium channel activation within four hours, but not later, after a known painful 
facet joint distraction prevents the development of both of these same behavioral and 
neuronal correlates (Crosby et al., 2014). As such, evaluation of additional time points for 
intra-articular delivery of anti-NGF after joint injury is necessary to determine if 
localized anti-NGF therapy is a feasible treatment for injury-induced joint pain. 
Moreover, only a single dose of the anti-NGF antibody was applied. Although the 
selected dose is effective when given immediately after injury, a higher dose may be 
required to alleviate existing pain. In fact, a dose-dependent alleviation of inflammatory 
and neuropathic pain is reported for systemic anti-NGF treatments in animal models of 
pain (Wild et al., 2007) as well as clinically for knee pain (Lane et al., 2010). Further, 
multiple injections of anti-NGF may be necessary to alleviate established facet joint-
mediated pain. Although multiple anti-NGF injections have not been applied in pre-
clinical models of joint pain, repeated anti-NGF treatment does alleviate sciatic nerve 
injury-induced pain in mice, while a single dose of anti-NGF only transiently relieves 
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pain (Wild et al., 2007). As such, additional work varying the dose and timing of anti-
NGF treatment is needed to fully evaluate whether or not the more invasive, but more 
focused, local treatment is effective in alleviating facet joint pain and is associated with 
fewer adverse events than systemic anti-NGF treatment for joint pain. Nevertheless, the 
prevention of injury-induced pain and neuronal hyperexcitability achieved with intra-
articular anti-NGF injection demonstrates that intra-articular NGF is necessary for the 
development of joint pain after facet injury. 
Although further studies are necessary to determine if intra-articular anti-NGF is 
sufficient to alleviate established facet joint pain, additional pain mediators might also 
maintain facet pain. Substance P has an established role in a variety of pain modalities, 
including neuropathic and joint pain (Keeble and Brain, 2004; Nichols et al., 1999), 
promoting inflammation and potentiating glutamatergic neurotransmission (Keeble and 
Brain, 2004; Seybold, 2009; Sharif Naeini et al., 2005). Ablation of substance P sensitive 
spinal neurons prevents the development of pain following either nerve injury or an 
inflammatory stimulus in the rat (Nichols et al., 1999). In fact, ablation of spinal neurons 
expressing the NK1 receptor two weeks prior to a facet joint injury prevents the 
development of facet-mediated pain (Weisshaar and Winkelstein, 2014), suggesting the 
central release of substance P is required for pain maintenance after facet joint injury. 
Yet, the actions of substance P are not limited to the spinal cord; peripheral nerve 
terminals innervating targets such as joints also release substance P (Keeble and Brain, 
2004). Similar to targeted elimination of NK1-bearing neurons in the spinal cord, ablation 
of substance P sensitive joint afferents prevents facet joint injury-induced pain (Figure 
5.4). Further, both intra-articular and intrathecal antagonism of substance P signaling 
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separately alleviate established arthritis pain (Keeble and Brain, 2004; Uematsu et al., 
2011), demonstrating that substance P in the periphery and in the spinal cord also 
maintains joint pain. Because expression and release of substance P from primary 
afferent neurons is regulated by NGF (Merighi et al., 2004), the increased intra-articular 
NGF that initiates pain following a facet joint injury likely stimulates substance P 
synthesis and release. In fact, substance P expression is increased in the DRG seven days 
after a painful facet joint injury (Lee and Winkelstein, 2009) in parallel with a similar 
increase in NGF expression (Figure 5.4). Moreover, ablation of joint afferents sensitive to 
substance P prevents both injury-induced and NGF-induced facet pain (Figures 5.4 & 
5.6). Antagonism of the NK1 receptor in the spinal cord prevents the behavioral effects of 
NGF applied systemically (Thompson et al., 1995), demonstrating that substance P 
signaling is necessary for NGF-induced pain. That connection between NGF-induced 
behavioral hypersensitivity and substance P release suggests that treatments targeting 
substance P might be more effective in alleviating established facet pain than targeting 
intra-articular NGF. Although not included in this thesis, additional studies to assess 
whether or not blockade of substance P signaling, either alone or in combination with 
inhibition of intra-articular NGF, is sufficient to alleviate established pain after a facet 
joint injury would clarify the relationship, if any, between NGF, substance P, and facet 
pain maintenance. 
 
5.6. Conclusions & Integration 
In conclusion, these data demonstrate a role for intra-articular NGF and 
peptidergic joint afferents in the development of pain and spinal neuronal 
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hyperexcitability following injurious trauma to the cervical facet joint. Despite clinical 
reports of increased NGF in degenerative and arthritic joints (Barthel et al., 2009; 
Raychaudhuri et al., 2011) and in rat arthritis models (Aloe et al., 1992; Orita et al., 
2011), this study is the first to establish that intra-articular NGF induces pain and central 
sensitization. Intra-articular anti-NGF given immediately after a joint injury prevents pain 
development; yet, when given one day after the injury, that same dose of intra-articular 
anti-NGF is ineffective in alleviating pain. Because only a single dose of anti-NGF was 
applied on day one after injury, further work applying a different anti-NGF treatment 
regimen, such as a higher dose and/or multiple injections, is needed to fully define 
whether or not intra-articular NGF contributes to the maintenance of joint pain. 
Additional pain mediators, such as prostaglandins and neuropeptides, are upregulated 
after joint injury (Kras et al., 2013c; Kras et al., 2014a; Lee and Winkelstein, 2009) and 
may contribute to pain maintenance. Regardless, this study provides the first evidence 
that intra-articular NGF is both necessary and sufficient for the development of facet 
joint-mediated pain. 
Although findings in the current set of studies identify intra-articular NGF as an 
initiator of injury-induced facet pain and spinal neuronal hyperexcitability, the cellular 
responses initiated by NGF that lead to behavioral hypersensitivity and spinal 
sensitization after facet injury are not defined. Among the pain mediators regulated by 
NGF, brain-derived neurotrophic factor (BDNF) contributes to behavioral sensitivity 
resulting from tissue insults ranging from inflammation to nerve damage (Coull et al., 
2005; Li et al., 2006; Mannion et al., 1999; Michael et al., 1997). BDNF is synthesized 
by peptidergic afferents in response to NGF signaling (Michael et al., 1997; Merighi et 
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al., 2008), so the finding that a majority of the afferents innervating the C6/C7 facet joint 
are peptidergic (Chapter 4) taken with the studies here demonstrating an injury-induced 
upregulation of NGF in the facet joint and DRG suggests that BDNF may be a 
downstream mediator of joint pain. In fact, BDNF produced in the primary afferents is 
transported to the spinal cord, where its release sensitizes spinal neurons via activation of 
trkB (Merighi et al., 2008; Pezet and McMahon, 2006; Zhou et al., 2008). Indeed, spinal 
BDNF contributes to pain and the central sensitization that maintains pain (Geng et al., 
2010; Lu et al., 2009; Merighi et al., 2008; Zhou et al., 2008); moreover, inhibition of 
spinal BDNF signaling alleviates existing pain after nerve injury (Coull et al., 2005; 
Zhang et al., 2011). Because NGF has a prominent role in initiating facet-mediated pain 
and spinal neuronal hyperexcitability and BDNF is known to contribute to both pain and 
central sensitization, studies in Chapter 6 characterize the BDNF response in this model 
of painful facet joint loading, as well as identify whether or not BDNF maintains injury-
induced joint pain. 
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CHAPTER 6 
Facet Joint Injury and the Neurotrophin 
Response: A Role for Spinal BDNF in Persistent 
Pain 
 
Parts of this chapter are adapted from: 
Kras JV, Weisshaar CL, Quindlen J, Winkelstein BA (2013). Brain-Derived 
Neurotrophic Factor is Upregulated in the Cervical Dorsal Root Ganglia and Spinal Cord 
and Contributes to the Maintenance of Pain From Facet Joint Injury in the Rat. Journal of 
Neuroscience Research, 91(10): 1312-1321. 
 
6.1. Overview 
 Although tensile loading of the cervical facet joint has been associated with 
inflammation and neuronal hyperexcitability (Crosby et al., 2013; Dong et al., 2013a; 
Quinn et al., 2010), the mechanisms of joint loading-induced pain remain unknown. 
Findings from the studies presented in Chapters 4 and 5 suggest a role for nerve growth 
factor (NGF) activation of the peptidergic joint afferents that innervate the C6/C7 facet 
joint in initiating the onset of sustained behavioral sensitivity and spinal neuronal 
hyperexcitability after mechanical joint injury (Kras et al., 2013b; Kras et al., 2014b). 
Further, expression of brain-derived neurotrophic factor (BDNF) is regulated by NGF 
and induces behavioral hypersensitivity and hyperexcitability of spinal neurons in models 
of both painful inflammation and nerve injury (Cho et al., 1997; Ha et al., 2001; Li et al., 
2006; Lu et al., 2009; Mannion et al., 1999; Pezet and McMahon, 2006). BDNF is 
normally produced in peptidergic afferent neurons before undergoing anterograde 
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transport to the superficial dorsal horn of the spinal cord where its release is stimulus 
dependent (Hartmann et al., 2001; Merighi et al., 2008; Pezet and McMahon, 2006; Zhou 
et al., 1999). Upon release into the synaptic cleft, BDNF sensitizes neurons through both 
pre- and post-synaptic receptor activation, contributing to hypersensitivity in a wide 
range of tissue injuries and disease states (Geng et al., 2010; Matayoshi et al., 2005; 
Merighi et al., 2008; Pezet et al., 2002). In fact, BDNF is upregulated in primary afferents 
in the DRG in response to NGF signaling, as well as peripheral inflammation (Cho et al., 
1997; Mannion et al., 1999; Michael et al., 1997).  Pain models of inflamed tissues or 
arthritic joints demonstrate upregulation of BDNF (Mannion et al., 1999; Ohtori et al., 
2002; Grimsholm et al., 2008). Despite increased BDNF expression being associated with 
inflammation (Mannion et al., 1999; Pezet and McMahon, 2006) and a reported 
contribution of inflammation to facet joint injury-induced pain (Dong et al., 2013a), no 
study has defined BDNF expression in the DRG and/or spinal cord following a painful 
mechanical joint injury. As such, characterization of the BDNF response in those tissues 
after facet joint injury can help identify whether or not BDNF contributes to the 
development and/or maintenance of injury-induced joint pain. 
 This chapter summarizes experiments under Aim 1b and Aim 3, which quantify 
the BDNF response to painful facet joint injury in the DRG (Aim 1b) and spinal cord 
(Aim 3). Intra-articular NGF is upregulated by mechanical facet joint injury and is 
necessary for the initiation of pain and neuronal hyperexcitability in the spinal cord after 
distraction of that joint (Chapter 5; Kras et al., 2014b). Because BDNF may be increased 
by NGF signaling and is associated with pain and neuronal hyperexcitability (Lu et al., 
2009; Mannion et al., 1999; Merighi et al., 2004; Pezet and McMahon, 2006), studies in 
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this chapter test the hypothesis that BDNF increases in the DRG and spinal cord after a 
painful facet joint distraction and contributes to the maintenance of joint-mediated 
behavioral sensitivity. Accordingly, BDNF expression is quantified in the DRG (Aim 1b) 
and the spinal cord (Aims 3a & 3b) after a painful joint distraction at day one and day 
seven to evaluate if it is associated with behavioral hypersensitivity. Further, the 
functional role of BDNF in facet-mediated pain is evaluated using intrathecal 
sequestration of BDNF (Aim 3c) to directly assess the contribution of BDNF signaling to 
join injury-induced pain symptoms. 
 
6.2. Relevant Background 
Animal models of facet joint injury support the assertion that mechanical injury to 
the facet can cause pain and report altered inflammatory mediators in the joint and DRG, 
as well as neuronal hyperexcitability associated with behavioral sensitivity (Cavanaugh et 
al., 1996; Kras et al., 2013a; Lee et al., 2008; Lu et al., 2005; Quinn et al., 2010; 
Tachihara et al., 2007). The facet capsule is innervated by Aδ- and C-fibers that are 
activated by mechanical stimulation and inflammation (Cavanaugh et al., 1996; Ohtori et 
al., 2001; Lu et al., 2005; Cavanaugh et al., 2006). Both types of stimuli induce 
behavioral sensitivity (Dong et al., 2008; Dong et al., 2013a; Lee et al., 2008; Tachihara 
et al., 2007) and lead to upregulation of inflammatory cytokines in the DRG (Lee et al., 
2008; Miyagi et al., 2006; Tachihara et al., 2007). The behavioral hypersensitivity 
induced by facet joint distraction is relieved by intra-articular application of the non-
steroidal anti-inflammatory drug ketorolac (Dong et al., 2013a), implicating inflammation 
in painful mechanical joint injury. Moreover, because NGF is increased in inflamed 
126 
tissues (Merighi et al., 2004), the upregulation of NGF in the injured facet joint and its 
contribution to the initiation of facet-mediated pain that were identified in Chapter 5 
(Kras et al., 2014b) further suggest that inflammation may be a key component of facet 
pain.  
Peripheral inflammation and NGF increase the neurotrophin BDNF in the DRG 
(Cho et al., 1997; Mannion et al., 1999; Michael et al., 1997). The number of BDNF-
expressing afferents innervating the facet joint has also been shown to increase seven 
days after inflammation induced by complete Freund’s adjuvant (CFA) in that same facet 
joint compared to controls (Ohtori et al., 2002). Despite the association of inflammation 
with increases in BDNF (Cho et al., 1997; Mannion et al., 1999; Michael et al., 1997; 
Ohtori et al, 2002) and an established contribution of joint inflammation to facet loading-
induced pain (Dong et al., 2013a), the relationships among facet joint injury, pain, and 
BDNF are unclear. 
 BDNF is involved in nociceptive signaling in many pain states (Cho et al., 1997; 
Li et al., 2006; Mannion et al., 1999; Michael et al., 1997; Zhou et al., 1999). BDNF 
released from primary afferents contributes to spinal hyperexcitability by activating its 
receptor, trkB (Lu et al., 2009; Merighi et al., 2008; Pezet and McMahon, 2006; 
Thompson et al., 1999), which in turn activates the MAP kinase, ERK, via 
phosphorylation (Ji et al., 2002; Pezet et al., 2002; Slack et al., 2004). Further, the 
amount of BDNF released in the spinal cord in response to neuronal stimulation is 
increased by exposure to NGF (Lever et al., 2001), suggesting that BDNF may be the 
central mediator of the NGF-dependent spinal hyperexcitability identified in Figure 5.8 
(Kras et al., 2014b). Inhibition of spinal BDNF activity by the sequestering molecule, 
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trkB-Fc, which binds endogenously released BDNF and prevents it from activating 
functional membrane-bound trkB receptors, alleviates nerve injury-induced sensitivity 
(Coull et al., 2005; Zhang et al., 2011). That sequestering molecule also reduces the 
spinal ERK activation that is induced by chemical stimulation of peripheral nociceptors 
with capsaicin (Pezet et al., 2002). BDNF levels in the DRG and spinal cord both 
increase as soon as one day after a painful intraplantar injection of inflammatory CFA in 
the rat (Duric and McCarson, 2007; Mannion et al., 1999). Although animal models of 
joint inflammation and arthritis have demonstrated increased BDNF expression in the 
synovial tissue of the affected joints and their associated DRGs (Grimsholm et al., 2008; 
Ohtori et al., 2002), behavioral outcomes were not evaluated in those studies, so the 
functional role of BDNF in joint-mediated pain remains unclear.   
 Based on the role of BDNF in nociceptive signaling and its effects on spinal 
neuronal excitation, the objectives of this study are to evaluate whether or not BDNF 
increases following painful facet joint injury and to determine the functional role of 
BDNF in facet-mediated pain. Because BDNF is transcribed and synthesized in the DRG 
but is transported to, and released in, the spinal cord, BDNF mRNA and protein levels are 
quantified in the DRG and in the spinal cord using RT-PCR and immunolabeling 
techniques in separate animals at early (day one) and late (day seven) time points after 
the painful facet joint injury described in Chapter 3 and used in Chapters 4 and 5. Based 
on those characterization studies, additional studies administered trkB-Fc intrathecally to 
evaluate effects of sequestering spinal BDNF on hyperalgesia and spinal ERK activation. 
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6.3. Methods 
6.3.1. Surgical Procedures & Behavioral Assessment 
 Male Holtzman rats (Harlan Sprague-Dawley, Indianapolis, IN) (402±24g) were 
housed under USDA- and AAALAC-compliant conditions with free access to food and 
water. All experimental procedures were approved by the University of Pennsylvania 
IACUC and carried out under the guidelines of the Committee for Research and Ethical 
Issues of the IASP (Zimmermann, 1983). 
 All surgical procedures were performed under inhalation isoflurane anesthesia 
(4% induction; 2.5% maintenance). The bilateral C6/C7 facet joints underwent a 
controlled distraction sufficient to induce sustained mechanical hypersensitivity using the 
same procedures described in Chapter 3 (Dong et al., 2008; Kras et al. 2013b). Briefly, 
the C6 and C7 laminae were exposed and attached to a loading device via microforceps 
to impose a distraction across the bilateral C6/C7 facet joints. Peak displacement of the 
C6 forceps during each distraction was recorded to quantify the severity of the applied 
injury. Separate groups of rats underwent joint distraction and were followed for one 
(n=13 rats) and seven days (n=12 rats), at which time both the C6 and C7 DRGs and C6-
C7 spinal cord were harvested.  Sham procedures that included device attachment with no 
joint distraction were performed in separate groups of rats (n=7 for day 1; n=10 for day 
7). All wounds were closed using polyester suture and surgical staples, and rats were 
recovered in room air. 
 The response to mechanical stimulation was quantified in the forepaws of each rat 
to measure behavioral hypersensitivity after surgical procedures, using previously 
validated methods  as described in Chapters 3, 4, and 5 (Dong et al., 2008; Hubbard and 
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Winkelstein, 2005; Lee and Winkelstein, 2009). Rats underwent behavioral testing on 
day one or days one, three, five, and seven, depending on the time of tissue harvest, as 
well as for three days prior to any surgical procedure in order to establish baseline 
responses. On each testing day, rats were acclimated to the testing environment for 15 
minutes followed by three rounds of mechanical stimulation to each forepaw using a 
series of ascending von Frey filaments (Stoelting; Wood Dale, IL). Responses from the 
bilateral forepaws were averaged to obtain a single measure of mechanical sensitivity for 
each rat. Sensitivity after the surgical procedures was normalized to the baseline response 
for each rat and expressed as the fold-increase relative to baseline. A two-way ANOVA 
with Tukey’s HSD test compared the normalized average mechanical sensitivity between 
distraction and sham groups with group and time point as factors, and significance at 
p<0.05. 
 
6.3.2. DRG & Spinal Cord Processing & BDNF mRNA Quantification 
 In order to define the BDNF mRNA levels in the DRG and spinal cord, tissue was 
harvested at the C6 and C7 spinal levels from both of the sham and distraction groups at 
day one or day seven for RT-PCR analysis. After behavioral testing on day one (n=7 
distraction; n=3 sham) or day seven (n=6 distraction; n=6 sham), rats were given an 
overdose of sodium pentobarbital (65mg/kg) and transcardially perfused with phosphate 
buffered saline (PBS). Because the injury is bilateral and behavioral responses are not 
different between the right and left sides, tissue responses to injury are also expected to 
not differ between right and left. As such, based on the symmetry assumption, only the 
left DRGs and spinal cord hemi-sections at the C6 and C7 levels were analyzed. Tissue 
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was harvested, immediately frozen on dry ice, and stored at -80ºC until further use. 
Tissue samples were homogenized in TRIzol® (Invitrogen; Carlsbad, CA). Total RNA 
was extracted and reverse-transcribed into single-stranded cDNA according to the 
manufacturer’s instructions (Invitrogen). Taqman® real time RT-PCR reactions were 
carried out using an ABI-7300 system (Applied Biosystems; Foster City, CA) with 
primers specific to BDNF (Forward: 5’-GGA-CAT-ATC-CAT-GAC-CAG-AAA-GAA-
A-3’; Reverse: 5’-GCA-ACA-AAC-CAC-AAC–ATT-ATC-GAG-3’; Probe: 5’-AGT-
CAT-TTG-CGC-ACA-ACT-TTA-AAA-GTC-TGC-ATT-3’) and the internal 
housekeeping gene 18S (Forward: 5’-CGG-CTA-CCA–CAT-CCA-AGG-AA-3'; 
Reverse: 5’-GCT-GGA–ATT-ACC-GCG-GCT-3’; Probe: 5’-CAC-CAG-ACT-TGC-
CCT-C-3’) (Gomez-Pinilla et al., 2002; Lossos et al., 2003). Cycle conditions were: 95°C 
for 10 minutes, 40 cycles at 95°C for 15 seconds and 60°C for 60 seconds. Samples were 
run in duplicate, and target gene expression was normalized to the internal housekeeping 
gene expression (18S) using the 2∆∆Ct method (Kras et al., 2013c; Lee et al., 2008; Lee 
and Winkelstein, 2009; Livak and Schmittgen, 2001). The mRNA level for each tissue 
for the distraction group was calculated as the fold-change relative to the average levels 
for sham in that tissue. BDNF mRNA levels were separately compared between 
distraction and sham groups for each tissue (DRG; spinal cord) at each time point (day 1; 
day 7), using t-tests. 
 
6.3.3. DRG & Spinal Cord Processing & BDNF Immunohistochemistry 
 BDNF is normally expressed in small and medium diameter neurons in the DRG, 
with less expression in the large diameter neurons (Zhou et al., 1999). Because injury or 
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inflammation shifts the neuronal phenotype that expresses BDNF towards larger diameter 
neurons (Ohtori et al., 2002; Zhou et al., 1999), painful facet joint injury is hypothesized 
to cause a similar phenotypic shift in BDNF expression. In order to identify any such 
phenotypic change, immunohistochemistry was used to evaluate BDNF protein in DRG 
neurons and in the superficial laminae of the spinal dorsal horn in additional separate 
groups of rats. After behavioral testing on day one (n=6 distraction; n=4 sham) or day 
seven (n=6 distraction; n=4 sham), rats were deeply anesthetized with an overdose of 
sodium pentobarbital (65mg/kg) and transcardially perfused with PBS followed by 4% 
paraformaldehyde in PBS.  
Cervical spinal cords with bilateral DRGs were harvested en bloc from the C6 and 
C7 levels and were post-fixed overnight at 4°C. Tissue was transferred to 30% sucrose in 
PBS for at least 4 days at 4°C and embedded in Tissue-Tek® OCT Compound (Sakura 
Finetek; Torrance, CA). Serial DRG and spinal axial sections (14µm thick) were taken 
for immunofluorescent histochemistry and thaw-mounted onto slides, with 3-5 sections 
per slide. Tissue sections were washed and blocked with normal donkey serum 
(Chemicon; Temecula, CA) for 2 hours. DRG sections were incubated at 4°C overnight 
with a rabbit polyclonal antibody specific to BDNF (1:100; sc-20981; Santa Cruz 
Biotechnology; Santa Cruz, CA). The following day, slides were washed and incubated 
with a Cy3 donkey anti-rabbit secondary antibody (1:500; Jackson ImmunoResearch; 
West Grove, PA) for 2 hours at room temperature. After additional washes with PBS and 
dH2O, slides were coverslipped with Fluoro-Gel anti-fade medium (Electron Microscopy 
Sciences; Hatfield, PA). Because there are multiple cellular sources for BDNF synthesis 
and release, including neurons, microglia, and astrocytes in the spinal cord and because 
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BDNF from specific cell types may underlie pain from different injuries (Coull et al., 
2005; Merighi et al., 2008; Zhang et al., 2011; Zhou et al., 1999; Zhou et al., 2011), the 
cellular sources of spinal BDNF were identified in addition to quantifying overall BDNF 
expression in the spinal cord. Spinal cord sections were incubated at 4°C overnight with 
the rabbit antibody to BDNF and one of the following: mouse monoclonal antibody to 
glial fibrillary acidic protein (GFAP; as a marker of astrocytes) (1:500; Millipore; 
Billerica, MA), mouse polyclonal antibody to microtubule associated protein-2 (MAP2; 
as a marker of neurons) (1:200; SMI 52; Covance; Princeton, NJ), or mouse monoclonal 
antibody to OX-42 (CD11b; as a marker of microglia) (1:300; Serotec; Raleigh, NC). The 
following day, the slides were washed and incubated at room temperature for 2 hours 
with Cy3 donkey anti-rabbit (1:500; Jackson ImmunoResearch) and Alexa488 donkey 
anti-mouse (1:500; Invitrogen) secondary antibodies. Tissue sections that were not 
incubated with primary antibodies were included as negative controls for all assays. 
 Each DRG section was imaged using a fluorescent microscope equipped with a 
digital camera (Olympus; Center Valley, PA) with standardized exposure times for all 
studies.  A blinded experimenter analyzed BDNF expression in at least three sections 
from each rat for a subset of distraction and sham rats at each time point (n=3 rats per 
group). For each section, at least 50 neurons were classified as being either positive or 
negative for BDNF immunoreactivity, and only those neurons with a visible nucleus were 
included in the count (Weisshaar et al., 2010). Mean signal intensity and cross-sectional 
area of the neurons were determined by manually outlining each neuron using ImageJ 
(NIH; Bethesda, MD). For each section, the BDNF intensity was normalized to the 
average background intensity calculated from the intensities of the BDNF-negative 
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neurons to determine the BDNF intensity ratio. BDNF-positive neurons were classified 
into seven neuronal sizes (from <200µm2 to >700µm2 in 100 µm2 bins) based on their 
soma area (Zhou et al., 1999). The average BDNF intensity ratio was compared between 
distraction and sham groups using a two-way ANOVA, with group and neuronal size as 
the factors, at day one and day seven. Total and BDNF-positive neuron cell counts were 
also calculated for each section, and the percentage of neurons positive for BDNF was 
compared between distraction and sham groups using t-tests. 
 At least 6 images of the spinal dorsal horn were taken from each rat for analysis 
by immunolabeling, with all exposure times standardized. Automated densitometry was 
performed using Matlab code that quantifies the BDNF expression in a standardized pixel 
area (1360x510) corresponding to laminae I-IV in the dorsal horn (Weisshaar et al., 
2010). Because BDNF expression data were positively skewed, the raw data were log-
transformed to achieve an approximately normal distribution prior to statistical analysis. 
All statistical analyses were performed on the transformed data, but the means and 95% 
confidence intervals are presented. BDNF expression in the dorsal horn was compared 
between groups at each time point using a t-test.  
 
6.3.4. BDNF Sequestration Study 
 To evaluate the role of spinal BDNF on behavioral sensitivity and phosphorylated 
ERK expression after pain has been established from facet joint injury, a separate study 
administered trkB-Fc intrathecally after injury in order to sequester spinal BDNF. Rats 
underwent a C6/C7 facet joint distraction as described in Chapter 3 (Dong et al., 2008; 
Kras et al., 2013b). Sensitivity to mechanical stimulation was quantified in the bilateral 
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forepaws as described in Chapter 3 before (day 0; baseline) and after joint distraction, on 
days one, three, five, six, and seven. Immediately after behavioral testing on day five, 
under inhalation isoflurane anesthesia, rats received a single injection of either the BDNF 
sequestering molecule trkB-Fc (trkB-Fc; n=6) or IgG-Fc as the matched vehicle control 
(vehicle; n=7) via lumbar puncture, which has previously been shown as capable of 
delivering agents to the cervical spinal cord in the rat (Rothman and Winkelstein, 2010). 
Both treatments (R&D Systems; Minneapolis, MN) were given at 5µg in 20µL of sterile 
PBS, a dose that was based on reports of its being an effective dose to prevent or alleviate 
behavioral sensitivity after nerve injury (Coull et al., 2005; Zhang et al., 2011). 
Mechanical response thresholds were compared to baseline responses using a repeated 
measures two-way ANOVA with Tukey’s HSD and group and time as factors. 
 Cervical spinal cord hemi-sections were harvested from the left side from both 
treatment groups at day seven, as described above, to quantify ERK activation using 
Western blot.  Tissue was homogenized in lysis buffer (150mM NaCl, 50mM tris Cl pH 
8.0, 1mM EDTA, 1% Triton® X-100) in the presence of protease and phosphatase 
inhibitors and centrifuged at 12,000g for 15 minutes at 4˚C. Supernatants were collected 
and stored at -80˚C. Protein samples were combined with NuPAGE® LDS Sample 
Buffer, NuPAGE® Reducing Agent, and NuPAGE® Antioxidant (Invitrogen) and heated 
at 95˚C for 5 minutes before loading onto a NuPAGE® 4-12% Bis-Tris gel (Invitrogen). 
Proteins were separated and transferred to an Immobilon®-FL transfer membrane 
(Millipore) and blocked for 2 hours with 5% non-fat dry-milk in 0.1% Tween-20 Tris-
buffered saline. Membranes were incubated overnight at 4˚C with rabbit anti-phospho-
ERK1/2 (pERK) (4370; Cell Signaling Technology; Danvers, MA) and mouse anti-
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ERK1/2 (ERK) (4696; Cell Signaling Technology) antibodies diluted at 1:500 and 
1:2000, respectively. The following day, membranes were incubated at room temperature 
for 2 hours with goat anti-rabbit IRDye 800CW and goat anti-mouse IRDye 680 
secondary antibodies (1:15,000; LI-COR; Lincoln, NE). Membranes were imaged using 
the Odyssey® Infrared Imaging System (LI-COR). Quantitative analysis of pERK and 
ERK fluorescent band intensity was performed using Odyssey Application Software v2.1. 
Expression of pERK1 and pERK2 was normalized to ERK1 and ERK2, respectively, as 
the loading control for each sample. pERK protein expression relative to ERK protein 
expression was compared between the trkB-Fc and vehicle groups using a two-way 
ANOVA with Tukey’s HSD test, with group and molecular weight (44kDa 
pERK1/ERK1; 42kDa pERK2/ERK2) as factors.  
 
6.4. Results 
6.4.1. Behavioral Responses to Mechanical Stimuli Following Injury 
 All rats undergoing joint distraction received the same severity of mechanical 
injury. A summary of the individual injury mechanics data (C6 forceps displacement) 
defining the severity of the joint injury for each rat used in these studies can be found in 
Appendix B. The mean displacement of the C6 forceps for the day one distraction group 
is 2.32±0.17mm, which is not different from that displacement imposed for the day seven 
group (2.65±1.45mm). Similarly, the joint distractions applied in the trkB study are also 
not different from each other (2.53±0.01mm trkB-Fc; 2.49±0.03mm vehicle) or when 
compared to the injured rats used to define the BDNF responses.  
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For all studies, since the responses to mechanical stimulation are not different 
between the right and left forepaws, the responses are averaged between forepaws for 
each rat. Mechanical sensitivity after sham procedures is not changed from baseline at 
either time point (Figure 6.1). Yet, facet joint distraction induces an immediate increase 
in mechanical sensitivity compared to baseline on day one (p<0.001) that is also evident 
at day seven (p<0.001) (Figure 6.1). Forepaw mechanical sensitivity in the distraction 
group also is significantly greater than sham (p<0.001) at both time points, and not 
different between days one and seven (p=0.183). The individual normalized behavioral 
sensitivity responses for each rat are summarized in Appendix C. 
 
6.4.2. BDNF mRNA Levels After Injury 
 Transcript levels of BDNF after a painful facet joint distraction differ from sham 
levels only in the spinal cord at day seven (Figure 6.2). BDNF mRNA is detected in the 
DRG and spinal cord in the distraction group, but is not different from sham in the DRG 
baseline 
Figure 6.1. Mechanical sensitivity in the forepaw as measured by a fold-change from 
baseline sensitivity in response to von Frey filament stimulation. Sensitivity 
significantly increases (*p<0.001) after joint distraction compared to sham on the days 
when tissue was harvested. 
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at either day one or day seven (Figure 6.2A). After painful joint distraction, BDNF 
mRNA is significantly increased (p=0.031) over sham in the spinal cord at day seven 
(Figure 6.2B). Individual mRNA quantification data for each tissue response are provided 
for each rat in Appendix D. 
 
6.4.3. BDNF Expression in the DRG Following Injury 
 Although neurons are identified in the DRG that express BDNF at both days one 
and seven for all rats, BDNF expression only increases in the DRG at day seven after 
painful distraction compared to sham (Figure 6.3). There is no change in the percentage 
of neurons expressing BDNF at either time point. The average BDNF-immunoreactive 
(BDNF-ir) intensity ratio across all neuron sizes is unchanged (p=0.078) after painful 
distraction compared to sham on day one (Figure 6.3A-6.3C). At day seven, the average 
BDNF-ir intensity ratio across all neuron sizes increases (p=0.016) after painful 
distraction compared to sham, but no change (p>0.338) in the response of neurons is 
Figure 6.2. Quantification of BDNF mRNA in the DRG (A) and spinal cord (B) at 
days one and seven. (A) Painful joint distraction does not alter BDNF mRNA levels in 
the DRG. (B) Spinal BDNF mRNA increases (*p=0.031) at day seven after a painful 
joint distraction compared to sham. 
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detected among the different sizes (p>0.338) (Figure 6.3D-6.3F). Individual neuronal size 
and BDNF labeling intensity data are detailed in Appendix E. 
 
Figure 6.3. BDNF-ir intensity in neurons in the C6 DRG on day one (A-C) and seven 
(D-F).  Average BDNF-ir intensity is not different between distraction (A) and sham 
(B) groups at day one (C). Average BDNF-ir intensity increases (*p=0.016) after 
distraction (D) relative to sham (E) on day seven (F). Quantitative data for BDNF-ir 
intensity ratios (C,F) are average±standard deviation for three rats/group and at least 
three sections/rat; scale bar=50µm in (A) and applies to panels (A,B,D,E). 
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6.4.4. BDNF Expression in the Spinal Dorsal Horn After Injury 
 BDNF protein also is detected in the spinal cords of all the rats receiving a joint 
distraction or sham procedure. Like the mRNA responses, there is no difference in BDNF 
in the superficial dorsal horn between distraction and sham at day one (p=0.252) (Figure 
6.4). But, BDNF expression in the spinal cord at day seven after painful distraction is 
significantly increased (p=0.047) over expression in shams at that same time point 
(Figure 6.4). A summary of the quantitative densitometry for BDNF expression for 
individual rats is included in Appendix E. 
Figure 6.4.  Representative images of BDNF in the spinal cord at day one (A,B) and 
day seven (C,D), and its quantification (E). (A-B) At day one, BDNF-ir intensity is 
not different between joint distraction and sham. (C-D) Joint distraction significantly 
(*p=0.047) increases BDNF-ir intensity over sham at day seven. Data in (E) are 
average±95% confidence limit. Scale bar=50µm in (A) and applies to panels (A-D).  
sham level 
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Double immunofluorescent labeling of spinal cord sections suggests that BDNF 
co-localizes with the neuronal marker MAP2 but not with the microglial marker OX-42 
(CD11b) or the astrocytic marker GFAP at day seven (Figure 6.5). A limited amount of 
BDNF is also found to co-localize with neurons, but not microglia or astrocytes, in the 
spinal cord in the sham group at day seven (Figure 6.5). The same patterns are observed 
at day one for both groups (data not shown). All double-labeled spinal cord images for 
each rat on both days one and seven for the distraction and sham groups are also included 
in Appendix E. 
 
6.4.5. Behavioral Responses & ERK Activation After Spinal BDNF Sequestration 
 Before treatment, a joint distraction significantly reduces the withdrawal threshold 
compared to baseline responses in both the trkB-Fc (p<0.017) and vehicle (p<0.005) 
groups that is evident on all days up to and including day five (Figure 6.6A). The single 
Figure 6.5. Representative co-labeling of BDNF with MAP2 (A,D), OX-42 (B,E), 
and GFAP (C,F). (A-C) BDNF immunolabeling (red) co-localizes (yellow) with 
MAP2 (A) but not with OX-42 (B) or GFAP (C) on day seven after facet distraction. 
(D-F) Similarly, BDNF co-localizes with MAP2 (D) but not OX-42 (E) or GFAP (F) 
on day seven after sham. Scale bar=100µm in (A) and applies to panels (A-F). MAP2, 
OX-42, GFAP label as green in (A-F). 
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intrathecal injection of trkB-Fc increases the withdrawal threshold on both day six and 
day seven, returning it to baseline levels (p>0.522) for those rats (Figure 6.6A). However, 
the vehicle injection has no effect on the withdrawal threshold, which remains 
significantly decreased compared to baseline (p<0.022) at both days six and seven 
(Figure 6.6A).  
 
Both phosphorylated ERK1/2 and total ERK1/2 are detected at the expected 
molecular weights in the spinal cords of all rats receiving either intrathecal trkB-Fc or 
Figure 6.6. (A) The withdrawal threshold for von Frey filament stimulation is 
significantly reduced from baseline responses after joint distraction in both the trkB-
Fc (#p<0.017; n=6) and vehicle (‡p<0.005; n=7) groups until treatment is given on 
day five. TrkB-Fc injection removes that decrease in the withdrawal threshold on days 
six and seven; vehicle injection has no effect on the withdrawal threshold, which 
remains significantly lower (‡p<0.022) than baseline on those days. (B) 
Representative immunoblots showing pERK1 (44kDa) & pERK2 (42kDa) and total 
ERK1 (44kDa) & total ERK2 (42kDa) in the spinal cord at day seven. (C) TrkB-Fc 
treatment significantly decreases both the ratio of pERK1/ERK1 (*p=0.013) and 
pERK2/ERK2 (*p=0.047). The pound symbol (#) indicates significant differences 
between trkB-Fc and the corresponding baseline response; the double-cross symbol 
(‡) indicates significant differences between vehicle and the corresponding baseline 
response; the asterisk (*) indicates significant differences between trkB-Fc and 
vehicle. 
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vehicle (Figure 6.6B). Paralleling the behavioral outcomes, both spinal pERK1/ERK1 
and pERK2/ERK2 are significantly decreased (p<0.045) at day seven after treatment with 
trkB-Fc. The individual behavioral data for each rat in this sequestration study are 
provided in Appendix C, and the quantification of ERK and pERK levels by Western blot 
is summarized in Appendix F. 
 
6.5. Discussion 
 These findings demonstrate that BDNF is upregulated by day seven in both the 
DRG and spinal cord after a painful facet joint injury (Figures 6.2-6.4). Although 
increased BDNF is associated with a variety of painful conditions, ranging from plantar 
incision to spinal nerve transection (Cho et al., 1997; Li et al., 2006; Li et al., 2008; 
Mannion et al., 1999; Obata et al., 2006; Zhou et al., 1999), this is the first demonstration 
for joint pain. Synovial BDNF is elevated in arthritic joints, and inflammation of the 
lumbar facet joint can upregulate BDNF in afferents that innervate that joint (Grimsholm 
et al., 2008; Ohtori et al., 2001; Ohtori et al., 2002; Rihl et al., 2005). Yet, none of those 
studies define BDNF in the context of pain. Behavioral sensitivity increases nearly 3-fold 
immediately after a painful distraction and is sustained through day seven (Figure 6.1); 
however, increases in BDNF are not as robust and only evident at day seven (Figures 6.2-
6.4). Sequestering spinal BDNF only partially attenuates the behavioral hypersensitivity 
after distraction (Figure 6.6). Spinal trkB-Fc significantly reduces spinal ERK activation, 
which is associated with pain and is known to be involved in BDNF-trkB signaling (Ji et 
al., 2002; Pezet et al., 2002; Slack et al., 2004). These findings indicate that a mechanical 
joint injury induces a functionally-relevant BDNF response but that it is not the sole 
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mediator of facet joint pain. Indeed, studies in Chapter 5 describe a contribution of NGF 
to the development of injury-induced joint pain (Kras et al., 2014b), and previous work 
with this injury model identified increased substance P levels in the DRG seven days 
after painful injury (Lee and Winkelstein, 2009). Expression of both BDNF and 
substance P are regulated by NGF signaling (Merighi et al., 2004; Pezet and McMahon, 
2006), so it may be possible that NGF initiates joint pain but that substance P and BDNF 
are downstream messengers that contribute to its maintenance. Nevertheless, 
inflammatory and neuropeptide mechanisms in addition to spinal BDNF signaling are 
likely involved in the complex response to painful joint injury. 
 Although mRNA levels of BDNF are altered at day seven in the spinal cord, no 
changes are detected in the DRG at either day one or seven (Figure 6.2). BDNF mRNA 
has been reported to increase in the DRG as early as one day after a painful CFA-induced 
inflammatory stimulus not causing mechanical damage to afferents (Kobayashi et al., 
2008; Mannion et al., 1999). A previous study using our same rat model found no change 
in substance P mRNA in the DRG after a painful joint injury but an increase over time 
after non-painful mechanical joint loading (Lee and Winkelstein, 2009). Because 
substance P and BDNF are produced in the same primary afferent neurons (Merighi et al., 
2008; Michael et al., 1997; Pezet and McMahon, 2006) and substance P mRNA is not 
altered by a painful joint distraction (Lee and Winkelstein, 2009), the lack of change in 
BDNF mRNA levels observed here is not surprising. Further, because substance P 
mRNA only changes over time after a non-painful, but not a painful, joint distraction 
(Lee and Winkelstein, 2009), it is possible that painful mechanical facet injury may 
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disrupt mRNA transcription, possibly via damage to the afferents in the facet joint 
capsule.  
The joint loading applied in our model produces mechanical strains in the capsule 
tissue that are similar to those (60-82%) that induce axonal damage in capsule afferents in 
a goat model of facet distraction (Kallakuri et al., 2008; Quinn et al., 2007). Further, 
axonal degeneration is not fully developed until day seven following axonal trauma 
(Hubbard and Winkelstein, 2008), suggesting that the absence of altered BDNF mRNA in 
the DRG that is observed here (Figure 6.2) may be due to the disruption of normal 
mRNA production via axonal damage from painful facet distraction. Although it has not 
been characterized in this model of facet joint injury in the rat, such loading-induced 
axonal damage to joint afferents may also contribute to elevated NGF in the DRG after 
facet injury (Figure 5.4). Neural tissue injuries, such as spinal nerve ligation or ventral 
root transection, increase expression of NGF in the DRG at the spinal level of the injured 
tissue (Lee et al., 1998; Obata et al., 2004). As such, characterization of the structural 
response of joint afferents to facet joint loading may provide further insight into the 
specific cellular mechanisms that are associated with facet pain from joint trauma. 
Alternatively, the lack of change in BDNF mRNA in the DRG after facet joint injury may 
be an artifact of the small number of joint afferents that are exposed to injurious loading 
relative to the total number of afferents with cell bodies in the DRG (Figure 4.2; Table 
4.1; Kras et al., 2013b). Retrograde tracing studies in Chapter 4 identified only 208 facet 
joint afferents at the C7 level, the level with the highest number of joint afferents, from 
thirteen total rats included in that study (Table 4.1; Kras et al., 2013b). Yet, a single 
cervical DRG in the rat is estimated to contain on the order of ten thousand sensory 
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neurons (Bergman and Ulfhake, 1998). The quantification technique used in the current 
study analyzed mRNA from the entire DRG and may not be sensitive enough to detect 
changes in mRNA in the joint afferents. Additional studies combining retrograde 
neuronal tracing techniques with in situ hybridization that can detect mRNA in individual 
cells (Michael et al., 1999) would better identify whether or not BDNF mRNA levels are 
increased after facet joint injury. 
BDNF mRNA increases in the spinal cord at day seven after painful distraction 
(Figure 6.2), which is consistent with observations of other acute and chronic pain 
models (Duric and McCarson, 2007; Li et al., 2006). Normally, BDNF mRNA is 
undetected in the dorsal horn, so any amount after injury is believed to be from novel 
expression (Li et al., 2006). Increased transcription of spinal BDNF after painful joint 
distraction supports the localized synthesis of BDNF in the spinal cord, though there are 
several possible cellular sources. Sensory and motor neurons, as well as activated 
microglia and astrocytes, can upregulate BDNF transcription after injury (Coull et al., 
2005; Dougherty et al., 2000; Ikeda et al., 2001; Li et al., 2006; Merighi et al., 2008). 
Although a 1.3-fold increase in spinal BDNF mRNA is detected by RT-PCR (Figure 6.2), 
that measurement technique prevents the cellular and regional localization of mRNA. The 
increase may be due to a large increase in a small region of the spinal cord or from a 
generalized increase throughout, or may be in a specific cell type. Identification of the 
spatiotemporal cellular sources of spinal and DRG BDNF mRNA will further clarify the 
biochemical mechanisms mediating facet pain.  
 The same cells that upregulate transcription of BDNF at day seven may also 
increase BDNF protein after joint distraction. Spinal BDNF is nearly doubled after a joint 
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distraction (Figure 6.4). Yet, this increase corresponds to a less than 20% increase in 
BDNF in the afferents in the DRG (Figure 6.3). Because neurons in the DRG normally 
produce and transport BDNF to the spinal cord, the change in BDNF that is observed in 
those neurons after distraction suggests that increased transport from the DRG may 
contribute to the elevated spinal BDNF at day seven. A previous study has shown that the 
dorsal nerve roots must be intact for increased BDNF to be evident in both the DRG and 
spinal cord (Zhou et al., 1999), implying that anterograde transport of BDNF from the 
DRG is the source of spinal BDNF. Although BDNF is elevated in DRG neurons after 
joint distraction at day seven, the increase is only slight compared to the more robust 
spinal response (Figures 6.3 & 6.4). Together with the increase in BDNF mRNA in the 
spinal cord, it is likely that there are sources other than the primary afferents that 
contribute to the increased spinal BDNF at day seven. Spinal astrocytes, microglia, and 
oligodendrocytes also produce BDNF and show increases in their expression of BDNF 
after injury to the spinal cord (Dougherty et al., 2000). Although spinal BDNF does not 
co-localize with astrocytes or microglia after facet joint injury (Figure 6.5), 
oligodendrocytes were not labeled in this study. Further investigations of BDNF co-
labeling in oligodendrocytes are needed to determine if these cells contribute to the 
injury-induced increase in spinal BDNF. 
Although mRNA and protein were assayed using different groups of rats, all rats 
received the same magnitude joint distraction and exhibited the same behavioral 
outcomes; further, since tissue assays used the same spinal levels (C6/C7) for both 
techniques, they can be taken as the same. Nevertheless, it is possible that variability in 
the magnitude of the changes in BDNF mRNA and protein in the spinal cord may be due 
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to inter-animal variation; future work quantifying both mRNA and protein levels in the 
same animals will help clearly define the relationships of BDNF and other responses in 
painful joint injury. Further, the current study does not identify which DRG neurons 
specifically innervate the injured facet joint, but retrograde neuronal tracing in this same 
model has identified over 50% of the DRG neurons innervating the C6/C7 facet joint to 
be peptidergic (Chapter 4; Kras et al., 2013b). The high percentage of peptidergic joint 
afferents, which are known to express BDNF, supports an important role for BDNF and 
this class of neurons in joint pain. Also using tracing methods, Ohtori found that facet 
joint inflammation increases the number of joint afferents expressing BDNF (Ohtori et 
al., 2002), providing evidence that stimulation to the facet joint does induce changes in 
BDNF expression in its afferents. Although the afferents innervating the facet joint were 
not identified in the current study, such studies would help determine if the increased 
spinal BDNF at day seven is due to localized synthesis or increased transport from joint 
afferents. Exogenous NGF increases BDNF expression in the DRG as well as the spinal 
cord, and BDNF accumulates in the axons proximal to the DRG when the nerve root is 
ligated (Michael et al., 1997), suggesting that transport of BDNF from the DRG 
contributes to NGF-induced increases in spinal BDNF. Injury to the sciatic nerve 
similarly induces increased spinal BDNF that is blocked when the dorsal nerve root is 
ligated or transected (Zhou et al., 1996; Zhou et al., 1999), adding further support to the 
notion that transport of BDNF from the DRG is a major source of spinal BDNF. Taking 
these studies demonstrating anterograde transport of BDNF to the spinal cord after injury 
or NGF application together with loading-induced increases in NGF in the facet joint 
(Figure 5.3) suggests that increased transport of BDNF from the DRG likely contributes 
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to the increase in spinal BDNF that is seen after joint injury (Figure 6.4). Nevertheless, 
blocking BDNF transport from the DRG to the spinal cord is necessary to determine if 
facet injury-induced spinal BDNF increases are a result of retrograde transport from the 
DRG or localized synthesis in the spinal cord. 
The increase in spinal BDNF protein (Figure 6.4) is consistent with other models 
of pain in the periphery (Cho et al., 1997; Mannion et al., 1999; Zhou et al., 2011). The 
increase in spinal BDNF at day 7 corresponds to a time point when spinal neurons are 
hyperexcitable and glutamate signaling is altered in this model (Chapter 5; Dong and 
Winkelstein, 2010; Kras et al., 2014b; Quinn et al., 2010). Elevated spinal BDNF has 
been associated with both neuronal and behavioral hyperexcitability through release from 
primary afferents and subsequent activation of glutamate receptors (Geng et al., 2010; 
Matayoshi et al., 2005; Slack et al., 2004). The co-localization of BDNF with the 
neuronal marker, MAP2, in the dorsal horn (Figure 6.5A) suggests that neurons may be 
responsible for the increase in spinal BDNF and supports a potential contribution of 
BDNF to the joint loading-induced neuronal hyperexcitability that is evident at day seven 
(Chapter 5; Kras et al., 2014b; Quinn et al., 2010). Yet, spinal hyperexcitability is also 
evident as early as one day after painful joint injury (Chapter 5; Crosby et al., 2013; Kras 
et al., 2014b), a time at which BDNF levels are no different from sham in either the DRG 
or spinal cord. Although BDNF may contribute to increased neuronal firing in the spinal 
cord, it is unlikely the sole mediator of facet injury-induced hyperexcitability. Indeed, 
PGE2 contributes to the development, but not the maintenance, of joint inflammation-
induced spinal neuronal hyperexcitability (Vasquez et al., 2001). In fact, since spinal 
PGE2 is increased by day one after facet joint injury (Kras et al., 2014a), it likely 
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contributes to neuronal hyperexcitability at this early time point. Sequestering spinal 
BDNF partially alleviates injury-induced pain together with reducing spinal pERK 
(Figure 6.6), which supports BDNF’s contribution to joint pain via an ERK-mediated 
pathway. In fact, the current data are in agreement with previous studies reporting 
reduced ERK activation due to BDNF sequestration (Pezet et al., 2002). ERK is activated 
when the BDNF receptor, trkB, is phosphorylated, as occurs during noxious mechanical 
stimulation of the paw (Pezet et al., 2002; Slack et al., 2004).  
Since activation of ERK is associated with inflammatory pain and interference 
with its activation inhibits the development of mechanical hypersensitivity in the rat after 
inflammatory stimuli in the paws (Ji et al., 2002; Kawasaki et al. 2004), ERK activation 
is a key intracellular signaling mechanism leading to pain. The current findings that both 
ERK activation and behavioral sensitivity are reduced after BDNF sequestration in the 
spinal cord (Figure 6.6) are consistent with the notion of ERK as a key contributor to pain 
and support a role for BDNF-trkB signaling in joint pain. Since BDNF induces long-term 
potentiation in spinal neurons through an ERK-dependent mechanism (Zhou et al., 2008), 
elevated spinal BDNF may contribute to the neuronal hyperexcitability after painful joint 
distraction. Further, glutamate receptor activation contributes to BDNF-induced 
mechanical sensitivity (Geng et al., 2010), and ERK activation is associated with 
phosphorylation of glutamate receptors (Slack et al., 2004).  Altered glutamate signaling, 
which also has been demonstrated to occur after a painful joint distraction (Dong and 
Winkelstein, 2010), may be a mechanism through which BDNF and ERK contribute to 
facet joint pain. Additional studies specifically determining the effects of BDNF on 
spinal neuronal excitability and glutamate signaling after painful and non-painful joint 
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injuries would further clarify the mechanism(s) through which spinal BDNF may 
contribute to facet joint-mediated pain.   
 
6.6. Conclusions & Integration 
 Studies in this chapter support at least a partial role for spinal BDNF in the 
maintenance of pain from injurious facet joint loading. Yet, contributions from other 
neuropeptides and inflammatory mediators, such as prostaglandin E2 and NGF, likely 
also contribute at both early and later time points (Kras et al., 2014a; Lee and 
Winkelstein, 2009). Indeed, intra-articular NGF has a critical role in the initiation of pain 
after facet joint injury (Chapter 5; Kras et al., 2014b), although the relationship between 
intra-articular NGF, neuronal BDNF, and chronic joint pain is not directly tested in this 
thesis.  Yet, NGF is a regulator of BDNF expression that is capable of increasing BDNF 
levels in both the DRG and spinal cord (Apfel et al., 1996; Michael et al., 1997). This 
relationship between NGF and BDNF expression suggests that NGF signaling 
immediately following joint injury may induce upregulation of BDNF in the primary 
afferents and increase transport to the spinal cord at later time points, contributing to 
persistent pain. Although spinal BDNF sequestration attenuates pain after joint 
distraction, it does not fully abolish it (Figure 6.6). Further studies clarifying the 
mechanisms by which spinal BDNF and ERK activation contribute to pain after 
mechanical joint injury are needed to define the relationship between that neurotrophin 
and the complex mechanisms underlying facet-mediated pain. Nevertheless, an 
upregulation of BDNF and partial alleviation of hypersensitivity via BDNF sequestration 
provides the first evidence of a role for spinal BDNF in joint pain. 
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Although spinal neuronal hyperexcitability (Chapter 5) and upregulation of 
BDNF protein in the spinal cord (Chapter 6) are associated with joint pain, the spinal 
cord only represents the first relay of nociceptive signaling from the periphery to the 
central nervous system. Many higher order structures in the brain, such as the brainstem, 
periaqueductal gray matter, amygdala, thalamus and cortex, receive information related 
to nociception (Basbaum et al., 2009; Merighi et al., 2008; Steeds, 2009). Although there 
is no single region of the brain responsible for the perception of pain (Apkarian et al., 
2005; Basbaum et al., 2009), the thalamus is a key structure in the processing of sensory 
information (Steeds, 2009), and the spinothalamic tract (STT) has traditionally been 
thought of as the main nociceptive pathway to the brain (Merighi et al., 2008). Models of 
painful arthritis report altered gene transcript levels and neuronal hyperexcitability in the 
thalamus in association with joint inflammation (Gautron and Guilbaud, 1982; Luo et al., 
2014; Neto et al., 2008), supporting thalamic involvement in inflammatory joint pain. 
Further, the cellular responses to painful loading-induced facet joint injury, of which joint 
inflammation is a component, may also extend to the thalamus. In fact, neurons of the 
STT, which project from both the superficial (I-II) and deeper (IV-VI) laminae of the 
dorsal horn to the thalamus, express receptors for BDNF (Slack et al., 2005). Further, 
ERK is activated in STT neurons in response to BDNF release in the spinal cord (Slack et 
al., 2005). These anatomical observations suggest that facet joint injury-induced increases 
in spinal BDNF and ERK activation associated with neuronal hyperexcitability may also 
lead to increased activation of thalamic neurons. Although injury-induced spinal neuronal 
hyperexcitability (Chapter 5) and the role of spinal BDNF in the maintenance of joint 
pain (Chapter 6) support a central component for facet-mediated pain; studies in Chapter 
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7 further define the central modifications associated with persistent facet joint pain by 
assessing electrophysiological responses in the thalamus after injury at a time point when 
spinal BDNF expression is elevated. 
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Chapter 7 
Thalamic Neuronal Hyperexcitability After Facet 
Joint Injury: Supraspinal Contributions to Facet-
Mediated Pain 
 
Parts of this chapter are adapted from: 
Weisshaar CL, Kras JV, Pall PS, Kartha S, Winkelstein BA (2015). Non-peptidergic 
afferents in the facet joint mediate injury-induced pain and mediate thalamic 
hyperexcitability via supraspinal and spinal glutamate transporters. Brain Research, 
submitted. 
 
7.1. Overview 
 Studies presented in Chapters 5 and 6 describe a joint injury-induced increase in 
spinal brain-derived neurotrophic factor (BDNF) (Chapter 6) at a time when spinal 
neurons are also hyperexcitable (Chapter 5) (Kras et al., 2013c; Kras et al., 2014b). Those 
findings support spinal neuronal hyperexcitability as contributing to facet-mediated pain. 
Hyperexcitability in neurons in the CNS can occur due to enhanced synaptic efficacy and 
membrane excitability, which are components of central sensitization (Latremoliere and 
Woolf, 2009). Such a sensitized state can result in normally innocuous stimuli being 
perceived as painful, even in the absence of any evidence of injury (Latremoliere and 
Woolf, 2009). However, the studies in Chapters 5 and 6 only evaluated joint injury-
induced responses in the spinal cord. Yet, nociceptive information is transmitted from the 
spinal cord to many regions of the brain; among those brain regions, the thalamus has a 
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major role in relaying pain signals for sensation (Basbaum et al., 2009; Merighi et al., 
2008; Steeds, 2009).  
Neurons from laminae I and V in the spinal dorsal horn, which are regions that 
receive nociceptive sensory input from primary afferents, project to the thalamus via the 
lateral spinothalamic track (STT) and the anterior STT, respectively (Dostrovsky and 
Craig, 2013) (see Section 1.2.2). Thalamic neurons activated by mechanical joint 
stimulation become hyperexcitable in states of painful arthritis and joint inflammation 
(Gautron and Guilbaud, 1982; Luo et al., 2014). Further, the number of thalamocortical 
neurons that respond to graded stimulation as wide dynamic range (WDR) neurons 
increases in arthritis (Dostrovsky and Craig, 2013); when taken together with arthritis-
induced thalamic neuronal hyperexcitability, supports enhanced thalamic neuronal 
activity in association with joint pain. Some thalamic neurons express the trkB receptor 
and are activated by spinal BDNF (Slack et al., 2005). Joint inflammation and elevated 
spinal levels of BDNF are associated with loading-induced facet pain (Dong et al., 2013a; 
Kras et al., 2013c). Despite documented activation and hyperexcitability of thalamic 
neurons in association with joint inflammation and spinal BDNF signaling (Gautron and 
Guilbaud, 1982; Slack et al., 2005), thalamic neuronal firing in facet joint injury-induced 
pain has not been evaluated. 
 Studies in this chapter characterize the evoked excitability of thalamic neurons 
after a painful facet joint distraction that is sufficient to induce sustained behavioral 
hypersensitivity and spinal neuronal hyperexcitability (Crosby et al., 2013; Dong et al., 
2013a; Kras et al., 2013c; Quinn et al., 2010). This work specifically tests the hypothesis 
that painful mechanical injury of the cervical facet joint induces hyperexcitability in 
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neurons within the thalamus. As such, evoked thalamic neuronal excitability is quantified 
at day seven after a painful joint distraction using a stimulus train of both innocuous and 
noxious stimuli applied to the forepaw, where behavioral sensitivity is also measured. 
Based on those findings and to complement studies in Chapter 5 demonstrating that intact 
innervation of the facet joint is necessary for facet-mediated pain (Figure 5.4), a second 
study tests the hypothesis that non-peptidergic afferents in the facet joint contribute to the 
development and maintenance of joint injury-induced pain and thalamic neuronal 
hyperexcitability. Accordingly, non-peptidergic joint afferents were ablated prior to joint 
injury using the same methods of isolectin B4-conjugated saporin injection described in 
Chapter 5, followed by quantifying thalamic neuronal excitability at day seven after joint 
injury. Together, these studies aim to identify whether or not non-physiologic facet joint 
loading conditionally enhances activity in the thalamus when injury-induced behavioral 
hypersensitivity is evident. 
 
7.2. Relevant Background 
 The facet joint is the most common source of neck pain (Bogduk, 2011; Lord et 
al., 1996), and biomechanical studies using cadavers as well as animal studies support 
non-physiologic loading of the facet joint capsular ligament as a potential initiator of pain 
(Barnsley et al., 1995; Bogduk and Aprill, 1993; Chen et al., 2006; Lu et al., 2005; 
Panjabi et al., 1998; Pearson et al., 2004; Sundararajan et al., 2004). Both Aδ- and C-fiber 
nociceptors innervate the cervical facet joint and are activated by tensile loading of that 
joint (Chen et al, 2006; Lu et al., 2005). Further, primary sensory neurons can be 
classified as peptidergic or non-peptidergic (see Section 1.2.2), and studies in Chapter 4 
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identified peptidergic afferents as representing greater than 50% of the neurons that 
innervate the C6/C7 facet joint in the rat (Chapter 4; Kras et al., 2013b; Merighi et al., 
2008). Moreover, peptidergic signaling among joint afferents is necessary for the 
development of loading-induced facet joint pain (Figure 5.4) (Kras et al., 2014b). 
However, non-peptidergic afferents may also have a role in facet joint pain. Ishikawa 
reported that 11±2% of the neurons innervating lumbar facet joints bind isolectin B4 
(IB4) and are non-peptidergic (Ishikawa et al., 2005). Up to one-third of nerve growth 
factor (NGF) sensitive neurons also bind IB4 (Joseph and Levine, 2010). Moreover, NGF 
facilitates inflammatory hyperalgesia by inducing a switch to a PKCε-dependent 
mechanism for PGE2 signaling in IB4-positive neurons (Joseph and Levine, 2010; Parada 
et al., 2005). This contribution of non-peptidergic afferents to pain associated with NGF 
and PGE2 signaling, taken in the context of facet joint loading-induced increases in NGF 
in the joint and PGE2 in the spinal cord (Chapter 5; Kras et al., 2014a; Kras et al., 2014b), 
suggests that non-peptidergic afferents may regulate the expression of pain mediators 
following facet joint injury that contribute to behavioral hypersensitivity. Moreover, 
because each of NGF and PGE2 are sufficient to induce hyperexcitability in the central 
nervous system in addition to behavioral hypersensitivity (Guilbaud et al., 1982; Hoheisel 
et al., 2007; Kras et al., 2014b; Vasquez et al., 2001), non-peptidergic afferents may have 
a role in the enhanced central neuronal excitability that maintains pain. Yet, no study has 
identified whether or not non-peptidergic joint afferents contribute to the neuronal 
hyperexcitability that is evident in the CNS after a painful facet joint injury. 
 Painful loading of the facet joint is associated with joint inflammation and spinal 
neuronal hyperexcitability and upregulates many pain mediators in the dorsal root 
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ganglion (DRG) and spinal cord, including PGE2, NGF, and BDNF (Chapters 5 & 6; 
Crosby et al., 2013; Dong et al., 2008; Dong et al., 2013a; Kras et al., 2013c; Kras et al., 
2014a; Kras et al., 2014b; Lee et al., 2008; Quinn et al., 2010). Spinal BDNF contributes 
to the maintenance of loading-induced facet pain and increases phosphorylation of the 
mitogen-activated protein kinase extracellular signal-regulated kinase (ERK) (Kras et al., 
2013c), which has been implicated in inflammatory pain cascades (Ji et al., 2002; 
Kawasaki et al. 2004). Moreover, spinal BDNF signaling increases the excitability of 
neurons in the spinal cord after neural tissue injury (Geng et al., 2010; Lu et al., 2009). 
Yet, nociceptive sensory information in the spinal cord is relayed to the thalamus via the 
spinothalamic tract where it undergoes further processing before being relayed to the 
brain structures, such as the cortex, that are involved in the conscious perception of pain 
(Dostrovsky, 2000; Millan, 1999). Sensory neurons with cutaneous input, as well as 
neurons that innervate deep tissues like joints and viscera, converge in the thalamus 
(Millan, 1999). Indeed, this convergence of sensory information from multiple 
anatomical regions may serve as a potential mechanism for development of referred pain 
and suggests that alterations in thalamic neuronal excitability may mediate 
hypersensitivity measured in the forepaw after a facet joint injury (Dong et al., 2013a; 
Kras et al., 2013c; Kras et al., 2014b). 
 All nociceptive information that reaches the cortex is first received and processed 
by the thalamus (Dostrovsky, 2000; Merighi et al., 2008); the STT is the major ascending 
pathway for pain transmission (Purves et al., 2001). A majority of the STT neurons 
projecting from the superficial and deep laminae of the dorsal horn are sensitive to BDNF 
and exhibit increased activation of ERK in response to BDNF signaling (Slack et al., 
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2005). Spinal BDNF is increased seven days after a painful facet joint injury (Figure 6.4), 
and sequestering spinal BDNF alleviates injury-induced pain and reduces spinal ERK 
activation (Figure 6.6) (Kras et al., 2013c), suggesting that increased spinal BDNF after 
joint injury may also activate thalamic neurons. In fact, alterations in thalamic neuronal 
firing patterns and evoked firing rates have been associated with inflammation- and 
neural tissue injury-induced pain (Huh et al., 2012; Iwata et al., 2011; Syré et al., 2014). 
Moreover, thalamic neurons receiving input from joints are hyperexcitable during 
arthritis and painful joint inflammation, such that normal joint movements or low 
threshold mechanical stimuli elicit neuronal firing in arthritic rats but not controls 
(Dostrovsky and Guilbaud, 1990; Gautron and Guilbaud, 1982; Luo et al., 2014). Since 
loading-induced facet joint pain is also associated with joint inflammation (Dong et al., 
2013a), the excitability of thalamic neurons is hypothesized to increase after painful joint 
injury. 
 Considering that the thalamus is the major relay center for nociceptive 
information from the spinal cord to the rest of the brain, one objective of this work is to 
identify if facet joint injury induces hyperexcitability in thalamic neurons in association 
with pain. Of the thalamic nuclei that receive nociceptive input via the STT, neurons in 
the ventral posterolateral nucleus (VPL) encode the intensity and location of noxious 
stimuli, with receptive fields encompassing the forepaw (Francis et al., 2008; Millan, 
1999). As such, excitability of thalamic neurons is quantified in the VPL in rats seven 
days after the painful facet joint injury that was described in detail in Chapter 3 and used 
for studies in Chapters 4-6. In addition, neurons were classified as either wide dynamic 
range (WDR), low threshold mechanoreceptive (LTM), or nociceptive specific (NS) 
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based on their responses to von Frey stimulation (Saito et al., 2008; Syré et al., 2014) 
since an increase in the number of neurons responding as WDR is believed to contribute 
to central sensitization (Coghill et al., 1993; Dostrovsky and Craig, 2013). Based on 
findings in that characterization study, a second study applied intra-articular IB4-saporin 
(as described in Chapter 5) two weeks prior to joint injury in order to ablate non-
peptidergic joint afferents. The goal of those studies was to define if non-peptidergic joint 
afferents have a role in thalamic neuronal hyperexcitability following a facet joint 
distraction of identical magnitude to the one applied in the characterization study. 
 
7.3. Methods 
Male Holtzman rats (Harlan Sprague-Dawley, Indianapolis, IN) (405±25g) were 
housed under USDA- and AAALAC-compliant conditions with a 12-12 hour light-dark 
cycle and free access to food and water.  Experimental procedures were approved by the 
IACUC and carried out under the guidelines of the Committee for Research and Ethical 
Issues of the International Association for the Study of Pain (Zimmermann, 1983). 
 
7.3.1. Surgical Procedures for Characterization Study 
 All surgical procedures were performed under inhalation isoflurane anesthesia 
(4% induction, 2.5% maintenance). Rats included in the characterization study underwent 
either a painful cervical facet joint distraction injury (FJD n=4) or a sham procedure 
(sham n=3), as described in Section 3.3.1 and used in previously published studies (Dong 
et al., 2011; Kras et al., 2013a). Briefly, the C6 and C7 laminae were exposed and 
attached to a loading device via microforceps, and C6 was displaced rostrally while C7 
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was held in place. A camera mounted to a surgical dissecting scope tracked markers that 
were placed on the C6 and C7 laminae during the joint injury. Peak displacement of the 
C6 forceps and the corresponding peak capsular ligament distraction and maximum 
principal strain of the capsule during each distraction were quantified as measures of the 
severity of the applied injury. An additional group of rats underwent sham surgical 
procedures with device attachment but no applied joint distraction to serve as controls.  
Following surgery, the incision was closed and rats were recovered in room air. 
 
7.3.2. Intra-Articular Saporin Injections & Facet Joint Distraction Procedures 
Neurons that bind IB4 are typically non-peptidergic (Basbaum et al., 2009; 
Merighi et al., 2008) and are involved in pain from nerve injury and also separately from 
inflammation (Hucho et al., 2005; Parada et al., 2005; Tarpley et al., 2004).  In order to 
identify the contribution, if any, of this population of sensory neurons in the joint to 
thalamic neuronal hyperexcitability in the case of facet pain, additional separate groups 
of rats received intra-articular injections of 5µg of saporin conjugated to isolectin B4 
(IB4-Sap n=12) in 5µL of PBS to ablate the IB4-binding neurons (Chapter 5; Kras et al., 
2014b). That dose of IB4-Sap was selected from a previously published report as 
sufficient to ablate non-peptidergic afferents (Tarpley et al., 2004) and is the same as the 
dose used in the earlier studies assessing intra-articular NGF-induced facet joint-mediated 
pain in Chapter 5. IB4-Sap was administered using established methods for intra-articular 
injection (Dong et al., 2013a; Kras et al., 2014b). Briefly, the bilateral C6/C7 facet joints 
were exposed as described above in Section 7.3.1. A 33-gauge beveled needle attached to 
a 10µL syringe (Hamilton Company; Reno, NV) was advanced manually into the facet 
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joint using a dorsal approach, and 5µg of IB4-Sap in 10µL of PBS was slowly injected 
into the bilateral facet joints. Following joint injections, wounds were closed with 
polyester suture and surgical staples, and the rats were recovered in room air.  
Because saporin has been documented to induce cell death within fourteen days 
(Weisshaar et al., 2014; Wiley et al., 2007), that time period was waited prior to the rats 
undergoing either a facet joint distraction or sham procedure. Under inhalation isoflurane 
anesthesia, the surgical staples and suture were removed, and rats underwent either a 
facet joint distraction (IB4-Sap+FJD n=6) or sham (IB4-Sap+sham n=6) procedure as 
described in Section 7.3.1. For all rats in the IB4-Sap+FJD group, peak displacement of 
the C6 forceps and the corresponding peak capsular ligament distraction and maximum 
principal strain in the capsule during each distraction were quantified as measures of the 
injury severity to enable comparison to the rats in the characterization study. Wounds 
were closed again, and the rats were recovered in room air. 
  
7.3.3. Behavioral Assessment of Mechanical Hyperalgesia 
Bilateral forepaw mechanical hyperalgesia was evaluated in all rats using the 
methods described in Section 3.3.2 (Lee and Winkelstein, 2009; Quinn et al., 2010; 
Weisshaar et al., 2010).  In the characterization study, baseline measurements were 
recorded for three days prior to any surgical procedure. Because the time course of 
behavioral hypersensitivity onset and maintenance following facet joint distraction has 
been well-documented in the rat (Chapters 3-6; Crosby et al., 2013; Dong et al., 2013a; 
Kras et al., 2013b; Lee and Winkelstein, 2009), in the current study, hyperalgesia was 
only measured on day seven after the injury or sham procedure in order to verify that 
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injury-induced behavioral hypersensitivity is evident on the day of electrophysiological 
assessment. For the saporin rats, forepaw mechanical withdrawal thresholds were 
measured for each rat at baseline (day 0) before surgery and on day seven following facet 
joint distraction or sham procedures. For assessing mechanical hyperalgesia, a given 
filament was recorded as the response threshold if the next higher filament also induced a 
positive response (Crosby et al., 2013; Lee and Winkelstein, 2009).  Although the applied 
joint distraction induces a bilateral injury, response thresholds from only the right 
forepaw were considered for analysis in order to parallel the electrophysiological studies 
in the VPL that recorded only from those neurons with input from that forepaw. For the 
characterization study, response thresholds at day seven were compared between the 
distraction and sham groups and to each of their respective baseline values using a two-
way repeated measures ANOVA with Tukey’s HSD test, with time and group as the 
factors. Behavioral responses for the IB4-saporin study were similarly compared using a 
two-way repeated measures ANOVA with group (IB4-Sap+FJD, IB4-Sap+sham) and 
time (day 0, day 7) as factors with post hoc Tukey’s HSD test. 
 
7.3.4. Electrophysiological Recordings in the Thalamus 
 In order to quantify thalamic neuronal excitability after facet joint injury, all rats 
were prepared for electrophysiological recordings in the VPL after behavioral testing on 
day seven. All rats were anesthetized with sodium pentobarbital (45mg/kg, i.p.). A 
midline incision was made over the skull, and the soft tissue was removed to reveal the 
coronal, sagittal, and lambdoid cranial sutures (Figure 7.1A). In order to gain access to 
the VPL (Figure 7.1B), the cortex overlying the thalamus was exposed via an 8mm by 
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8mm craniotomy over the left hemisphere beginning at bregma and extending caudally 
and laterally (Syré et al., 2014). The mid-cervical trachea was exposed, cannulated, and 
ventilated (CWE Inc.; Ardmore, PA) with room air at approximately 40 breaths/minute, 
and the end tidal CO2 concentration was monitored. The rat was mounted onto a 
stereotaxic frame with blunt ear bars (Figure 7.1C), and the head was adjusted so bregma 
and lambda were in the horizontal plane. The dura was removed, and the brain was 
bathed in 37°C mineral oil. The core temperature of the rat was maintained at 35-37°C 
using a feedback controlled heating plate with a rectal probe (Physitemp Instruments Inc.; 
Clifton, NJ). Anesthesia was maintained throughout all procedures with supplemental 
doses of sodium pentobarbital (5-10mg/kg, i.p.) as needed. 
 
Figure 7.1. (A) Exposed rat skull illustrating bregma and lambda. (B) Cross-section of 
a rat brain illustrating the location of the VPL. (C) Instrumentation for extracellular 
recordings in the rat. A tungsten electrode measures extracellular signals in the VPL 
during stimulation of the forepaw with a series of mechanical stimuli, including four 
von Frey filaments, a non-noxious brush, and a noxious pinch by a microvascular clip. 
During each experiment, the temperature of the rat was monitored via the rectal probe 
attached to a feedback controlled heating plate. 
(C) 
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 Extracellular voltage potentials were recorded in the VPL using glass-insulated 
tungsten electrodes (FHC; Bowdoin, ME). The signal was amplified, processed, and 
digitally sampled and stored as described in Chapter 5 (Dong et al., 2013b; Syré et al., 
2014). Beginning at -2.5mm from bregma and 2.2mm left lateral, the electrode was 
lowered 5-7mm below the pial surface (Figure 7.1). Subsequent locations were probed at 
1mm intervals in the anterior-posterior and medial-lateral planes, based on known 
coordinates and somatatopy of the rat VPL (Francis et al., 2008; Paxinos and Watson, 
2007). Neurons were identified by light brushing of the plantar surface of the right 
forepaw using a cotton swab. A stimulus train identical to that described in Chapter 5 was 
applied to the forepaw (Figure 7.2) (Crosby et al., 2013; Kras et al., 2014b; Syré et al., 
2014). The stimulus train consists of a light brush (applied for 10 seconds), a series of 
non-noxious and noxious von Frey filaments (1.4g, 4g, 10g, 26g), and a noxious pinch 
(60g vascular clip (WPI; Sarasota, FL); applied for 10 seconds) (Figure 7.2).  
 
Figure 7.2. The stimulus train applied to the right forepaw consists of a light brush, 
von Frey filaments (1.4g, 4g, 10g, 26g), and a noxious pinch. Spikes are summed over 
the entire period of each stimulus application (evoked). Baseline spikes are summed 
over an equivalent time period (baseline) prior to the first application of each stimulus. 
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The strengths of the von Frey filaments used for the stimulus span the range used during 
mechanical withdrawal threshold testing for behavioral sensitivity. Each filament was 
applied for five stimulations of one second followed by one second of recovery. The 
different stimuli were applied at intervals of at least 60 seconds, and the evoked spikes 
were recorded. 
 To analyze individual neurons, recordings during the stimulus train were spike-
sorted using Spike2 (CED; Cambridge, UK). Evoked spikes were summed over the 
continuous 10-second stimulus period for both the brush and pinch stimuli. The number 
of spikes evoked from the initial application of a von Frey filament until one second after 
the 5th application of the filament were counted for each neuron (Figure 7.2). The 
duration of each stimulus was identified, and baseline firing was determined by counting 
the number of spikes over an equivalent time period (~10s) prior to initiation of the brush 
and pinch stimuli, as well as before the first application of each von Frey filament (Figure 
7.2). Baseline spikes were subtracted from the total spike count for each stimulus in order 
to evaluate the evoked responses.  
Neurons were classified based on their responses to von Frey stimulation (Saito et 
al., 2008; Syré et al., 2014). Wide dynamic range (WDR) neurons exhibited a graded 
response to increasing von Frey filament strength. Low threshold mechanoreceptors 
(LTM) responded to both non-noxious and noxious stimuli, and nociceptive specific (NS) 
neurons only responded to noxious von Frey filament stimulation. Because the 
distribution of spike totals for each stimulus exhibited a positive skew, spike counts were 
log-transformed to obtain a normal distribution for statistical analyses. Evoked firing for 
each stimulus was compared between groups using a two-way nested ANOVA, with 
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group and stimulus as factors, neurons nested within rats, and rats nested within group, 
with post hoc Tukey’s HSD test. Within each study, evoked spike counts were compared 
between groups (FJD, sham; IB4-Sap+FJD, IB4-Sap+sham). Differences in the ratio of 
WDR neurons were also compared between groups in each study using Pearson’s chi-
square test.  
 
7.4. Results 
 All rats undergoing joint distraction received the same severity of mechanical 
injury. The C6 forceps displacement, maximum capsular ligament distraction, and 
maximum principal strain across the ligament were compared between the IB4-Sap+FJD 
injury group and the FJD group using t-tests. The average displacement of the C6 forceps 
for the distraction group is 2.52±0.04mm, which is not different from the IB4-Sap+FJD 
group (2.51±0.03mm). Similarly, no differences are detected between injury groups for 
either the peak capsular ligament distraction (FJD 0.39±0.18mm; IB4-Sap+FJD 
0.23±0.09mm) or the maximum principal strain in the ligament (FJD 40.31±9.48%; IB4-
Sap+FJD 41.15±46.55%). These mechanical data demonstrate that the same magnitude 
of joint injury was applied to all groups undergoing an injury and that any differences in 
behavioral sensitivity or thalamic neuronal excitability are not due to differences in the 
injury itself. The maximum capsule distractions, as well as the associated maximum 
capsular ligament strains, for each rat included in this chapter are detailed in Appendix B. 
The mechanical withdrawal threshold at day seven after sham procedures is not 
different from baseline (Figure 7.3). However, facet joint distraction induces 
hypersensitivity such that the withdrawal threshold is significantly reduced at day seven 
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compared to baseline (p<0.036) (Figure 7.3). Yet, despite a trend towards a reduced 
threshold (p<0.631) seven days after distraction compared to sham, statistical 
significance is not achieved between groups with these small group sizes (n=3-4 rats for 
each group). The individual mechanical withdrawal thresholds for each rat included in 
this study are summarized in Appendix C. 
 
A total of 59 mechanosensitive neurons with input from the forepaw was recorded 
in the VPL at an average depth of 6.41±0.33mm below the pial surface in those rats that 
underwent distraction (24 neurons at 6.45±0.32mm depth) or sham (35 neurons at 
6.38±0.33mm depth) procedures for the characterization study. Increased evoked firing is 
evident at day seven after injury, as observed in the representative traces during 
stimulation of the forepaw with the brush, von Frey, and pinch stimuli (Figure 7.4A). In 
fact, quantification of the neuronal firing in the left VPL demonstrates an increase in the 
number of spikes evoked by all of the von Frey filament strengths (p<0.044), except the 
non-noxious 1.4g filament after distraction (Figure 7.4B). Further, joint distraction 
induces an increase in the number of spikes evoked by both the brush (p=0.003) and the 
pinch (p=0.001) stimuli compared to the number evoked in sham animals (Figure 7.4C). 
Figure 7.3. Mechanical sensitivity in the right forepaw as measured by the withdrawal 
threshold in response to von Frey filament stimulation. Withdrawal threshold 
decreases (#p<0.034) from baseline at day seven after facet joint distraction. 
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Despite an increase in neuronal excitability, there is no change in the proportion of 
neurons that respond to stimulation as WDR neurons. In the sham group, 63% of neurons 
were classified as WDR and 37% were LTM (Figure 7.4D); similarly, after distraction, 
54% of neurons responded as WDR and 46% as LTM (Figure 7.4D). None of the 
recorded neurons were identified as nociceptive specific. The individual spinal neuronal 
firing data for each rat is summarized in Appendix G. 
 
Figure 7.4. Hyperexcitability of thalamic neurons after distraction. (A) Representative 
traces illustrate increased evoked firing in the left VPL after distraction compared to 
sham. (B & C) Significantly more spikes are evoked by the 4g-26g von Frey filaments 
(B) and the brush and pinch (C) stimuli (*p<0.044) after FJD.  (D) The percentage of 
neurons responding as WDR or LTM is unchanged between distraction and sham. 
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Ablating the IB4-positive joint afferents with saporin prior to a typically painful 
joint distraction prevents the development of mechanical hypersensitivity. On day seven, 
the withdrawal threshold to mechanical stimulation of the right forepaw is unchanged 
from baseline in both the IB4-Sap+FJD and the IB4-Sap+sham groups, and those two 
groups do not differ from each other (Figure 7.5A). Likewise, the excitability of VPL 
neurons also is not different between the IB4-Sap+FJD and the IB4-Sap+sham groups at 
day seven. In the VPL, 74 total neurons were recorded from both groups at an average 
depth of 6.27±0.42mm. The number of spikes evoked by each of the applied stimuli is 
not different between the IB4-Sap+FJD (33 neurons at 6.30±0.37mm depth) and the IB4-
Sap+sham (41 neurons at 6.25±0.46mm depth) groups (Figure 7.5), and no differences 
are detected in the proportion of WDR neurons between groups (IB4-Sap+FJD 75.8%; 
IB4-Sap+sham 80.5%). Mechanical withdrawal thresholds for each rat are summarized in 
Appendix C; the individual spinal neuronal firing data for each rat is detailed in 
Appendix G. 
 
7.5. Discussion 
 This study demonstrates that a painful facet joint injury induces hyperexcitability 
in the thalamus (Figures 7.3 & 7.4). Moreover, ablation of non-peptidergic joint afferents 
prevents the development of the behavioral hypersensitivity and thalamic neuronal 
hyperexcitability that are both evident seven days after a joint distraction (Figures 7.3-
7.5). Hyperexcitability of thalamic neurons is associated with a variety of painful 
conditions, including injury to the peripheral nerve and nerve root (Syré et al., 2014; 
Zhao et al., 2006), but these data are the first evidence of increased thalamic activity in 
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joint pain from mechanical injury. Although increased evoked firing in the thalamus has 
been described for inflammatory arthritis (Gautron and Guilbaud, 1982), that study did 
not define neuronal excitability in the context of pain. Despite the association of thalamic 
neuronal hyperexcitability with joint pain, its functional role and the cellular mechanisms 
underlying the increased excitability are unknown. 
 
 
 Thalamic neuronal hyperexcitability at day seven after joint injury is evident for 
both noxious (10g, 26g, & pinch) and non-noxious (4g & brush) stimuli applied to the 
forepaw.  Yet, evoked spikes induced by stimulation with the non-noxious 1.4g von Frey 
Figure 7.5. Ablation of non-peptidergic joint afferents prevents the development of 
injury-induced hypersensitivity and thalamic neuronal hyperexcitability. (A) Forepaw 
withdrawal threshold is unchanged after distraction (IB4-Sap+FJD) compared to 
baseline (day 0) or sham (IB4-Sap+sham) in rats given intra-articular IB4-Sap. (B & 
C) Excitability of neurons in the VPL is not different between IB4-Sap+FJD or IB4-
Sap+sham rats for any of the applied stimuli. 
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filament are no different between the painful FJD and the non-painful sham groups. Of 
note, both the 1.4g and 4g von Frey filaments are considered non-noxious since they do 
not frequently evoke responses in normal rats (Dong et al., 2008; Dong and Winkelstein, 
2010). The increased neuronal excitability that is observed in this study for mechanical 
forepaw stimuli greater than or equal to 4g is consistent with previous reports of facet 
joint injury-induced allodynia (Dong and Winkelstein, 2010; Dong et al., 2013a) in which 
significantly more forepaw withdrawals are evident for a 4g von Frey filament stimulus 
after a facet joint injury compared to sham controls. Since the average forepaw 
withdrawal threshold to mechanical stimulation has been reported to decrease to nearly 
4g after painful facet joint distraction (Chapter 4; Crosby et al., 2014; Dong et al., 2011; 
Dong et al., 2013b), the neuronal hyperexcitability induced by stimulation with the 4g 
filament is not surprising. Yet, the withdrawal thresholds after injury do not approach 
1.4g in those studies, so it is not surprising that the number of spikes evoked by the 1.4g 
filament is not elevated (Figure 7.4). Of note, in the current study, the withdrawal 
threshold for the forepaw is between 10g and 26g after joint injury (Figure 7.3). That 
withdrawal threshold suggests that thalamic neuronal hyperexcitability would not be 
evident for the 4g stimulus. However, only four rats were included in the injury group, 
and one of those rats (PSP11) exhibited an abnormally high withdrawal threshold (~20g; 
see Appendix C) after injury, shifting that group’s average withdrawal threshold to over 
10g. Including additional rats in the injury group would likely decrease the average 
withdrawal threshold, aligning it more with the electrophysiological findings in this study 
(Figures 7.3 & 7.4). A similar pattern of increased neuronal firing in response to both 
noxious (10g, 26g, & pinch) and normally non-noxious (4g & brush) stimuli is also 
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evident in the spinal cord at day seven in this model (Crosby et al., 2014; Quinn et al., 
2010). Such similarities in neuronal responses between the two regions of the central 
nervous system may be a result of the neurons in the dorsal horn projecting to the 
thalamus. However, neuronal responses have not been quantified in both the thalamus 
and the spinal cord in the same animals. As such, it is not known if thalamic neuronal 
excitability is a direct result of spinal neuronal hyperexcitability. Because input from 
spinal neurons located in the deep laminae of the dorsal horn converges onto thalamic 
neurons, it is highly likely that hyperexcitability within spinal neurons drives the 
hyperexcitability of the thalamic neurons. 
The apparent disconnect between evoked thalamic neuronal firing and the 
forepaw withdrawal threshold suggests that additional regions of the brain likely 
contribute to the overall response to forepaw stimulation. Indeed, the periaqueductal gray 
(PAG), the anterior cingulate cortex (ACC), and the primary somatosensory cortex (S1) 
are implicated in arthritis-mediated joint pain (Desantana et al., 2009; Guo et al., 2005; 
Lamour et al., 1983). The ACC has a role in the emotional aspect of pain sensation and 
contributes to the unpleasantness of pain (Guo et al., 2005); yet, activity in the ACC does 
not affect the threshold to withdrawal from a stimulus applied to the paw (Chen et al., 
2012; LaGraize and Fuchs, 2007). Although hyperexcitability in the thalamus suggests 
the rats can detect the sensory aspect of the von Frey filament stimulation, the sensory 
information transmitted to the thalamus is further relayed to higher order regions 
involved in the sensory discriminative perception of pain, such as the primary 
somatosensory cortex. The excitability of neurons in S1 is increased during 
inflammation, and a lesion in this region alleviates inflammation-induced pain (Guilbaud 
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et al., 1993; Uhelski et al., 2012). Moreover, a unilateral noxious stimulus can activate 
neurons in S1 bilaterally, and this bilateral activity has been speculated to contribute to 
the motor responses to the stimulus (Wang et al., 2003). As such, the lack of a forepaw 
withdrawal in response to a stimulus that evoked thalamic neuronal hyperexcitability may 
be due to additional higher order processing of that sensory stimulus. Additional studies 
quantifying neuronal excitability in regions of the brain, such as the primary 
somatosensory cortex, are necessary to fully define the central responses to painful facet 
joint injury that mediate behavioral hypersensitivity and to contextualize the relationships 
between the threshold eliciting a forepaw withdrawal and that magnitude at which 
thalamic neuronal hyperexcitability is evident. 
 Thalamic neuronal hyperexcitability is not a central adaptation unique to painful 
facet joint injury. Rather, injury to additional soft tissues in the cervical spine like the 
cervical nerve roots also increases excitability of thalamic neurons. Neuronal firing in the 
VPL evoked by forepaw stimulation is increased in response to noxious stimuli (10g, 
26g, & pinch) after a fifteen minute cervical nerve root compression in association with 
behavioral hypersensitivity (Syré et al., 2014), following the same pattern as in these 
studies (Figure 7.4). Yet, enhanced firing in the VPL is also evident for all non-noxious 
stimuli (1.4g, 4g, & brush) after the nerve root compression (Syré et al., 2014). However, 
enhanced firing is only evident for the 4g and brush stimuli following facet joint injury 
(Figure 7.4). The electrophysiological studies presented here were performed seven days 
after facet joint injury and those after nerve root injury were fourteen days after the initial 
injury (Syré et al., 2014). Any difference in the response to non-noxious stimuli between 
the two injuries may be due to differences in the injuries themselves or in the timing of 
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the measurements. Indeed, both painful nerve root compression and painful facet joint 
injury exhibit the same pattern of neuronal hyperexcitability in the spinal cord at day 
seven after injury, with all stimuli except the 1.4g von Frey filament evoking 
significantly more spikes after injury compared to controls (Nicholson et al., 2014; Quinn 
et al., 2010). Moreover, both spinal neurons and thalamic neurons exhibit the same 
pattern of hyperexcitability on day seven after facet joint injury (Figure 7.4; Quinn et al., 
2010). As such, it may be that spinal and thalamic neurons also exhibit the same 
excitability pattern seven days after a nerve root injury. Alternatively, thalamic neuronal 
hyperexcitability may be evident across all stimuli (1.4g, 4g, 10g, 26g, brush, & pinch) 
on day seven after a nerve root compression.  
The magnitude of behavioral hypersensitivity is the same at day seven and day 
fourteen after nerve root injury (Syré et al., 2014), so it follows that thalamic neuronal 
hyperexcitability may likewise be the same at those same time points after a nerve root 
injury. As such, painful facet joint and nerve root injuries would exhibit different patterns 
of thalamic neuronal hyperexcitability at day seven. Similarly, since facet joint injury 
induces behavioral hypersensitivity that is sustained at both days seven and fourteen to 
the same degree (Lee et al., 2004; Rothman et al., 2007), the pattern of thalamic neuronal 
hyperexcitability (4g, 10g, 26g, brush, & pinch) that is identified here at day seven might 
also be sustained at day fourteen and, thus, would be different from a nerve root injury at 
that same time (Syré et al., 2014). Further studies comparing these two painful cervical 
spine injuries at the same time points are needed to identify whether or not a common 
pattern of thalamic neuronal hyperexcitability exists across different pain etiologies and 
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origins. Such a common hyperexcitability pattern would support the potential for a single 
intervention at the thalamic level in alleviating pain from multiple types of injury. 
 The existence of hyperexcitability of neurons in the VPL supports central 
sensitization, which sustains ongoing pain and leads to referred pain, as a mediator of 
injury-induced facet pain. Yet, despite a trend towards a decrease in withdrawal threshold 
after joint distraction (Figure 7.3), this decrease did not reach significance when 
compared to sham. This lack of change in withdrawal threshold may be due to the small 
group sizes used in the characterization study because power analysis indicates that group 
sizes of at least six rats would be necessary to detect changes in behavioral responses 
between groups in this study. Regardless, the applied C6 forceps displacement 
(2.52±0.04mm) is similar to the C6 forceps displacements applied in Chapter 6 
(2.65±1.45mm), and the capsule distraction (0.39±0.18mm) and maximum principal 
strains (40.31±9.48%) are consistent with those values of injury metrics (capsule 
distraction 0.23-0.34mm; maximum principal strain 21.5-31.2%) quantified in previously 
published reports of facet joint loading associated with behavioral hypersensitivity (Dong 
et al., 2008; Dong et al., 2011). It is, therefore, reasonable to assume that if the group 
sizes were expanded for the current study, such differences in behavioral responses 
between distraction and sham would be significant. As such, additional animals were not 
included in this study, but future studies identifying the specific cellular mechanisms 
responsible for thalamic neuronal hyperexcitability after joint injury should include larger 
group sizes.  
Based on the findings in the characterization study, larger group sizes (n=6 for 
each group) were used in the IB4-saporin study to ensure sufficient power to detect any 
176 
potential differences in behavioral sensitivity between the IB4-Sap+FJD and IB4-
Sap+sham groups. Such group sizes are sufficient to detect differences in behavioral 
sensitivity following painful facet joint loading (Chapters 4 & 6; Kras et al., 2013b; Kras 
et al., 2014a). Yet, no differences in withdrawal threshold are detected between the IB4-
Sap+FJD and IB4-Sap+sham groups (Figure 7.5). The injury metrics quantified for the 
IB4-Sap+FJD rats (capsule distraction 0.23±0.09mm; maximum principal strain 
41.1±46.5%; maximum rostrocaudal strain 22.4±18.2%) are not different from the 
respective distraction and strain values measured for either the SSP-Sap+FJD 
(0.23±0.07mm; 24.9±14.0%; 19.4±14.0%) or the Blank-Sap+FJD (0.22±0.06mm; 
21.3±13.3%; 14.7±7.1%) groups that were used in Chapter 5 in which differences in 
behavioral sensitivity were detected. The lack of differences in the biomechanical metrics 
of applied injury severity across groups supports the injury applied to the IB4-Sap+FJD 
rats in this study to be sufficient to induce behavioral hypersensitivity. As such, the lack 
of difference in withdrawal threshold between the IB4-Sap+FJD and IB4-Sap+sham 
groups in the current study (Figure 7.5) can be taken as a result of the IB4-saporin 
treatment and not due to an insufficient injury. Further, running a power analysis on these 
groups indicates that group sizes in excess of 1,000 rats are required to detect differences 
in withdrawal threshold in the IB4-saporin treated groups. Such a large group size far 
exceeds the number of rats used to detect differences in behavioral sensitivity and 
confirms that the withdrawal thresholds between these groups are indeed the same, with 
the lack of difference not being an artifact of small group sizes. 
In parallel with the withdrawal thresholds, the evoked spikes from thalamic 
neurons also are not different between the IB4-Sap+FJD and IB4-Sap+sham groups 
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(Figure 7.5). In a nerve root injury model, significant differences in thalamic neuronal 
excitability were detected between injury and control groups from 57 distinct neurons 
(Syré et al., 2014), suggesting the number of neurons recorded in the thalamus in the 
current study (74 neurons) would be sufficient to detect any differences between the IB4-
Sap+FJD and IB4-Sap+sham groups. In fact, power analysis indicates that at least 900 
neurons would be needed per group to detect differences in the number of spikes evoked 
by any of the brush, von Frey, and pinch stimuli. As such, the finding of no difference in 
thalamic neuronal excitability between the IB4-Sap+FJD and IB4-Sap+sham groups also 
is not likely a result of insufficient group sizes but rather reflects a true lack of difference 
between these groups. For comparisons of the ratio of WDR neurons between groups, 
Pearson’s chi-square test requires a minimum of five observations for each group and 
classification. Since the number of neurons classified as WDR and LTM for the IB4-
Sap+FJD and IB4-Sap+sham groups meet the required number of observations, the 
finding that the proportions of WDR neurons between the two injury groups are 
equivalent is not due to an insufficient number of neurons included in the test. Based on 
the sufficient power of these statistical tests, the ablation of the non-peptidergic joint 
afferents prior to injury can be taken as the underlying reason for the lack of difference in 
either the behavioral or the electrophysiological responses between the IB4-Sap+FJD and 
IB4-Sap+sham groups. 
 Despite sensitization of thalamic neurons in painful inflammatory conditions or 
following neural tissue injury (Huh et al., 2012; Syré et al., 2014; Zhao et al., 2006), the 
molecular responses underlying sensitization of neurons in the VPL are poorly defined. 
Because STT neurons express the trkB receptor for BDNF (Slack et al., 2005), spinal 
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BDNF may contribute to thalamic neuronal sensitization. Indeed, spinal BDNF induces 
long-term potentiation in spinal neurons via ERK mediated signaling (Zhou et al., 2008), 
and BDNF induces ERK activation in STT neurons (Slack et al., 2005). As such, the 
increased spinal BDNF observed at day seven after a painful facet joint distraction 
(Chapter 6) may also activate and sensitize STT neurons through a similar ERK-
dependent mechanism. Moreover, NGF regulates BDNF expression (Merighi et al., 2004) 
and is increased in both the facet joint and the DRG after painful joint loading (Chapter 
5). Accordingly, NGF may be a local initiator of joint pain and upregulation of 
neurotransmitters, such as BDNF expression, that can induce central sensitization. NGF 
mainly activates peptidergic afferents (McMahon, 1996; Merighi et al., 2004), but 
ablation of non-peptidergic joint afferents prevents the development of injury-induced 
behavioral sensitivity and thalamic hyperexcitability (Figure 7.5). Up to one-third of 
neurons that bind IB4 also express the NGF receptor trkA (Joseph and Levine, 2010), so 
it is possible that ablation of the IB4-expressing neurons may also disrupt NGF-mediated 
responses leading to joint pain after injury.  
Additional mechanisms, such as those involving prostaglandin signaling, may 
also contribute to thalamic sensitization. Guilbaud identified disruption of prostaglandin 
synthesis as having a depressing effect on excitability of neurons in the thalamus of 
arthritic rats (Guilbaud et al., 1982). In fact, intra-articular ketorolac, a non-steroidal anti-
inflammatory drug that disrupts prostaglandin synthesis, alleviates facet-mediated pain in 
this same injury model (Dong et al., 2013a). When taken together with the role for 
prostaglandins in thalamic sensitization (Guilbaud et al., 1982), the necessity of 
prostaglandins for the maintenance of facet-mediated pain suggests that prostaglandins 
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may also contribute to hyperexcitability in the VPL after painful facet joint injury. Non-
peptidergic afferents have a role in potentiating behavioral responses to PGE2 signaling 
(Joseph and Levine, 2010). In the context of the Joseph and Levine study, the current 
findings that ablating non-peptidergic joint afferents prevents the development of 
behavioral hypersensitivity and thalamic neuronal hyperexcitability after a facet joint 
injury (Figure 7.5) further supports PGE2 as a mediator of thalamic excitability induced 
by facet injury. Although both BDNF and prostaglandins are potential mediators of 
thalamic sensitization, further studies specifically disrupting BDNF and prostaglandin 
signaling are necessary to define which cellular responses in the primary afferents and/or 
the spinal cord contribute to pain and central sensitization after facet joint injury. 
 Regardless of the cellular mechanisms involved, the finding of injury-induced 
hyperexcitability in the VPL demonstrates that facet joint injury elicits central 
modifications in the brain and suggests that interventions targeting the brain may have 
therapeutic potential for facet pain. Structural differences have been identified in the 
brains of pain patients with persistent low back pain or painful osteoarthritis (Gwilym et 
al., 2010; Saab, 2012; Seminowicz et al., 2011), and interventions like facet joint 
injections that alleviate pain also mitigate differences in brain structure between pain 
patients and control subjects (Seminowicz et al., 2011). As such, following painful facet 
joint injury, localized interventions in the facet joint that alleviate pain may also 
normalize brain modifications such as VPL hyperexcitability. Indeed, targeted ablation of 
non-peptidergic joint afferents prevents injury-induced thalamic hyperexcitability (Figure 
7.5). Yet, it is unknown if VPL hyperexcitability is maintained by continuous input from 
the injured facet joint or if the initial injury is sufficient to sensitize thalamic neurons via 
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the joint afferents, spinal circuits, or gene expression changes within the thalamic neurons 
themselves. The effectiveness of radiofrequency neurotomy, which eliminates neurons 
innervating painful facet joints, in alleviating pain (Smith et al., 2014) supports a role for 
ongoing input from the joint afferents in the maintenance of facet pain.  
In addition to neuronal ablation, deep brain stimulation (DBS) may provide an 
additional therapeutic option for alleviating facet pain. DBS in the thalamus has shown 
effectiveness in reducing pain and neuronal hyperexcitability in a rat neuropathic pain 
model (Iwata et al., 2011). Similarly, burst stimulation of the thalamus is effective in 
alleviating inflammatory pain associated with thalamic neuronal hyperexcitability in mice 
(Huh and Cho, 2013). Clinically, enhanced local field potentials are evident in the 
thalamus, periventricular gray (PVG), and periaqueductal gray (PAG) in patients 
experiencing pain (Llinás et al., 1999; Pereira et al., 2013). Stimulation of such brain 
regions as the VPL, PVG, and PAG reduces clinical pain in a variety of conditions, 
including low back pain, chronic regional pain syndrome, brachial plexus injury, and 
phantom limb pain (Pereira et al., 2013; Rasche et al., 2006). Further, stimulation of the 
anterior cingulate cortex to reduce the emotional impact of chronic pain has also been 
implemented in those patients for which thalamic or PVG/PAG DBS is ineffective 
(Pereira et al., 2013). DBS has not previously been applied to treat joint pain, either 
clinically or in pre-clinical studies. Because thalamic neurons are hyperexcitable in 
association with facet joint pain, further investigation of the relationship between 
thalamic neuronal activity and injury-induced pain is warranted.  Implanting electrodes 
into the VPL to regulate thalamic neuronal firing would determine that relationship, as 
well as any therapeutic potential of DBS in alleviating established facet joint pain. Yet, 
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before such complicated studies are undertaken, additional studies are first needed to 
establish the time course of facet joint injury-induced thalamic neuronal hyperexcitability 
at times longer than seven days. If thalamic neuronal hyperexcitability is only transient, 
then an invasive treatment such as DBS would likely be inappropriate for alleviating 
facet-mediated hypersensitivity. 
 
7.6. Conclusions & Integration 
Studies in this chapter support modifications in the brain, specifically in the VPL, 
as likely contributing to facet joint injury-induced pain. Specifically, the prevention of 
both behavioral sensitivity and thalamic neuronal hyperexcitability that are normally 
evident after facet joint injury by ablating non-peptidergic joint afferents supports a 
contribution of VPL sensitization to facet-mediated pain. Moreover, the increase in 
thalamic excitability is evident at a time when spinal BDNF, which is capable of 
activating thalamic neurons, is also elevated (Chapter 6; Kras et al., 2013c). In fact, 
sequestration of spinal BDNF alleviates facet pain (Figure 6.6), but excitability of 
thalamic neurons was not assessed after BDNF sequestering. As such, it is not known if 
thalamic hyperexcitability after a painful facet joint injury is mediated by increased spinal 
BDNF signaling, nor is it known if the mechanism through which spinal BDNF 
contributes to behavioral hypersensitivity involves increased neuronal firing in the 
thalamus. Nevertheless, BDNF activates neurons projecting to the thalamus and is 
regulated by NGF (McMahon, 1996; Merighi et al., 2004; Slack et al., 2005). The 
increases in NGF in the joint and DRG (Figures 5.2 & 5.3) and increases in BDNF in the 
DRG and spinal cord (Figures 6.3 & 6.4) (Kras et al., 2013c; Kras et al., 2014b) that are 
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induced by facet injury imply that a neurotrophin-mediated mechanism is involved in 
both the initiation and maintenance of facet pain. Since disruption of intra-articular NGF 
signaling immediately after a facet joint injury prevents the development of spinal 
hyperexcitability at day seven (Chapter 5), it might also prevent the development of 
thalamic hyperexcitability at that same time. Yet, blocking intra-articular NGF signaling 
also prevents the development of spinal hyperexcitability at day one after injury. If 
neurotrophins drive hyperexcitability of neurons in the thalamus after facet joint injury, 
then it is likely that thalamic hyperexcitability would also be evident at earlier time points 
than day seven in parallel with the development of spinal neuronal hyperexcitability. 
Thalamic neuronal hyperexcitability was only assessed at day seven after joint injury, so 
it is not known if the excitability of thalamic neurons also increases at earlier time points 
when spinal neuronal hyperexcitability develops. Behavioral hypersensitivity and spinal 
neuronal hyperexcitability are evident as early as one day after a facet joint injury 
(Crosby et al., 2013; Kras et al., 2014b). PGE2 is increased in the spinal cord at day one 
after facet joint injury (Kras et al., 2014a). Since PGE2 is both sufficient to induce 
hyperexcitability in spinal neurons and contributes to joint inflammation-induced 
thalamic hyperexcitability (Guilbaud et al., 1982; Vasquez et al., 2001), PGE2 probably 
contributes to facet injury-induced hyperexcitability in the thalamus at early time points, 
likely at day one.  
Further, behavioral hypersensitivity is maintained as late as six weeks after the 
facet joint injury (Rothman et al., 2007). Although the maintenance of behavioral 
sensitivity implies that thalamic neuronal excitability might also be maintained at later 
time points beyond day seven, the cellular mechanisms that might sustain such prolonged 
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hyperexcitability have not been investigated. However, activation of astrocytes in the 
spinal cord is evident at both day seven and day fourteen after a painful facet joint injury 
(Dong et al., 2013b; Lee et al., 2004). Astrocytes contribute to pain through several 
mechanisms, including release of inflammatory cytokines and regulation of extracellular 
glutamate levels (Gao and Ji, 2010). Further, astrocytic activation in the thalamus has 
been associated with both inflammatory and post-stroke pain (Raghavendra et al., 2004; 
Wasserman and Koeberle, 2009). Inflammatory cascades have a role in facet-mediated 
pain (Dong et al., 2013a; Kras et al., 2014a), so astrocyte activation might also occur in 
the VPL after a painful facet joint injury and may also contribute to the associated 
thalamic neuronal hyperexcitability that is observed there. Since astrocytes are activated 
in the spinal cord as late as day fourteen following facet joint injury, a similar long-term 
activation of astrocytes may exist in the VPL and contribute to sustained behavioral 
hypersensitivity and thalamic neuronal hyperexcitability. Yet, studies are needed to 
identify whether or not astrocytes are activated in the thalamus following facet joint 
injury, as well as to investigate the time course of thalamic neuronal hyperexcitability in 
the context of facet-mediated pain, before such a mechanism can be considered. Other 
pain mediators may contribute to thalamic neuronal hyperexcitability in mechanical facet 
joint injury, such as altered expression of voltage-gated sodium channels, as has been 
documented for neural tissue injury (Zhao et al., 2006). Regardless, these data are the 
first identifying hyperexcitability in thalamic neurons in the context of pain following 
facet joint injury, and as a result, the brain represents a potential target for the 
development of therapeutics to treat persistent joint pain. 
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Chapter 8 
Synthesis and Future Work 
 
 
8.1. Introduction 
 Clinically, the cervical facet joint is the most common source of neck pain, and 
non-physiological stretching of the capsular ligament that encloses the facet joint space is 
a mechanism of neck pain that is supported by biomechanical studies (Barnsley et al., 
1995; Lord et al., 1996; Manchikanti et al., 2002; Pearson et al., 2004; Siegmund et al., 
2001; van Eerd et al., 2010; Yoganandan et al., 2002). Previous studies utilizing a rat 
model of painful mechanical facet joint injury demonstrate that facet joint distraction 
sufficient to induce behavioral hypersensitivity also induces joint inflammation within 
one day of injury, upregulates the expression of neuropeptides and inflammatory 
cytokines, and sensitizes spinal neurons (Crosby et al., 2013; Dong et al., 2013a; Dong et 
al., 2013b; Kras et al., 2014a; Lee and Winkelstein, 2009; Quinn et al., 2010). More 
recent work has identified afferent activity from the joint early after facet distraction as 
being required for the development of behavioral hypersensitivity and spinal neuronal 
hyperexcitability (Crosby et al., 2014). Collectively, these findings suggest that the 
inflammation and spinal neuronal dysfunction that maintain pain develop in response to 
local pain mediators and associated afferent activity within the injured facet joint that 
initiate pain immediately after injury. However, no specific cellular mechanism in the 
joint had been identified in studies as an initiating factor in facet injury-induced pain. In 
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addition, the relationship between such a local mechanism and the subsequent spinal 
modifications that maintain facet-mediated pain was not previously defined. Therefore, 
the goal of this thesis was to investigate one such potential cellular mechanism local to 
the facet joint by defining the roles of intra-articular nerve growth factor (NGF) in the 
initiation of facet pain and spinal neuronal dysfunction and spinal brain-derived 
neurotrophic factor (BDNF) in the maintenance of facet-mediated pain after a mechanical 
joint injury in the rat. Since contributions of NGF to inflammation- and arthritis-induced 
pain have been reported both clinically and experimentally (Amaya et al., 2004; Ghilardi 
et al., 2012; Lane et al., 2010; Rukwied et al., 2014; Woolf et al., 1994), intra-articular 
NGF was investigated as a promising candidate molecule likely involved in the induction 
and/or maintenance of facet joint pain after traumatic joint injury. 
 
8.2. Summary & Synthesis of Major Findings 
 Tensile loading of the C6/C7 facet joint at magnitudes simulating the magnitude 
of capsular ligament stretch that occurs during neck trauma that is associated with motor 
vehicle collisions induces referred pain in the forepaw of the rat (Dong et al., 2011; Kras 
et al., 2013b; Lee and Winkelstein, 2009), which is consistent with the hypersensitivity 
that is observed clinically in neck pain patients (Fernandez-Perez et al., 2012; Herren-
Gerber et al., 2004; Scott et al., 2005). Mechanical hyperalgesia develops within one day 
of a painful facet joint distraction (Chapters 3 & 4) and is maintained for at least six 
weeks (Rothman et al., 2007). Such a time course of immediate and sustained pain 
parallels the appearance of clinical pain symptoms that have been reported approximately 
24 hours after a motor vehicle collision-induced neck trauma (Chien et al., 2010), with up 
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to 50% of patients with whiplash-associated pain still reporting symptoms at one year 
after injury (Carroll et al., 2009). Initiation of persistent pain within 24 hours of an injury 
suggests there may be a brief time period during which the initial cellular responses to 
injury could be manipulated in order to effectively treat injury-induced joint pain. Indeed, 
systemic infusion of the corticosteroid, methylprednisolone, within eight hours after a 
traumatic neck injury reduces long-term disability in neck pain patients (Pettersson et al., 
1998), and an intra-articular injection of the sodium channel blocker, bupivacaine, within 
eight hours of a facet joint injury in the rat prevents the development of pain symptoms 
after injury (Crosby et al., 2014). Together, those clinical and basic science studies 
highlight the importance of the timing of potential interventions in the treatment of 
injury-induced neck pain and suggest that the early cellular responses to injury are likely 
a key determinant in the long-term pain outcomes following ligament injury. 
 Capsular ligament strains as low as 10%, induced by tensile loading of the 
cervical facet joint, activate the primary afferent fibers that innervate the joint (Chen et 
al., 2006; Lu et al., 2005). Injury-induced firing of primary afferents is one mechanism 
thought to initiate pain (Ji et al., 2003). Because the animal model of tensile capsular 
ligament stretch utilized for studies throughout this thesis induces maximum principal 
strains of 22.18±13.57% in the joint capsule (Chapter 3), activation of joint afferents by 
capsule stretch is a likely mechanism for initiating mechanical facet joint pain. Further, a 
majority of the neurons that innervate the cervical facet joint capsule are peptidergic 
(Chapter 4; Kras et al., 2013b). Peptidergic afferents are typically small diameter 
nociceptors, contain the neuropeptides substance P and/or calcitonin gene-related peptide 
(CGRP), and are sensitive to NGF (Merighi et al., 2008). Injury-induced activation of 
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peptidergic afferents not only leads to propagation of action potentials to the central 
nervous system, but activation of one branch of a peptidergic afferent propagates the 
signal into adjacent branches of that neuron, resulting in peripheral release of 
neuropeptides − this phenomenon is known as neurogenic inflammation (Birklein and 
Schmelz, 2008; Ringkamp et al., 2013). Peripherally-released substance P sensitizes 
articular afferents (Heppelmann and Pawlak, 1997), but it also induces the degranulation 
of mast cells (Birklein and Schmelz, 2008; Kumar and Mahal, 2012; Levine et al., 1984; 
Ringkamp et al., 2013). Mast cells are sources of NGF, and their degranulation releases 
NGF into the inflamed tissue (McMahon, 1996; Nicol and Vasko, 2007). Because NGF 
itself sensitizes primary afferents and regulates the expression and release of 
neuropeptides from those same neurons, injury-induced activation of facet joint afferents 
could initiate a positive feedback loop whereby substance P and NGF promote their own 
release within the injured joint, sensitizing joint afferents and ultimately inducing pain. 
 In addition to mechanical activation of joint afferents, inflammation has a well-
established role in afferent sensitization and pain (Schaible et al., 2002; Woolf et al., 
1997). As such, inflammation may also, in and of itself, promote injury-induced facet 
joint pain. Indeed, within 24 hours of a traumatic injury of the knee in humans, there is 
upregulation of the inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis 
factor-α (TNF-α) in the intra-articular space (Furman et al., 2014). Mechanical facet joint 
injury upregulates prostaglandin E2 and inflammatory cytokines (Kras et al., 2014a; Lee 
et al., 2008), and the increased intra-articular NGF evident one day after painful facet 
distraction is further evidence of injury-induced joint inflammation (Figure 8.1) (Chapter 
5; Kras et al., 2014b). NGF itself has a particularly important role in the development of 
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pain since exogenous NGF applied either subcutaneously or intra-dermally is sufficient to 
induce pain in both human volunteers and in animal models (Dyck et al., 1997; Woolf et 
al., 1994). Indeed, exogenous intra-articular NGF induces pain within 24 hours of its 
application to the facet joint (Chapter 5; Kras et al., 2014b). Further, increased NGF in 
the joint after injury parallels the induction of behavioral sensitivity at day one (Chapter 
5; Kras et al., 2014b). In conjunction with that finding, the notion that elevated levels of 
NGF in the facet joint after its injury initiate joint pain is supported by the fact that 
blocking NGF at the time of injury prevents the development of pain (Chapter 5; Kras et 
al., 2014b).  
 
Figure 8.1. Painful facet joint distraction induces increased expression of neurotrophic 
factors in the facet joint, the primary afferents, and the spinal cord, as well as 
hyperexcitability in both spinal and thalamic neurons. NGF is elevated in the facet 
joint at day one after painful injury. Upregulation of NGF contributes to the spinal 
neuronal hyperexcitability also evident at day one. BDNF expression is unchanged in 
both the primary afferents and the spinal cord at one day after injury. At day seven, 
both NGF and BDNF are increased in the DRG, and spinal BDNF is also elevated 
after injury. Increases in spinal BDNF may be a central mediator of both spinal and 
thalamic neuronal hyperexcitability at day seven.  
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The elevated levels of intra-articular NGF identified clinically in inflamed and 
arthritic joints and the success of anti-NGF treatments in alleviating joint pain confirm 
that NGF signaling is a key mediator of arthritic joint pain (Barthel et al., 2009; Brown et 
al., 2012; Lane et al., 2010; Raychaudhuri et al., 2011; Schnitzer et al., 2014). Intra-
articular NGF increases due to both arthritis and traumatic facet joint injury in the rat 
(Chapter 5; Kras et al., 2014b; McNamee et al., 2010; Orita et al., 2011). Further, NGF 
contributes to pain in both such joint conditions, as evidenced by the effectiveness of 
anti-NGF treatments applied either intra-articularly or systemically in preventing or 
alleviating pain (Chapter 5; Kras et al., 2014b; Lane et al., 2010; Schnitzer et al., 2014). 
In light of those parallels, NGF likely has a role in a broad range of painful joint 
conditions, possibly including other traumatic joint injuries or arthritis.  
Despite the possibility that NGF may be a common factor in joint pain, the 
specific role of intra-articular NGF in persistent joint pain may vary across the different 
joint pain conditions. That notion is supported by the fact that intra-articular NGF seems 
to initiate, but not maintain, pain following facet joint injury since blocking it only 
prevents pain from developing after injury but does not alleviate facet pain that has 
already been established (Chapter 5; Kras et al., 2014b). In contrast, although chemically-
induced joint osteoarthritis (OA) pain develops by day four after the initiating stimulus, 
NGF does not increase in the joint until day seven (Orita et al., 2011). However, that 
timing of increased NGF at day seven corresponds to when pain reaches its maximum in 
that OA model (Orita et al., 2011), suggesting that rather than initiating OA pain, intra-
articular NGF may exacerbate existing pain. Indeed, intra-articular injection of NGF into 
osteoarthritic knees in the rat exacerbates existing OA pain (Ashraf et al., 2014). 
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Moreover, NGF as an amplifier of OA joint pain is consistent with clinical findings of 
relief, but not complete abolishment, of pain in patients (Brown et al., 2012; Lane et al., 
2010; Schnitzer et al., 2014). Although growing evidence supports NGF as contributing 
to pain in multiple painful joint conditions, there may not be a single treatment paradigm 
(i.e. dose, timing, route of administration) for anti-NGF to effectively treat pain. 
Although NGF levels increase in the facet joint one day after its painful injury, 
the source of NGF within the injured joint is still unknown. Immune cells, such as 
lymphocytes, macrophages, and mast cells, infiltrate inflamed joints in both animal 
models and patients with osteoarthritis and rheumatoid arthritis (Aloe et al., 1992; de 
Lange-Brokaar et al., 2012). Those immune cells are potential sources of NGF 
(McMahon, 1996). In addition to releasing NGF, macrophages and mast cells can also 
release inflammatory cytokines, such as IL-1β and TNF-α (de Lange-Brokaar et al., 
2012), both of which are themselves mediators of behavioral hypersensitivity and potent 
inducers of NGF expression and release (Safieh-Garabedian et al., 1995; Woolf et al., 
1997). 
  Interestingly, antagonism of either IL-1 or TNF-α via an intra-articular injection 
of a selective inhibitor for either cytokine at one day after a painful facet joint injury is 
ineffective in alleviating facet-mediated behavioral hypersensitivity (Dong, 2011). The 
ineffectiveness of cytokine antagonism suggests that neither of those pain mediators 
contributes to facet joint pain, although in that work, only a single dose of either 
antagonist was applied, leaving open the possibility that a higher dose or multiple doses 
might be effective in alleviating or attenuating pain. However, a study of IL-1β-induced 
knee pain also found that a single intra-articular injection of an IL-1 inhibitor failed to 
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alleviate pain despite the known overexpression of IL-1β within that joint (Allen et al., 
2011). Moreover, the lack of pain relief following injection of the IL-1 inhibitor may be 
an artifact of the times selected for behavioral assessment. Safieh-Garabedian reported 
that injection of an IL-1 inhibitor reduced inflammatory pain 90 minutes after injection 
but that mechanical hyperalgesia returned within three hours of the initial injection 
(Safieh-Garabedian et al., 1995), which is well before behavioral responses were assessed 
following cytokine antagonism in the other studies (Allen et al., 2011; Dong, 2011). As 
such, it may be possible that intra-articular IL-1β contributes to facet-mediated pain and 
intra-articular NGF overexpression. Although, the cellular sources of increased NGF 
within the facet joint after its painful injury are still unknown, the documented role of 
inflammation in facet pain supports macrophages and mast cells as likely sources. 
NGF induces sensitivity through post-translational modifications of ion channels 
as well as transcriptional regulation of neurotransmitters released at central and 
peripheral synapses (Mantyh et al., 2011). Within hours of exposure to NGF, modulation 
of ion channels such as voltage-gated sodium channels, potassium channels, and transient 
receptor potential vanilloid 1 (TRPV1) increases the excitability of primary afferent 
neurons that express the NGF receptor, trkA (Kerr et al., 2001; Mantyh et al., 2011; 
Zhang et al., 2002). Sensitization of the primary afferents innervating joints leads to a 
lower mechanical activation threshold for those neurons such that normally innocuous 
joint motions may activate nociceptors, and afferent activation releases more 
neurotransmitters into the spinal cord (Heppelmann and Pawlak, 1997; Schaible et al., 
2002). Additionally, retrograde transport of the NGF-trkA receptor complex from the 
peripheral terminal to the cell body in the DRG increases synthesis of substance P, 
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CGRP, and BDNF, all of which are pro-algesic (Mantyh et al., 2011). Indeed, the 
increased NGF in the DRG seven days after painful facet joint injury (Chapter 5; Kras et 
al., 2014b) parallels the increased expression of both BDNF (Figure 8.1) (Chapter 6; Kras 
et al., 2013c) and substance P (Lee and Winkelstein, 2009) in the DRG at that same time.  
Retrograde transport of NGF can take hours to days before alterations in protein 
synthesis are detected in the DRG (Mantyh et al., 2011), so the increased NGF in the 
facet joint that is evident on day one could be the source of the elevated NGF levels in the 
DRG at day seven. Yet, given the relatively close proximity of the cervical facet joint to 
the DRG and a reported rate of axonal NGF transport of approximately 3mm per hour in 
vitro (Delcroix et al., 2003), an effect of NGF on protein synthesis earlier than day seven 
is expected. Indeed, both BDNF and substance P expression exhibit trends towards 
elevation as early as day one after injury, although neither increase is significant (Kras et 
al., 2013c; Lee and Winkelstein, 2009). Such a trend suggests that NGF-induced 
synthesis of pain mediators in the primary afferents likely begins earlier than day seven, 
when injury-induced pain is already established. Nevertheless, the lack of changes in 
substance P and BDNF at day one does not preclude a contribution of those mediators to 
pain development at that time point since noxious stimulation of afferents induces the 
release of existing stores of substance P and BDNF from the central terminals of 
nociceptors (Lever et al., 2001; Pezet and McMahon, 2006). 
Even though transcriptional regulation of BDNF and substance P by NGF at day 
one is too early to induce pain development, increased release of those pain mediators 
that is induced by NGF can initiate pain. Exposure to NGF increases evoked release of 
both BDNF and substance P in the spinal cord (Lever et al., 2001; Thompson et al., 
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1995). Systemic NGF induces behavioral hypersensitivity and spinal neuronal 
sensitization within two hours after NGF exposure, and those effects are a result of an 
increased release of substance P into the dorsal horn (Thompson et al., 1995). Moreover, 
that NGF induced sensitivity is transient, lasting only 24 hours (Thompson et al., 1995). 
As such, substance P release likely has a role in the transient behavioral hypersensitivity 
and spinal neuronal hyperexcitability that are induced by exogenous intra-articular NGF 
application (Chapter 5; Kras et al., 2014b). Further, ablation of spinal cord neurons that 
express the NK1 receptor (NK1R) for substance P prevents the development of both pain 
and spinal hyperexcitability after a joint injury sufficient to elevate intra-articular NGF 
levels (Kras et al., 2014b; Weisshaar and Winkelstein, 2014). As described earlier, 
substance P release from primary afferents is not restricted to the spinal cord but is also 
evoked in the periphery when peptidergic afferents are activated (Birklein and Schmelz, 
2008; Ringkamp et al., 2013). Substance P signaling has an established role in joint pain, 
with injection of substance P intra-articularly sensitizing joint afferents in otherwise 
normal rats (Heppelmann and Pawlak, 1997) and intra-articular inhibition of activation of 
NK1R alleviating established joint pain (Uematsu et al., 2011). Indeed, ablation of NK1 
receptor-bearing joint afferents, but not non-peptidergic joint afferents, prevents both the 
behavioral hypersensitivity and the spinal neuronal hyperexcitability that are 
characteristic of intra-articular NGF application from developing (Figure 8.2) (Chapter 
5). Similarly, ablation of those same joint afferents that express NK1R prior to facet joint 
injury prevents loading-induced pain from developing (Figure 8.2) (Chapter 5), in 
agreement with published reports that pre-emptive inhibition of NK1 receptor activation 
prevents inflammatory joint pain initiation (Keeble and Brain, 2004). Intra-articular NGF 
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may directly contribute to the onset of injury-induced facet pain by facilitating the release 
of substance P from primary afferents both peripherally within the joint and centrally 
within the spinal cord.  
 
Regardless of the subpopulations of afferents that it activates, intra-articular NGF 
is necessary for facet joint injury-induced pain and the associated development of spinal 
neuronal hyperexcitability. Blocking NGF signaling with an anti-NGF antibody injected 
into the facet joint immediately after an otherwise painful injury prevents behavioral 
hypersensitivity and spinal hyperexcitability (Chapter 5; Kras et al., 2014b). Given that 
Figure 8.2. Intra-articular application of NGF is sufficient to induce both behavioral 
sensitivity and spinal neuronal hyperexcitability at day one after injection. Ablation of 
those neurons that express the NK1 receptor (NK1R+) prior to NGF injection prevents 
the increases in behavioral sensitivity and excitability of spinal neurons; yet, ablating 
non-peptidergic afferents that bind IB4 (IB4
+
) has no effect. Distraction of the facet 
joint increases behavioral sensitivity and induces spinal neuronal hyperexcitability at 
day seven. Selective inhibition of intra-articular NGF at the time of injury (D0), but 
not at a later time (D1), prevents the development of behavioral hypersensitivity and 
spinal neuronal hyperexcitability at day seven. Ablation of NK1R
+
 joint afferents prior 
to a facet joint distraction with no other treatment prevents the initiation of behavioral 
hypersensitivity. 
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pre-treatment with anti-NGF prior to a painful inflammatory stimulus prevents pain 
development (Safieh-Garabedian et al., 1995; Woolf et al., 1994) and that inflammation 
contributes to facet joint pain (Dong et al., 2013a; Kras et al., 2014a; Lee et al., 2008), it 
is not surprising that blocking NGF prevents injury-induced facet pain. Yet, the lack of 
effect when intra-articular NGF is blocked one day after injury, when pain and spinal 
hyperexcitability are already established, suggests that several mechanisms may induce 
persistent joint pain, with NGF as the initiator (Chapter 5; Kras et al., 2014b). PGE2 is a 
known regulator of inflammation and pain and has a major role in joint pain (Lee et al., 
2013; Lin et al., 2006). Intra-articular ketorolac, which disrupts synthesis of 
prostaglandins, reverses established facet joint pain, but only when given one day after 
injury when PGE2 expression is elevated (Dong et al., 2013a; Kras et al., 2014a). In 
inflamed tissue, NGF promotes hyperalgesia by inducing a switch in PGE2 signaling that 
increases the duration of PGE2-mediated behavioral hypersensitivity (Joseph and Levine, 
2010; Parada et al., 2005). Early anti-NGF treatment may prevent nociceptor priming by 
blocking intra-articular NGF after injury, a notion supported by the finding that intra-
articular anti-NGF given one day after injury does not alleviate established pain (Chapter 
5; Kras et al., 2014b). In fact, the different effects of anti-NGF and ketorolac may be due 
to early NGF facilitating later PGE2-mediated nociception. As such, the timing of local 
joint interventions to correspond with the temporal contribution of their targeted 
mechanisms is crucial for effectively treating facet joint pain. 
Within one day of facet joint injury, sensitization of spinal neurons is already 
evident (Chapter 5; Crosby et al., 2013; Kras et al., 2014b). Increased synaptic efficacy in 
the spinal cord is a hallmark of chronic pain that leads to reduced pain thresholds and 
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spreading of hypersensitivity to regions beyond the initial tissue injury (Ji et al., 2003; 
Latremoliere and Woolf, 2009). Facet joint injury in the rat induces hypersensitivity in 
anatomical regions that are remote from the neck, including the shoulder and forepaw 
(Chapter 3; Dong et al., 2013a; Lee and Winkelstein, 2009), similar to clinical neck 
trauma patients (Chien et al., 2009; Curatolo et al., 2001; Fernandez-Perez et al., 2012; 
Greening et al., 2005; Sterling and Kenardy, 2008; Sterling et al., 2002); that finding 
supports a spinal contribution to facet-mediated pain. Spinal maintenance of facet joint 
pain may explain why many current treatments for facet-mediated pain have proven to be 
effective only transiently (Barnsley, 2005; Manchikanti et al., 2008; van Eerd et al., 
2014). They only treat the peripheral symptoms and do not alter the underlying spinal 
mechanisms that potentiate pain. Unlike the DRG and peripheral axons, the spinal cord is 
protected by the blood brain barrier (Sapunar et al., 2012), so treatments applied in the 
periphery are much less likely to penetrate into the spinal cord.  
Since spinal neuronal hyperexcitability develops by day one after facet joint 
injury (Crosby et al., 2013; Kras et al., 2014b), peripheral treatment of facet pain is likely 
most effective prior to the onset of sensitization of spinal neurons. Indeed, anti-NGF 
treatment is only effective at the time of injury (Chapter 5; Kras et al., 2014b), and 
blocking activation of facet joint afferents via the sodium channel blocker bupivacaine is 
only effective when applied within eight hours of a joint injury (Crosby et al., 2014).  
However, the duration of the effects bupivacaine is only expected to be 8-12 hours when 
applied post-operatively (Skolnik and Gan, 2014). Because bupivacaine was applied 
intra-articularly at least 12 hours before behavioral sensitivity was measured in this 
model (Crosby et al., 2014), ongoing afferent input from the injured facet joint cannot be 
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ruled out as contributing to the maintenance of facet pain.  Disruption of prostaglandin 
synthesis via intra-articular ketorolac alleviates facet pain when applied one day after 
injury (Dong et al., 2013a), suggesting that joint afferents do contribute to the 
maintenance of facet-mediated pain. Yet, unlike NGF, which is not transported to the 
spinal cord, prostaglandins are released in the spinal cord where they reduce transmission 
of inhibitory signals and increase release of neurotransmitters such as substance P from 
presynaptic primary afferents, both of which contribute to spinal neuronal excitability (Ji 
et al., 2003; Latremoliere and Woolf, 2009; Seybold, 2009; Vasquez et al., 2001).  Spinal 
PGE2 is increased at day one after painful facet joint injury (Kras et al., 2014a), 
supporting a spinal contribution for prostaglandins in facet pain. Intra-articular ketorolac 
could alleviate established facet pain by disrupting PGE2 synthesis in primary afferents 
that would otherwise release it into the spinal cord. Antagonists of prostaglandin 
receptors have been developed (Jiang et al., 2013); using such antagonists to block spinal 
activation of PGE2 receptors would clarify if spinal action of PGE2 maintains facet-
mediated pain. Regardless of whether or not PGE2 contributes to pain via spinal 
signaling, the effectiveness of intra-articular ketorolac in alleviating facet pain at a time 
when anti-NGF treatment is ineffective supports different mechanisms being responsible 
for initiating and maintaining injury-induced facet pain.  
Although intra-articular NGF induces the pain and spinal neuronal 
hyperexcitability that are associated with facet joint injury, multiple different 
mechanisms contribute to their maintenance. In the spinal cord, BDNF is generally 
localized to the superficial laminae (I-II) (Chapter 6), where nociceptors terminate. Its 
upregulation in that region of the spinal cord on day seven after painful injury implicates 
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BDNF as contributing to the spinal neuronal hyperexcitability that is evident at that time 
(Crosby et al., 2014; Kras et al., 2013c; Quinn et al., 2010). Spinal BDNF sensitizes 
neurons via activation of pre- and post-synaptic trkB receptors that leads to 
phosphorylation of glutamate receptors (Merighi et al., 2008; Slack et al., 2004) in an 
extracellular signal regulated kinase (ERK) dependent mechanism (Figure 8.3). 
 
Figure 8.3. Schematic of BDNF release in the spinal cord at day seven. After a painful 
facet joint distraction, BDNF is upregulated in the superficial dorsal horn. BDNF 
released from primary afferent terminals activates post-synaptic trkB receptors, which 
leads to activation of ERK in second order sensory neurons in the dorsal horn and 
subsequent phosphorylation of NMDA receptors (NMDARs). Phosphorylation of the 
NMDARs leads to increased activation of the receptors and hyperexcitability of the 
spinal neuron. Downregulation of glutamate transporters on activated astrocytes 
prolongs the excitatory effects of glutamate binding the NMDARs. Because both 
BDNF and substance P (sub P) are released from the same pre-synaptic neurons, 
ablating spinal neurons expressing the substance P receptor NK1 (NK1R) will disrupt 
BDNF signaling mechanisms in the spinal cord as well. 
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Phosphorylation of the NR1 subunit of the NMDA glutamate receptor contributes to its 
activation and increases neuronal excitability. After facet joint injury, spinal BDNF is 
increased at the same time that both ERK and NR1 are phosphorylated in the spinal cord 
and spinal neurons are hyperexcitable (Crosby et al., 2014; Kras et al., 2013c), further 
supporting a contribution of spinal BDNF to neuronal hyperexcitability in the spinal cord. 
Moreover, selective inhibition of BDNF signaling in the spinal cord alleviates facet joint 
injury-induced behavioral hypersensitivity and reduces spinal ERK activation (Kras et al., 
2013c), suggesting that increased spinal BDNF release will also underlie NR1 
phosphorylation after injury.  
Spinal BDNF is increased in the superficial dorsal horn where the number of 
excitatory synapses also increases after injury (Crosby et al., 2015; Kras et al., 2013c). 
Because BDNF released in synaptic clefts in the spinal cord is itself excitatory, the 
excitatory synapses in the superficial dorsal horn likely contain BDNF, and increases in 
the number of synapses may contribute to the overall increase in BDNF in that region. 
Spinal BDNF can contribute to sprouting of Aβ fibers, which normally transmit 
innocuous tactile information, from the deeper laminae into the superficial dorsal horn 
(Matayoshi et al., 2005). The sprouting Aβ fibers could form new synaptic connections 
with nociceptive circuits in the superficial dorsal horn and could, therefore, account for 
both the increase in excitatory synapses in that region and the increased excitability of 
spinal neurons. In either case, increased spinal BDNF contributes to facet joint injury-
induced behavioral hypersensitivity (Chapter 6; Kras et al., 2013c) and likely contributes 
to spinal neuronal hyperexcitability either by directly sensitizing post-synaptic neurons or 
by inducing aberrant synaptic connections between Aβ fibers and nociceptive circuits in 
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the spinal cord. Since intrathecal inhibition of BDNF signaling after painful facet joint 
injury only partially alleviates behavioral hypersensitivity (Chapter 6; Kras et al., 2013c), 
BDNF may induce a combination of spinal neuronal sensitization and aberrant fiber 
sprouting. Disrupting BDNF signaling could block BDNF-mediated sensitization of 
spinal neurons at that time but would not disrupt existing aberrant synaptic connections. 
The continued activity of those aberrant synapses could be sufficient to maintain some 
pain. Interestingly, daily intrathecal injection of the BDNF inhibitor trkB-Fc started 
before a painful nerve injury does prevent the development of behavioral hypersensitivity 
and spinal neuronal hyperexcitability (Zhou et al., 2011). Continuous disruption of spinal 
BDNF signaling beginning early after facet injury when pain and spinal neuronal 
hyperexcitability are already established, but prior to any spinal synaptogenesis or 
increased BDNF (Crosby et al., 2015; Kras et al., 2013c; Kras et al., 2014b), would be 
needed to identify if spinal BDNF contributes to the neuronal hyperexcitability after a 
painful facet joint injury.   
In the thalamus, neuronal hyperexcitability is also evident at day seven after a 
painful facet joint injury (Figure 8.1) (Chapter 7). Since the thalamus receives inputs 
from spinal neurons located in both the superficial (I-II) and deep (IV-VI) laminae of the 
dorsal horn, mechanisms mediating spinal neuronal hyperexcitability may also increase 
excitatory input to the thalamus. Indeed, inhibition of glutamate transporters increases the 
synaptic pool of glutamate and induces action potentials in neurons in the dorsal horn, 
including those that project to the thalamus (Nie et al., 2010). Further, many of the STT 
neurons are activated by BDNF (Slack et al., 2005) and substance P (Al-Khater et al., 
2008), suggesting that those neurotransmitters may contribute to the thalamic neuronal 
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hyperexcitability that is observed in facet pain. Moreover, because STT neurons express 
NK1R, ablation of spinal neurons via SSP-saporin (SSP-Sap) may also ablate many STT 
neurons and modulate thalamic excitability in a similar manner to its effects on spinal 
neuronal hyperexcitability. Of note, ablation of non-peptidergic joint afferents via IB4-
saporin (IB4-Sap) injection prior to facet joint injury prevented the development of 
thalamic neuronal hyperexcitability (Chapter 7), suggesting that peptidergic signaling that 
includes BDNF and substance P release is not the sole mediator of the excitability of 
thalamic neurons. However, up to a third of the neurons that bind IB4 can express the 
receptor for NGF and, so, may also express those neuropeptides that can sensitize STT 
neurons (Joseph and Levine, 2010). Despite these potential mediators of thalamic 
neuronal excitability, the specific mechanisms leading to thalamic neuronal 
hyperexcitability and its relationship to facet joint injury-induced pain remain uncertain 
at present.  
 
8.3. Facet Joint Injury & Osteoarthritis 
 Osteoarthritis (OA) is a degenerative joint disease and is one of the most common 
forms of arthritis, affecting nearly 27 million Americans (Furman et al., 2014; Smelter 
and Hochberg, 2013). Although any joint can be affected by OA, the most frequent sites 
are load-bearing joints, such as those in the hand, knee, hip, and spine (Goldring and 
Goldring, 2007). Indeed, facet joint osteoarthritis is thought to be a common cause of 
back and neck pain (Gellhorn et al., 2013). OA is a leading source of physical disability 
in the United States and comes at a staggering economic cost, with healthcare costs alone 
of more than sixty billion dollars (Lee et al., 2013). Pain is the hallmark symptom of OA 
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and is a major contributor to the disability and healthcare costs associated with that 
disease (Neogi, 2013). Osteoarthritis does not resolve and typically progresses over the 
course of many years; in fact, age is one of the biggest risk factors for developing OA 
(Lee et al., 2013; Litwic et al., 2013). However, joint injury, including soft tissue injuries, 
also initiates degeneration within the joint (Dare and Rodeo, 2014; Furman et al., 2014). 
An estimated 12% of OA cases have a post-traumatic origin (Furman et al., 2014). 
Traumatic neck injuries induce chronic pain frequently originating from the facet joint 
(Barnsley et al., 1995; Carroll et al., 2009; Lord et al., 1996; Pedler et al., 2013); yet, the 
potential role of osteoarthritis in injury-induced facet pain has not been investigated. 
 In the normal joint, the extracellular matrix of articular cartilage perpetually 
undergoes a balance between anabolic and catabolic remodeling. During OA, the 
equilibrium is upset, so there is a progressive loss of joint cartilage (Goldring and 
Goldring, 2007; Lee et al., 2013). Chondrocytes proliferate in an attempt to repair the 
damage, but inflammatory cytokines and matrix-degrading enzymes cause further 
cartilage degradation (Buchanan and Kean, 2002; Goldring and Goldring, 2007). 
Eventual loss of cartilage exposes the subchondral bone, leading to alterations in bone 
density and the formation of new bone at the joint margins (osteophyte formation) 
(Buchanan and Kean, 2002; Lee et al., 2013). Progression of osteoarthritis can be 
confirmed radiographically, with joint space loss, osteophyte formation, and hardening of 
the subchondral bone visible (Swagerty et al., 2001). 
 Several mechanical factors contribute to the development of OA following an 
injury, including joint instability and/or malalignment, joint laxity, and altered load 
distribution (Dare and Rodeo, 2014; Goldring and Goldring, 2007; Litwic et al., 2013). 
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Biomechanical analysis of cervical facet joints identifies increased laxity after a traumatic 
neck injury (Ivancic et al., 2008), and increased capsular ligament laxity is thought to 
contribute clinically to chronic neck pain and instability (Ivancic et al., 2008; Panjabi et 
al., 1998; Steilen et al., 2014). Indeed, a similar increase in facet joint capsular ligament 
laxity is induced by painful facet joint injury in the rat (Quinn et al., 2007), and altered 
facet kinematics due to the increased laxity may contribute to the later development of 
joint degeneration. Yet, joint laxity is not the only risk factor for injury-induced OA 
associated with traumatic neck injury. Articular impact and/or fracture also lead to post-
traumatic OA (Furman et al., 2014). Biomechanical simulations of traumatic neck injury 
using cadavers suggest that in addition to tensile stretch of the capsular ligament, facet 
joint compression occurs and can lead to articular impact (Pearson et al., 2004). Further, 
post-mortem analysis of cervical spines following fatal motor vehicle impacts reveals 
damage to articular cartilage and subchondral bone (Bogduk, 2011). Those findings 
further demonstrate additional risk factors for the development of OA during traumatic 
neck injuries that are not accounted for in the injury model utilized throughout this thesis. 
Nevertheless, the link between joint laxity and facet joint loading suggests that joint 
degeneration may be a long-term consequence of traumatic neck injury. Therefore, 
assessing whether or not degeneration develops after facet injury in association with joint 
laxity is needed since the long-term success of any treatments would depend not only on 
alleviating pain but also preventing further degeneration. Any laxity and subsequent 
altered distribution of stresses in the joint can lead to cartilage degradation (Lee et al., 
2013; Lipowitz and Newton, 1985), which contributes to degeneration. In fact, increased 
joint laxity is reported in patients in the early stages of OA (Wada et al., 1996). Because 
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surgically-induced joint instability is sufficient to induce signs of joint degeneration 
within one week (Janusz et al., 2002) and pain is the hallmark symptom of OA (Neogi, 
2013), evaluating joint degeneration after a mechanical facet joint injury like the one used 
in this thesis could determine if the pain after a facet joint and ligament injury can induce 
progressive joint degeneration.  
 Besides mechanical risk factors for developing OA, joint inflammation is a major 
contributor to joint degeneration and associated pain. Joint inflammation is evident in 
both post-traumatic and chemically-induced osteoarthritis (Bove et al., 2003; Furman et 
al., 2014; Gong et al., 2011; Huebner et al., 2014). Inflammatory cytokines are 
upregulated within the injured joint within 24 hours and not only sensitize joint afferents, 
but they also exacerbate catabolism within the joint (Dare and Rodeo, 2014; Furman et 
al., 2014; Lee et al., 2013). Interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) are 
both potent promoters of cartilage breakdown and contribute to the pathophysiology of 
OA (Lee et al., 2013). For instance, IL-1 promotes expression of the collagen-degrading 
matrix metalloproteinases (MMPs) such as MMP-1, which degrades type II collagen, the 
predominant type of collagen in articular cartilage (Goldring and Goldring, 2007; Xu et 
al., 2013). In addition to promoting joint degeneration, both IL-1 and TNF-α are reported 
to induce behavioral sensitivity in the rat (Safieh-Garabedian et al., 1995; Woolf et al., 
1997), suggesting that their expression in the joint after injury (Furman et al., 2014) also 
promotes joint pain. Although intra-articular inhibition of IL-1 or TNF-α failed to 
alleviate facet-mediated pain one day after injury (Section 8.2; Dong, 2011), inhibition of 
IL-1 impedes the progressive destruction of cartilage in experimental OA (Caron et al., 
1996). Further evaluation of whether or not joint degeneration is a long-term 
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consequence of facet joint injury is necessary since joint inflammation contributes to OA 
as well as traumatic facet joint injury. If degeneration is evident, revisiting cytokine 
antagonism in facet pain could prove effective in minimizing progressive joint 
destruction.  
 In addition to promoting OA progression, both IL-1 and TNF-α increase the 
synthesis of PGE2 and NGF within the osteoarthritic joint (Goldring and Goldring, 2007; 
Jacobs et al., 2011). Both PGE2 and NGF are elevated within one day of a facet joint 
injury (Kras et al., 2014a; Kras et al., 2014b), and PGE2 not only contributes to spinal 
neuronal sensitization and joint pain (Ji et al., 2003; Schaible et al., 2009), it also 
stimulates chondrocytes via the EP2 receptor and diminishes proteoglycan synthesis and 
type 2 collagen levels (Li et al., 2009). Following facet joint injury, intra-articular 
disruption of PGE2 synthesis on day one after injury attenuates established pain (Dong et 
al., 2013a). Moreover, facet injury upregulates expression of the EP2 receptor at that 
same time (Kras et al., 2013a). Yet, that study quantified EP2 expression in the primary 
afferent neurons and so cannot necessarily be extended to altered receptor expression 
within the facet joint. Nevertheless, that finding, in combination with reports 
documenting upregulation of PGE2 expression in the spinal cord and the role of PGE2 in 
maintaining facet pain (Dong et al., 2013a; Kras et al., 2014a), clearly demonstrates that 
PGE2 signaling is directly involved in the pathogenesis of injury-induced facet pain. In 
addition to maintaining facet pain, the catabolic properties of PGE2 within joints could 
indicate that PGE2 is also an initiator of post-traumatic facet joint degeneration. Although 
a contribution of NGF to OA progression is less clear, blocking NGF signaling in OA 
patients alleviates hip, knee, and low back pain (Katz et al., 2011; Lane et al., 2010; 
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Schnitzer et al., 2014). Indeed, increased levels of intra-articular NGF are a consequence 
of OA both clinically and in animal models (Lane et al., 2010; Surace et al., 2009; Orita 
et al., 2011). It is, therefore, possible that the upregulation of NGF within the injured 
facet joint, along with evidence of early inflammatory responses following facet injury 
(Dong et al., 2013a; Kras et al., 2014a), may reflect initial stages of a degenerative 
process.  
 Furthermore, the effectiveness of anti-NGF treatments in both OA and facet joint 
injury-induced pain suggest that facet joint distraction might also induce joint pathology 
that is similar to OA (Chapter 5; Kras et al., 2014b; Lane et al., 2010; Schnitzer et al., 
2014); however, such a relationship is by no means certain. NGF contributes to multiple 
pain syndromes, such as neuropathic and inflammatory pain, including inflammatory 
joint pain (Ghilardi et al., 2012; Longo et al., 2013; Wild et al., 2007). Clinically, since 
NGF is detected in degenerative joints as well as in inflamed joints from rheumatoid 
arthritis patients (Barthel et al., 2009; Raychaudhuri et al., 2011; Surace et al., 2009), its 
potential for joint pain is not limited only to OA. Moreover, in clinical trials, the 
application of the same anti-NGF antibodies that are known to alleviate OA pain in 
patients experiencing lower back, neuropathic, and visceral pain has also shown positive 
outcomes for pain relief (Bramson et al., 2015; Evans et al., 2011; Katz et al., 2011). In 
light of the contribution of NGF to pain across a broad range of conditions both in animal 
models and clinically, its role in joint pain does not imply that joint degeneration is also 
involved. In fact, the mechanisms that lead to increasing NGF expression and pain may 
differ dramatically for OA and trauma-induced facet pain. Because facet joint injury 
induces joint inflammation within a day of ligament injury, it is hypothesized that 
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elevated intra-articular NGF is produced by, and released from, infiltrating immune cells 
in the joint (Aloe et al., 1992; de Lange-Brokaar et al., 2012; Dong et al., 2013a; 
McMahon, 1996). However, in vitro studies have identified chondrocytes subject to 
mechanical stress as sources of NGF (Pecchi et al., 2014). In fact, stress-induced 
production of NGF from chondrocytes could explain why NGF is not elevated one week 
after the induction of OA (Orita et al., 2011). Chondrocytes may not synthesize NGF 
until joint degeneration alters their local mechanical environment. In contrast, infiltrating 
immune cells can rapidly upregulate NGF within the inflamed facet joint after its injury, 
which could explain the increase in NGF that is evident at one day after injury (Chapter 
5; Kras et al., 2014b). Yet, the cellular source of elevated intra-articular NGF is not 
known for either experimental OA or traumatic facet joint injury.  
It is also unknown if intra-articular NGF expression is only transiently increased 
after a facet joint injury. NGF levels in the joint were only quantified at one time point 
after injury (Chapter 5; Kras et al., 2014b); yet, the increase in NGF expression that is 
evident in the DRG at day seven (Chapter 5) suggests that NGF may be transported to the 
DRG from the joint. Regardless, currently there is too little information available to 
establish temporal causative schema describing pain mechanisms for OA and facet joint 
trauma, despite a known contribution of NGF to pain in both joint conditions. 
Characterizing the spatiotemporal NGF expression in the facet joint and DRG, in parallel 
with joint degeneration, with long-term time points is needed to meaningfully understand 
NGF responses, joint degeneration, and pain in both OA and traumatic joint injuries.  
 Preventing onset of injury-induced facet joint pain by blocking intra-articular 
NGF supports anti-NGF as a potential treatment for trauma-induced neck pain (Chapter 
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5; Kras et al., 2014b). Yet, clinical trials administer the anti-NGF antibody systemically 
via intravenous injection and alleviate established pain (Brown et al., 2012; Katz et al., 
2011; Lane et al., 2010; Schnitzer et al., 2014). In contrast, in our model of experimental 
facet joint injury-induced pain, NGF signaling was blocked locally within the facet joint; 
that local disruption of NGF signaling in the joint prevented pain onset after joint 
distraction when given at the time of injury but was ineffective when given even one day 
after the injury, when pain was already established (Chapter 5; Kras et al., 2014b). The 
lack of effect of anti-NGF treatment on established facet pain may be due to the dose 
being too small; 10µg of anti-NGF (~25µg/kg) was applied to each facet joint (Kras et 
al., 2014b); whereas anti-NGF applied to treat low back pain was given at a nearly ten-
fold higher dose (200µg/kg) in humans (Katz et al., 2011). Yet, doses of anti-NGF as low 
as 10µg/kg are reported to effectively alleviate joint pain in OA in humans (Lane et al., 
2010). As such, intra-articular anti-NGF not alleviating existing facet joint-mediated pain 
could be due to the fact that the site of action of NGF shifts from the joint immediately 
after its injury to the DRG once pain is established. Indeed, although NGF increases in 
the DRG by day seven after facet joint injury (Chapter 5; Kras et al., 2014b), it is not 
known if it is also elevated in the DRG at earlier time points. The serum half-life of IgG 
antibodies is reported to be nearly five days in the rat (Ishidate et al., 1990); but, it is 
unknown if intra-articularly injected antibodies are cleared from the joint quickly enough 
or if they reach the DRG. Intra-articular anti-NGF might not reach the DRG since even 
small molecular weight proteins (<50kDa) take hours to clear from the synovial fluid of 
joints (Allen et al., 2011), and IgG antibodies such as the one used in our studies are 
much larger (>150kDa). Since the DRG is not protected by the blood brain barrier 
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(Sapunar et al., 2012), systemic application of anti-NGF does reach it. As such, the 
systemic delivery of anti-NGF used clinically might be a more effective means of treating 
existing injury-induced facet pain. 
 Studies are ongoing to determine the optimal dose of anti-NGF to alleviate 
clinical OA pain while also minimizing the incidence of adverse events such as 
paresthesia, pain in the extremities, neuropathy, and even joint degeneration (Schnitzer et 
al., 2014; Schnitzer and Marks, 2015). In fact, in 2010, a hold was placed on the clinical 
studies utilizing anti-NGF treatments due to the risk of rapidly progressing joint 
degeneration; however, the hold was removed in 2012 following a thorough review of 
existing data (Schnitzer et al., 2014). The efficacy of anti-NGF treatments increases with 
increasing dose; however, the incidence of adverse events likewise increases (Schnitzer 
and Marks, 2015). Similarly, combination therapies including anti-NGF and oral NSAID 
treatment improve pain relief over either individual therapy, but they also incur a higher 
incidence of adverse events (Schnitzer et al., 2014). Experimentally, rats receiving intra-
articular anti-NGF to prevent joint injury-induced pain exhibited normal weight gain and 
grooming behavior and were otherwise indistinguishable from control rats, with no 
obvious ill-effects associated with that local anti-NGF treatment (Chapter 5; Kras et al., 
2014b). However, if systemic anti-NGF is administered in future studies with the goal of 
treating established pain after facet joint injury, close monitoring of animals for signs of 
adverse events similar to those identified during the treatment of clinical OA pain, such 
as pain and neuropathy in the extremities, will be necessary in order to identify an 
effective dose that also maximizes safety.  
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Administration of anti-NGF systemically, rather than intra-articularly, likely has 
greater potential for off-target effects as a result of its circulation throughout the entire 
body. In addition to blocking the effects of increased NGF in the painful joint, systemic 
anti-NGF also has the potential to disrupt normal NGF signaling in other tissues, such as 
the skin (McMahon, 1996). Indeed, loss of target-derived NGF available to sensory 
neurons and subsequent dysregulation of voltage-gated sodium channels is thought to 
contribute to pain after a nerve injury (Dib-Hajj and Waxman, 2010). A disruption of 
NGF signaling in peripheral tissues could underlie the reports of pain, paresthesia, and 
neuropathy in the extremities associated with anti-NGF treatment clinically (Brown et al., 
2014; Schnitzer et al., 2014). Although paresthesia in the clinical trials was reported to be 
transient (Schnitzer et al., 2014) and would thus be difficult to quantify in the rat, pain in 
the extremities can be readily quantified using behavioral testing methods similar to those 
used throughout this thesis (Chapters 4, 5, & 6; Kras et al., 2013b; Kras et al., 2013c; 
Kras et al., 2014b). As such, in addition to monitoring weight gain and grooming 
behavior, rats receiving systemic anti-NGF should be evaluated behaviorally for signs of 
pain in the hindpaws since pain in the extremities is an adverse event associated with 
systemic anti-NGF clinically (Schnitzer et al., 2014). 
In a rat model of facet joint osteoarthritis, injection of a chemical stimulus to 
induce OA is associated with inflammation and pain lasting only three days (Gong et al., 
2011). However, three weeks after the initiating stimulus when joint degeneration is 
severe, pain returns and persists for at least an additional three weeks (Gong et al., 2011). 
Since the studies in this thesis were only through day seven, it is likely that joint 
degeneration itself may not contribute to the behavioral and electrophysiological 
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responses that are observed here. In experimental knee OA in the rat, surgical joint 
destabilization via transection of the meniscus induces joint degeneration by as early as 
one week (Janusz et al., 2002). Similarly, the first signs of joint degeneration following 
chemically-induced OA are visible within days of induction (Shuang et al., 2014). 
However, both surgically- and chemically-induced models of OA are designed to 
accelerate disease progression (Teeple et al., 2013), so joint degeneration following 
painful facet joint loading, in which no gross ligament damage is evident (Quinn et al., 
2007), likely progresses more slowly, if at all. As such, a role for joint degeneration in the 
maintenance of injury-induced facet pain would likewise require more than a week to 
develop. Because behavioral hypersensitivity lasts for at least six weeks following facet 
joint distraction in this model (Rothman et al., 2007), additional studies extending on the 
order of weeks after injury are needed to define relationships between mechanical facet 
joint injury, joint degeneration, and persistent pain. 
 
8.4. Limitations & Future Work 
Collectively, the studies included in this thesis demonstrate contributions of NGF 
in the periphery, and BDNF in the central nervous system, to the development (NGF) and 
maintenance (BDNF) of facet-mediated pain and spinal neuronal hyperexcitability after a 
mechanical facet joint injury. Building upon previous studies utilizing this injury model 
that established inflammation and spinal neuronal hyperexcitability as contributing to 
facet pain (Crosby et al., 2013; Crosby et al., 2014; Dong et al., 2013a; Quinn et al., 
2010), this work identifies NGF as one specific molecule in the joint that is an initiator of 
both persistent pain and spinal neuronal dysfunction associated with mechanical loading 
212 
of the facet joint. Yet, in this context, there are a number of limitations that warrant 
consideration. This section addresses several major limitations, including the use of 
purely tensile joint loading, evoked behavioral responses, and the lack of identifying a 
specific mechanism through which NGF induces behavioral hypersensitivity and spinal 
neuronal hyperexcitability. This section also suggests additional studies that would define 
the potential relationship between facet joint injury and OA and identify molecular 
pathways through which NGF contributes to persistent pain after injury. 
The joint injury applied in this thesis imposes only tensile stretch of the facet joint 
capsular ligament. Although tensile stretch of the capsular ligament has been proposed as 
a mechanism underlying facet-mediated pain after a neck trauma (Panjabi et al., 1998; 
Pearson et al., 2004; Sundararajan et al., 2004), the facet joint also undergoes 
compression during a whiplash injury to the neck (Barnsley et al., 1994; Ono et al., 1997; 
Panjabi et al., 1998; Pearson et al., 2004). Simulations of whiplash-like neck trauma 
using cadaveric cervical spine specimens identify that the facet joint initially undergoes 
compression resulting from extension of the lower cervical spine (Pearson et al., 2004). 
Specifically, the inferior articular facet of the superior vertebra extends relative to the 
superior articular facet of the inferior vertebra, resulting in compression of the facet joint 
(Pearson et al., 2004). As discussed earlier (Section 8.3), compression of the facet joint 
can lead to articular impact and even fracture, damaging the joint cartilage and increasing 
the risk of OA development (Bogduk, 2011; Furman et al., 2014; Pearson et al., 2004). 
Biomechanical models of whiplash-like loading in the cervical spine identify the 
potential of articular impact during injury, but the magnitude of that compressive load has 
not been determined (Pearson et al., 2004). Because articular damage caused by impact is 
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a risk factor for OA (Furman et al., 2014), studying pain induced by isolated tensile 
loading of the facet joint neglects accounting for the possibility of cartilage damage that 
can lead to long-term degeneration of the joint.  
Joint degeneration, including that of the facet joint, is a major source of pain 
clinically (Gellhorn et al., 2013; Lee et al., 2013). However, the contribution of 
degeneration of the joint to trauma-induced facet pain has not been investigated. 
Biomechanical simulations of traumatic neck injury using human spines demonstrates 
that maximum facet joint compression occurs nearly 40 milliseconds prior to the peak 
tensile strain in the capsular ligament (Pearson et al., 2004). If compressive loading to the 
facet joint were to be added to the injury model used in this thesis, in order to model neck 
trauma due to a motor vehicle collision, the compressive load would peak prior to 
distracting the facet joint. The magnitude of tensile loading applied to the rat throughout 
this thesis was scaled to be equivalent to distractions experienced by humans (Lee et al., 
2004); as such, the magnitude of the compressive load experienced by humans during 
traumatic neck injury would also need to be appropriately scaled to the rat. Although that 
compressive load is unknown for humans, the peak magnitude of joint compression 
during neck trauma simulations in humans has been reported as 2.0±1.5mm for the 
C6/C7 facet joint (Pearson et al., 2004). That compression can be geometrically scaled 
between species by comparing the average facet joint space thickness in either species. In 
humans, the average thickness of the cervical facet space has been reported to be 
1.9±0.5mm, computed using magnetic resonance imaging (Jaumard et al., 2014). Using a 
similar analysis, the corresponding joint space height in the rat could be used to develop a 
ratio of facet joint space thickness between the two species. That ratio could be used to 
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scale the magnitude of joint compression to be applied in the rat simulating the joint 
compression sustained during a motor vehicle collision-induced neck trauma. Inclusion 
of appropriately scaled compressive loading of the facet joint prior to tensile stretch of 
the capsular ligament in the rat will expand this model even more to be the first in vivo 
platform to study the contributions, if any, of facet joint articular impact to persistent pain 
and joint degeneration associated with traumatic neck injury. 
 Throughout this thesis, evoked measures of mechanical and thermal behavioral 
hypersensitivity are utilized as quantitative measures of pain, but spontaneous pain and 
activity-evoked pain are both major contributors to disability and a lower quality of life in 
chronic pain patients (Hagström et al., 1996; Mogil et al., 2010). Indeed, following neck 
trauma, spontaneous or ongoing pain is frequently reported (Hagström et al., 1996; Kosek 
and Januszewska, 2008; Mankovsky-Arnold et al., 2014). Further, in human volunteers, 
NGF sensitizes nociceptors and induces spontaneous pain (Rukwied et al., 2013). 
Because NGF is increased after a facet joint injury and is also necessary for the 
development of evoked behavioral hypersensitivity (Chapter 5; Kras et al., 2014b), 
spontaneous pain is also likely induced by the facet injury used in these studies. Yet, 
measures of spontaneous pain were not quantified. Metrics for quantifying spontaneous 
pain in animal models, such as food intake, grooming, and paw guarding, have proven 
unreliable in their specificity due to inherent susceptibility to confounding factors 
unrelated to pain (Mogil and Crager, 2004; Mogil et al., 2010). Due to the difficulty in 
quantifying spontaneous pain in experimental chronic pain models (Sotocinal et al., 
2011), additional clinically-relevant measures of pain, such as activity-evoked pain, have 
been identified and implemented experimentally (Little and Zaki, 2012; Teeple et al., 
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2013). Assessments of low back and osteoarthritis joint pain include, respectively, the 
Roland-Morris Disability Questionnaire (RMDQ) and the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) questionnaires that assess the 
impact of pain on normal daily activities such as standing up, walking, and climbing 
stairs (Katz et al., 2011; Lane et al., 2010). Indeed, those questionnaires have been used 
to evaluate the effectiveness of anti-NGF therapies for low back and knee pain (Katz et 
al., 2011; Lane et al., 2010). Although measures of activity-evoked pain and functional 
deficits, including gait analysis, weight distribution, and locomotive activity (Larsen and 
Arnt, 1985; Matson et al., 2007; Teeple et al., 2013) have been quantified in animal 
models of OA, those measures are best suited to analysis of hindpaw function. Yet, neck 
trauma patients exhibit pain evoked by lifting objects with their arms (Mankovsky-
Arnold et al., 2014), so assessment of activity-evoked pain in the upper limb is clinically 
relevant for facet pain.  
Functionally, the grip strength of neck pain patients is diminished relative to 
healthy controls (Peolsson et al., 2014). A novel model of work-related repetitive use 
injury has been developed to study the effects of forelimb overuse on musculoskeletal 
and neural tissues (Barbe et al., 2013; Fisher et al., 2015). In that model, rats are trained 
to reach and pull a lever with their forelimbs in order to obtain a food pellet reward 
(Barbe et al., 2013). That protocol for that forelimb reaching task in the rat could be 
modified to assess voluntary use of and functional deficits in the forelimb after a painful 
facet joint injury in the rat. Since neck trauma patients exhibit diminished grip strength as 
well as pain evoked by lifting with their arms (Mankovsky-Arnold et al., 2014; Peolsson 
et al., 2014), a functional assay requiring both reaching and pulling in the rat is 
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translatable to the clinic. Implementation of that functional test in our facet joint injury 
model will not only increase its clinical relevance, but also enable assessment of whether 
or not interventions to treat pain also improve functional deficits.  
 Clinically, exposure to neck trauma initiates pain as early as 24 hours after the 
initial injury (Chien et al., 2010), and as many as 50% of those neck pain patients will 
report that their pain persists at one year after injury (Carroll et al., 2009). Yet, behavioral 
and cellular responses to facet joint injury in the rat were only investigated in this thesis 
as late as day seven post-injury, despite the fact that facet joint injury-induced pain is 
maintained as late as six weeks after the initiating injury (Rothman et al., 2007). Due to 
lifespan differences between the rat and the human, the persistence of pain for weeks in 
the rat approximates chronic pain in the human (Sengupta, 2013), with a single day in the 
life of a rat approximated as roughly equivalent to a month in the lifecycle of a human 
(Sengupta, 2013). Accordingly, pain maintained through seven days in the rat can be 
taken as persistent and is one of the primary reasons that rats were followed only through 
day seven after injury in this thesis. In addition, the abundance of data pertaining to the 
behavioral and molecular responses at that time after facet joint injury, including 
evidence for joint inflammation and the development and maintenance of spinal neuronal 
hyperexcitability (Crosby et al., 2013; Dong et al., 2013a; Quinn et al., 2010), enables 
comparison to previous work. However, by limiting studies to this time point, it is not 
possible to evaluate several potential long-term responses that have been uncovered in 
this work, such as joint degeneration that may develop over weeks in the rat. Indeed, 
facet joint injury induces mechanical laxity and inflammation (PGE2, NGF upregulation) 
associated with joint degeneration and OA pain (Dare and Rodeo, 2014; Dong et al., 
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2013a; Goldring and Goldring, 2007; Kras et al., 2014b; Lane et al., 2010; Orita et al., 
2011; Quinn et al., 2007). However, the structural integrity of the joint was not 
investigated at any time point after injury in this thesis. Even if it was, day seven would 
likely be too early to detect signs of degeneration (Section 8.3). Nevertheless, the 
elevation of inflammatory mediators such as NGF and PGE2 that are associated with OA 
suggests that degeneration may be initiated in the joint after injury. Because OA of the 
facet joints is a source of neck pain clinically (Gellhorn et al., 2013), joint degeneration 
should be evaluated following facet joint injury in the rat. Development of joint 
degeneration after a motor vehicle collision-induced neck trauma could explain why 
chronic facet-mediated pain is refractory to treatment; however, the relationship between 
loading-induced facet joint injury and degeneration is as yet undefined.  
 OA models of joint pain also demonstrate upregulation of inflammatory cytokines 
and NGF within the joint immediately following arthritis induction (Gong et al., 2011; 
McNamee et al., 2010; Orita et al., 2011), and blocking NGF prevents the initiation of 
pain (McNamee et al., 2010). Yet, NGF is also upregulated several weeks after induction 
of arthritis when degeneration is prominent, and blocking NGF also alleviates pain when 
OA is advanced (McNamee et al., 2010; Orita et al., 2011). Indeed, intra-articular levels 
of NGF are elevated in clinical OA patients, and disruption of NGF signaling via anti-
NGF treatment alleviates clinical joint pain in patients with joint degeneration (Schnitzer 
et al., 2014). However, the temporal expression of intra-articular NGF is unknown after a 
facet joint injury. Chemical induction of OA in the knee increases intra-articular NGF by 
one week after the initiating stimulus and maintains that elevated level through at least 
four weeks (Orita et al., 2011). Similar chemical induction of OA in the facet joint 
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produces signs of degeneration, such as fissures in the cartilage and cartilage erosion, 
within one week and progressing to severe degeneration by four weeks (Gong et al., 
2011). Chemically-induced OA may progress more rapidly than in models that surgically 
destabilize joints to induce OA, and differences in the time course of joint degeneration 
exist depending on the technique used to destabilize the joint (Teeple et al., 2013). Yet, 
even in surgically-induced OA in the knee, joint degeneration is evident by four weeks 
(Appleton et al., 2007). Because both chemically- and surgically-induced models of OA 
exhibit joint degeneration within four weeks but may show signs at one week (Appleton 
et al., 2007; Orita et al., 2011), preliminary investigations of joint degeneration and intra-
articular NGF overexpression associated with facet joint loading should be investigated at 
both one week and four weeks after injury. Quantifying NGF expression in addition to 
joint degeneration should also identify additional time points at which disruption of NGF 
signaling might alleviate established facet pain. 
 In addition, the specific mechanism(s) through which NGF initiates facet joint 
injury-induced behavioral hypersensitivity and spinal neuronal hyperexcitability remain 
unknown. The upregulation of BDNF in the DRG and spinal cord at day seven in parallel 
with increased NGF in the DRG at that time after facet joint injury (Chapter 5; Kras et 
al., 2013c) demonstrates that transcriptional regulation of BDNF by NGF contributes to 
facet pain. Yet, gene regulation is only one mechanism through which NGF sensitizes 
neurons and induces pain. A major function of NGF is to promote axonal growth and 
survival of neurons; indeed, NGF knockout models are fatal perinatally (Chen et al., 
2005). NGF applied to the spinal cord promotes sprouting of nociceptive afferents (Tang 
et al., 2004). Yet, the neurotrophic activity of elevated NGF expression in the facet joint 
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following its injury was not evaluated in this thesis. Rather, the relationship between 
intra-articular NGF and spinal neuronal hyperexcitability after a painful facet joint injury 
was the primary focus of the studies reported here. NGF expression was quantified within 
the joint capsule and synovium, and immunohistochemical labeling of the C6/C7 facet 
joint confirmed that expression of NGF in the soft tissues surrounding the joint is higher 
after injury than in sham control joints (Chapter 5; Kras et al., 2014b). Indeed, that 
overexpression of NGF suggests that afferent fiber sprouting might also occur after 
injury. Moreover, a majority of joint afferents are peptidergic and, thus, sensitive to NGF 
(Chapter 4; Kras et al., 2013b). Since targeted ablation of neurons involved in peptidergic 
signaling prevents both NGF- and injury-induced behavioral hypersensitivity and spinal 
neuronal hyperexcitability (Chapter 5), it is likely that any NGF-mediated fiber sprouting 
would also be specific to that subpopulation of afferents. Those findings demonstrate that 
intact innervation of the facet joint is necessary for NGF-induced pain and neuronal 
dysfunction in the spinal cord. Yet, those studies are unable to distinguish whether NGF 
mediates hyperexcitability of spinal neurons through increased transcription of pain 
mediators or if sprouting of joint afferents leads to joint hyperinnervation and thus 
increased sensitivity to motion of the joint.  
Studies of arthritis pain report sprouting of peptidergic and sympathetic fibers 
within the joint that is blocked by anti-NGF treatment (Ghilardi et al., 2012; Longo et al., 
2013). Moreover, blocking sympathetic fiber growth alleviates arthritis pain (Longo et 
al., 2013), demonstrating that hyperinnervation of the joint contributes to pain 
maintenance. Although those studies evaluated fiber growth four weeks after induction of 
arthritis, in vitro studies demonstrate that NGF promotes DRG neurite outgrowth within 
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days of exposure (Tang et al., 2013), so evidence of nerve growth such as increased 
expression of growth associated protein-43 (GAP-43) should be apparent by day seven 
after facet joint injury. Indeed, increased synaptogenesis in the spinal cord is evident at 
day seven after injury, with a trend toward significant increases as early as day one after 
injury (Crosby et al., 2015). It is likely that neuronal growth would also occur in the facet 
joint on a similar time frame. In light of the evidence for overexpression of NGF in the 
joint after injury and the abundance of NGF-responsive afferents innervating the joint, 
NGF-mediated fiber sprouting in the injured facet joint should be quantified in order to 
evaluate whether or not hyperinnervation of the joint contributes to long-term facet pain.  
Interestingly, blocking intra-articular afferent activation with bupivacaine does 
not alleviate pain when it is done four days after the pain is initiated (Crosby et al., 2014); 
however, bupivacaine is only expected to alleviate clinical pain for 8-12 hours when 
applied post-operatively (Skolnik and Gan, 2014). As such, input from the facet joint 
might contribute to facet pain maintenance, as it does clinically (Barnsley, 2005; 
Manchikanti et al., 2008). It is possible that a block of the nerves lasting longer than 8-12 
hours may be necessary to detect analgesic effects behaviorally in this rat model. 
Ablating joint afferents pharmacologically is one means of blocking joint afferent activity 
over an extended period of time. Ablation of NK1R-expressing joint afferents prior to 
injury via intra-articular application SSP-saporin prevents the development of pain after a 
subsequent facet joint injury (Figure 8.2). However, no study has identified whether or 
not ablation of joint afferents alleviates established pain after joint injury. Although 
saporin requires up to fourteen days to induce neuronal cell death (Weisshaar et al., 2014; 
Wiley et al., 2007), such a time course is not prohibitive to studying the potential 
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relationship between joint afferent signaling and the maintenance of facet pain since facet 
injury induces pain that lasts at least six weeks (Rothman et al., 2007). Indeed, ablation of 
the nerves innervating a painful facet joint alleviates facet pain in approximately 60% of 
patients, with pain relief lasting at least three months (Lord et al., 1996; Smith et al., 
2014). Yet, clinical pain relief is not permanent after ablation of facet joint afferents. It 
may be that chronically elevated levels of NGF within the facet joint precipitate regrowth 
of afferent fibers back into the joint and, consequently, a return of the pain. As such, in 
addition to identifying whether or not intra-articular NGF induces fiber sprouting in the 
injured facet joint, studies assessing the role of joint afferents in the maintenance of facet 
pain should ablate joint afferents as well as inhibit NGF signaling to prevent any potential 
reinnervation of the joint. Those studies would further define the ongoing role of joint 
input to persistent pain, but they could also provide a means of prolonging the pain-
alleviating effects of neuronal ablation currently used to treat clinical neck pain.  
Recent reports promote the idea of nociceptive priming, referring to a transient 
insult causing a subsequent stimulus to elicit a prolonged pain state, as a potential 
mechanism underlying chronic pain. Several studies report that following exposure to 
stimuli such as carrageenan, TNF-α, or NGF that induce transient pain in the rat, PGE2 
injected into the paw can induce long-lasting pain (Joseph and Levine, 2010; Parada et 
al., 2003; Reichling and Levine, 2009). Indeed, following carrageenan-induced priming, 
administration of PGE2 to the paw induces pain lasting several weeks, although in the 
unprimed state, PGE2 induces only transient pain lasting on the order of hours (Aley et 
al., 2000; Reichling and Levine, 2009). Further, that purported primed state can last for 
weeks after the initial priming stimulus (Aley et al., 2000). Recent work in our rat model 
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demonstrates that priming in the spinal cord results in a facet joint distraction injury of a 
magnitude normally insufficient to induce pain to instead cause sustained behavioral 
hypersensitivity (Crosby et al., 2015). Moreover, preliminary work suggests that intra-
articular NGF is sufficient to similarly prime the joint afferents in the rat (Figure 8.4). In 
pilot studies, NGF at a dose insufficient to induce pain (1µg in 5µL of sterile phosphate 
buffered saline) was injected into the bilateral C6/C7 facet joints (n=3 rats). On day two 
after the NGF injection, a normally non-painful facet joint distraction was applied 
(Crosby et al., 2015; Dong et al., 2012; Lee and Winkelstein, 2009); yet, the forepaw 
mechanical withdrawal threshold significantly decreased below baseline levels (p<0.043) 
and remained at the lower level through day seven (Figure 8.4).  
 
Figure 8.4. Mechanical sensitivity in the forepaw as measured by the withdrawal 
threshold in response to von Frey filament stimulation. Withdrawal threshold is 
unchanged from baseline on days one and two following intra-articular injections of 
1µg NGF into the bilateral C6/C7 facet joints. Following a normally non-painful facet 
joint distraction (FJD) on day two, the withdrawal threshold significantly decreases 
from baseline at all subsequent time points (*p<0.043). On days three, four, and five, 
the withdrawal threshold also decreases relative the pre-distraction threshold on day 
two (#p<0.028). 
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Intra-articular NGF increases within the facet joint by day one after a painful facet 
joint injury (Chapter 5; Kras et al., 2014b); yet, it is unclear if a non-painful facet joint 
distraction is also sufficient to increase even slightly the intra-articular NGF levels. If so, 
a non-painful facet joint distraction could prime the sensory neurons such that a 
subsequent low-level joint distraction would induce a prolonged hypersensitivity. Indeed, 
mechanical or chemical priming is a potential and even likely mechanism through which 
an equivalent neck trauma in different patients induces transient pain in some but chronic 
pain in others (Jull et al., 2011; Sterling et al., 2003). It may be that a subset of those 
people undergoing a traumatic neck injury had previously sustained a minor neck trauma 
that primed them for experiencing a subsequent injury as painful. Although these findings 
are preliminary (Figure 8.4), the potential for intra-articular NGF to induce priming 
without inducing pain could profoundly shift the way neck trauma is treated. Rather than 
focusing only on the treatment of pain after an injury, interventions to disrupt neuronal 
priming would also then need to be developed so that even those trauma patients who do 
not experience pain after a neck trauma are not at greater risk of chronic pain in the event 
of a later trauma. Sustained activity of protein kinase C epsilon (PKCε) is reported as 
necessary for the maintenance of neuronal priming (Reichling and Levine, 2009). 
Antisense knockdown of PKCε expression eliminates priming and prevents its return 
even when PKCε levels return to normal (Reichling and Levine, 2009). Antagonists of 
PKCε have been developed (Inagaki et al., 2006). Further study is needed to determine if 
a non-painful facet joint injury upregulates intra-articular NGF and induces priming 
similar to that induced by a non-painful intra-articular injection of NGF. If priming is 
induced, PKCε antagonists could be evaluated for their potential to disrupt loading-
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induced priming; such studies would be invaluable for developing therapies to prevent, 
rather than treat, trauma-induced chronic pain clinically.  
 
8.5. Conclusions 
In summary, studies presented in this thesis define contributions of the 
neurotrophins NGF and BDNF to mechanically-induced facet-mediated pain. 
Interestingly, a single molecule acting on a subpopulation of joint afferents is able to 
initiate facet pain. Intra-articular NGF is sufficient to induce both pain and spinal 
neuronal hyperexcitability, but only when those neurons involved in peptidergic signaling 
are intact. Painful facet joint injury upregulates NGF expression within the injured joint, 
which, in turn, can initiate both pain and spinal neuronal hyperexcitability at day one. 
Injury-induced elevation of NGF in the DRG by day seven stimulates overexpression of 
BDNF, which is released into the spinal cord where it maintains behavioral 
hypersensitivity and likely contributes to the long-term hyperexcitability of spinal 
neurons.  
The work in this thesis is the first to identify a specific cellular mechanism within 
the joint that initiates pain and to define the relationship between that local mechanism 
and the spinal modifications that maintain facet-mediated pain. Since intra-articular NGF 
signaling is critical in increasing afferent excitability through translational and post-
translation modifications and in stimulating neuronal growth (Longo et al., 2013; Nicol 
and Vasko, 2007), additional work characterizing the spontaneous component of facet-
mediated pain as well as defining the contributions of neuronal priming and/or sprouting 
in the joint and spinal cord to the maintenance of pain is necessary. Moreover, NGF 
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signaling has a close relationship to joint pain from osteoarthritis; neck trauma that 
upregulates NGF also exhibits several risk factors for osteoarthritis. As such, identifying 
if there are potentially parallel mechanisms between osteoarthritis and facet joint trauma-
induced pain involving NGF signaling would help determine if anti-NGF treatments that 
are being developed for OA may also be applicable to facet-mediated pain. However, 
joint laxity and inflammation, which are associated with facet joint loading sufficient to 
induce pain (Dong et al., 2013a; Quinn et al., 2007), also support joint degeneration as a 
factor that may contribute to long-term facet pain and disability. Yet, a role for 
degeneration in chronic facet pain has not been defined. The prevention of facet pain 
development and spinal neuronal hyperexcitability after injury with immediate anti-NGF 
treatment provides a foundation for future investigations into the specific molecular and 
structural mechanisms that promote neuronal hyperexcitability and persistent pain after 
facet joint injury. Although further studies are needed to identify the time course and 
optimal delivery method for effective anti-NGF treatment of facet pain, demonstrating 
that a single molecule in the facet joint is sufficient to initiate pain provides an important 
step toward developing targeted pharmacological therapies to effectively treat facet-
mediated chronic pain. 
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Appendix A 
Matlab Codes 
 
This appendix contains the Matlab code that was used to generate the input file 
for LS-DYNA (LSTC; Livermore, CA) to calculate capsular ligament strains for all of 
the studies throughout this thesis. The Matlab code used to calculate the ratio of pixels 
positive for BDNF labeling relative to the total number of pixels in immunolabeled spinal 
cord sections for studies in Chapter 6 is also included. For the strain calculations, the 
Matlab code (Section A.1; Dyna_KatieFile.m) requires two input files containing: (1) the 
initial and final coordinates (i.e. xi yi; xf yf) for each capsule marker and (2) the start and 
stop times for the joint distraction. The user must separately input the number of rows 
and columns of markers that cover the joint capsule as a grid. The output file from the 
code is then input into LS-DYNA, which is used to generate a mesh of elements for the 
capsule and to calculate the strain in each element for the applied distraction. 
The second Matlab code (Section A.2; densitometry_manual_threshold_fluor.m) 
included in this appendix was used for all densitometric quantifications of BDNF in the 
spinal cord (Chapter 6). This code requires that all of the images that are to be analyzed 
be located in the same file directory as the code file. In addition, this code requires the 
image files to be in the .tif format and must have ‘BDNF’ at the start of each file name. 
BDNF-labeled sections are imaged in the red channel; accordingly, this code only 
analyzes the red channel of images in the rgb format. A threshold for positive pixels (0-
255) must be defined and manually applied to the pos_thresh variable in the code. In 
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order to define the positive pixel threshold for normal spinal BDNF expression, BDNF-
labeled sections from a normal rat must be analyzed by running the script using a range 
of threshold values. The threshold that identifies positive pixels in the dorsal horn of the 
normal rat that most closely match the observed BDNF labeling in that region should be 
selected and then applied during analysis of all experimental groups. Although the 
positive pixel threshold must be defined separately for each immunolabeling study (day 
one, day seven) due to the inherent variability associated with immunohistochemical 
labeling, the positive pixel threshold applied for analysis of BDNF expression at day one 
and day seven in these studies (Chapter 6) is 95. An excel file that contains the ratio of 
positive pixels relative to all pixels for the red channel is generated for each image at the 
completion of the code. 
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Section A.1. Dyna_KatieFile.m 
%MATLAB code to create a DYNA deck 
%will allow for analysis of strain and generation of strain field data 
%JUNE 2004: coded by Andrew Franklin (DYNA.m) 
%JULY 2005: modified by Katie Lee (DYNA2.m) to allow for input of incremental data 
%Modied by Ling Dong -  
%% OBTAIN USER INPUT TO DEFINE VARIABLES 
 
loadfile = input('Enter the name of the file containing incremental x & y coordinates 
(with .txt extension): \n','s'); 
filename=loadfile; 
timefile = input('Enter the name of the file containing a list of incremental times (in 
seconds) (with .txt extension): \n','s'); 
rows = input('How many rows in the marker matrix? \n'); 
cols = input('How many cols in the marker matrix? \n'); 
timestep = input('Enter the analysis timestep.\nThe value must be greater than 0 and less 
than 1.\nSuggest using a very small timestep for greater accuracy of results, i.e. 
0.001.\n'); 
plotstep = input('Enter the timestep to be used for displaying results.\nIt should be at least 
as big as the analysis timestep.\nSuggest using 0.1 to optimize plot display timing.\n'); 
% headerlines = input('How many lines of header or extraneous data are there?  \n '); 
 
nodes = rows*cols; 
 
%% IMPORT COORDINATE DATA 
% initial x and y coordinates 
loadfile=load(loadfile); 
colxrow = size(loadfile); 
numrows = colxrow(2); 
numframes=numrows/2; 
xini=loadfile(:,1); 
yini=loadfile(:,2); 
 
% generate x and y displacement matrices 
xdisp=zeros(nodes,numframes); 
ydisp=zeros(nodes,numframes); 
 
for i=1:numframes 
    for j=1:nodes 
    xdisp(j,i)=loadfile(j,((2*i)-1))-xini(j); 
    ydisp(j,i)=loadfile(j,(2*i))-yini(j); 
    end 
end 
 
%% IMPORT TIMING DATA (TIME @ EACH LOADING STEP) 
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timefile=load(timefile); 
 
%% *NODE 
node_matrix = zeros(nodes,4); 
for i = 1:nodes 
    node_matrix(i,1) = i; 
    node_matrix(i,2) = xini(i,1); 
    node_matrix(i,3) = yini(i,1); 
    node_matrix(i,4) = 0; 
end 
 
%% *ELEMENT_SHELL 
elements = (rows - 1)*(cols - 1); 
elem_matrix = zeros(elements,6); 
pos = 1; 
counter = 0; 
for i = 1:rows - 1 
   counter = counter + 1; 
   for j = 1:cols - 1 
    elem_matrix(pos,1) = pos; 
    elem_matrix(pos,2) = 1; 
    elem_matrix(pos,3) = counter; 
    elem_matrix(pos,4) = counter+cols; 
    elem_matrix(pos,5) = counter+cols+1; 
    elem_matrix(pos,6) = counter+1; 
    pos = pos + 1; 
    counter = counter + 1; 
   end 
end 
 
%% *BOUNDARY_PRESCRIBED_MOTION_NODE 
motion_matrix = zeros((nodes*2),6); 
% motion_matrix = zeros(nodes*3,6); %when the #of frames > nodes*2 
counter = 1;    
    for i = 1:nodes 
%       for i = 1:(nodes+2); 
        for j = 0:1 
            motion_matrix((2*i)+j-1,1) = i; 
            motion_matrix((2*i)+j-1,2) = j+1; 
            motion_matrix((2*i)+j-1,3) = 2; 
            motion_matrix((2*i)+j-1,4) = counter; 
            motion_matrix((2*i)+j-1,5) = 1; 
            motion_matrix((2*i)+j-1,6) = 0; 
            counter = counter + 1; 
        end 
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    end 
 
%% CREATE LOADING CURVES 
% generate first line of input (description of load curve) 
load_matrix = zeros(nodes*2,7); 
% load_matrix = zeros (nodes*3,7); %when the #of frames > nodes*2 
counter = 1; 
    for i = 1:(nodes*2) 
%     for i = 1:nodes*3;       %when the #of frames > nodes*2 
        load_matrix(i,1) = counter; 
        load_matrix(i,2) = 0; 
        load_matrix(i,3) = 1; 
        load_matrix(i,4) = 1; 
        load_matrix(i,5) = 0; 
        load_matrix(i,6) = 0; 
        load_matrix(i,7) = 0; 
        counter = counter+1; 
    end 
 
load_matrix = load_matrix'; 
    
% generate remainder of loading curve input (incremental displacement) 
step_matrix = zeros(numframes,(nodes*2)); 
% step_matrix = zeros(numframes,(nodes*3)); 
    for i = 1:nodes 
       step_matrix(:,(i*2)-1) = xdisp(i,:); 
       step_matrix(:,(i*2)) = ydisp(i,:); 
    end 
    
%% *CONTROL_TIMESTEP 
control_timestep = [timestep,0.9,0,0,timestep,0,0,0]; 
 
%% *CONTROL_TERMINATION 
control_termination = [timefile(length(timefile)),0,0,0,0]; 
 
%Printing the data to a dyna file 
fileoutput = strrep(filename, 'txt', 'dyn'); 
fid = fopen(fileoutput, 'wt'); 
fprintf(fid,'*KEYWORD\n'); 
fprintf(fid,'*TITLE\n'); 
fprintf(fid,'FacetMarkers\n'); 
fprintf(fid,'*PART\n'); 
fprintf(fid,'PART PID = 1 NAME = FacetMarkers\n'); 
fprintf(fid,'1,1,1\n'); 
fprintf(fid,'*NODE\n'); 
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fprintf(fid,'%5.0f,%5f,%5f,%5f\n',node_matrix'); 
fprintf(fid,'*SET_NODE_GENERAL\n'); 
fprintf(fid,'1,0,0,0,0\n'); 
fprintf(fid,'ALL\n'); 
fprintf(fid,'*ELEMENT_SHELL\n'); 
fprintf(fid,'%2.0f,%2.0f,%2.0f,%2.0f,%2.0f,%2.0f\n',elem_matrix'); 
fprintf(fid,'*MAT_ELASTIC\n'); 
fprintf(fid,'1,1,100000,0.2\n'); 
fprintf(fid,'*SECTION_SHELL\n'); 
fprintf(fid,'1,13,0.833\n'); 
fprintf(fid,'0,0,0,0\n'); 
fprintf(fid,'*CONTROL_SHELL\n'); 
fprintf(fid,'15,0,-1,0,13,2,1,0\n'); 
fprintf(fid,'*DATABASE_EXTENT_BINARY\n'); 
fprintf(fid,'0,0,3,1,1,1,2,1\n'); 
fprintf(fid,'0,0,0,0,0,3,1\n'); 
fprintf(fid,'*BOUNDARY_SPC_SET\n'); 
fprintf(fid,'1,0,0,0,1,1,1,1\n'); 
fprintf(fid,'*BOUNDARY_PRESCRIBED_MOTION_NODE\n'); 
fprintf(fid,'%2.0f,%2.0f,%2.0f,%2.0f,%2.0f,%2.0f\n',motion_matrix'); 
    for i = 1:length(step_matrix) 
        fprintf(fid,'*DEFINE_CURVE\n'); 
        fprintf(fid,'%2.0f,%2.0f,%2.0f,%2.0f,%3f,%2.0f,%2.0f\n',load_matrix(:,i)); 
        for j=1:numframes 
            fprintf(fid,'%5f,%6f\n',timefile(j),step_matrix(j,i)); 
        end 
    end 
fprintf(fid,'*DATABASE_NODOUT\n'); 
fprintf(fid,'%1.3f\n',plotstep); 
fprintf(fid,'*DATABASE_BINARY_D3PLOT\n'); 
fprintf(fid,'%1.3f\n',plotstep); 
fprintf(fid,'*CONTROL_TIMESTEP\n'); 
fprintf(fid,'%1.3f,%1.2f,%1.0f,%1.0f,%1.3f,%1.0f,%1.0f,%1.0f\n',control_timestep); 
fprintf(fid,'*CONTROL_TERMINATION\n'); 
fprintf(fid,'%4f,%1.0f,%1.0f,%1.0f,%1.0f\n',control_termination); 
fprintf(fid,'*END\n'); 
fclose(fid); 
 
%end of program 
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Section A.2. densitometry_manual_threshold_fluor.m 
%% This script was written to calculate and visualize percent positive 
%% pixels per image. To run the file, u want to create an excel file that  
%% has the detailed information abt the images to be analyzed, then number 
%% those images with a common name that has an ordered numerical (1, 2...)  
%% ending. NOTE: for the excel file, please have the following columns (in 
%% order): rat #, tissue type, injury type, image no., threshold, raw 
%% results, normalized results. Number normals last. 
 
%% requires MATLAB 7.0 (or higher) and imaging toolbox. 
 
%% Written by Ling Dong (modified from K. Quinn) on Feb 2, 2009. 
%% Modified by Kristen Nicholson December 2009 
 
clear all; 
close all; 
 
D = dir('BDNF*.tif');%specify which images to analyze (* = wildcard character) 
 
for k=1:length(D); 
     
    %reads file in 
    file=D(k).name; 
    
    % Load the image 
    imag_orig = imread(file);  
    % converts to grayscale 
    imag_orig = imag_orig(:,:,1);%grab the red labeled image 
    %imag_orig = imag_orig(:,:,2);%grab the green labeled image 
    %imag_orig = rgb2gray(imag_orig); 
    imag = imag_orig; 
    invImag = (max(max(imag)) + min(min(imag))) - imag; 
    imag = invImag; 
     
    %calc number of pixels 
    [a b]=size(imag); 
    tsize=a*b;     
    low=double(min(imag(:))); 
    high=double(max(imag(:))); 
    whiteSpace = 0.96*high;  
    pos_thresh = 95; %input based on normal run, remember for DAB staining 
    % higher value corresponds to a higher +ive threshold. 
 
    backg=sum(sum(imag>whiteSpace)); 
    posp=sum(sum(imag<pos_thresh)); 
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    %calc percent of positive pixels in tissue 
    percpos(k)=  posp/(tsize-backg); 
 
    %map out pos and neg pixels 
    pmap=(imag<pos_thresh); 
    nmap=(imag>whiteSpace); 
 
    %   make figure for each image, if you are processing a bunch of images, you 
    %   may want to comment this part out  
 
    %make positive pixels more green, and background pixels less blue 
    imag1(:,:,1)=double(imag)/255; 
    imag1(:,:,2)=(1-pmap).*double(imag)/255+pmap; 
    imag1(:,:,3)=double(imag)/255.*(1-nmap); 
     
 
    h = figure; 
    subplot(3,1,3); 
    subimage(imag); 
    axis image 
    axis off 
    subplot(3,1,2); 
    subimage(imag1); 
    axis image 
    axis off 
    colormap gray 
    subplot(3,1,1); 
    subimage(imag_orig); 
    axis image; 
    axis off; 
    %drawnow; 
     
    %save the gray-scale, inverted, and pos/neg images as a new figure 
    saveas(h, ['densitometry-' D(k).name], 'jpg') 
     
    clear imag imag1; 
end 
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Appendix B 
Facet Joint Distraction Mechanics 
 
 
This appendix summarizes the loading parameters during facet joint injury, 
including the forces and displacements of the facet joint distraction device, the capsular 
ligament stretch, and the resultant strain fields across the capsule for all of the joint 
distractions for the rats used in this thesis. Table B.1.1 summarizes the C6 displacement 
and force responses across the C6/C7 facet joint during joint distraction measured for 
each rat in the studies in Chapter 3. The C6 displacement is measured by the linear 
variable differential transducer (LVDT) attached to the C6 forceps. A load cell attached 
to the C7 forceps captures the load imposed across the joint during distraction. The 
maximum principal strain fields were calculated at the peak joint distraction using LS-
DYNA for each of the rats included in the studies in Chapter 3 and are presented in Table 
B.1.2. A Matlab program was used to generate the input files for calculating strain in LS-
DYNA; that associated Matlab code is included separately in Appendix A. The strain 
values displayed with each strain field represent engineering strain, which is the default 
output for LS-DYNA. The maximum C6 displacements, the corresponding maximum 
vertebral and capsule distractions, and the maximum principal strain (MPS) and the 
maximum rostrocaudal strain for each rat presented in Chapter 3 are provided in Table 
B.1.3, in addition to Table 3.1. All of the strains presented have been converted to 
Lagrangian strain. 
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For all of the rats that underwent joint distraction in the studies presented in 
Chapters 4 and 5, only the C6 displacements, the vertebral and capsule distraction 
magnitudes, and the MPS and maximum rostrocaudal strain are summarized here. Table 
B.2 details the C6 displacements, vertebral and capsule distractions, and capsular 
ligament strains after facet joint injury for the rats used to characterize the innervation 
pattern of the C6/C7 facet joint (Chapter 4). Table B.3.1 provides the C6 displacements, 
vertebral and capsule distraction magnitudes, and capsule strains for the rats used to 
characterize nerve growth factor (NGF) expression in the facet joint and DRG after injury 
(Chapter 5). Specifically, the loading mechanics are summarized for the rats that 
underwent facet joint distraction (FJD), as well as for those that received intra-articular 
SSP-Sap (SSP-Sap+FJD) or Blank-Sap (Blank-Sap+FJD) prior to a joint distraction. 
Table B.3.2 summarizes the loading mechanics for all rats after FJD with immediate 
C6/C7 intra-articular anti-NGF (FJD+anti-NGF) or vehicle IgG (FJD+vehicle) injections 
as well as those rats receiving intra-articular anti-NGF one day after FJD (FJD+Anti-
NGFD1) (Chapter 5).  
For those rats that underwent joint distraction in the studies included in Chapter 6, 
technical difficulties prevented recording from several of the rats. As such, only the C6 
displacements and vertebral distraction magnitudes are presented. Table B.4.1 
summarizes the displacement and vertebral distraction values for the rats used to 
characterize BDNF expression in the spinal cord and dorsal root ganglion after FJD in 
Chapter 6. Table B.4.2 presents the displacements and vertebral distractions after painful 
joint loading with day 5 trkB-Fc (trkB-Fc) or vehicle IgG-Fc (vehicle) treatment in 
Chapter 6. Finally, the C6 displacements, vertebral and capsule distractions, and capsular 
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ligament strains after facet joint injury for rats used in Chapter 7, including those that 
underwent injury alone (FJD) and those that had intra-articular IB4-Saporin applied prior 
to injury (IB4-Sap+FJD), are summarized in Table B.5. 
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Table B.1.1. Force-displacement plots for Chapter 3. 
 
Note: For rats A-I, facet joint distraction procedures were performed by Ben A. Bulka, and the naming 
scheme reflects his records. 
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Table B.1.2. Maximum principal strain fields for Chapter 3. 
 
Rat 413 Rat 415 
Rat 417 Rat 418 
Rat A Rat B 
Rat I Rat D 
Rat E 
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Table B.1.3. C6 displacements, vertebral distractions, capsule distractions, and 
capsular ligament strains for Chapter 3. 
Group Rat 
C6 
displacement 
(mm) 
Vertebral 
distraction 
(mm) 
Capsule 
distraction 
(mm) 
Maximum 
principal 
strain (%) 
Maximum 
rostrocaudal 
strain (%) 
FJD 
413 2.47 0.44 0.19 15.03 5.41 
415 2.50 0.36 0.25 17.92 17.81 
417 2.50 0.59 0.32 21.40 19.28 
418 2.50 0.96 0.59 54.59 40.97 
A 2.50 0.45 0.27 17.67 8.93 
B 2.53 0.45 0.17 30.84 8.68 
I 2.48 0.34 0.26 7.91 2.14 
D 2.51 0.55 0.25 18.41 18.00 
E 2.54 0.35 0.23 15.84 7.87 
For rats A-I, facet joint distraction procedures were performed by Ben A. Bulka, and the naming scheme 
reflects his records. 
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Table B.2. C6 displacements, vertebral distractions, capsule distractions, and 
capsular ligament strains for Chapter 4. 
Group Rat 
C6 
displacement 
(mm) 
Vertebral 
distraction 
(mm) 
Capsule 
distraction 
(mm) 
Maximum 
principal 
strain (%) 
Maximum 
rostrocaudal 
strain (%) 
FJD 
134 2.51 0.48 0.22 17.84 17.70 
143 2.49 0.46 0.12 9.30 9.29 
152 2.52 0.40 0.15 11.17 10.88 
155 2.55 0.53 0.18 14.99 10.71 
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Table B.3.1. C6 displacements, vertebral distractions, capsule distractions, and 
capsular ligament strains for rats used for NGF characterization (Chapter 5). 
Group Rat 
C6 
displacement 
(mm) 
Vertebral 
distraction 
(mm) 
Capsule 
distraction 
(mm) 
Maximum 
principal 
strain (%) 
Maximum 
rostrocaudal 
strain (%) 
FJD 
381 2.50 0.34 0.19 13.81 3.00 
382 2.48 0.96 0.54 42.36 25.15 
386 2.50 0.89 0.44 35.39 26.13 
389 2.50 0.52 0.29 22.96 13.66 
390 2.50 0.64 0.30 25.48 25.48 
408 2.47 0.52 0.36 21.36 16.57 
409 2.51 0.84 0.53 24.74 22.98 
410 2.49 0.93 0.35 44.23 33.38 
SSP-Sap+ 
FJD 
F136 2.49 0.44 0.18 20.61 9.69 
F137 2.50 0.32 0.13 15.02 7.31 
F138 2.50 0.86 0.31 30.32 29.12 
F181 2.52 0.66 0.30 30.46 25.69 
F185 2.55 0.25 0.25 51.77 44.38 
F190 2.51 0.39 0.26 11.83 9.85 
F199 2.51 0.39 0.20 14.54 9.98 
Blank-
Sap+ 
FJD 
F140 2.53 0.50 0.20 12.72 12.15 
F141 2.51 0.31 0.17 19.89 5.00 
F143 2.51 0.59 0.28 20.72 17.96 
F179 2.51 0.29 0.19 14.36 13.32 
F182 2.52 0.75 0.16 49.68 26.01 
F196 2.56 0.93 0.20 10.03 8.72 
F197 2.51 0.50 0.31 21.89 19.48 
Note: Rats 385-390 were used to quantify NGF expression in the cervical facet joint using 
immunohistochemical labeling. Rats 381-382 and 408-410 were used to quantify NGF levels in the soft 
tissues of the cervical facet joint using Western blot. All rats in the SSP-Sap+FJD and Blank-Sap+FJD 
groups were generated by Christine L. Weisshaar, and the naming scheme reflects her records. 
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Table B.3.2. C6 displacements, vertebral distractions, capsule distractions, and 
capsular ligament strains for rats used for anti-NGF injection studies (Chapter 5). 
Group Rat 
C6 
displacement 
(mm) 
Vertebral 
distraction 
(mm) 
Capsule 
distraction 
(mm) 
Maximum 
principal 
strain (%) 
Maximum 
rostrocaudal 
strain (%) 
FJD+ 
anti-NGF 
250 2.54 0.55 0.32 59.06 41.89 
251 2.52 0.96 0.28 34.98 24.64 
254 2.53 0.73 0.35 44.25 23.18 
277 2.50 1.07 0.63 36.62 36.42 
279 2.50 0.55 0.28 28.19 26.45 
340 2.46 1.04 0.37 92.87 46.96 
306 2.48 0.85 0.42 44.58 43.08 
308 2.49 0.81 0.19 57.39 34.89 
353 2.50 0.83 0.34 50.98 50.91 
354 2.49 0.78 0.38 66.39 41.57 
355 2.48 0.54 0.30 47.58 31.17 
FJD+ 
vehicle 
272 2.47 0.38 0.26 19.01 15.59 
273 2.58 0.80 0.44 40.15 28.83 
274 2.53 0.92 0.36 46.10 35.19 
275 2.57 0.61 0.29 22.07 16.07 
276 2.53 0.63 0.26 19.43 18.30 
280 2.49 0.79 0.31 47.19 25.31 
305 2.49 0.58 0.18 16.97 15.80 
307 2.27 0.79 0.30 26.81 17.96 
309 2.52 0.82 0.30 35.16 27.89 
356 2.48 0.81 0.33 26.05 25.86 
357 2.46 0.69 0.31 21.89 17.45 
358 2.49 0.46 0.18 28.71 17.57 
FJD+ 
anti-
NGFD1 
345 2.47 1.18 0.45 41.16 41.16 
347 2.50 0.92 0.28 37.87 36.40 
359 2.46 1.03 0.57 30.06 29.24 
360 2.57 0.92 0.40 21.56 21.05 
361 2.56 0.66 0.35 38.65 27.78 
362 2.47 1.05 0.64 38.88 36.43 
363 2.48 0.93 0.46 58.41 58.25 
364 2.55 0.81 0.28 32.16 28.92 
Note: For this study, rats highlighted in gray were used for electrophysiological recordings at day one. The 
remaining rats were used for electrophysiological recordings at day seven. 
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Table B.4.1. C6 displacements and vertebral distractions for rats used for BDNF 
characterization studies (Chapter 6). 
Group Rat 
C6 
displacement 
(mm) 
Vertebral 
distraction 
(mm) 
FJD 
47 6.65 0.80 
48 1.43 0.58 
49 1.86 0.80 
52 1.29 0.68 
53 2.54 0.66 
54 1.44 0.72 
KEL315 2.61 0.73 
KEL316 3.00 0.72 
KEL317 3.19 0.76 
KEL318 1.65 0.73 
KEL319 3.10 0.70 
KEL320 3.06 0.70 
F13 2.49 0.46 
F14 2.46 0.57 
F19 2.38 0.45 
F20 2.49 0.55 
F21 2.46 0.60 
F24 2.44 0.54 
F3 2.04 - 
F4 2.05 0.47 
F7 2.21 0.41 
F8 2.28 - 
F11 2.26 - 
Note: For this study, tissue from rats highlighted in gray was harvested at day one. All rats that were 
harvested at day one were generated by Christine L. Weisshaar, and the naming scheme reflects her 
records. The remaining rats were harvested at day seven. For rats F3, F8, and F11, technical difficulties 
prevented video recording of the joint distraction, so vertebral distraction could not be calculated. Rats 
KEL315-KEL320 were generated by Kathryn E. Lee, and the numbering scheme reflects her records. 
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Table B.4.2. C6 displacements and vertebral distractions for rats used for the spinal 
BDNF sequestration study (Chapter 6). 
Group Rat 
C6 
displacement 
(mm) 
Vertebral 
distraction 
(mm) 
trkB-Fc 
195 2.55 0.69 
196 2.59 0.59 
197 2.55 0.73 
202 2.51 0.56 
204 2.51 0.72 
206 2.52 0.69 
209 2.53 0.73 
vehicle 
203 2.52 0.87 
205 2.51 0.91 
207 2.53 0.64 
246 2.48 0.65 
247 2.49 1.01 
248 2.45 0.67 
249 2.48 0.73 
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Table B.5. C6 displacements, vertebral distractions, capsule distractions, and 
capsular ligament strains for Chapter 7. 
Group Rat 
C6 
displacement 
(mm) 
Vertebral 
distraction 
(mm) 
Capsule 
distraction 
(mm) 
Maximum 
principal 
strain (%) 
Maximum 
rostrocaudal 
strain (%) 
FJD 
PSP1 2.55 0.66 0.24 38.09 27.39 
PSP5 2.56 0.67 0.25 30.35 25.54 
PSP7 2.49 0.99 0.50 39.66 39.65 
PSP11 2.49 1.12 0.59 53.15 41.50 
IB4-Sap+ 
FJD 
F240 2.50 0.34 0.26 15.31 13.33 
F241 2.56 0.44 0.21 128.58 32.91 
F242 2.54 0.27 0.18 9.97 9.94 
F246 2.49 0.50 0.35 20.79 20.44 
F249 2.50 0.54 0.10 12.84 4.18 
F251 2.49 0.19 0.27 59.40 53.60 
Note: For this study, electrophysiological recordings were performed by Parul S. Pall, which is reflected in 
the naming scheme of the rats included in the FJD group in accordance with my records. Surgical 
procedures for the IB4-Sap+FJD group were performed by Christine L. Weisshaar, and the naming scheme 
for those rats reflects her records. 
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Appendix C 
Mechanical and Thermal Behavioral Sensitivity 
 
 
This appendix details the individual responses for mechanical and thermal 
sensitivity for all of the rats included in the behavioral studies in Chapters 3-7. 
Mechanical hyperalgesia is reported as the response threshold (gram) averaged between 
the forepaws for each rat. The response threshold is determined by applying a series of 
von Frey filaments to each forepaw in an ascending series. The filament strength eliciting 
a response is recorded as the withdrawal threshold if the next consecutive filament also 
elicits a positive response (see Chapter 3 for further details). Thermal hyperalgesia is 
reported as the latency to forepaw withdrawal (seconds) from a radiant heat source 
averaged between forepaws for each rat. The heat source is applied separately to each 
forepaw, and a timer synchronized to the thermal stimulus measures the latency time 
between the initial application of the heat source and when the paw is withdrawn (i.e. the 
withdrawal latency) (see Chapter 3 for further details). The facet joint distraction (FJD) 
group refers to rats for which the C6 forceps was displaced by 2.5mm as recorded by the 
linear variable differential transducer (LVDT) (See Chapter 3 for details). The sham 
group underwent the same surgical procedure with no applied distraction. 
 Each table summarizes behavioral data for each group arranged by studies in the 
order they are presented in each chapter. Baseline responses (day 0) are included for all 
tables. Tables C.1.1 and C.1.2 itemize the individual responses to mechanical and thermal 
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stimulation, respectively, at all baseline and post-surgical time points for rats in the FJD 
and sham groups presented in Chapter 3. Table C.2 summarizes the mechanical 
withdrawal thresholds for the groups used to characterize the innervation pattern of the 
C6/C7 facet joint in the studies included in Chapter 4.  
Tables C.3.1-C.3.9 report the behavioral response data for all of the rats included 
in the studies of intra-articular nerve growth factor (NGF)-mediated facet joint pain that 
are presented in Chapter 5. Table C.3.1 details the individual responses to mechanical 
stimulation of the forepaw following FJD or sham procedures for those rats used to 
identify and quantify NGF expression in the C6/C7 facet joint. Table C.3.2 contains the 
mechanical withdrawal thresholds for rats that received intra-articular [Sar9,Met(O2)11]-
substance P-saporin (SSP-Sap) or control saporin (Blank-Sap) prior to FJD or sham 
procedures. Table C.3.3 details the mechanical withdrawal thresholds following intra-
articular injection of nerve growth factor (NGF) or phosphate buffered saline (vehicle). 
Tables C.3.4 and C.3.5 summarize the individual mechanical (Table C.3.4) and thermal 
(Table C.3.5) hyperalgesia responses for the rats that received intra-articular SSP-Sap or 
Blank-Sap prior to NGF (SSP-Sap+NGF, Blank-Sap+NGF) or vehicle (SSP-Sap+veh, 
Blank-Sap+veh) injection into the facet joint. Likewise, the next two tables report the 
mechanical (Table C.3.6) and thermal (Table C.3.7) responses for all rats that received 
intra-articular saporin conjugated to isolectin B4 (IB4-Sap) or unconjugated control 
saporin (Saporin) prior to application of intra-articular NGF (IB4-Sap+NGF, 
Saporin+NGF) or vehicle (IB4-Sap+NGF). Table C.3.8 details the forepaw withdrawal 
thresholds to mechanical stimulation for all rats that were given intra-articular anti-NGF 
or control immunoglobulin G immediately following FJD (FJD+anti-NGF, FJD+vehicle) 
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or sham (sham+anti-NGF, sham+vehicle) to identify if intra-articular NGF initiates facet 
joint loading-induced pain (see Chapter 5 for further details). Lastly, Table C.3.9 
summarizes the mechanical hyperalgesia responses of those rats that underwent FJD 
followed by intra-articular anti-NGF on post-surgical day one.  
Table C.4.1 details the mechanical sensitivity for each rat used to characterize 
BDNF responses at days one and seven following FJD or sham procedures (Chapter 6). 
Table C.4.2 contains the withdrawal thresholds for the rats that received intrathecal trkB-
Fc (trkB-Fc) or control IgG-Fc (vehicle) on day five after distraction (Chapter 6). Table 
C.5 reports the individual mechanical hyperalgesia responses on all days tested for all of 
the rats used to quantify thalamic neuronal hyperexcitability in the studies presented in 
Chapter 7. Those rats underwent FJD or sham surgery. Additional rats received intra-
articular IB4-Sap prior to distraction or sham surgery for those studies and are also 
detailed. 
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Table C.1.1. Mechanical hyperalgesia thresholds (g) for one or seven days following 
facet joint distraction (FJD) (Chapter 3). 
Group Rat day 0 day 1 day 3 day 5 day 7 
FJD 
413 24.17 13.33 - - - 
415 9.83 7.00 - - - 
417 14.17 8.83 - - - 
418 13.83 3.67 - - - 
A 15.17 10.17 7.67 7.67 6.67 
B 16.00 6.83 6.67 9.50 5.00 
I 13.00 7.33 7.00 8.83 7.33 
D 19.67 7.17 12.00 8.33 8.17 
E 16.00 8.33 8.50 8.83 8.50 
sham 
414 13.33 15.00 - - - 
416 14.00 14.83 - - - 
G 24.17 18.17 15.17 15.00 16.83 
H 17.83 14.00 11.83 12.17 15.17 
Note: For this study, tissue from half of the rats was harvested at day one and at day seven for the other half 
of the rats. For rats A-I, facet joint distraction procedures were performed by Ben A. Bulka, and the naming 
scheme reflects his records. 
 
Table C.1.2. Thermal hyperalgesia latencies (sec) for one or seven days following 
facet joint distraction (Chapter 3). 
Group Rat day 0 day 1 day 7 
FJD 
413 10.25 6.70 - 
415 9.45 9.46 - 
417 13.93 10.89 - 
418 13.84 11.59 - 
A 14.49 15.17 10.18 
B 8.61 8.97 7.97 
I 11.68 9.42 10.73 
D 10.02 10.96 9.75 
E 15.51 10.70 12.39 
sham 
414 10.85 11.29 - 
416 10.57 10.24 - 
G 12.26 6.86 7.81 
H 13.86 14.84 13.55 
Note: Thermal behavioral testing was only performed at baseline, day one and day seven. As in Table 
C.1.1, only half of the rats were followed beyond day one. For rats A-I, facet joint distraction procedures 
were performed by Ben A. Bulka, and the naming scheme reflects his records. 
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Table C.2. Mechanical hyperalgesia thresholds (g) following facet joint distraction 
(Chapter 4). 
Group Rat day 0 day 1 day 3 day 5 day 7 
FJD 
134 8.67 3.67 5.00 3.67 3.67 
143 13.33 5.00 4.33 5.00 4.67 
152 20.50 3.23 5.67 6.67 6.33 
155 10.00 3.67 2.03 2.37 2.47 
sham 
132 18.67 11.50 20.50 19.67 22.33 
141 21.50 17.50 17.83 14.83 17.83 
142 17.00 18.67 19.67 16.83 16.83 
150 19.67 17.83 19.67 15.17 14.17 
154 14.00 12.17 11.33 15.67 13.67 
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Table C.3.1. Mechanical hyperalgesia thresholds (g) following facet joint distraction 
(Chapter 5). 
Group Rat day 0 day 1 
FJD 
381 20.50 9.33 
382 19.67 9.17 
386 20.50 9.33 
389 16.00 10.83 
390 13.33 7.67 
408 22.33 8.67 
409 22.33 8.83 
410 18.67 8.17 
sham 
380 24.17 22.33 
383 22.33 21.50 
384 24.17 22.33 
385 19.67 22.33 
387 24.17 22.33 
388 21.50 17.50 
407 16.17 17.17 
411 20.50 16.83 
Note: Rats 385-390 were used to identify NGF expression in the cervical facet joint using 
immunohistochemical labeling. All other rats were used to quantify NGF levels in the soft tissues of the 
cervical facet joint using Western blot. 
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Table C.3.2. Mechanical hyperalgesia thresholds (g) after saporin treatment and 
following facet joint distraction (Chapter 5). 
Group Rat day 0 day 1 day 3 day 5 day 7 
SSP-Sap+ 
FJD 
F136 19.67 15.00 11.00 16.00 15.17 
F137 14.33 11.00 12.17 15.67 12.17 
F138 22.33 18.67 20.50 16.67 18.67 
F181 18.67 18.50 20.50 17.00 21.50 
F185 17.83 14.67 11.83 11.33 14.33 
F190 22.33 24.17 13.00 18.83 22.33 
F199 14.17 24.17 21.17 19.67 24.17 
Blank-Sap+ 
FJD 
F140 10.00 4.67 2.80 3.13 4.67 
F141 18.83 8.00 5.00 4.67 4.23 
F143 20.50 6.00 6.33 6.33 4.67 
F179 21.50 6.67 5.67 9.67 9.00 
F182 17.00 5.67 5.67 3.67 5.00 
F196 14.00 8.50 5.67 4.00 3.13 
F197 16.33 4.57 5.00 5.67 5.33 
SSP-Sap+ 
sham 
F188 24.17 26.00 18.83 22.33 17.00 
F189 10.83 20.50 18.67 18.17 24.17 
F198 16.00 21.50 22.33 18.67 20.50 
F200 22.33 26.00 22.33 14.17 15.83 
Note: All rats included in this study were generated by Christine L. Weisshaar, and the naming scheme 
reflects her records. 
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Table C.3.3. Mechanical hyperalgesia thresholds (g) for one or seven days following 
NGF joint injection (Chapter 5). 
Group Rat day 0 day 1 day 3 day 5 day 7 
NGF 
144 15.28 15.67 17.83 18.67 20.50 
145 20.44 10.83 22.33 20.50 17.83 
146 9.44 4.90 9.83 11.83 10.17 
147 20.89 14.50 23.00 18.67 21.50 
148 20.22 17.83 22.33 24.17 20.50 
149 16.78 12.33 16.67 19.67 18.83 
252 17.72 13.33 - - - 
253 22.06 7.17 - - - 
255 20.83 9.50 - - - 
256 13.94 8.00 - - - 
257 21.72 15.00 - - - 
278 16.08 9.67 - - - 
282 18.72 9.00 - - - 
vehicle 
341 21.50 21.50 24.17 16.00 22.33 
342 21.50 22.33 22.33 17.00 21.50 
344 18.17 15.83 17.00 18.17 21.17 
265 16.06 14.17 - - - 
266 25.08 22.33 - - - 
267 25.11 22.33 - - - 
268 16.00 16.83 - - - 
269 19.06 20.50 - - - 
281 17.33 18.67 - - - 
Note: For this study, rats were followed for seven days after injection in order to characterize the time 
course of NGF-induced sensitivity. Additional NGF-injected rats were used for electrophysiological 
recordings at day one when sensitivity was evident. 
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Table C.3.4. Mechanical hyperalgesia thresholds (g) at day one after SSP-saporin 
treatment followed by an NGF joint injection (Chapter 5). 
Group Rat day 0 day 1 Group Rat day 0 day 1 
Blank-Sap+ 
vehicle 
293 15.17 18.67 
Blank-Sap+ 
NGF 
212 13.00 7.00 
294 19.92 24.17 213 22.33 12.50 
295 21.00 15.67 216 19.67 14.00 
296 23.75 26.00 217 24.17 18.83 
325 24.17 26.00 299 6.33 4.33 
326 7.25 8.00 300 10.33 4.67 
331 21.42 24.17 303 13.42 6.33 
332 22.33 23.33 304 10.92 4.33 
SSP-Sap+ 
NGF 
210 21.42 18.83 321 13.17 7.00 
211 22.33 24.17 322 19.67 12.17 
214 23.25 22.33 329 21.00 8.83 
215 24.17 22.33 330 16.83 5.00 
297 22.33 22.33 
SSP-Sap+ 
vehicle 
289 19.25 16.33 
298 17.50 20.50 290 15.83 22.33 
301 21.50 22.33 291 23.25 24.17 
302 7.67 8.33 292 22.83 14.17 
319 6.17 7.33 323 14.50 10.83 
320 20.08 20.50 324 22.33 24.17 
327 24.17 20.50 333 14.25 15.00 
328 12.00 8.67 334 11.92 22.33 
391 20.50 14.83 393 13.83 20.50 
392 16.83 20.50 394 16.92 18.67 
395 26.00 24.17 397 22.83 20.50 
396 18.42 18.50 398 25.08 21.50 
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Table C.3.5. Thermal hyperalgesia latencies (sec) at day one after SSP-saporin 
treatment followed by an NGF joint injection (Chapter 5). 
Group Rat day 0 day 1 
Blank-Sap+ 
NGF 
299 8.26 9.08 
300 10.28 8.17 
303 10.90 7.15 
304 12.26 5.54 
321 10.12 7.85 
322 10.54 9.19 
329 12.05 6.18 
330 9.44 7.49 
Blank-Sap+ 
vehicle 
325 11.56 8.82 
326 10.63 7.47 
333 10.18 12.52 
334 13.53 12.24 
SSP-Sap+ 
NGF 
297 9.83 11.05 
298 9.96 11.92 
301 13.00 9.59 
302 9.89 9.23 
319 9.85 10.13 
320 12.37 9.10 
327 10.92 12.25 
328 11.23 8.62 
SSP-Sap+ 
vehicle 
323 12.05 8.92 
324 10.72 11.45 
331 11.39 10.81 
332 14.73 13.01 
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Table C.3.6. Mechanical hyperalgesia thresholds (g) at day one after IB4-saporin 
treatment followed by an NGF joint injection (Chapter 5). 
Group Rat day 0 day 1 
Saporin+ 
NGF 
311 23.25 11.83 
312 17.17 7.00 
313 11.42 7.67 
374 12.42 8.17 
375 22.33 10.67 
376 19.58 10.00 
377 20.50 10.67 
378 23.25 14.83 
IB4-Sap+ 
NGF 
315 12.50 9.67 
316 25.08 16.00 
317 13.92 7.33 
318 21.42 9.17 
346 20.08 5.33 
349 13.17 8.50 
350 17.33 7.33 
371 22.33 9.83 
372 13.17 4.33 
373 20.50 11.50 
399 13.61 8.83 
400 22.06 16.00 
IB4-Sap+ 
vehicle 
401 18.78 16.67 
402 20.56 20.50 
403 22.06 22.33 
404 10.33 13.67 
405 16.89 16.00 
406 20.72 19.67 
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Table C.3.7. Thermal hyperalgesia latencies (sec) at day one after IB4-saporin 
treatment followed by an NGF joint injection (Chapter 5). 
Group Rat day 0 day 1 
Saporin+ 
NGF 
374 10.43 7.03 
375 13.17 6.35 
376 12.16 6.70 
377 12.82 7.96 
378 12.91 6.55 
IB4-Sap+ 
NGF 
346 9.80 10.29 
349 10.25 5.54 
350 14.99 9.00 
371 15.99 13.18 
372 10.15 7.74 
373 11.72 6.69 
399 13.24 6.17 
400 11.44 7.32 
IB4-Sap+ 
vehicle 
401 8.65 7.39 
402 8.79 6.53 
403 11.17 10.92 
404 14.93 13.57 
405 11.43 11.92 
406 10.08 10.26 
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Table C.3.8. Mechanical hyperalgesia thresholds (g) for one or seven days following 
facet joint distraction and intra-articular treatments (Chapter 5). 
Group Rat day 0 day 1 day 3 day 5 day 7 
FJD+     
anti-NGF 
250 20.58 18.67 24.17 16.83 24.17 
251 23.56 20.50 22.33 24.17 24.17 
254 20.22 20.50 21.50 20.67 24.17 
277 13.33 17.83 15.17 18.67 18.67 
279 12.61 9.67 17.83 17.83 13.00 
340 22.06 24.17 22.33 26.00 22.33 
306 18.83 18.83 - - - 
308 21.72 17.00 - - - 
353 23.56 24.17 - - - 
354 19.17 19.33 - - - 
355 20.38 20.50 - - - 
FJD+ 
vehicle 
272 19.00 11.33 10.83 11.33 10.50 
273 15.33 8.33 8.50 8.50 9.67 
274 19.89 16.17 7.33 7.67 9.00 
275 13.06 8.17 4.00 5.33 7.00 
276 24.78 11.67 10.67 11.00 11.17 
280 19.61 9.17 9.50 9.83 9.83 
305 14.00 4.33 - - - 
307 16.00 8.50 - - - 
309 18.94 8.50 - - - 
356 13.72 8.50 - - - 
357 12.00 7.00 - - - 
358 15.78 10.17 - - - 
sham+  
anti-NGF 
335 20.72 21.17 21.50 20.50 22.33 
336 22.33 22.33 18.67 17.83 22.33 
337 18.22 19.33 21.50 26.00 20.50 
338 16.44 20.50 20.50 17.83 17.00 
339 19.83 22.33 20.50 18.67 17.83 
sham+ 
vehicle 
283 20.17 21.50 22.33 20.50 19.67 
285 17.22 19.67 18.67 16.67 17.83 
286 21.78 24.17 26.00 24.17 24.17 
287 17.56 21.50 20.50 22.33 18.67 
288 19.33 22.33 24.17 24.17 24.17 
365 11.28 11.33 - - - 
366 26.00 24.17 - - - 
367 22.67 18.50 - - - 
368 17.50 19.33 - - - 
370 17.61 19.67 - - - 
Note: For this study, some rats were used for electrophysiological recordings at day one, so withdrawal 
thresholds were only assessed at baseline and day one. The remaining rats were used for 
electrophysiological recordings at day seven. 
 
 
  
259 
Table C.3.9. Mechanical hyperalgesia thresholds (g) following facet joint distraction 
and a delayed joint injection of anti-NGF at day one (Chapter 5). 
Group Rat day 0 day 1 day 2 day 3 day 4 day 5 day 6 day 7 
FJD+ 
anti- 
NGFD1 
345 16.17 9.00 13.67 16.33 11.00 18.17 11.83 11.50 
347 14.00 5.33 11.50 20.50 10.00 8.33 11.33 8.67 
359 22.67 8.50 13.50 14.83 13.17 17.83 16.00 14.33 
360 19.44 14.00 11.67 10.00 10.83 16.00 13.00 11.50 
361 14.72 7.67 8.50 4.67 8.17 10.00 8.67 8.33 
362 19.83 9.67 7.83 4.67 6.17 6.83 9.00 7.83 
363 19.94 12.67 14.50 14.00 11.67 10.17 14.00 14.33 
364 19.44 13.00 13.00 18.67 20.50 12.83 8.00 9.83 
Note: For this study, intra-articular anti-NGF was applied to the C6/C7 facet joints immediately following 
behavioral testing on day one. 
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Table C.4.1. Mechanical sensitivity following facet joint distraction (Chapter 6). 
Group Rat day 0 day 1 day 7 Group Rat day 0 day 1 day 7 
FJD 
47 1.11 2.40 4.58 
sham 
50 0.83 0.88 0.91 
48 0.97 2.96 2.10 55 1.23 1.12 1.40 
49 0.92 2.10 2.19 56 0.84 0.81 0.81 
52 0.77 2.65 2.40 60 1.25 1.13 1.13 
53 0.90 1.34 1.94 KEL307 1.04 0.64 1.25 
54 1.72 3.68 2.96 KEL308 1.04 1.43 1.37 
KEL315 1.24 8.27 7.40 KEL309 1.81 2.02 1.49 
KEL316 0.89 6.59 5.48 KEL310 0.67 1.23 0.61 
KEL317 0.71 4.22 3.40 KEL321 0.69 1.14 0.77 
KEL318 1.34 9.37 3.83 KEL322 1.72 1.72 1.43 
KEL319 1.16 8.78 4.22 F15 0.88 0.76 - 
KEL320 0.95 6.59 6.02 F17 0.88 1.03 - 
F13 0.82 1.72 - F22 1.47 1.04 - 
F14 3.56 3.06 - F23 0.97 1.16 - 
F19 0.86 3.41 - F9 1.20 1.80 - 
F20 1.13 2.18 - F10 0.60 1.20 - 
F21 0.85 2.05 - F12 1.20 1.80 - 
F24 0.78 3.14 -           
CLW1 1.52 3.65 -           
F3 0.30 3.96 -           
F4 2.74 2.13 -           
CLW6 0.61 3.35 -           
F7 0.61 3.65 -           
F8 0.30 3.04 -           
F11 0.91 3.65 -           
Note: For this study, some rats were used to quantify BDNF expression in the spinal cord and dorsal root 
ganglion at day one, so sensitivity was only measured through day one. Rats 47-60 and F13-F24 were used 
to quantify BDNF expression using immunohistochemical labeling; all other rats were used to quantify 
BDNF mRNA using real time reverse-transcription polymerase chain reaction. All rats that were harvested 
at day one were generated by Christine L. Weisshaar, and the naming scheme reflects her records. Rats 
KEL307-KEL322 were generated by Kathryn E. Lee, and the numbering scheme reflects her records. 
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Table C.4.2. Mechanical hyperalgesia thresholds (g) following facet joint distraction 
and intrathecal trkB-Fc injection at day five (Chapter 6). 
Group Rat day 0 day 1 day 3 day 5 day 6 day 7 
trkB-Fc 
195 22.06 8.00 6.67 7.00 5.00 10.00 
196 16.50 10.33 9.00 12.50 20.50 15.50 
197 21.11 15.83 10.67 11.83 12.33 20.50 
202 20.50 15.67 18.67 17.00 20.50 20.50 
204 14.83 7.50 6.67 6.33 10.00 11.83 
206 12.17 7.00 7.33 6.33 11.83 11.33 
209 24.17 10.67 8.67 9.83 17.50 9.83 
vehicle 
203 14.33 6.00 7.67 6.67 7.33 8.50 
205 12.50 8.00 8.17 7.33 9.83 11.00 
207 22.33 10.33 10.67 8.33 12.17 11.33 
246 18.67 8.50 9.00 7.33 7.00 6.33 
247 19.67 6.33 7.00 7.67 8.33 8.17 
248 16.83 12.50 12.67 16.67 18.17 17.83 
249 24.17 12.17 11.67 11.33 10.67 8.33 
Note: For this study, rats received an intrathecal injection of trkB-Fc or vehicle immediately following 
behavioral testing on day five. 
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Table C.5. Mechanical hyperalgesia thresholds (g) following facet joint distraction 
with or without prior intra-articular IB4-saporin treatment (Chapter 7). 
Group Rat Day 0 Day 1 Day 3 Day 5 Day 7 
FJD 
PSP1 13.33 16.33 18.67 8.67 7.33 
PSP5 17.00 7.67 8.67 9.00 8.67 
PSP7 26.00 10.00 8.67 13.33 13.33 
PSP11 26.00 26.00 26.00 26.00 20.67 
sham 
PSP4 16.33 9.33 9.33 6.67 9.33 
PSP8 26.00 26.00 26.00 26.00 26.00 
PSP12 18.67 15.30 10.33 13.33 20.67 
IB4-Sap+ 
FJD 
F240 9.00 9.33 - - 13.33 
F241 9.50 8.00 - - 9.33 
F242 9.17 15.00 - - 18.67 
F246 22.33 22.33 - - 26.00 
F249 23.56 15.33 - - 22.33 
F251 4.00 11.00 - - 10.33 
IB4-Sap+ 
sham 
F244 4.67 11.00 - - 7.33 
F245 13.50 15.00 - - 13.33 
F247 11.67 22.33 - - 22.33 
F250 24.78 17.00 - - 26.00 
F252 26.00 26.00 - - 26.00 
F253 8.67 22.33 - - 13.33 
Note: For this study, withdrawal thresholds for rats that received IB4-saporin prior to facet joint distraction 
or sham procedures were quantified on day 1 to verify that behavioral sensitivity did not develop in either 
group and again on day 7 in order to confirm that behavioral sensitivity was not evident prior to 
electrophysiological assessment. Electrophysiological recordings were performed by Parul S. Pall, which is 
reflected in the naming scheme of the rats included in the FJD and sham groups in accordance with my 
records. Surgical procedures for the IB4-Sap+FJD and IB4-Sap+sham groups were performed by Christine 
L. Weisshaar, and the naming scheme for those rats reflects her records. 
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Appendix D 
Quantification of Brain-Derived Neurotrophic 
Factor mRNA Using Real-Time RT-PCR 
 
This appendix provides a summary of the brain-derived neurotrophic factor 
(BDNF) mRNA levels in the dorsal root ganglion (DRG) and spinal cord in the 
characterization study in Chapter 6. BDNF mRNA was quantified in both tissues at days 
one and seven after facet joint distraction or sham procedures using real-time reverse 
transcription polymerase chain reaction (RT-PCR). RT-PCR was carried out using 
primers specific to BDNF (Forward: 5’-GGA-CAT-ATC-CAT-GAC-CAG-AAA-GAA-
A-3’; Reverse: 5’-GCA-ACA-AAC-CAC-AAC–ATT-ATC-GAG-3’; Probe: 5’-AGT-
CAT-TTG-CGC-ACA-ACT-TTA-AAA-GTC-TGC-ATT-3’) and the housekeeping gene 
18S (Forward: 5’-CGG-CTA-CCA–CAT-CCA-AGG-AA-3'; Reverse: 5’-GCT-GGA–
ATT-ACC-GCG-GCT-3’; Probe: 5’-CAC-CAG-ACT-TGC-CCT-C-3’). Separately for 
each tissue (DRG, spinal cord), BDNF mRNA levels for each rat at each time point were 
normalized to the housekeeping gene 18S and are reported as the fold-change relative to 
the average sham levels at that same time point. As such, the average of all of the 
samples in each sham group for each tissue and each time point that are presented in this 
appendix have an average BDNF mRNA value of 1. For rats in the facet joint distraction 
(FJD) group, the C6 forceps was displaced by 2.5mm as recorded by a linear variable 
differential transducer (LVDT) (See Chapter 3 for details). The sham group underwent 
the same surgical procedure with no applied distraction. 
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Table D.1 provides the quantification of BDNF mRNA levels in the C6 DRGs of 
separate groups of rats at days one and seven following facet joint distraction or sham 
procedures (Chapter 6). Table D.2 summarizes BDNF mRNA levels in the C6 spinal cord 
at both time points after distraction or sham procedures (Chapter 6). 
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Table D.1. BDNF mRNA in the C6 DRG following painful facet joint distraction in 
separate groups of rats at day one and day seven (Chapter 6). 
Group Day Rat BDNF mRNA  (fold-change relative to sham) 
FJD 
Day 1 
CLW1 0.70 
F3 1.96 
F4 0.62 
CLW6 0.94 
F7 1.34 
F8 0.84 
F11 0.97 
Day 7 
315 0.41 
316 0.86 
318 1.25 
sham 
Day 1 
F9 1.52 
F10 0.62 
F12 0.86 
Day 7 
310 0.95 
321 0.97 
322 1.09 
Note: All rats used in the day one study were generated by Christine L. Weisshaar, and the naming scheme 
reflects her records. All rats used in the day seven study were generated by Kathryn E. Lee, and the 
numbering scheme reflects her records. 
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Table D.2. BDNF mRNA in the C6 spinal cord following painful facet joint 
distraction in separate groups of rats at day one and day seven (Chapter 6). 
Group   Rat BDNF mRNA  (fold-change relative to sham) 
FJD 
Day 1 
CLW1 1.32 
F3 0.87 
F4 0.74 
F7 1.09 
F8 1.12 
F11 0.95 
Day 7 
315 1.65 
316 0.76 
318 1.51 
319 1.51 
320 1.45 
sham 
Day 1 
F9 0.92 
F10 1.26 
F12 0.82 
Day 7 
307 0.80 
308 1.11 
309 0.97 
310 0.66 
321 1.23 
322 1.24 
Note: All rats used in the day one study were generated by Christine L. Weisshaar, and the naming scheme 
reflects her records. All rats used in the day seven study were generated by Kathryn E. Lee, and the 
numbering scheme reflects her records. 
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Appendix E 
Quantification of Nerve Growth Factor Protein in 
the DRG and Brain-Derived Neurotrophic Factor 
Protein in the DRG and Spinal Cord Using 
Immunohistochemistry 
 
 
This appendix summarizes the quantification of immunolabeling of nerve growth 
factor (NGF) and brain-derived neurotrophic factor (BDNF) for the studies presented in 
Chapters 5 and 6. NGF expression was quantified in the C7 dorsal root ganglion (DRG) 
of rats that received intra-articular [Sar9,Met(O2)11]-substance P-saporin (SSP-Sap) or 
control saporin (Blank-Sap) prior to facet joint distraction (FJD) or sham procedures 
(Chapter 5). At day seven after FJD or sham, four images of the C7 DRG were taken 
from each rat in the SSP-Sap+FJD, Blank-Sap+FJD, and SSP-Sap+sham groups for 
analysis by immunolabeling, with all exposure times standardized. Automated 
densitometry was performed using Matlab code (provided in Appendix A) that quantifies 
the NGF expression in the dorsal root ganglion (DRG) (Weisshaar et al., 2010). Each 
DRG image is digitally stored under the generalized file name 
Rat#_NGF_DRGside_20X_175ms_Section#.tif. The side distinction is either R (right) or 
L (left) for all sections. Because the injury is bilateral and behavioral responses are not 
different between the right and left sides, tissue responses to injury are also expected to 
not differ between right and left. As such, the distinction between right and left is only 
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made in this appendix for clarity in identifying the exact tissue location corresponding to 
each image.  
In separate studies, BDNF expression was quantified in the DRG and spinal cord 
after FJD or sham procedures (Chapter 6). For analysis of the C6 dorsal root ganglion 
sections on either day one or day seven after facet joint distraction (FJD) or sham, the 
mean signal intensity and cross-sectional area of the neurons were determined by 
manually outlining each neuron using ImageJ (NIH; Bethesda, MD). For each tissue 
section, the BDNF intensity was normalized to the average background intensity, which 
was calculated from the intensities of the BDNF-negative neurons, in order to determine 
the BDNF intensity ratio. BDNF-positive neurons were classified into seven neuronal 
sizes (from <200µm2 to >700µm2 in 100 µm2 bins) based on their soma area (Zhou et al., 
1999), and the average BDNF intensity ratio is reported for each bin size, as well as the 
overall average for all neurons for each section (All). Each DRG image is digitally stored 
with a generalized file name of BDNF_Rat#_Section#_C6L DRG_20x.tif. 
The C6 spinal cord was also assayed for BDNF expression on each of day one 
and day seven after FJD or sham. At least 6 images of the spinal dorsal horn were taken 
from each rat for analysis by immunolabeling, with all exposure times standardized. 
Automated densitometry was performed using Matlab code (provided in Appendix A) 
that quantifies the BDNF expression in a standardized pixel area (1360x510) 
corresponding to laminae I-IV in the dorsal horn (Weisshaar et al., 2010). Each spinal 
cord image is digitally stored under the generalized file name 
BDNF_Rat#_Section#_Side_20x_ExposureTime.tif. The side distinction is either RDH 
(right dorsal horn) or LDH (left dorsal horn) for all sections. As described above, the 
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distinction between right and left is only made for clarity in identifying the exact tissue 
location corresponding to each image because the injury is bilateral.   
In order to identify the cellular sources of spinal BDNF on days one and seven 
after FJD or sham procedures, spinal cord sections were immunolabeled for BDNF and 
one of the following: glial fibrillary acidic protein (GFAP; as a marker of astrocytes), 
microtubule associated protein-2 (MAP2; as a marker of neurons), or OX-42 (CD11b; as 
a marker of microglia). Digital copies of spinal cord sections labeled for each cell type 
are also stored under the previously listed general file name 
Label_Rat#_Section#_Side_20x_ExposureTime.tif with the exception that ‘Label’ is 
replaced with either ‘GFAP’, ‘MAP2’, or ‘OX42’, accordingly. Throughout this 
appendix, the FJD group refers to rats for which the C6 forceps was displaced by 2.5mm 
as recorded by the linear variable differential transducer (LVDT); the sham group 
underwent the same surgical procedure with no applied distraction (Kras et al., 2013c). 
The quantification of NGF expression in the C7 DRG seven days after FJD or 
sham with saporin treatment is reported in Table E.1. Figures E.1.A-E.1.C itemize each 
of the DRG sections in which NGF expression was quantified and reported in Table E.1. 
Tables E.2 and E.3 summarize the BDNF intensity ratio for the neuronal sizes described 
above in the C6 DRGs of both FJD and sham groups. Table E.2 details the intensity ratio 
on day one after surgical procedures, and Table E.3 reports the intensity ratio on day 
seven. Figures E.2 and E.3 present all of the DRG sections included in analyses for day 
one and day seven, respectively. Quantification of expression of BDNF in the C6 spinal 
cord one day after FJD or sham is provided in Table E.4.1. Because BDNF expression 
data were positively skewed, the raw data were log-transformed to achieve an 
270 
approximately normal distribution prior to statistical analysis, and the corresponding log-
transformed data are presented in Table E.4.2. The log-transformation applied was: 
log(10,000*ratio of positive pixels). Figures E.4.A and E.4.B illustrate all of the spinal 
cord sections included in the analyses presented in Tables E.4.1 and E.4.2. Tables E.5.1 
and E.5.2 summarize the raw BDNF expression and corresponding log-transformed data, 
respectively, at seven days following FJD or sham. The log-transformation applied was: 
log(100,000*ratio of positive pixels). Figures E.5.A and E.5.B present all of the spinal 
cord sections in which BDNF was quantified in Tables E.5.1 and E.5.2. Figure E.6 
provides representative spinal cord images that are double-labeled for BDNF and each 
cell type for all of the rats included in the day one BDNF quantification study. Similarly, 
the corresponding representative double-labeled spinal cord images on day seven after 
FJD or sham are included in Figure E.7. 
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Table E.1. Percentage of pixels positive for NGF in the C7 DRG seven days 
following FJD or sham with saporin treatment (Chapter 5). 
Group Rat Section Positive pixels (%) Group Rat Section 
Positive 
pixels (%) 
SSP-Sap+ 
FJD 
F136 
2L 2.30 
Blank-Sap+ 
FJD 
F143 
1L 4.39 
1R 0.23 4L 8.28 
2R 0.27 1R 6.44 
3R 2.64 3R 7.66 
F137 
1L 0.93 
F179 
2L 14.62 
3L 0.20 5L 12.27 
4L 0.15 2R 21.64 
4R 1.63 4R 18.45 
F138 
1L 0.00 
F182 
2L 6.99 
4L 0.26 3L 1.49 
1R 0.26 4R 3.30 
3R 0.66 5R 7.70 
F181 
3L 0.44 
F196 
1L 11.84 
1R 5.55 2L 9.99 
2R 0.10 1R 13.48 
5R 15.94 2R 17.09 
F185 
3L 1.94 
F197 
1L 0.00 
4L 6.43 2L 0.03 
5L 0.34 3L 5.00 
6L 0.17 4L 10.60 
F190 
5L 1.50 
SSP-Sap+ 
sham 
F188 
1L 1.26 
6L 3.02 4L 2.81 
3R 1.44 6L 0.14 
4R 3.61 3R 4.44 
F199 
3L 3.63 
F189 
5L 1.33 
2R 3.67 1R 0.24 
3R 0.00 3R 1.33 
4R 0.00 6R 2.23 
Blank-Sap+ 
FJD 
F140 
1L 0.30 
F198 
4L 0.00 
4L 1.54 5L 0.00 
1R 11.33 
F200 
5L 0.00 
2R 13.11 3R 5.28 
F141 
3L 3.24 5R 0.00 
5L 6.12 
  
4R 6.95 
6R 4.87 
Note: The section number refers to the position of the tissue section on each slide, beginning in the top left 
corner and proceeding in numerical order from top to bottom, then resuming at the top of the adjacent 
column to the right. The designators R and L indicate that the tissue section was from the right or left DRG, 
respectively. Tissue was generated by Christine L. Weisshaar, and the naming scheme for each rat reflects 
her records. 
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Figure E.1.A. NGF expression in the C7 DRG seven days after SSP-Sap+FJD (F136, 
F137, F138, F181, F185, 190, F199). For each rat, the sections presented correspond 
to those sections for which the percentage of NGF-positive pixels is summarized in 
Table E.1 with section number increasing from left to right. 
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Figure E.1.B. NGF expression in the C7 DRG seven days after Blank-Sap+FJD 
(F140, F141, F143, F179, F182, F196, F197). For each rat, the sections presented 
correspond to those sections for which the percentage of NGF-positive pixels is 
summarized in Table E.1 with section number increasing from left to right. 
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Figure E.1.C. NGF expression in the C7 DRG seven days after SSP-Sap+sham 
(F188, F189, F198, F200). For each rat, the sections presented correspond to those 
sections for which the percentage of NGF-positive pixels is summarized in Table E.1 
with section number increasing from left to right. 
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Table E.2. Average BDNF intensity ratio in neurons in the C6 DRG based on cell 
body area one day following painful FJD (Chapter 6). 
  
Neuronal cross-sectional area (µm2)   
Group Rat Section <200 200-299 
300-
399 
400-
499 
500-
599 
600-
699 >700 All 
FJD 
F13 
5 1.36 1.49 1.40 1.37 1.43 1.48 1.17 1.41 
7 1.49 1.42 1.44 1.48 1.35 1.20 1.24 1.42 
8 1.83 1.73 1.79 1.62 1.97     1.77 
9 1.75 1.79 1.59 1.52       1.68 
F20 
7 1.77 2.07 1.53 1.98 1.84 1.68   1.77 
8 1.55 1.71 1.73 1.43 1.57 1.70 1.77 1.57 
9 1.41 1.54 1.48 1.73 1.84 1.52   1.58 
10 1.39 1.57 1.53 1.51 1.81 1.50   1.55 
F21 
8 1.49 1.52 1.59 1.31 1.37 1.69 1.35 1.51 
10 1.82 1.67 1.66 1.75 1.44 1.65 1.79 1.70 
11 1.29 1.48 1.54 1.56 1.74 1.56 1.53 1.50 
sham 
F15 
10 2.40 1.94 1.72 1.86 1.70   1.39 1.90 
11 1.40 1.25 1.32 1.25 1.20 1.27   1.32 
12 1.42 1.34 1.29 1.31 1.27 1.31   1.33 
15 1.66 1.65 1.52 1.52 1.47 1.44 1.38 1.56 
F22 
5 1.48 1.43 1.42 1.40 1.36 1.13 1.58 1.41 
6 1.54 1.37 1.28 1.47 1.29 1.30 1.33 1.41 
9 1.59 1.55 1.67 1.29 1.36 1.33 1.53 1.47 
10 1.49 1.48 1.34 1.45 1.53 1.45   1.44 
11 1.53 1.50 1.66 1.53 1.58 1.50 1.19 1.55 
F23 
13 1.40 1.30 1.32 1.38 1.27 1.21 1.49 1.33 
14 1.26 1.28 1.28 1.27 1.25 1.11 1.16 1.26 
15 1.84 1.80 1.75 1.82 1.70 1.70 1.49 1.73 
Note: The section number refers to the position of the tissue section on each slide, beginning in the top left 
corner and proceeding in numerical order from top to bottom, then resuming at the top of the adjacent 
column to the right. Gray boxes indicate that no neurons of the given size were analyzed in that section. 
The ‘All’ column provides the overall average BDNF intensity ratio for all neurons in the corresponding 
section, calculated by combining all neurons included in each of the seven bin sizes into a single group and 
taking the overall average. Tissue was generated by Christine L. Weisshaar, and the naming scheme for 
each rat reflects her records. 
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Figure E.2. BDNF expression in the C6 DRG one day after facet joint distraction 
(F13, F20, F21) or sham (F15, F22, F23). Tissue was generated by Christine L. 
Weisshaar, and the naming scheme for each rat reflects her records. For each rat, the 
sections presented correspond to those sections for which the BDNF-ir intensity ratio 
is summarized in Table E.2 with section number increasing from left to right. 
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Table E.3. Average BDNF intensity ratio in neurons in the C6 DRG based on cell 
body area seven days following painful FJD (Chapter 6). 
  
Neuronal cross-sectional area (µm2)   
Group Rat Section <200 
200-
299 
300-
399 
400-
499 
500-
599 
600-
699 >700 All 
FJD 
47 
2 1.54 1.55 1.55 1.61 1.55   1.31 1.53 
3 1.56 1.40 1.55 1.63 1.76 1.59 1.26 1.52 
4 1.90 1.88 2.19 1.96 1.95 3.43   2.01 
5 1.73 1.83 1.83 2.01 1.98 1.99 2.09 1.87 
48 
1 1.68 1.73 1.68 1.53 1.65 1.93 1.86 1.71 
2 1.45 1.52 1.34 1.65 1.58 1.48 1.75 1.51 
4 1.38 1.42 1.42 1.52 1.47 1.52   1.40 
6 1.91 1.73 1.82 1.74 1.40 1.45 1.19 1.73 
49 
3 1.42 1.44 1.45 1.47 1.47 1.46 1.58 1.45 
4 1.39 1.52 1.70 1.70 1.53 1.29 1.62 1.51 
5 1.26 1.41 1.54 1.45 1.58   1.34 1.36 
6 1.34 1.29 1.20 1.32 1.27 1.58 1.57 1.31 
sham 
55 
4 1.36 1.37 1.37 1.37 1.38 1.30 1.16 1.36 
6 1.24 1.34 1.34 1.27 1.15 1.27 1.40 1.27 
7 1.64 1.56 1.42 1.46 1.66 1.36 1.66 1.56 
8 1.39 1.48 1.44 1.47 1.35 1.39   1.45 
56 
8 1.35 1.39 1.35 1.37 1.26   1.09 1.36 
9 1.31 1.35 1.44 1.35 1.36 1.47 1.52 1.37 
11 1.34 1.37 1.57 1.50 1.40 1.35 1.50 1.42 
12 1.29 1.39 1.39 1.38   1.40   1.37 
60 
5 1.43 1.46 1.43 1.54 1.59     1.50 
6 1.47 1.52 1.56 1.48 1.49 1.67 1.44 1.52 
7 1.41 1.52 1.52 1.46 1.52 1.49 1.56 1.49 
8 1.41 1.36 1.54 1.55 1.40 1.24   1.43 
Note: As noted in Table E.2, the section number refers to the position of the tissue section on each slide, 
beginning in the top left corner and proceeding in numerical order from top to bottom, then resuming at the 
top of the adjacent column to the right. Gray boxes indicate that no neurons of the given size were analyzed 
in that section. The ‘All’ column provides the overall average BDNF intensity ratio for all neurons in the 
corresponding section, calculated by combining all neurons included in each of the seven bin sizes into a 
single group and taking the overall average. 
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Figure E.3. BDNF expression in the C6 DRG seven days after facet joint distraction 
(47, 48, 49) or sham (55, 56, 60). For each rat, the sections presented correspond to 
those sections for which the BDNF-ir intensity ratio is summarized in Table E.3 with 
section number increasing from left to right. 
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Table E.4.1. Ratio of pixels positive for BDNF in laminae I-IV in the dorsal horn one 
day following FJD or sham (Chapter 6). 
  
Section 
Group Rat 1L 1R 2L 2R 3L 3R 4L 4R 5L 5R 6L 6R 
FJD 
F13 0.005 0.000 0.009 0.006 0.003 0.003 0.010 0.006 0.015 0.079 0.005 0.007 
F19 0.005 0.000 0.028 0.013 0.054 0.019 0.174 0.098 0.005 0.040 0.013 0.005 
F20   0.000     0.029   0.103 0.001 0.008   0.005   
F21 0.013   0.033 0.038 0.147 0.049 0.001   0.002 0.004 0.020 0.017 
F24 0.001   0.120 0.025 0.003 0.008 0.002 0.016 0.001 0.009 0.023   
sham 
F15   0.134 0.119   0.009 0.012 0.101 0.003 0.052 0.116   0.002 
F17 0.014 0.009 0.014 0.014 0.001 0.002 0.002 0.006 0.004 0.007 0.001 0.002 
F22 0.002 0.000 0.001 0.008 0.027 0.009 0.001 0.000   0.061   0.018 
Note: For each rat, six sections were analyzed, and both the right (R) and left (L) dorsal horns were 
included in analysis because of the assumption of a symmetric joint injury. Gray boxes indicate tissue 
sections that were excluded from analysis. All tissue was generated by Christine L. Weisshaar, and the 
naming scheme for each rat reflects her records. 
 
Table E.4.2. Log-transformation of the ratio of pixels positive for BDNF in laminae 
I-IV in the dorsal horn one day following FJD or sham (Chapter 6). 
  
Section 
Group Rat 1L 1R 2L 2R 3L 3R 4L 4R 5L 5R 6L 6R 
FJD 
F13 1.66 0.41 1.97 1.77 1.48 1.42 2.01 1.78 2.18 2.90 1.72 1.86 
F19 1.70 0.58 2.45 2.12 2.73 2.28 3.24 2.99 1.70 2.61 2.11 1.73 
F20   0.07     2.47   3.01 1.11 1.90   1.72   
F21 2.10   2.51 2.59 3.17 2.69 0.75   1.33 1.59 2.30 2.23 
F24 0.86   3.08 2.39 1.48 1.88 1.22 2.20 1.03 1.97 2.36   
sham 
F15   3.13 3.08   1.95 2.10 3.00 1.45 2.72 3.06   1.32 
F17 2.14 1.96 2.16 2.13 1.05 1.39 1.29 1.80 1.61 1.84 1.13 1.22 
F22 1.26 0.59 0.96 1.88 2.42 1.96 0.90 0.31   2.78   2.26 
Note: Because BDNF expression data were positively skewed, the raw data were log-transformed to 
achieve an approximately normal distribution prior to statistical analysis. The log-transformation applied 
was: log(10,000*ratio of positive pixels). All tissue was generated by Christine L. Weisshaar, and the 
naming scheme for each rat reflects her records. 
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Figure E.4.A. BDNF expression in the C6 spinal cord one day after FJD (F13, F19, 
F20, F21, F24). Images are arranged in the order in which they appear in Table E.4.1. 
Six sections were analyzed per rat. For each rat, images from section 1 (left, right) and 
section 2 (left right) are presented in the first row. Sections 3 and 4 (second row) and 5 
and 6 (third row) are also presented. Blank spaces represent tissue that was damaged 
and was not included in analyses. All tissue was generated by Christine L. Weisshaar, 
and the naming scheme for each rat reflects her records. 
F1
3 
F1
9 
F2
0 
F2
1 
F2
4 
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Figure E.4.B. BDNF expression in the C6 spinal cord one day after sham (F15, F17, 
F22). Images are arranged in the order in which they appear in Table E.4.1 as 
described in Figure E.4.A. All tissue was generated by Christine L. Weisshaar, and the 
naming scheme for each rat reflects her records. 
F1
5 
F1
7 
F2
2 
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Table E.5.1. Ratio of pixels positive for BDNF in laminae I-IV in the dorsal horn 
seven days following FJD or sham (Chapter 6). 
  
Section 
Group Rat 1L 1R 2L 2R 3L 3R 4L 4R 5L 5R 6L 6R 
FJD 
47 0.003 0.002 0.003 0.020 0.082   0.015 0.071 0.006 0.162 0.029 0.030 
48     0.001 0.001 0.037 0.001   0.002 0.006 0.013 0.033   
49     0.002 0.001 0.001 0.002     0.001 0.011 0.001   
52   0.001 0.008 0.000 0.009   0.003 0.022 0.007 0.068 0.002 0.003 
53       0.001       0.086 0.005 0.008 0.001 0.001 
54 0.020 0.046     0.064     0.145 0.073 0.096   0.093 
sham 
50 0.005   0.007 0.001 0.008 0.001 0.002 0.001 0.003 0.002   0.001 
55 0.018 0.041 0.005 0.008 0.003 0.002 0.013     0.017 0.016 0.005 
56 0.015   0.003 0.061 0.009   0.009 0.004   0.005 0.064 0.023 
60 0.008 0.074 0.000 0.005 0.010 0.000 0.000 0.001 0.004 0.002 0.000 0.000 
Note: For each rat, six sections were analyzed, and both the right (R) and left (L) dorsal horns were 
included in analysis because of the assumption of a symmetric joint injury. Gray boxes indicate tissue 
sections that were excluded from analysis. 
 
Table E.5.2. Log-transformation of the ratio of pixels positive for BDNF in laminae 
I-IV in the dorsal horn seven days following FJD or sham (Chapter 6). 
  
Section 
Group Rat 1L 1R 2L 2R 3L 3R 4L 4R 5L 5R 6L 6R 
FJD 
47 2.48 2.26 2.50 3.31 3.91   3.16 3.85 2.79 4.21 3.46 3.47 
48     1.73 1.99 3.56 2.12   2.39 2.79 3.12 3.52   
49     2.39 2.03 2.05 2.29     1.90 3.04 1.79   
52   1.82 2.88 1.69 2.94   2.45 3.35 2.83 3.83 2.28 2.43 
53       2.02       3.94 2.70 2.91 1.98 2.11 
54 3.30 3.66     3.81     4.16 3.86 3.98   3.97 
sham 
50 2.71   2.87 2.09 2.90 2.05 2.30 2.08 2.47 2.23   1.79 
55 3.26 3.61 2.69 2.92 2.43 2.39 3.12     3.22 3.20 2.70 
56 3.16   2.43 3.78 2.97   2.93 2.57   2.67 3.81 3.36 
60 2.92 3.87 1.66 2.74 3.00 1.51 1.64 2.01 2.60 2.28 1.47 0.95 
Note: Because BDNF expression data were positively skewed, the raw data were log-transformed to 
achieve an approximately normal distribution prior to statistical analysis. The log-transformation applied 
was: log(100,000*ratio of positive pixels). 
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Figure E.5.A. BDNF expression in the C6 spinal cord seven days after FJD (47, 48, 
49, 52, 53, 54). Images are arranged in the order in which they appear in Table E.5.1 
and follow the pattern described in Figure E.4. 
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Figure E.5.B. BDNF expression in the C6 spinal cord seven days after sham (50, 55, 
56, 60). Images are arranged in the order in which they appear in Table E.5.1 and 
follow the pattern described in Figure E.4. 
50
 
55
 
56
 
60
 
285 
 
 
  
MAP2 OX42 GFAP 
F1
3 
F1
9 
F2
0 
F2
1 
F2
4 
F1
7 
F2
2 
F1
5 
MAP2 OX42 GFAP 
Figure E.6. Representative co-labeling of BDNF (red) with MAP2, OX-42, and 
GFAP (Green) one day after FJD or sham. All tissue was generated by Christine L. 
Weisshaar, and the naming scheme for each rat reflects her records. 
FJD sham 
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Figure E.7. Representative co-labeling of BDNF (red) with MAP2, OX-42, and 
GFAP (Green) seven days after FJD or sham. 
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Appendix F 
Quantification of Proteins in the Facet Joint and 
Spinal Cord Using Western Blot 
 
This appendix details the levels of protein expression determined using Western 
blot for individual rats included in the studies in Chapters 5 and 6. Specifically, levels of 
nerve growth factor (NGF) protein were quantified in the soft tissues of the C6/C7 facet 
joint at day one in the NGF characterization study in Chapter 5. In separate studies, spinal 
cord was assayed at day seven to assess activation of extracellular signal-regulated kinase 
(ERK) after facet joint distraction (FJD) with spinal sequestration of brain-derived 
neurotrophic factor (BDNF) in Chapter 6. For each blot, a loading control was included 
in addition to the experimental and study control groups. Levels of the target protein for 
each study are reported relative to expression of a housekeeping protein and are 
normalized to the loading control. The FJD group refers to rats for which the C6 forceps 
was displaced by 2.5mm as recorded by a linear variable differential transducer (LVDT). 
The sham group underwent the same surgical procedure with no applied distraction. 
 Table F.1 lists individual levels of NGF in the soft tissues of the C6/C7 facet 
joint, including the capsular ligament and synovial tissue, one day after FJD or sham 
procedures (Chapter 5). Table F.2 summarizes levels of phosphorylated ERK (pERK1/2) 
relative to total ERK in the spinal cord seven days after FJD with intrathecal trkB-Fc 
(trkB-Fc) or non-specific IgG-Fc (vehicle) injection that was given on day five (Chapter 
6). 
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Table F.1. NGF protein in the soft tissues of the C6/C7 facet joint one day after its 
painful distraction (Chapter 5). 
Group Rat NGF (28kDa) relative to β-tubulin (normalized to loading control) 
FJD 
381 2.98 
382 4.18 
408 4.39 
409 1.26 
410 5.71 
sham 
380 2.34 
383 2.81 
384 0.87 
407 2.12 
411 1.51 
 
Table F.2. Phosphorylated ERK (pERK) levels in the spinal cord after facet joint 
distraction and intrathecal trkB-Fc injection at day 5 (Chapter 6). 
Group Rat 
pERK1 relative to total ERK1 
(44kDa) 
 (normalized to loading control) 
pERK2 relative to total ERK2 
(42kDa)  
(normalized to loading control) 
trkB-Fc 
195 1.68 1.60 
196 1.86 1.76 
197 1.64 1.52 
204 1.42 1.58 
206 1.59 1.52 
209 1.19 0.88 
vehicle 
203 1.55 1.67 
205 2.00 1.85 
207 1.89 1.73 
246 2.18 2.07 
247 2.49 2.02 
248 2.18 1.89 
249 1.98 1.83 
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Appendix G 
Quantification of Neuron Firing in the Dorsal 
Horn and Thalamus 
 
 
This appendix summarizes the number of action potentials evoked during 
stimulation of the forepaw for individual spinal and thalamic neuronal recordings in the 
studies included in Chapters 5 and 7. All rats are separated into their respective 
experimental groups for the electrophysiology studies. For all tables, the neurons are 
numbered according to the rat from which they were recorded (Rat) and the order in 
which each neuron was identified within that rat’s testing session (Neuron). Action 
potentials evoked by ten light brush strokes (Brush), five consecutive one second 
applications of each von Frey filament (vF), and a ten second pinch (Pinch) were 
counted; the total number of evoked action potentials for each stimulus is detailed in the 
tables.  
All neurons were classified as wide dynamic range (WDR) or low threshold 
mechanoreceptive (LTM). For all neurons recorded in the spinal cord (Chapter 5), the 
electrode depth (µm) relative to the pial surface is also provided. The detailed protocol 
for electrophysiological recordings in the spinal cord is presented in Chapter 5. For all 
neurons recorded in the thalamus (Chapter 7), the electrode coordinates are provided for 
the left lateral distance from the midline (lateral, mm), the rostrocaudal distance from the 
intersection of the sagittal and coronal sutures (distance from Bregma, mm) with the 
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negative direction caudal to Bregma, and the depth relative to the pial surface (depth, 
µm), as presented previously (Syré et al., 2014). The protocol for electrophysiological 
recordings in the thalamus is detailed in Chapter 7. The facet joint distraction (FJD) 
group refers to rats for which the C6 forceps was displaced by 2.5mm as recorded by a 
linear variable differential transducer (LVDT) (See Chapter 3 for details). The sham 
group underwent the same surgical procedure with no applied distraction. 
Table G.1 through Table G.6 detail the neuronal firing data for the studies 
included in Chapter 5. Table G.1 summarizes the evoked action potentials for rats that 
received intra-articular nerve growth factor (NGF) or sterile phosphate-buffered saline 
(vehicle) in the bilateral C6/C7 facet joints. For rats in which peptidergic signaling in 
joint afferents was disrupted prior to NGF (SSP-Sap+NGF) or vehicle (SSP-Sap+veh) 
facet joint injection, the evoked firing is detailed in Table G.2. Similarly, Table G.3 
reports the evoked spikes for rats in which non-peptidergic joint afferents were ablated 
prior to NGF (IB4-Sap+NGF) or vehicle (IB4-Sap+veh) joint injections. Evoked firing 
quantified one day after facet joint distraction with an intra-articular anti-NGF antibody 
(FJD+anti-NGF) or a non-specific IgG (FJD+veh) facet joint injection are summarized in 
Table G.4. Rats that underwent sham procedures with the vehicle injection (sham+veh) 
are also included in Table G.4. Table G.5 details the action potentials evoked seven days 
after surgical procedures from additional rats in those same groups (FJD+anti-NGF, 
FJD+veh, sham+veh) as well as a sham group with an intra-articular anti-NGF injection 
(sham+anti-NGF). Additional rats underwent FJD and received intra-articular anti-NGF 
on day one after FJD (FJD+anti-NGFD1). For those rats, the spikes evoked seven days 
after the joint distraction are reported in Table G.6.  
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Table G.7 summarizes quantification of the evoked firing in thalamic neurons 
after FJD or sham procedures on day seven. Table G.8 details thalamic neuronal spikes 
on day seven in rats that were given intra-articular IB4-saporin to ablate non-peptidergic 
joint afferents prior to FJD (IB4-Sap+FJD) or sham (IB4-Sap+sham) procedures (see 
Chapter 7 for further details).  
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Table G.1. Spinal neuronal firing counts at one day following intra-articular NGF 
application (Chapter 5). 
G
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Pi
n
c
h 
Br
u
s
h 1.4g 
vF 
4g 
vF 
10g 
vF 
26g 
vF 
NGF 
252 
2 500 LTM 44 12 0 0 13 29 
3 830 WDR 35 29 13 33 68 68 
4 550 WDR 4 7 1 2 11 25 
253 
2 610 WDR 69 24 6 21 67 47 
3 150 WDR 17 12 10 11 36 39 
4 500 WDR 139 73 54 97 195 238 
5 510 WDR 59 3 2 5 56 84 
7 1000 WDR 50 4 14 21 39 61 
255 
1 150 LTM 44 34 28 56 87 73 
3 950 WDR 67 20 49 89 79 122 
4 830 WDR 31 26 79 75 76 97 
6 820 WDR 74 10 18 22 30 62 
7 800 WDR 109 85 15 14 44 72 
8 780 WDR 69 24 57 19 32 87 
256 
1 500 WDR 103 89 65 70 53 49 
2 920 WDR 25 17 8 91 112 85 
3 800 WDR 103 15 18 20 87 174 
4 1000 WDR 99 13 7 7 30 121 
5 840 WDR 279 29 6 13 45 90 
6 740 WDR 91 71 41 55 104 95 
8 800 WDR 151 38 18 65 80 148 
257 
1 650 WDR 323 17 3 6 43 84 
3 1010 WDR 83 32 11 7 15 62 
4 700 WDR 155 4 46 75 68 82 
5 870 WDR 278 44 16 30 88 273 
6 1000 WDR 125 31 42 61 65 78 
7 1090 WDR 145 41 10 38 69 95 
278 
1 160 LTM 87 54 77 257 302 253 
2 670 WDR 219 9 1 38 82 107 
3 180 WDR 75 48 89 108 144 129 
4 590 WDR 117 56 30 89 87 145 
5 600 WDR 101 17 28 77 85 110 
6 600 WDR 128 43 37 57 101 85 
7 700 WDR 83 15 16 69 59 71 
8 650 WDR 226 86 107 159 208 236 
282 
3 300 WDR 34 42 83 96 83 91 
4 650 WDR 132 86 49 142 157 217 
5 580 WDR 169 47 39 102 69 81 
6_1 860 WDR 372 0 1 2 17 190 
6_2 860 WDR 206 3 2 5 205 226 
7 630 WDR 387 32 14 9 35 133 
8 740 WDR 127 49 23 43 88 138 
9 770 WDR 72 8 20 46 88 98 
10 500 WDR 43 40 35 99 192 196 
Note: Table continued on next page. 
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h 1.4g 
vF 
4g 
vF 
10g 
vF 
26g 
vF 
vehicle 
265 
1 600 WDR 39 20 4 10 38 61 
2 550 WDR 40 12 17 25 41 45 
3 870 WDR 57 51 18 59 99 114 
4 880 WDR 62 15 1 5 85 89 
5 700 WDR 35 23 25 29 28 52 
6 800 LTM 4 29 2 4 14 36 
7 880 LTM 50 22 15 15 34 76 
8 510 WDR 284 23 6 8 24 62 
9 540 WDR 120 22 27 44 124 130 
266 
1 800 LTM 38 45 8 14 25 54 
2 660 LTM 21 17 4 96 30 21 
3 500 WDR 18 22 15 7 52 45 
4 480 WDR 33 7 3 48 85 71 
5 720 WDR 42 22 16 40 73 109 
7 580 LTM 10 13 3 0 12 30 
8 530 WDR 60 9 6 5 40 69 
267 
1 900 LTM 7 19 4 4 2 33 
2 200 LTM 5 10 4 1 19 53 
3 650 WDR 61 85 13 22 50 75 
4 600 WDR 81 35 14 20 35 62 
5 670 WDR 53 39 16 24 34 88 
6 630 WDR 66 33 5 18 57 69 
7 660 WDR 129 34 8 46 94 75 
8 230 LTM 4 1 0 0 1 110 
9 900 WDR 42 1 0 0 15 63 
10 1010 WDR 37 28 11 11 43 51 
268 
1 710 WDR 31 13 2 5 25 65 
2 600 WDR 141 9 2 32 76 71 
3 910 WDR 55 6 1 8 62 119 
5 940 LTM 12 11 20 39 70 94 
6 730 WDR 26 13 28 24 46 43 
7 430 WDR 106 37 19 24 60 80 
269 
1 570 LTM 24 21 14 26 29 38 
2 840 WDR 35 0 0 3 43 75 
3 740 WDR 30 24 93 64 71 75 
4 680 WDR 160 24 15 31 62 92 
5 1030 WDR 46 9 10 9 36 36 
6 450 WDR 44 25 12 31 32 119 
7 620 WDR 113 21 58 120 85 101 
9 660 WDR 56 15 31 39 47 75 
10 910 LTM 0 2 1 4 45 31 
281 
1_1 550 WDR 304 45 0 12 55 150 
1_2 550 WDR 77 25 6 15 66 158 
2 660 LTM 29 10 82 88 193 204 
3 650 WDR 58 10 6 131 168 106 
4 760 WDR 186 10 9 33 117 130 
5 470 WDR 56 21 3 64 168 157 
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Table G.2. Spinal neuronal firing counts at one day following intra-articular NGF 
application in SSP-saporin treated rats (Chapter 5). 
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h  1.4g 
vF 
4g 
vF 
10g 
vF 
26g 
vF 
SSP-Sap+ 
NGF 
391 
1 730 WDR 42 30 14 35 41 99 
2 650 WDR 111 40 22 45 129 196 
3 670 WDR 7 8 7 6 15 54 
4 590 WDR 92 57 30 34 66 110 
5_1 740 WDR 119 23 11 22 51 95 
5_2 740 LTM 12 15 19 18 18 24 
6 620 WDR 166 32 38 53 99 123 
7 360 WDR 219 55 19 87 199 207 
8_1 630 WDR 19 15 5 13 18 48 
8_2 630 WDR 35 9 1 7 29 43 
9 710 WDR 45 101 31 59 96 95 
10_1 810 WDR 14 0 1 4 26 48 
10_2 810 WDR 110 29 22 55 95 145 
392 
1 540 WDR 91 8 24 44 91 96 
2 890 WDR 26 42 23 36 50 79 
3 630 WDR 165 37 12 14 22 48 
4 500 WDR 161 38 34 44 70 92 
5_1 700 LTM 98 2 5 13 6 9 
5_2 700 WDR 17 50 29 40 58 64 
6 840 WDR 128 0 0 1 38 262 
395 
1 250 WDR 9 17 7 11 14 25 
2 940 WDR 37 37 15 37 78 86 
3 710 WDR 129 89 36 41 129 175 
4 220 WDR 88 47 9 6 22 86 
6_1 570 WDR 363 45 25 30 60 163 
6_2 570 WDR 210 63 56 105 101 166 
396 
1 590 WDR 25 12 20 32 57 58 
3 870 LTM 5 40 29 41 24 15 
4 550 WDR 122 20 11 12 19 61 
5 770 WDR 135 39 10 73 122 130 
6 800 WDR 56 9 0 44 94 120 
7 720 WDR 55 55 15 24 39 101 
8 450 LTM 139 146 73 55 83 97 
10 800 WDR 4 52 19 1 12 66 
Note: Table continued on next page. 
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4g 
vF 
10g 
vF 
26g 
vF 
SSP-Sap+ 
veh 
393 
1 430 WDR 19 27 6 17 33 60 
2 670 WDR 24 19 7 8 50 72 
3 710 WDR 282 92 119 189 238 297 
7 470 LTM 284 48 53 83 106 80 
8 700 LTM 36 13 14 40 33 32 
9 430 WDR 53 44 25 27 59 61 
10 800 LTM 348 13 73 45 56 102 
394 
1 430 LTM 95 28 45 73 35 90 
2 720 WDR 67 2 0 62 74 169 
3 850 WDR 159 67 37 52 225 205 
4 600 WDR 80 48 29 36 56 84 
5 400 WDR 91 67 12 34 85 107 
6 930 WDR 4 13 1 8 47 93 
7 840 WDR 197 0 2 12 88 159 
397 
1 750 LTM 248 89 96 133 170 153 
2_1 620 WDR 41 8 1 4 8 34 
2_2 620 WDR 32 11 1 6 25 58 
3 620 WDR 87 37 10 15 37 63 
4 700 LTM 112 130 85 96 63 161 
5 940 WDR 27 11 3 27 126 230 
6 1000 WDR 127 2 0 0 5 71 
7 500 WDR 197 26 18 40 119 158 
398 
1 910 WDR 89 7 3 5 17 63 
2 880 LTM 12 25 18 18 36 35 
3 900 WDR 103 27 18 49 71 100 
4 650 WDR 136 21 24 79 140 134 
5 750 WDR 105 16 15 19 21 60 
6 800 WDR 58 42 1 5 18 34 
7 750 WDR 133 6 0 5 38 196 
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Table G.3. Spinal neuronal firing counts at one day following intra-articular NGF 
application in IB4-saporin treated rats (Chapter 5). 
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vF 
26g 
vF 
IB4-Sap+ 
NGF 
371 
1 940 WDR 19 21 21 26 37 81 
2 900 LTM 146 199 167 211 259 278 
3 800 WDR 44 56 10 26 83 214 
4 880 WDR 14 19 10 13 94 166 
5 560 WDR 211 29 43 81 125 119 
6 850 WDR 179 64 44 61 79 142 
7 780 WDR 67 7 15 43 258 251 
8 1100 WDR 7 29 6 10 32 168 
9 820 WDR 30 9 70 55 122 186 
372 
2 760 WDR 124 6 10 25 286 322 
3 770 WDR 49 0 0 2 74 184 
4 1000 WDR 21 9 10 20 65 164 
5 830 WDR 313 36 19 74 187 323 
6 860 WDR 92 12 20 39 75 189 
7 940 WDR 6 13 6 4 22 60 
8 900 WDR 20 36 17 30 56 81 
373 
1_1 730 WDR 260 31 26 83 162 218 
1_2 730 WDR 65 22 3 10 51 114 
3 230 WDR 15 16 6 161 226 277 
4 690 WDR 39 42 9 7 30 61 
5 860 WDR 91 50 10 31 49 139 
6 170 LTM 36 30 6 51 87 51 
7 760 LTM 62 73 99 93 87 125 
8 880 WDR 23 1 0 5 46 81 
9 740 WDR 113 0 3 18 41 144 
10 800 WDR 15 15 19 57 201 219 
11 900 WDR 260 31 17 32 206 266 
12 880 WDR 82 34 3 6 24 128 
399 
1 710 LTM 468 65 75 190 196 180 
2 680 LTM 203 170 200 169 178 222 
3 610 WDR 93 20 39 45 129 108 
4 830 WDR 100 7 0 7 57 98 
5 890 WDR 63 5 5 47 80 108 
6 690 LTM 89 35 117 147 133 144 
7 670 LTM 56 15 23 113 141 150 
9 870 WDR 391 30 1 18 71 308 
400 
1 600 LTM 252 32 112 134 178 138 
2 700 LTM 6 28 29 32 59 48 
3 750 WDR 221 15 13 28 139 224 
4 740 WDR 320 24 23 121 179 282 
5 530 LTM 82 13 42 95 94 141 
6 770 WDR 213 51 36 114 271 320 
Note: Table continued on next page. 
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402 
1 650 LTM 52 29 30 70 66 78 
2 430 LTM 120 33 107 96 74 97 
3_1 810 WDR 24 15 1 6 11 32 
3_2 810 WDR 120 45 33 74 157 164 
4 500 WDR 4 24 7 16 25 24 
5 700 WDR 62 38 58 171 230 285 
6 910 LTM 10 52 51 34 32 56 
7 950 WDR 168 16 7 15 76 132 
9 760 LTM 206 43 120 196 247 181 
10 900 WDR 11 29 5 19 44 41 
403 
1 760 LTM 6 16 12 13 25 12 
2 710 LTM 85 35 98 117 76 102 
3 720 LTM 30 51 33 67 53 59 
4 500 WDR 93 63 22 51 132 171 
5 430 WDR 45 46 22 28 51 50 
6_1 700 WDR 135 0 3 4 2 25 
6_2 700 WDR 169 8 3 9 22 74 
6_3 700 WDR 115 11 5 39 66 74 
7 740 LTM 46 36 40 17 48 65 
8 810 WDR 61 3 7 33 49 57 
10 890 LTM 54 35 16 38 42 47 
11 490 LTM 16 35 14 18 26 27 
404 
1_1 510 WDR 66 67 30 28 65 75 
1_2 510 LTM 28 67 26 75 50 31 
2 780 WDR 27 15 17 31 52 48 
3 420 LTM 28 51 50 76 80 46 
4 820 LTM 5 34 9 26 38 30 
5 850 WDR 245 15 36 122 245 237 
7 290 WDR 220 57 125 167 287 267 
405 
1 620 WDR 53 32 4 47 114 131 
2 700 WDR 35 14 8 16 28 35 
3 550 LTM 292 17 104 203 172 163 
4 690 WDR 57 51 6 24 47 66 
5 770 LTM 63 21 35 148 146 155 
6 950 WDR 564 51 31 137 201 232 
7 890 WDR 284 23 20 22 39 106 
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Table G.4. Spinal neuronal firing counts in rats at one day following facet joint 
distraction and immediate intra-articular anti-NGF application (Chapter 5). 
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FJD+veh 
305 
1 410 LTM 4 2 14 79 73 231 
2 840 WDR 13 1 1 34 42 49 
3 630 WDR 54 5 39 227 288 228 
4 880 WDR 55 48 9 6 24 108 
309 
1 910 WDR 42 13 6 20 84 91 
2_1 780 WDR 65 10 3 4 63 90 
2_2 780 WDR 249 97 82 156 261 355 
3 1000 WDR 111 22 16 23 47 211 
4 330 WDR 55 50 8 30 50 104 
5_1 260 WDR 68 6 72 69 80 77 
5_2 260 WDR 46 17 60 70 66 63 
6 700 WDR 239 11 66 169 221 248 
7 850 WDR 16 1 0 2 59 55 
8 640 WDR 87 50 18 58 105 133 
9 850 WDR 45 38 31 78 80 89 
10 760 WDR 186 17 15 12 54 198 
356 
1 640 WDR 361 58 25 100 256 297 
2 810 WDR 166 50 32 33 94 131 
3 690 LTM 18 50 23 56 49 52 
4 890 WDR 169 31 40 61 140 101 
5 450 WDR 35 67 103 20 24 18 
6 870 WDR 89 0 3 14 215 567 
7 450 LTM 10 7 3 5 32 95 
8 800 WDR 98 16 15 16 121 169 
9 950 WDR 264 21 7 18 185 267 
10_1 800 LTM 15 75 61 190 170 182 
10_2 800 WDR 100 25 36 42 99 114 
357 
1 910 WDR 12 3 0 3 4 69 
2 690 WDR 119 42 41 98 108 169 
3 660 WDR 253 96 78 228 346 393 
4 150 LTM 13 12 1 25 141 123 
5 750 WDR 44 18 10 13 112 175 
6 690 WDR 37 51 48 44 67 87 
7 940 LTM 49 24 24 43 94 210 
8 820 WDR 61 19 12 33 69 316 
9_1 700 WDR 40 17 8 12 34 136 
9_2 700 WDR 66 32 68 85 101 59 
Note: Table continued on next page. 
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306 
1 740 WDR 28 14 3 3 7 123 
2 820 WDR 241 24 43 83 119 157 
3 790 WDR 133 29 35 145 124 102 
4 700 WDR 62 80 25 50 61 97 
5 410 WDR 26 17 13 16 26 41 
6_1 590 WDR 26 24 14 22 42 44 
6_2 530 WDR 49 23 19 24 41 68 
308 
1 620 WDR 86 35 27 38 101 176 
2 640 WDR 132 36 6 17 72 148 
3 650 LTM 0 20 0 0 1 54 
353 
1 860 LTM 22 8 6 20 55 97 
2 880 LTM 5 0 0 0 3 6 
3 920 LTM 5 9 5 3 19 39 
4 140 LTM 16 1 0 30 114 129 
5 500 WDR 32 31 59 136 84 69 
6 910 WDR 12 42 24 7 29 80 
7 670 WDR 32 57 56 49 119 84 
8 600 LTM 20 40 33 58 176 204 
354 
1 590 LTM 46 47 20 41 69 191 
2 750 WDR 70 28 15 11 95 66 
3 620 LTM 20 16 20 62 171 136 
5 850 LTM 31 10 10 18 21 42 
6 970 LTM 48 20 16 22 44 111 
355 
1 80 LTM 2 16 3 1 27 117 
2 770 WDR 50 15 9 18 53 136 
4_1 730 LTM 33 11 7 26 94 119 
4_2 730 WDR 59 0 10 27 144 169 
5 700 WDR 230 17 18 48 117 438 
6 800 WDR 33 19 19 22 30 39 
Note: Table continued on next page. 
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365 
1 870 LTM 14 38 11 15 38 123 
2_1 880 WDR 20 21 9 24 32 50 
2_2 880 WDR 326 14 10 21 98 83 
4 1050 LTM 20 36 20 26 38 112 
5 950 WDR 9 28 26 26 31 21 
6 950 LTM 15 25 10 13 14 78 
7 790 WDR 37 25 20 21 30 89 
8 630 LTM 21 26 16 13 23 63 
9 650 WDR 36 13 27 97 130 124 
366 
1 820 WDR 24 15 16 38 50 51 
2 500 WDR 0 10 14 37 27 70 
3 900 WDR 46 3 10 12 99 71 
4 980 WDR 30 16 24 88 228 141 
5 950 LTM 10 11 4 6 13 21 
6 900 LTM 9 1 0 2 31 164 
7 930 WDR 15 24 14 31 48 47 
8 910 LTM 9 17 1 4 19 24 
367 
1 840 WDR 252 34 18 93 168 211 
3 300 WDR 10 18 9 10 28 81 
5 830 LTM 33 22 1 2 6 38 
6 860 LTM 16 10 5 7 65 75 
7 900 WDR 119 0 0 35 180 221 
8 700 WDR 10 26 27 61 40 41 
368 
1 860 WDR 32 52 29 48 40 62 
2 670 WDR 27 26 14 45 42 48 
3 800 WDR 117 31 68 74 82 114 
4 450 LTM 7 4 3 10 56 85 
5 590 WDR 82 44 81 89 151 214 
6 850 LTM 0 36 9 27 58 81 
8 500 WDR 16 36 9 17 24 38 
9 900 WDR 73 13 11 17 32 81 
10 950 WDR 62 20 11 8 39 148 
370 
1 560 WDR 126 29 118 237 256 230 
2 700 WDR 49 19 29 86 61 63 
3_1 900 LTM 3 10 4 9 34 70 
3_2 900 WDR 61 25 17 40 54 88 
4 980 LTM 24 31 23 27 70 107 
5 780 LTM 31 26 7 6 36 77 
6 750 LTM 23 9 0 6 9 22 
8 760 LTM 6 10 8 13 15 18 
9 700 WDR 15 4 8 31 138 178 
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Table G.5. Spinal neuronal firing counts in rats at seven days following facet joint 
distraction and immediate intra-articular anti-NGF application (Chapter 5). 
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FJD+veh 
272 
1 440 WDR 105 54 13 70 145 146 
3 650 WDR 325 5 13 39 259 244 
4 790 WDR 33 31 11 7 68 120 
5 570 WDR 57 64 76 74 86 98 
274 
1 500 WDR 251 89 39 104 192 159 
2 620 WDR 61 35 8 12 49 111 
3 560 WDR 135 129 98 180 237 169 
4 360 WDR 350 44 39 156 139 145 
5 440 WDR 64 41 55 61 92 160 
6 530 WDR 72 81 14 23 78 155 
7 310 WDR 195 34 72 322 419 381 
8 70 WDR 35 3 12 57 94 68 
275 
1_1 450 WDR 182 6 4 8 177 219 
1_2 450 WDR 224 64 51 109 112 181 
3 530 WDR 135 36 9 67 116 166 
4 680 WDR 247 25 15 64 63 150 
5 570 WDR 305 180 60 116 246 186 
6 780 WDR 150 2 11 22 115 243 
7_1 530 WDR 272 34 7 36 84 132 
7_2 530 WDR 120 64 3 65 137 132 
8 580 WDR 123 93 48 200 217 199 
9 600 WDR 215 47 33 141 144 203 
10 670 WDR 111 48 32 55 69 81 
276 
1 480 WDR 193 28 42 119 153 156 
2 590 WDR 119 75 9 26 70 175 
3 530 WDR 127 14 21 102 111 87 
4 680 WDR 55 89 20 40 69 95 
5 450 WDR 128 108 20 42 182 210 
7 580 WDR 80 37 21 37 90 77 
8_1 490 WDR 151 42 19 34 71 116 
8_2 490 WDR 63 10 12 39 64 52 
9 640 WDR 69 33 10 67 85 85 
280 
1 560 WDR 242 58 32 43 98 250 
2_1 550 WDR 159 39 45 47 115 231 
2_2 550 WDR 1 52 31 46 49 51 
3 510 WDR 647 1 0 1 134 374 
4 610 WDR 55 25 68 55 99 171 
5 470 WDR 72 24 12 28 96 70 
6_1 650 WDR 435 90 29 14 141 202 
6_2 650 WDR 27 19 5 7 51 139 
7 780 WDR 145 7 13 24 101 146 
8 820 WDR 79 33 96 76 147 155 
Note: Table continued on next page. 
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250 
1 210 LTM 0 35 20 63 54 58 
2 750 WDR 97 5 2 3 7 14 
3 580 WDR 89 163 34 54 64 86 
4 760 WDR 34 47 7 3 32 36 
5 140 LTM 20 14 0 7 25 57 
6 600 WDR 45 51 19 32 50 42 
7 600 WDR 5 26 11 10 11 36 
8 580 WDR 8 28 10 39 19 44 
9 690 WDR 104 21 8 20 10 68 
10 750 WDR 166 44 21 31 51 104 
11 70 WDR 73 3 0 14 21 80 
12 470 WDR 26 106 13 24 48 36 
13 280 WDR 93 6 20 44 81 107 
14 590 LTM 12 25 8 16 26 21 
15 830 WDR 85 25 23 44 91 56 
251 
1 640 WDR 90 41 8 7 11 27 
2 710 WDR 51 38 20 35 65 53 
3 850 LTM 21 19 5 10 20 36 
4 550 WDR 69 18 14 20 27 36 
5 820 WDR 24 19 9 16 15 49 
254 
1 530 WDR 30 68 28 66 87 35 
2 730 WDR 165 79 13 36 76 152 
3 620 WDR 65 43 26 37 50 63 
4 860 WDR 61 56 10 10 29 63 
5 450 WDR 131 46 7 30 48 91 
6 690 WDR 121 7 9 38 94 82 
7 650 WDR 60 11 17 32 65 115 
8 490 WDR 134 7 3 12 37 106 
9 760 WDR 251 19 12 33 119 142 
10 620 WDR 98 41 25 16 44 59 
277 
1 670 WDR 38 12 3 12 12 62 
2 560 WDR 186 73 31 129 100 97 
3 610 WDR 14 15 11 1 39 55 
4 480 WDR 425 43 37 177 123 246 
5 300 WDR 97 14 16 79 88 113 
6 60 LTM 11 9 0 36 156 255 
7 710 LTM 0 30 125 170 142 154 
8_1 530 WDR 342 52 56 78 142 272 
8_2 530 WDR 6 14 15 29 18 31 
9 590 WDR 76 16 8 29 91 118 
10 450 WDR 44 23 2 18 44 50 
11 400 WDR 58 14 54 47 50 52 
279 
1_1 590 WDR 44 40 4 30 68 69 
1_2 590 WDR 24 43 13 18 51 49 
2_1 930 WDR 91 4 1 1 10 109 
2_2 930 WDR 90 64 32 17 54 73 
3 500 WDR 292 18 23 40 89 117 
4 770 WDR 34 1 45 81 113 68 
5 720 WDR 36 23 7 15 42 58 
6 580 WDR 58 37 109 116 113 166 
7 620 WDR 144 28 15 21 50 158 
8 700 WDR 65 70 68 73 131 210 
340 
1 630 WDR 103 89 6 11 18 54 
2 530 LTM 10 91 11 13 25 23 
3 660 LTM 19 11 5 6 20 122 
4 640 WDR 94 46 9 11 80 101 
5 500 WDR 16 34 4 16 67 97 
6 660 LTM 30 25 14 50 69 48 
7 570 WDR 146 69 29 52 131 109 
8 660 LTM 49 51 9 8 116 166 
9 610 LTM 8 15 11 9 71 71 
10 700 WDR 94 57 32 26 79 135 
11_1 250 WDR 18 4 7 45 93 174 
11_2 250 WDR 0 29 0 27 19 21 
12 700 WDR 183 27 16 30 58 86 
Note: Table continued on next page. 
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283 
1 500 WDR 124 29 7 22 74 98 
2 610 WDR 125 15 1 3 32 118 
3 800 WDR 86 26 39 75 102 85 
4 520 WDR 78 2 51 49 60 59 
5 450 WDR 231 34 72 118 173 198 
6 310 LTM 21 0 5 21 83 119 
7 480 WDR 33 16 1 42 34 41 
284 
1 620 WDR 32 38 51 97 83 98 
2 620 WDR 118 32 24 59 88 101 
3 910 WDR 74 18 3 10 32 61 
4 780 WDR 18 10 11 19 56 78 
5 760 LTM 64 5 2 2 19 69 
6 240 LTM 34 2 1 41 78 73 
7 750 WDR 146 86 20 54 215 227 
8 770 WDR 84 37 20 35 83 116 
285 
1 670 WDR 26 21 12 10 62 102 
2 630 WDR 50 24 9 19 40 100 
3 750 WDR 27 42 1 6 24 57 
4 640 WDR 56 24 21 43 66 73 
5 700 WDR 149 20 13 23 49 70 
286 
1 720 WDR 103 15 63 131 149 178 
2 700 WDR 104 19 23 28 137 162 
3 820 WDR 116 58 61 183 123 224 
4 880 WDR 41 71 29 48 51 57 
5 790 WDR 195 49 43 61 141 238 
7 610 WDR 62 9 6 8 18 57 
8 600 WDR 62 20 11 17 27 100 
287 
1 730 WDR 38 18 10 20 40 55 
2 230 LTM 40 0 0 0 134 163 
3 910 LTM 39 38 2 11 72 123 
4 590 WDR 24 49 15 19 43 62 
5 580 WDR 12 26 7 14 50 99 
6 840 LTM 16 25 20 33 52 74 
7 550 WDR 133 40 25 45 108 167 
8 870 WDR 45 8 4 8 31 137 
9 820 LTM 21 25 19 59 42 36 
10 950 WDR 91 6 4 26 165 70 
Note: Table continued on next page. 
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335 
1 850 WDR 14 41 20 34 32 37 
2 690 WDR 23 2 3 3 9 61 
3 900 WDR 40 22 27 27 110 166 
4 750 WDR 55 177 8 37 116 293 
5 680 LTM 26 42 21 73 149 155 
6 330 LTM 10 6 3 128 105 104 
7 880 WDR 48 108 5 51 84 169 
8 830 WDR 26 5 30 69 82 66 
9 960 LTM 49 40 10 15 46 97 
336 
1 630 WDR 103 4 17 105 177 195 
2_1 900 WDR 20 7 29 73 88 57 
2_2 900 WDR 6 55 18 31 22 23 
3 740 WDR 62 34 38 87 109 128 
4 830 LTM 4 6 31 111 87 47 
5 640 WDR 31 20 23 110 141 207 
6 920 WDR 81 37 3 26 156 161 
7 720 WDR 17 18 45 25 20 19 
8 960 LTM 4 70 34 21 33 22 
9 590 WDR 97 1 3 12 174 203 
337 
1 630 WDR 44 25 52 29 73 91 
2 750 WDR 115 10 15 25 86 126 
4 740 WDR 27 22 0 3 24 59 
5_1 870 LTM 6 24 10 11 16 44 
5_2 870 WDR 27 16 20 15 10 65 
6 600 WDR 99 8 2 13 29 75 
338 
1 240 WDR 1 6 8 6 13 38 
2 820 LTM 34 25 18 20 33 55 
3 460 LTM 37 28 27 44 78 115 
4_1 700 WDR 31 0 0 1 12 9 
5_2 700 WDR 98 56 39 97 81 99 
6_1 570 WDR 92 4 19 29 69 119 
6_2 570 WDR 65 31 63 60 71 68 
339 
2 360 LTM 13 52 25 18 74 137 
3_1 750 LTM 20 37 21 22 36 49 
3_2 750 WDR 5 4 10 7 19 7 
4 490 WDR 52 20 40 79 79 75 
5 550 WDR 69 28 33 41 56 45 
6 780 LTM 45 87 21 36 65 119 
7 470 WDR 25 14 16 16 33 38 
8_1 310 WDR 18 1 7 9 10 48 
8_2 310 WDR 80 46 24 16 41 25 
9 600 WDR 84 38 3 9 30 92 
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Table G.6. Spinal neuronal firing counts in rats at seven days following facet joint 
distraction with intra-articular anti-NGF application on day one (Chapter 5). 
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345 
1 780 LTM 44 45 10 34 93 111 
2 760 WDR 35 110 36 75 280 192 
3 720 WDR 17 73 28 51 78 74 
4 930 LTM 76 5 1 1 0 232 
347 
1 680 LTM 14 1 1 45 70 84 
2 550 WDR 98 55 37 116 145 241 
3_1 720 WDR 10 0 0 1 11 45 
3_2 720 WDR 42 18 14 13 152 281 
4 850 WDR 162 61 49 47 203 193 
5 570 WDR 225 17 20 51 142 174 
6 290 LTM 9 0 1 18 131 172 
7 610 WDR 32 31 11 10 45 47 
8 690 LTM 47 1 2 3 11 90 
359 
2 840 WDR 8 24 42 70 64 89 
3 610 LTM 17 15 4 21 23 32 
4 700 WDR 37 49 16 120 213 178 
5 550 WDR 142 75 120 189 240 178 
6 810 WDR 138 74 96 174 352 450 
7 750 WDR 59 87 29 28 106 242 
8 930 WDR 195 45 37 52 85 244 
360 
1 420 WDR 23 42 0 1 28 34 
2 900 LTM 9 1 0 1 5 58 
3 300 WDR 35 58 18 32 32 102 
4 970 WDR 10 33 37 26 60 52 
5 650 LTM 31 55 1 15 51 80 
361 
1 280 WDR 33 8 52 100 75 120 
2 600 WDR 79 74 29 86 125 130 
3 810 WDR 43 23 24 26 136 190 
4 820 WDR 58 31 145 193 240 275 
5 570 WDR 185 4 1 12 293 325 
6 950 WDR 79 37 47 103 86 144 
7 820 WDR 48 70 35 133 143 278 
8 720 WDR 13 32 9 10 75 107 
9 620 LTM 18 15 2 14 71 136 
10 800 WDR 37 54 24 46 60 129 
362 
1 710 WDR 19 22 52 58 73 114 
2 880 LTM 57 8 23 25 40 82 
3 740 WDR 0 52 61 120 176 120 
4 740 WDR 39 60 51 79 107 107 
5 800 WDR 28 4 16 36 67 40 
6 250 LTM 12 15 11 28 60 58 
7 770 WDR 89 28 154 173 110 100 
8 770 WDR 109 37 8 26 103 81 
9 1000 WDR 93 45 41 67 170 178 
10 930 WDR 54 27 13 36 85 151 
11 950 LTM 10 3 26 93 105 124 
363 
1 870 WDR 111 57 107 153 169 171 
2 610 WDR 51 32 49 74 118 101 
3 830 WDR 109 20 16 74 103 203 
4 760 WDR 16 11 21 49 57 36 
5 500 LTM 15 36 33 75 106 115 
6 690 LTM 14 13 5 9 51 80 
7 960 WDR 26 4 15 32 153 153 
8 890 WDR 168 16 21 59 96 180 
9 860 WDR 14 116 35 58 67 69 
10 940 LTM 29 83 41 69 139 215 
364 
1 980 WDR 57 34 22 52 136 159 
2 680 WDR 97 47 66 72 137 112 
3 60 LTM 14 116 27 51 73 83 
4 850 WDR 66 59 13 47 83 100 
5 870 WDR 38 22 23 58 79 105 
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Table G.7. Thalamic neuronal firing counts in rats at seven days following facet 
joint distraction (Chapter 7). 
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FJD 
PSP1 
1 3.4 -2.5 6780 LTM 269 386 133 217 186 209 
2 3.6 -2.5 6100 LTM 76 99 21 77 78 95 
3 2.4 -3.1 7000 LTM 66 161 78 75 90 117 
PSP5 
1 2.0 -2.5 6000 WDR 76 102 44 73 130 175 
3 2.2 -3.1 6650 LTM 24 74 45 93 95 129 
4 2.4 -3.1 6900 LTM 54 163 61 92 97 111 
5 2.6 -3.1 6400 WDR 109 218 23 70 190 162 
PSP7 
1 3.6 -3.3 6550 LTM 94 137 22 93 111 144 
10_1 2.4 -3.5 6750 WDR 113 97 15 48 83 168 
11 2.6 -3.5 5950 LTM 125 68 96 49 82 174 
12 2.6 -3.5 6400 WDR 26 91 1 82 121 163 
14 2.8 -3.5 6550 LTM 61 86 3 147 128 126 
16 2.8 -3.7 6275 LTM 31 126 0 100 115 118 
17 2.8 -3.7 6275 WDR 110 159 108 157 224 264 
18 2.6 -3.7 6200 WDR 66 161 14 36 90 117 
19 2.6 -3.7 6650 WDR 44 52 30 45 70 113 
PSP11 
1 2.0 -3.1 6450 LTM 189 391 68 222 179 316 
9 2.4 -3.4 6550 WDR 136 275 45 95 212 241 
11 2.6 -3.5 5850 WDR 96 173 68 78 128 203 
12 2.6 -3.5 6700 WDR 209 101 71 158 391 392 
13 2.4 -3.5 5900 WDR 63 108 47 56 151 143 
14 2.2 -3.5 6400 LTM 86 187 13 98 109 144 
15 2.2 -3.5 6950 WDR 75 69 43 62 125 107 
17 2.0 -3.5 6400 WDR 234 97 32 72 129 173 
Note: Table continued on next page. The naming scheme for these rats refers to the fact that they were 
generated for electrophysiological recordings that were performed by Parul S. Pall. 
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PSP4 
3 3.8 -3.1 5725 LTM 61 43 0 48 41 71 
4 3.8 -3.1 6350 WDR 33 2 12 0 5 28 
6 3.4 -3.1 7100 LTM 41 15 37 0 0 25 
7 3.2 -3.1 6340 WDR 22 30 0 9 18 59 
8 3.2 -3.1 6150 WDR 16 2 5 1 17 35 
10 3.0 -3.1 5750 WDR 65 30 0 10 39 100 
11 3.0 -3.1 6350 LTM 34 43 24 32 46 24 
12 3.0 -3.1 6800 LTM 11 31 24 25 28 27 
13 2.8 -3.1 6100 LTM 35 53 20 39 1 1 
14 3.6 -3.3 6200 LTM 32 184 70 95 80 89 
15 3.2 -3.3 7050 WDR 12 106 9 60 68 131 
16 3.0 -3.3 6800 WDR 17 36 6 11 13 17 
PSP8 
1 3.2 -3.1 6050 WDR 63 133 3 24 61 100 
2 3.2 -3.1 6100 WDR 26 75 25 27 29 56 
3 3.2 -3.1 6250 LTM 14 45 32 31 39 41 
4 3.2 -3.1 6300 WDR 26 58 9 23 49 52 
5 3.4 -3.1 5800 WDR 27 32 10 13 37 36 
8 3.4 -3.3 6200 WDR 15 74 9 3 25 53 
11_1 3.2 -3.3 6100 WDR 14 7 34 43 70 84 
12 3.2 -3.3 6250 LTM 103 46 65 128 107 150 
14 3.0 -3.3 6350 LTM 16 37 31 34 38 59 
15 3.0 -3.3 6600 WDR 67 87 70 111 166 187 
16 3.0 -3.5 6500 WDR 14 51 5 24 46 68 
17 3.0 -3.5 6400 WDR 31 179 30 41 49 76 
19 3.2 -3.5 6350 WDR 9 45 8 13 18 30 
20 3.2 -3.5 6500 LTM 3 27 15 10 15 11 
PSP12 
1_1 2.2 -3.5 6000 WDR 12 29 1 3 15 47 
2 2.2 -3.5 6500 WDR 78 22 7 4 57 135 
3 2.4 -3.5 6450 WDR 17 55 0 10 27 33 
4 2.4 -3.5 6625 LTM 49 123 105 107 57 84 
5 2.4 -3.3 6675 LTM 23 162 29 57 69 52 
7 2.5 -3.5 6750 WDR 47 35 1 15 49 71 
8 2.6 -3.5 6550 WDR 21 37 10 21 67 64 
9 2.7 -3.5 6350 WDR 10 89 11 21 37 54 
14 2.5 -3.6 6800 LTM 25 65 14 37 41 44 
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Table G.8. Thalamic neuronal firing counts in rats following facet joint distraction 
for seven days with IB4-saporin pretreatment (Chapter 7). 
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10g 
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26g 
vF 
IB4-Sap+ 
FJD 
F240 
1_1 2.2 -3.5 6100 WDR 9 21 6 9 19 37 
2 2.0 -3.5 6375 WDR 117 35 0 7 146 180 
3 2.4 -3.5 6350 LTM 33 142 40 50 60 34 
4 2.3 -3.5 6325 WDR 141 21 19 62 109 130 
5 2.0 -3.6 6475 WDR 100 54 9 52 70 93 
6 2.2 -3.6 6540 WDR 39 52 23 40 44 86 
7 2.2 -3.6 6675 LTM 58 80 48 35 68 81 
F241 1 2.0 -3.5 6325 WDR 41 45 10 32 69 98 
F242 
1_1 2.0 -3.1 5900 LTM 0 15 0 8 3 3 
2 2.0 -3.3 6250 LTM 4 11 8 38 58 43 
3 2.2 -3.3 5500 WDR 58 6 1 8 13 43 
5 2.4 -3.3 5400 LTM 46 43 42 23 33 49 
6 2.6 -3.3 6200 WDR 46 17 20 45 59 106 
7 2.8 -3.3 5350 WDR 19 14 10 37 70 32 
8 2.0 -3.0 6150 LTM 46 48 25 122 134 179 
F246 
1 3.4 -3.5 6000 WDR 38 53 4 7 56 98 
3 3.4 -3.7 6650 WDR 81 33 1 33 64 122 
4 3.3 -3.7 6450 WDR 37 25 11 34 43 69 
5 3.1 -3.7 6050 WDR 43 79 26 38 97 138 
6 2.9 -3.7 6450 WDR 8 20 0 1 59 67 
7 2.7 -3.7 7000 WDR 27 28 22 28 71 195 
8 2.5 -3.7 6820 WDR 23 25 12 23 23 35 
F249 
2 3.2 -3.5 6630 WDR 33 69 16 15 56 114 
3 3.4 -3.5 6500 WDR 21 55 26 45 104 103 
4 3.4 -3.5 6650 WDR 57 100 31 48 82 97 
5 3.4 -3.7 6250 LTM 26 34 29 37 32 54 
6 3.4 -3.7 6150 WDR 42 55 17 28 57 75 
7_1 3.2 -3.7 6500 WDR 75 99 19 71 105 171 
8 3.2 -3.7 6650 WDR 60 50 22 64 88 135 
9 3.0 -3.7 6250 WDR 30 7 1 5 57 114 
10 3.2 -3.8 6450 LTM 71 52 53 61 119 102 
F251 
1 2.2 -3.3 6200 WDR 20 24 1 15 140 129 
2 2.4 -3.3 6250 WDR 4 27 14 24 44 50 
Note: Table continued on next page. All surgical procedures for these rats were performed by Christine L. 
Weisshaar, and the naming scheme reflects her records. 
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IB4-Sap+ 
sham 
F244 
2 2.0 -3.1 6650 WDR 61 81 21 83 171 230 
3 2.2 -3.1 5500 LTM 4 8 4 0 3 8 
4 2.2 -3.1 5600 WDR 10 53 13 60 124 160 
5 2.4 -3.1 5550 WDR 0 27 3 33 65 90 
6 2.6 -3.1 5425 WDR 28 32 8 0 26 24 
8 2.4 -3.0 5150 WDR 133 57 41 58 127 159 
9 2.2 -3.0 5200 WDR 33 24 10 28 48 61 
10 2.0 -3.0 5950 WDR 29 1 0 16 24 41 
F247 
1 2.0 -3.1 6200 LTM 29 18 21 22 30 31 
2 2.2 -3.1 6000 WDR 235 184 27 95 129 215 
3 2.4 -3.1 6300 WDR 32 25 2 4 41 86 
6 2.3 -3.3 6235 WDR 5 13 8 21 59 133 
7 2.3 -3.4 6300 WDR 45 20 9 21 46 54 
8 2.3 -3.4 6500 WDR 16 50 52 129 168 182 
10 2.1 -3.4 6250 WDR 150 54 9 28 102 166 
11 2.1 -3.4 6350 WDR 87 124 0 4 132 135 
12 2.0 -3.5 6650 LTM 24 61 13 55 69 75 
F250 
1 2.4 -3.0 6200 WDR 118 36 5 12 38 144 
2 2.6 -3.0 6650 WDR 27 21 0 0 16 85 
3 2.8 -3.0 5650 WDR 45 73 32 42 53 119 
4 2.8 -3.0 6250 WDR 32 169 5 19 41 34 
F252 
1 3.0 -3.0 6700 LTM 26 54 20 15 22 36 
2 3.2 -3.0 6300 WDR 20 64 20 24 33 50 
3 3.4 -3.0 6550 WDR 86 132 41 60 94 134 
4 3.6 -3.0 6850 WDR 49 74 34 52 68 80 
5 3.0 -2.8 6350 WDR 103 60 11 51 87 113 
6 2.8 -2.8 6200 LTM 47 52 2 20 17 40 
7 2.8 -2.8 6850 WDR 51 33 74 140 190 252 
8 3.2 -2.8 6400 WDR 19 5 0 4 11 43 
9 2.6 -2.8 6200 WDR 107 105 21 77 114 186 
F253 
1 2.6 -3.0 6200 LTM 58 74 56 76 117 102 
3 2.8 -3.1 6750 WDR 25 22 0 22 22 48 
4 2.6 -3.1 6800 WDR 88 185 51 115 167 172 
6 2.3 -3.1 6450 WDR 95 76 15 39 82 147 
7 2.3 -3.3 7200 LTM 32 46 2 45 58 40 
9 2.8 -3.3 6400 WDR 15 11 6 10 17 25 
10 2.8 -2.9 6200 WDR 172 1 2 3 155 368 
11 2.6 -2.9 6000 WDR 67 20 4 12 32 83 
12_1 2.4 -2.9 6300 WDR 28 31 7 14 40 67 
13 2.2 -2.9 6050 WDR 210 119 46 46 112 218 
14 2.2 -2.9 6750 LTM 6 15 8 26 16 22 
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Appendix H 
Identification of C6/C7 Facet Joint Afferents and 
Calcitonin Gene-Related Peptide Expression in 
the DRG Using Immunohistochemistry 
 
 
This appendix summarizes the characterization of afferents that innervate the right 
C6/C7 facet joint for the studies presented in Chapter 4. Each tissue section throughout 
the entire dorsal root ganglion (DRG) for each spinal level from C5 to C8 was analyzed 
visually to identify afferents labeled positively for cholera toxin subunit b (CTb) at day 
seven after facet joint distraction (FJD) or sham procedures; normal tissues were also 
included. CTb was injected into the joint three days prior to FJD or sham procedures, so 
tissues harvested at day seven post-injury correspond to day ten after the CTb injection. 
For further details on the labeling technique, see Section 4.3.1 in Chapter 4. The total 
number of CTb-positive neurons was summed for each rat at each DRG level. Each DRG 
image was digitally stored with a generalized file name of CTb_Rat#_SpinalLevel_ 
Slide#_Section#_ExposureTime_20x.tif. For all sections from a given spinal level in each 
individual rat, the exposure time was standardized. However, due to the large number of 
sections that were labeled and analyzed, immunolabeling experiments were separately 
undertaken for each spinal level of each individual rat. As such, the exposure times vary 
between rats and spinal levels. On each slide, sections were numbered beginning in the 
top left corner and proceeding in numerical order from top to bottom, then resuming at 
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the top of the adjacent column to the right. Throughout this appendix, the FJD group 
refers to rats for which the C6 forceps was displaced by 2.5mm as recorded by the linear 
variable differential transducer (LVDT); the sham group underwent the same surgical 
procedure with no applied distraction (Kras et al., 2013c). 
In order to identify the joint afferents as peptidergic, all tissue sections also were 
immunolabeled for the neuropeptide calcitonin gene-related peptide (CGRP) in addition 
to the fluorescent CTb label. For all CTb-positive neurons, the mean CGRP signal 
intensity and cross-sectional area (µm2) of the neurons were determined by manually 
outlining each neuron using ImageJ (NIH; Bethesda, MD). Each neuron was identified as 
being either CGRP-positive or CGRP-negative based on its intensity of CGRP labeling. 
Further details about these analysis methods can be found in Section 4.3.2 of Chapter 4 
(Kras et al., 2013b). The number of CTb-positive neurons also positively labeled for 
CGRP was counted at each level for each rat. Each CGRP-labeled image corresponding 
to an image containing a CTb-positive neuron was digitally stored with a generalized file 
name of CGRP_Rat#_SpinalLevel_Slide#_Section#_ExposureTime_20x. For all sections 
from individual rats at each spinal level, the exposure times were standardized as 
described above. 
Table H.1 summarizes the total number of CTb-positive neurons for each rat at 
each spinal level. Table H.2 reports the total number of those CTb-positive neurons that 
are also positively labeled for CGRP for each rat and spinal level. Exposure times for all 
CTb and CGRP labeled images for each rat and each spinal level are tabulated in Table 
H.3. The size (µm2) and the CGRP classification (+/-) for each CTb-positive neuron for 
all rats in the FJD group are detailed in Table H.4. Figures H.1.A-H.1.D itemize each of 
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the DRG tissue sections at each spinal level containing at least one CTb-positive neuron 
as well as the CGRP-labeled image corresponding to each CTb-labeled section for all 
four of the rats in the FJD group. Table H.5 provides the size and CGRP classification for 
the CTb-positive neurons of rats in the sham group. All of the DRG sections containing 
CTb-positive neurons and the corresponding CGRP-labeled images for each section for 
the five rats in the sham group are presented in Figures H.2.A-H.2.D. For the normal 
group, the neuronal size and CGRP classification of CTb-positive joint afferents are 
provided in Table H.6; Figures H.3.A-H.3.D illustrate all CTb-positive neurons in DRG 
sections that were also immunolabeled for CGRP for all rats in the normal group. In all 
figures, the DRG images are presented such that the CGRP-labeled image of each section 
containing a CTb-positive neuron is provided immediately below the corresponding CTb-
labeled image. 
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Table H.1. Summary of the number of CTb-labeled joint afferents for each rat at 
each cervical level at seven days after FJD (Chapter 4). 
Group Rat C5 C6 C7 C8 Total 
FJD 
134 1 2 17 4 24 
143 1 2 15 10 28 
152 0 2 9 4 15 
155 1 5 23 13 42 
sham 
132 0 2 8 13 23 
141 0 0 4 3 7 
142 2 11 15 4 32 
150 0 3 14 6 23 
154 2 5 20 15 42 
normal 
135 0 3 29 13 45 
136 1 3 15 6 25 
138 4 11 22 11 48 
140 1 10 17 15 43 
 
Table H.2. Summary of the number of CGRP-positive CTb-labeled joint afferents 
for each rat at each cervical level at seven days after FJD (Chapter 4). 
Group Rat C5 C6 C7 C8 Total 
FJD 
134 1 1 9 3 14 
143 1 1 5 5 12 
152 0 0 7 2 9 
155 0 4 14 9 27 
sham 
132 0 1 5 7 13 
141 0 0 2 3 5 
142 0 7 6 0 13 
150 0 3 10 6 19 
154 1 5 15 14 35 
normal 
135 0 2 11 6 19 
136 0 0 6 5 11 
138 1 6 9 10 26 
140 1 7 11 12 31 
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Table H.3. Summary of the exposure times for all CTb and CGRP images from all 
sections from each rat at each spinal level (Chapter 4). 
Group Rat Spinal level 
CTb 
(ms) 
CGRP 
(ms) Group Rat 
Spinal 
level 
CTb 
(ms) 
CGRP 
(ms) 
FJD 
134 
C5 100 200 
normal 
135 
C5 N/A N/A 
C6 120 60 C6 100 65 
C7 200 80 C7 150 60 
C8 200 100 C8 200 150 
143 
C5 150 70 
136 
C5 200 200 
C6 150 100 C6 100 65 
C7 150 100 C7 150 60 
C8 150 150 C8 200 150 
152 
C5 N/A N/A 
138 
C5 200 150 
C6 150 70 C6 200 100 
C7 150 80 C7 200 100 
C8 150 70 C8 200 150 
155 
C5 100 30 
140 
C5 200 150 
C6 100 60 C6 200 100 
C7 180 80 C7 200 100 
C8 200 80 C8 200 150 
sham 
132 
C5 N/A N/A 
  
C6 120 60 
C7 200 80 
C8 200 100 
141 
C5 N/A N/A 
C6 N/A N/A 
C7 150 100 
C8 150 150 
142 
C5 150 70 
C6 150 100 
C7 150 100 
C8 150 150 
150 
C5 N/A N/A 
C6 150 70 
C7 150 80 
C8 150 70 
154 
C5 100 30 
C6 100 60 
C7 180 80 
C8 200 80 
Note: For exposure times labeled N/A, no CTb-positive neurons were detected for that rat at that spinal 
level. 
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Table H.4. Neuronal size and CGRP classification for each CTb-positive neuron for 
each rat at day seven after FJD (Chapter 4). 
Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C5 
134 8 9 410.6 + 
143 2 6 909.4 + 
152 N/A N/A N/A N/A 
155 2 6 1019.7 - 
C6 
134 1 6 524.2 - 2 1 1139.1 + 
143 2 5 777.1 - 3 9 636.9 + 
152 5 3_top left 621.1 - 3_bottom 1389.5 - 
155 
6 9 906.1 + 
8 
1 408.1 - 
4 613.2 + 
7 914.4 + 
9 7 545.8 + 
C7 
134 
4 5 625.7 - 
5 4 582.4 + 
6 
5 602.8 - 
6 717.2 - 
9 587.8 - 
7 
2 1098.3 + 
4_left 572.9 + 
5_middle 789.6 + 
6_left 791.3 + 
10 804.2 - 
8 
4 738.4 - 
8_right 895.3 - 
8_left 918.6 - 
10 922.7 + 
9 
8 991.0 + 
27 460.1 + 
33 663.6 + 
143 
1 5 648.6 - 6 470.9 + 
2 6 309.9 - 
3 
1 349.9 - 
4 332.4 - 
10 461.4 + 
4 4 690.2 - 
5 
1 329.1 - 
8 679.8 - 
9 left 754.3 + 
9 right 809.2 - 
6 
4 592.0 - 
9 left 639.4 + 
9 right 809.2 - 
10 1005.5 + 
Note: Table continued on next page. In the Section column, designators such as left, right, top, & bottom 
are used to specify a single neuron when multiple CTb-positive neurons are evident in that section. For 
cells labeled N/A, no CTb-positive neurons were detected for that rat at that spinal level. 
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Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C7 
152 
5 2 765.5 + 
7 
6 861.6 + 
8 1111.6 + 
8 2 725.1 - 4 896.1 + 
9 
4 1157.8 + 
6 832.1 - 
7_top 1023.0 + 
10 9 869.5 + 
155 
2 
8 521.7 + 
9 932.7 - 
3 
4_top 535.0 + 
4_low right 707.7 - 
5_left 482.2 - 
5_right 676.5 + 
6_low left 923.6 - 
9 589.5 - 
4 
4 701.0 + 
7 973.1 + 
10 796.7 - 
5 
2 626.5 + 
6 657.7 - 
8_top right 580.8 + 
9_bottom 628.6 + 
6 5_left 867.4 - 5_right 549.2 + 
7 2 816.2 + 
8 
1 523.8 + 
4 512.1 + 
10 753.4 + 
9 2 598.7 + 
4 483.0 - 
C8 
134 
5 1 686.4 - 
6 6 715.6 + 
8 5 1118.7 + 
9 6 876.6 + 
143 
3 
10_1 580.4 - 
10_2 598.7 - 
12 494.2 - 
4 
1 383.2 + 
3 756.7 + 
6 1008.9 + 
14 823.3 + 
5 10 713.1 + 
12 1213.5 - 
7 13 1158.2 - 
Note: Table continued on next page. In the Section column, designators such as left, right, top, & bottom 
are used to specify a single neuron when multiple CTb-positive neurons are evident in that section. A 
Section number followed by a numerical designator (i.e. 10_1 & 10_2) indicates a section that contains 
multiple neurons that could not be captured in one image frame. As such, two separate images had to be 
taken for that section. 
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Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C8 
152 
4 1 833.3 - 
8 3 1032.6 + 9 675.2 + 
9 10 813.3 - 
155 
3 
2_left 781.7 + 
2_right 1031.7 + 
8 392.7 - 
4 3 691.8 - 
10 591.6 + 
7 
7 865.3 - 
9 781.7 + 
8 
4 1221.9 + 
6 870.3 + 
9 639.4 + 
9 
1 617.4 + 
5 702.3 + 
6 1218.1 - 
Note: In the Section column, designators such as left, right, top, & bottom are used to specify a single 
neuron when multiple CTb-positive neurons are evident in that section. 
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Figure H.1.A. CTb and CGRP-labeled sections of the C5 DRG from Rats 134, 143, 
and 155 in the FJD group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.4. 
For each CTb-labeled image, the corresponding CGRP-labeled image is presented 
immediately below it. 
319 
 
CT
b 
CG
RP
 
CT
b 
CG
RP
 
CT
b 
CG
RP
 
CT
b 
CG
RP
 
R
at
 
13
4 
R
at
 
14
3 
R
at
 
15
2 
R
at
 
15
5 
C6 
Figure H.1.B. CTb and CGRP-labeled sections of the C6 DRG from rats in the FJD 
group. For each rat, the images presented correspond to those sections for which CTb-
labeled neurons were identified as summarized in Table H.4. For each rat, slide 
number and section number increase from left to right. For each CTb-labeled image, 
the corresponding CGRP-labeled image is presented immediately below it. 
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Figure H.1.C. CTb and CGRP-labeled sections of the C7 DRG from Rat 134 in the 
FJD group. For each rat, the images presented correspond to those sections for which 
CTb-labeled neurons were identified as summarized in Table H.4. For each rat, slide 
number and section number increase from left to right. For each CTb-labeled image, 
the corresponding CGRP-labeled image is presented immediately below it. Figure is 
continued on the next page. 
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Figure H.1.C. CTb and CGRP-labeled sections of the C7 DRG from Rats 143 and 
152 in the FJD group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.4. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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Figure H.1.C. CTb and CGRP-labeled sections of the C7 DRG from Rats 152 and 
155 in the FJD group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.4. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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Figure H.1.C. CTb and CGRP-labeled sections of the C7 DRG from Rat 155 in the 
FJD group. For each rat, the images presented correspond to those sections for which 
CTb-labeled neurons were identified as summarized in Table H.4. For each rat, slide 
number and section number increase from left to right. For each CTb-labeled image, 
the corresponding CGRP-labeled image is presented immediately below it.  
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Figure H.1.D. CTb and CGRP-labeled sections of the C8 DRG from Rats 134, 143, 
and 152 in the FJD group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.4. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. Figure is continued on the next page. 
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Figure H.1.D. CTb and CGRP-labeled sections of the C8 DRG from Rat 155 in the 
FJD group. For each rat, the images presented correspond to those sections for which 
CTb-labeled neurons were identified as summarized in Table H.4. For each rat, slide 
number and section number increase from left to right. For each CTb-labeled image, 
the corresponding CGRP-labeled image is presented immediately below it.  
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Table H.5. Neuronal size and CGRP classification for each CTb-positive neuron for 
each rat at day seven after sham (Chapter 4). 
Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C5 
132 N/A N/A N/A N/A 
141 N/A N/A N/A N/A 
142 1 1 604.9 - 3 1 503.4 - 
150 N/A N/A N/A N/A 
154 5 2 863.7 - 6 7 740.5 + 
C6 
132 4 4 727.6 - 
7 2 697.7 + 
141 N/A N/A N/A N/A 
142 
4 
9 412.7 + 
11 551.6 + 
12 332.0 + 
5 
1 463.0 + 
3 585.8 - 
6 455.5 + 
7 457.6 + 
12 596.2 + 
7 
2 399.4 - 
8 378.6 - 
8 4 632.8 - 
150 
1 2 1419.9 + 
5 2 747.2 + 
9 3 842.5 + 
154 
4 7 532.5 + 
7 
9 1115.4 + 
10 978.5 + 
8 3 703.1 + 10 463.0 + 
C7 
132 
2 
7 426.0 + 
9 458.5 - 
4 4 560.4 + 
5 12 557.9 - 
6 
3 394.4 - 
6 672.7 + 
7 648.2 + 
7 11 554.6 + 
141 
2 
7 641.5 - 
9 461.8 - 
3 7 515.9 + 
4 10 542.1 + 
Note: Table continued on next page. For cells labeled N/A, no CTb-positive neurons were detected for that 
rat at that spinal level. 
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Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C7 
142 
1 12 672.3 + 
3 3 988.5 + 
3 7_1 405.2 - 7_2 398.6 - 
4 
5 748.4 - 
8 647.3 - 
10_1 right 478.0 + 
10_2 middle 432.7 - 
11 left 428.5 - 
11 right 671.9 + 
12 717.6 + 
5 12 521.7 - 
6 6 558.7 - 
8 2 808.8 + 8 358.6 - 
150 
1 2 902.8 + 
3 2 708.9 + 8 1124.9 + 
5 
3 782.1 + 
5_1 714.7 - 
6 1205.6 + 
9 913.2 + 
6 1 1266.8 + 9 1193.6 - 
7 1 1105.8 - 
9 
1 778.8 + 
3 1120.8 + 
6 1039.6 - 
10 872.4 + 
154 
2 2 459.3 - 6 602.0 - 
3 10 553.3 + 
4 8 410.6 + 
5 3 341.1 + 8 602.8 + 
6 4 595.3 + 
7 
1 522.9 + 
4 1058.0 + 
9 409.4 + 
10 446.0 + 
8 
1 583.7 + 
6 859.5 + 
8_2 658.6 - 
9 1013.0 + 
9 4 right 843.3 + 5 left 713.1 - 
10 
1 807.5 + 
3 767.6 - 
6 645.7 + 
Note: Table continued on next page. In the Section column, designators such as left, right, top, & bottom 
are used to specify a single neuron when multiple CTb-positive neurons are evident in that section. A 
Section number followed by a numerical designator (i.e. 7_1 & 7_2) indicates a section that contains 
multiple neurons that could not be captured in one image frame. As such, two separate images had to be 
taken for that section. 
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Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C8 
132 
5 
1 825.8 - 
2 1097.1 - 
9 788.0 - 
6 6 852.4 + 
7 6 966.4 - 
8 8 927.3 + 
10 805.8 + 
9 4 754.3 + 5 693.9 - 
10 
4_top 839.1 + 
4_bottom 899.0 - 
7 642.8 + 
10 369.8 + 
141 
5 6 610.3 + 8 662.3 + 
6 5 632.4 + 
142 
3 11 643.6 - 
4 7 790.4 - 
5 3 373.2 - 
7 9 1200.6 - 
150 
5 7 1213.1 + 
10 827.1 + 
6 7 1296.7 + 
9 7 1180.3 + 9 800.4 + 
10 7 1122.0 + 
154 
3 8 1083.7 + 
5 
4_1 low left 411.4 + 
4_2 top right 816.7 + 
6 
5 716.0 + 
7 836.2 + 
7 5 815.8 + 
8 1 490.1 + 
9 
3_1 645.7 - 
3_2 left 738.9 + 
10 689.4 + 
10 
3 955.6 + 
6 808.8 + 
8 654.4 + 
14 top right 569.5 + 
14 bottom left 1029.7 + 
Note: In the Section column, designators such as left, right, top, & bottom are used to specify a single 
neuron when multiple CTb-positive neurons are evident in that section. 
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Figure H.2.A. CTb and CGRP-labeled sections of the C5 DRG from Rats 142 and 
154 in the sham group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.5. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
330 
 
CT
b 
CG
RP
 
CT
b 
CG
RP
 
CT
b 
CG
RP
 
CT
b 
CG
R
P 
R
at
 
14
2 
C6 
Figure H.2.B. CTb and CGRP-labeled sections of the C6 DRG from Rats 132 and 
142 in the sham group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.5. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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Figure H.2.B. CTb and CGRP-labeled sections of the C6 DRG from Rats 150 and 
154 in the sham group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.5. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
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Figure H.2.C. CTb and CGRP-labeled sections of the C7 DRG from Rats 132, 141, 
and 142 in the sham group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.5. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. Figure is continued on the next page. 
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Figure H.2.C. CTb and CGRP-labeled sections of the C7 DRG from Rats 142 and 
150 in the sham group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.5. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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Figure H.2.C. CTb and CGRP-labeled sections of the C7 DRG from Rats 150 and 
154 in the sham group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.5. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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Figure H.2.C. CTb and CGRP-labeled sections of the C7 DRG from Rat 154 in the 
sham group. For each rat, the images presented correspond to those sections for which 
CTb-labeled neurons were identified as summarized in Table H.5. For each rat, slide 
number and section number increase from left to right. For each CTb-labeled image, 
the corresponding CGRP-labeled image is presented immediately below it.  
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Figure H.2.D. CTb and CGRP-labeled sections of the C8 DRG from Rats 132 and 
141 in the sham group. For each rat, the images presented correspond to those sections 
for which CTb-labeled neurons were identified as summarized in Table H.5. For each 
rat, slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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Figure H.2.D. CTb and CGRP-labeled sections of the C8 DRG from Rats 142, 150, 
and 154 in the sham group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.5. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. Figure is continued on the next page. 
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Figure H.2.D. CTb and CGRP-labeled sections of the C8 DRG from Rat 154 in the 
sham group. For each rat, the images presented correspond to those sections for which 
CTb-labeled neurons were identified as summarized in Table H.5. For each rat, slide 
number and section number increase from left to right. For each CTb-labeled image, 
the corresponding CGRP-labeled image is presented immediately below it. 
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Table H.6. Neuronal size and CGRP classification for each CTb-positive neuron for 
each rat in the normal group (Chapter 4). 
Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C5 
135 N/A N/A N/A N/A 
136 5 3 664.0 - 
138 
1 
13_top right 744.3 + 
13_bottom left 1109.5 - 
2 
6 950.2 - 
9 760.9 - 
140 4 4 453.1 + 
C6 
135 
1 5 451.4 - 
6 4 683.1 + 
8 7 814.6 + 
136 
2 8 1216.5 - 
3 8 1626.2 - 
5 1 833.3 - 
138 
1 
8_bottom 483.0 - 
8_top 974.7 - 
10 664.0 + 
2 
3 877.4 + 
6 1142.0 - 
8 561.6 + 
10 869.9 - 
14 1125.8 - 
3 
1 835.4 + 
4 1137.4 + 
4 5 869.9 + 
140 
1 9 1266.4 - 
2 
10 1061.3 - 
14 309.5 - 
3 
2 1214.0 + 
11_top right 656.5 + 
11_bottom left 713.5 + 
4 
2 466.4 + 
4 1474.4 + 
5 
15 1147.8 + 
16 1456.1 + 
Note: Table continued on next page. In the Section column, designators such as left, right, top, & bottom 
are used to specify a single neuron when multiple CTb-positive neurons are evident in that section. For 
cells labeled N/A, no CTb-positive neurons were detected for that rat at that spinal level. 
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Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C7 
135 
1 
2 926.1 + 
5 723.5 - 
9 847.4 - 
10 485.9 + 
2 
3 882.8 - 
5 611.6 + 
8 810.8 - 
9 852.0 - 
3 
1 681.0 - 
2 570.4 - 
5 702.3 + 
6 1520.6 + 
4 
2 580.4 - 
5 590.8 - 
5 
2 586.2 - 
8 727.6 - 
9 708.1 - 
6 
2 459.7 - 
7 709.3 - 
8_top 746.3 + 
8_bottom left 946.9 + 
8_bottom right 587.4 + 
7 
2_top left 525.0 - 
2_bottom right 864.1 + 
10 432.7 - 
8 
2 591.2 - 
4 676.0 + 
6_top 628.2 + 
6_bottom 582.0 - 
136 
2 10 953.1 + 
3 5 1426.5 - 
4 
5 421.4 + 
9 663.1 - 
5 9 1016.8 - 
6 
6_top 892.4 - 
6_bottom 587.0 - 
8 694.3 - 
7 
5 597.4 + 
6 998.9 - 
8 
1 796.7 - 
6 764.7 - 
7 903.2 + 
9 
2_top left 669.8 + 
2_bottom right 842.0 + 
Note: Table continued on next page. In the Section column, designators such as left, right, top, & bottom 
are used to specify a single neuron when multiple CTb-positive neurons are evident in that section. 
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Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C7 
138 
3 
12 765.9 + 
13 934.8 + 
15 719.3 - 
4 
1 822.9 - 
5 685.6 + 
8 949.4 - 
10 932.3 + 
13_left 633.2 - 
13_right 1014.7 + 
15 627.8 + 
5 
1_top 590.8 - 
2 840.4 - 
6 815.0 - 
14_middle 660.6 - 
14_top left 1356.2 - 
6 
1 696.8 - 
3 745.1 - 
10 361.9 - 
13 842.9 + 
7 7 881.1 + 
8 2_top 527.5 + 2_bottom 815.8 - 
140 
1 9 651.5 + 
2 10 428.1 + 
3 5 425.2 + 
4 
4_right 1015.9 + 
4_left 615.3 + 
5_top left 689.4 - 
5_bottom right 669.8 + 
6 632.8 - 
8_right 518.8 - 
8_left 615.3 + 
11 773.4 + 
13 527.9 - 
5 
1 368.6 - 
2_right 473.0 + 
2_left 712.2 - 
3 808.8 + 
11 449.3 + 
C8 135 
2 6 384.0 + 
3 6 628.2 - 
4 
4 347.0 - 
5 712.7 - 
7 470.9 + 
5 2_left 709.3 - 3 510.0 + 
6 5 596.6 + 
7 8 773.4 + 
8 
1 644.4 + 
2 800.8 - 
8 800.4 - 
11 629.9 - 
Note: Table continued on next page. In the Section column, designators such as left, right, top, & bottom 
are used to specify a single neuron when multiple CTb-positive neurons are evident in that section. 
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Level Rat Slide Section Area (µm2) 
CGRP 
expression 
C8 
136 
2 6 902.4 + 
6 9 738.4 + 
7 
1 674.4 + 
7 795.4 - 
9 
4 945.2 + 
6 546.7 + 
138 
2 
6 852.4 - 
7_bottom 909.8 + 
10 627.4 + 
3 
12 981.8 + 
13_top 1056.7 + 
4 
8 964.3 + 
13 1037.6 + 
5 
5 492.2 + 
10 593.7 + 
11 674.0 + 
14 1039.2 + 
140 
2 9 784.2 + 
3 
8 842.0 + 
9 677.3 + 
11 635.7 - 
12_top right 732.2 + 
12_bottom left 677.3 - 
14_top 993.5 + 
14_bottom 745.9 + 
4 
3 991.4 + 
4 487.6 - 
13 800.0 + 
14 734.3 + 
5 
7 808.3 + 
8 1430.7 + 
10 716.8 + 
Note: In the Section column, designators such as left, right, top, & bottom are used to specify a single 
neuron when multiple CTb-positive neurons are evident in that section. 
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Figure H.3.A. CTb and CGRP-labeled sections of the C5 DRG from Rats 136 and 
140 in the normal group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.6. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. 
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Figure H.3.B. CTb and CGRP-labeled sections of the C6 DRG from Rats 135, 136, 
and 138 in the normal group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.6. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. Figure is continued on the next page. 
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Figure H.3.B. CTb and CGRP-labeled sections of the C6 DRG from Rat 140 in the 
normal group. For each rat, the images presented correspond to those sections for 
which CTb-labeled neurons were identified as summarized in Table H.6. For each rat, 
slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
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Figure H.3.C. CTb and CGRP-labeled sections of the C7 DRG from Rat 135 in the 
normal group. For each rat, the images presented correspond to those sections for 
which CTb-labeled neurons were identified as summarized in Table H.6. For each rat, 
slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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Figure H.3.C. CTb and CGRP-labeled sections of the C7 DRG from Rats 135 and 
136 in the normal group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.6. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. Figure is continued on the next page. 
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Figure H.3.C. CTb and CGRP-labeled sections of the C7 DRG from Rat 138 in the 
normal group. For each rat, the images presented correspond to those sections for 
which CTb-labeled neurons were identified as summarized in Table H.6. For each rat, 
slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
Figure is continued on the next page. 
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C7 
Figure H.3.C. CTb and CGRP-labeled sections of the C7 DRG from Rat 140 in the 
normal group. For each rat, the images presented correspond to those sections for 
which CTb-labeled neurons were identified as summarized in Table H.6. For each rat, 
slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
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Figure H.3.D. CTb and CGRP-labeled sections of the C8 DRG from Rats 135 and 
136 in the normal group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.6. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. Figure is continued on the next page. 
R
at
 
13
6 
351 
 
  
CT
b 
CG
RP
 
CT
b 
CG
RP
 
CT
b 
CG
RP
 
CT
b 
CG
R
P 
R
at
 
13
8 
C8 
Figure H.3.D. CTb and CGRP-labeled sections of the C8 DRG from Rats 136 and 
138 in the normal group. For each rat, the images presented correspond to those 
sections for which CTb-labeled neurons were identified as summarized in Table H.6. 
For each rat, slide number and section number increase from left to right. For each 
CTb-labeled image, the corresponding CGRP-labeled image is presented immediately 
below it. Figure is continued on the next page. 
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Figure H.3.D. CTb and CGRP-labeled sections of the C8 DRG from Rat 140 in the 
normal group. For each rat, the images presented correspond to those sections for 
which CTb-labeled neurons were identified as summarized in Table H.6. For each rat, 
slide number and section number increase from left to right. For each CTb-labeled 
image, the corresponding CGRP-labeled image is presented immediately below it. 
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